

Control of Meiotic Recombination At A Human Crossover Hotspot

**Mahmut Cerkez Ergoren
University of Leicester**

Thesis submitted for the degree of Doctor of Philosophy

May 2013

Control of Meiotic Recombination At A Human Crossover Hotspot

ACKNOWLEDGEMENTS.....	VII
ABBREVIATIONS.....	X
ABSTRACT.....	XI
CHAPTER 1: INTRODUCTION.....	1
1.1 OVERVIEW OF MEIOSIS	1
1.1.1 Prophase I.....	4
1.2 MEIOTIC RECOMBINATION.....	5
1.2.1 Homologue Recognition and Pairing	5
1.2.2 Meiotic Recombination Is Initiated by Double Strand Breaks (DSB).....	5
1.2.2.1 Models of Meiotic Recombination.....	7
1.2.2.2 D-loop Nicking Pathway in <i>S. pombe</i>	9
1.2.2.3 The Crossover/ Non-Crossover Decision	10
1.2.3 The Synaptonemal Complex (SC) Links Homologous Chromosomes.....	10
1.2.4 Recombination Nodules Mark The Locations of Recombination Events	11
1.2.5 Two Homologous Non-Sister Chromatids Exchange Genetics Material During Crossover at Chiasmata	12
1.2.6 The Numbers And Distribution of Crossovers Are Controlled by Interference	12
1.2.7 Mis-Match Repair Proteins Involved In Recombination	13
1.3 RECOMBINATION HOTSPOTS IN EXPERIMENTAL ORGANISMS...13	
1.3.1 Recombination Hotspots in Yeast	13
1.3.2 Maize Recombination Hotspots	15
1.3.3 Mouse Recombination Hotspots	15

1.4 MEASURING RECOMBINATION RATES IN HUMANS	16
1.4.1 Pedigree Analysis	16
1.4.2 Linkage Disequilibrium.....	17
1.4.2.1 Linkage Disequilibrium Unit (LDU) Maps	19
1.4.3 Coalescent Analysis.....	20
1.5 MEASURING RECOMBINATION RATES IN HUMANS	21
1.5.1 Single Sperm Typing Technique	21
1.5.2 Recombination Detection Using High-Resolution Sperm Typing (Batch Sperm Typing)	22
1.6 HUMAN RECOMBINATION HOTSPOTS	24
1.6.1 Hotspots Within The Major Histocompatibility Complex (MHC) Region	26
1.6.2 The MS32 Region	26
1.6.3 Recombination Hotspot In The β -globin Region	27
1.6.4 SHOX Hotspot In The Xp/Yp Pseudoautosomal Region	27
1.7 HOTSPOT EVOLUTION AND GENE CONVERSION IN HUMANS	28
1.8 THE HAPMAP PROJECT	29
1.8.1 Confirming Human Hotspots from LD Data by High-Resolution Sperm Crossover Analysis	31
1.9 DNA SEQUENCE MOTIFS ASSOCIATED WITH RECOMBINATION HOTSPOTS	31
1.10 TRANS-REGULATOR EFFECTS ON RECOMBINATION HOTSPOTS.....	33
1.11 WORK IN THIS THESIS	37
 CHAPTER 2: MATERIAL AND METHODS	 40
 2.1 MATERIALS	 40
2.1.1 Suppliers	40
2.1.2 Chemical Reagents.....	40
2.1.2.1 Enzymes	40
2.1.2.2 Molecular Weight Markers	40
2.1.2.3 Oligonucleotides	41

2.1.2.4 Human DNA	41
2.1.2.5 Standard Solutions	42
2.1.2.6 Preparing 11.1 X PCR Buffer	42
2.1.2.7 Whole Genome Amplification by Multiple Displacement Amplification (MDA)	43
2.1.3 Computers	44
2.2 METHODS	45
2.2.1 DNA Extraction from Semen	45
2.2.2 DNA Extraction from Blood	46
2.2.3 Measuring DNA Concentration	47
2.2.4 Gel Electrophoresis	47
2.2.5 PCR Amplification	47
2.2.6 PCR Cleanup by Exonuclease I and Shrimp Alkaline Phosphatase (SAP) Purification	48
2.2.7 Automated DNA Sequencing	48
2.2.8 Dot Blots	49
2.2.9 Dot Blot Hybridization	49
2.2.10 Probe Removal from Membrane	50
2.2.11 Crossover (Recombination) Assay	50
2.2.11.1 Allele Specific Primers (ASPs)	53
2.2.11.2 Primary PCR	54
2.2.11.3 Secondary PCR	54
2.2.11.4 Tertiary PCR	54
2.2.11.4 Mapping crossovers to SNP intervals	54
 CHAPTER 3: HIGH-RESOLUTION LINKAGE DISEQUILIBRIUM ANALYSIS OF PUTATIVE HOTSPOTS CONTAINING A MOTIF- DISRUPTING SNP	 60
 3.1 INTRODUCTION	 60
3.2 FOUR SELECTED LD HOTSPOTS	62
3.2.1 SNP Discovery and Annotating	63
3.2.2. Typing SNPs In Semen Donors by Allele Specific Oligo (ASO) Hybridisation	65

3.2.3 Linkage Disequilibrium (LD) and Linkage Disequilibrium Unit (LDU) Mapping, and Coalescent Analysis	75
3.4 DISCUSSION	80

CHAPTER 4: FREQUENCY AND DISTRIBUTION OF RECOMBINATION EVENTS AT A HOTSPOT82

4.1 INTRODUCTION.....	82
4.2 THE CROSSOVER ASSAY STRATEGY FOR THE HOTSPOT DA.....	82
4.3 SELECTION OF SEMEN DONORS FROM THE DONOR PANEL	83
4.4 OPTIMISATION FOR RECOMBINATION ASSAY	83
4.4.1 Recombination Assay for The Hotspot DA	84
4.4.1.1 Optimisation of Forward Allele-Specific Primers (ASPs)	84
4.4.1.2 Optimisation of Reverse Allele-Specific Primers (ASPs)	85
4.4.1.3 Linkage Phasing of Donors	86
4.4.1.4 Performing The Recombination Assay on Donor 7	89
4.4.1.5 Mapping Recombinant PCR Products	93
4.5 DISTIBUTION OF CROSSOVERS WITHIN HOTSPOT DA	95
4.5.1 Calculating Crossover Activity	95
4.5.2 Distribution of Crossovers and The Centre of The Hotspot	97
4.5.3 Biased Gene Conversion In Crossover Progeny	98
4.6 RECOMBINATION ASSAY IN MORE INFORMATIVE DONORS	98
4.6.1 Recombination Assay Performed On Sperm DNA of Donor 6	98
4.6.2 Recombination Assay Performed On Other Sperm Donors	102
4.6.3 Calculating Crossover Activity	105
4.6.4 Distribution of Crossover and The Centre of The Hotspot	107
4.6.5 Biased Gene Conversion In Crossover Progeny	109
4.7 GENE CONVERSION AT THE HOTSPOTS DA	111
4.7.1 Strategy of Recovering Crossovers and Non-Crossovers	111
4.7.2 Crossover and Non-crossover Frequencies	113
4.7.3 Reciprocal Crossover and Conversion Asymmetry	114
4.7.4 Conversion Tract Lengths	116

4.7 DISCUSSION	117
 CHAPTER 5: EFFECT OF TRANS-REGULATOR FACTOR PRDM9 ON HOTSPOT DA	120
5.1 INTRODUCTION	120
5.2 DESIGNING THE CROSSOVER ASSAYS	122
5.2.1 SNP Discovery and Annotation for The African Panel	122
5.2.2 LDU Mapping for African Panel	124
5.2.3 Allele-Specific Primers (ASPs) and Optimisation of Selector Sites	125
5.2.4 Phasing of Selector Alleles	127
5.2.5 The Crossover Assays	128
5.2.6 Determining Crossover Frequencies	131
5.2.7 Tertiary PCR Carried Out On Men Homozygous for The Suppressed Allele (T/T) for The Motif Disrupting SNP DA7.5	135
5.2.8 Effect of The <i>Trans</i> -Regulator PRDM9 On Hotspot DA	136
5.2.9 Re-Sequencing of Donors	139
5.3 DISCUSSION	142
 CHAPTER 6: DISCUSSION	144
6.1 HIGH-RESOLUTION LINKAGE DISEQUILIBRIUM ANALYSIS OF PUTATIVE HOTSPOTS CONTAINING A MITF-DISRUPTING SNP	144
6.2 DETERMINING THE RECOMBINATION RATE AND HOTSPOT POLYMORPHISM IN HOTSPOT DA	146
6.3 THE RELATIONSHIP BETWEEN CROSSOVERS AND NON-CROSSOVERS	148
6.4 THE PATHWAYS OF GENERATING CROSSOVERS AND NON-CROSSOVERS	149
6.5 PRDM9 REGULATION ON HOTSPOT DA	151
6.5.1 The Protein Encoded by PRDM9 Binds To A 13 bp Motif	152
6.6 FINAL REMARKS	153
6.7 FUTURE WORK	154

APPENDIX I: DNA SEQUENCES OF TARGET HOTSPOTS	156
APPENDIX II: PCR PROFILES AND PRIMERS	181
Appendix II.I PCR Cycles	181
Appendix II.II Primers	190
APPENDIX III: ALLELE-SPECIFIC OLIGOS (ASOs)	194
APPENDIX IV: RE-SEQUENCING RESULTS	199
REFERENCES	255

ACKNOWLEDGEMENTS

First and foremost I would like to thank Alec for accepting me in his group, for his great help and helpful guidance, also importantly, for being very patient with me.

There are many people in the lab and the department, past and present, who were very helpful. To Rita, thank you for your great technical help and great support during my PhD; Celia, a special thanks for your priceless help, you are one in a million; Ingrid, for all your help, advice and surprise gifts, thank you; Nancy thank you very much for your incredible constant support and it was very nice dancing with you, love you; Raheleh, thanks for being a good and supportive friend in the lab; Lenny, thanks for helping me to adjust to the department; Rob, without you this thesis would not have been completed, thanks man; Pille thanks for the great statistical help during the Jubilee weekend.

To my amazing Leicester crew for making this city tolerable and enjoyable, you guys are very special to me. Thanks for being here and for your support; Tutku (ahbabım) THANK YOU; “my beeatches”, Danielle and Angelica, without you Leicester and my life would not be so great and important, love you; Chiara, a perfect person always in the right place, thank you very much, ti amo; Housemate Aline and George, you guys are very important to me, miss you both.

To my specials, Irmak, Gunseli, Bahar and Mustafa; thank you for the last twelve years.

To my friends around the world, thank you for your support and being a call away. Andrea, “study bello!”, “did you study today?”, the first three chapters of this thesis were written with your great support, grazie mille bello, MK&DB; Davita and Keith, my tele-therapists, thanks for always being on the other side of the phone; Baldo, my little brother, ti voglio bene; Ryan, my special personal supporter, thanks for being there; Yeliz, how can I forget your great help, kuzen? And the others: Nasser (I do not know how to thanks, hayati!), Nick (Gaga), Enrico, Melek, Berya, Edge Gokhan, Argyris, Pierpaolo and Shanow.

Finally, and most importantly, to my family.

Annem ve Babam, bana inandı ınız ve g vendi iniz icin  ok te ekk r ederim, sizi  ok seviyorum; Ahmet, sabrın icin  ok te ekk rler karde im, Teyzem, canım, deste in ve yardımların olmasa heralde b g n burada olamazdım. Son olarak, dede, bu tezi benimle her zaman gururlandı ın ve  vg yle bahsetti in icin, bir te ekk r olarak sana ithaf ediyorum.

*This thesis is
dedicated to my
grandfather
Mahmut Cerkez...*

ABBREVIATIONS

AE	axial element
ASO	allele-specific oligonucleotide
ASP	allele-specific primer
ASW	African ancestry in the south- western USA
CEPH	Centre d'Etude du Polymorphisme Humaine
CEU	the Centre d'Etude du Polymorphisme Humain in Utah
CHB	the Han Chinese of Beijing
CHD	Chinese in metropolitan Denver, Colorado, USA
CO	crossovers
dbSNP	database SNP
DNA	deoxyribonucleic acid
dNTP	deoxynucleotide triphosphate
DSB	double strand break
DSBR	double strand break repair
EN	early (recombination) nodule
GIH	Gujarati Indians in Houston, Texas, USA
JPT	the Japanese of Tokyo
LD	linkage disequilibrium
LDU	linkage disequilibrium unit
LE	lateral element
LINE	long interspersed nuclear element
LN	late (recombination) nodule
LR	likelihood ratio
LWK	Luhya in Webuye, Kenya
Mb, kb, bp	Mega-, kilo-, base pair
MDA	multiple displacement amplification
MHC	major histocompatibility complex
MKK	Maasai in Kinyawa, Kenya
MMR	mismatch repair
MXL	Mexican ancestry in Los Angeles, California, USA
NCO	no gene conversions
PAR	pseudoautosomal region
PCR	polymerase chain reaction
PRDM9	PR domain-containing 9, is a meiosis-specific histone
H3	methyltransferase
RN	recombination nodule
RF	recombination frequency
SEI	strand exchange intermediates
SINE	short interspersed nuclear element
SC	synaptonemal complex
SDSA	synthesis dependent strand annealing
SNP	single nucleotide polymorphism
TSI	Tuscans in Italy
WGA	whole genome amplification
YRI	Yoruba people of the Ibadan region in Nigeria
ZnF	zinc finger

Control of Meiotic Recombination At A Human Crossover Hotspot

Mahmut Cerkez Ergoren

ABSTRACT

Meiotic recombination plays a key role in reshuffling haplotypes in human populations, thus profoundly affecting evolution. However, our understanding of recombination dynamics is largely limited to descriptions of variation in populations and families. Higher resolution analysis (0.0001 cM or less) of *de novo* recombination events in human sperm DNA has revealed clustering into very narrow hotspots (1-2 kb) that generally coincide with abrupt breakdown of linkage disequilibrium (LD).

Myers *et al.* (2008) used population genetics approaches to survey HapMap Phase II genotype data across the whole genome to infer sites of historical recombination. Around 40% of ~30,000 hotspots so identified contain a 13-bp motif CCNCCNTNNCCNC which appears to be involved in hotspot specification and which may also drive modes of genome instability such as disease-causing genomic rearrangements, minisatellite mutation and common mitochondrial deletions. In addition, recent studies identified that the *trans*-regulator PRDM9 of meiotic recombination hotspots in humans and mice, contains a zinc finger array that can recognize the 13-bp sequence motif associated with hotspots, with binding to this motif possibly triggering hotspot activity via chromatin re-modelling in humans. Berg *et al.*, (2010) reported that PRDM9 is a major global regulator of hotspots in humans, even hotspots lacking the sequence motif, and influences aspects of genome instability.

To examine the effect of the 13-bp motif on crossover frequencies and distribution, four candidate putative hotspots located on different chromosomes and identified from HapMap data were studied. These hotspots had the motif at their centre, and a SNP that disrupts the motif. LDU analysis confirmed the locations of the putative hotspots to a 1-2-kb interval. However, only the first candidate LD hotspot, 'Hotspot DA' could be analysed in detailed high-resolution analyses for understanding the influences of *cis*-regulation on hotspot activity. The other candidate LD hotspots were eliminated because of their disrupting SNP locations on the hotspot or because of a lack of suitable donors in our sperm donor panel.

Comparing the rates and distributions of sperm crossover events between donors heterozygous for the disrupting SNP showed that there is a huge asymmetry between the two alleles with the derived and motif-disrupting allele suppressing hotspot activity. This direct study to understand the effect of the disrupting allele on crossover initiation revealed that Hotspot DA is the first to show very strong direct *cis*-regulation for hotspot activity, and despite being influenced by the *trans*-factor PRDM9, it is not the major regulator for this hotspot.

CHAPTER 1: INTRODUCTION

Genetic variation between individuals is the product of two main processes: mutation and meiotic recombination. While recombination and independent assortment of chromosomes reshuffle DNA to create novel allelic combinations of the genetic material, it is mutation that drives novel variants into the genome. Sometimes these processes have deleterious effects, for instance by causing inherited disease. The other fundamental role of meiotic recombination is to ensure the proper segregation of homologous chromosomes during meiotic division. This chapter will introduce the basic features of meiosis and meiotic recombination in lower eukaryotes such as yeast, as well as in mice and humans, and discuss the current understanding of meiotic recombination hotspots in these three organisms.

1.1 OVERVIEW OF MEIOSIS

Meiosis consists of two sub-stages: meiosis I and meiosis II. In meiosis I there is pairing of homologous chromosomes followed by their subsequent segregation away from each other, and in meiosis II there is a mitosis-like division. Each sub-stage is divided further into prophase, metaphase, anaphase and telophase. The first stage of prophase of meiosis I is called leptotene, in which individual chromosomes begin to condense from long strands within the nucleus. However, the two sister chromatids are still so tightly bound that they are indistinguishable from one another. The zygotene stage occurs as the homologous chromosomes line up with each other and at this point the combined homologous chromosomes are said to be bivalent. They may also be referred to as a tetrad, in reference to the four sister chromatids. The two pairs of chromatids become “zipped” together, via the synaptonemal complex, in a process known as synapsis. The pachytene stage heralds crossing-over where non-sister chromatids of homologous chromosomes randomly exchange segments of genetic information over regions of homology. Exchange takes place at sites of recombination events, where the exchange of information between the non-sister chromatids can be either reciprocal or non-reciprocal.

During the diplotene stage, the synaptonemal complex degrades and homologous chromosomes begin to separate from one another. The chromosomes themselves begin to uncoil, allowing some transcription of DNA. However, the homologous chromosomes of each bivalent remain tightly bound at chiasmata (the regions where crossing-over has occurred). Chromosomes condense further during the diakinesis stage – this is the first point in meiosis where the four parts of the tetrads are actually visible under a light microscope. Sites of crossing-over entangle together and effectively overlap to make chiasmata clearly visible. Apart from this observation, the remainder of diakinesis closely resembles prometaphase of meiosis I: the nucleoli disappear, the nuclear membrane disintegrates into vesicles, and the meiotic spindle begins to form.

Following prophase I, homologous pairs enter metaphase I where the chromosomes line up along the centre of the cell and are independently and randomly assorted. In anaphase I, the cell elongates in preparation for division down the middle, and homologous chromosomes closely associated in synapsis exchange segments of DNA by crossing-over. The first division effectively ends when the centromeres arrive at the poles. Each daughter cell now has half the number of chromosomes, but each chromosome consists of a pair of chromatids. In prophase II, the nucleoli and the nuclear envelope begin to disappear again and chromatids shorten and thicken. Centrioles move to the polar regions and are arranged by spindle fibres. In metaphase II, the centromeres contain three kinetochores, organising fibres from the centrosomes on each side. This is followed by anaphase II, where the centromeres are cleaved, allowing the kinetochores to pull the sister chromatids apart. The sister chromatids by convention are now called sister chromosomes, and they are pulled towards opposing poles. The process ends with telophase II, which is similar to telophase I, marked by uncoiling and lengthening of the chromosomes together with the disappearance of the microtubules. Nuclear envelopes reform, and cleavage and cell wall formation eventually produces a total of four daughter cells, each with a haploid set of chromosomes. Meiosis is now complete (Figure 1-1).




Figure 1-1 Overview of meiosis

1.1.1 Prophase I

Leptotene, zygotene, pachytene and diplotene/diakinesis are the phases of prophase I (Figure 1-2). During leptotene, homologous chromosomes physically line up with one another and axial elements (AE) form. Zygotene is the stage of initiation of synapsis between homologous chromosomes in the form of synaptonemal complexes (SC). Synapsis is then finished and the bivalent is stabilised by the time the cell reaches pachytene. In diplotene and diakinesis the SCs are disassembled and chiasmata are visible as the homologous chromosomes begin to separate. Metaphase I follows prophase I where the bivalent chromosomes are aligned on the metaphase plate. Until the transition to anaphase I, bivalents are held at metaphase I.




Figure 1-2 Interactions of one pair of homologous chromosomes (blue and red) during the stages of prophase. Replicated chromosomes during interphase are denoted by strands of different shades. Chromosomes condense during leptotene, and synapsis is initiated during zygotene and completed in pachytene. Chiasmata, can be seen during the diplotene/diakinesis stage. In metaphase I, breakdown of the nuclear envelope and formation of meiotic spindle are observed. DSB refers to double strand breaks: AE is axial element, RN is recombination nodules and SC is the synaptonemal complex (shown in yellow) (adapted from Page and Hawley, 2003; Roeder 1997).

1.2 MEIOTIC RECOMBINATION

Correct synapsis and proper segregation of homologous chromosomes occur during meiosis I by meiotic recombination. There are many proteins involved in the various steps of meiotic recombination: homologue recognition and pairing; the initiation of recombination and subsequent repair of homologous DNA strands; synapsis; and maintenance of the physical bonds between homologues.

1.2.1 Homologue Recognition and Pairing

Homologous pairing occurs prior to chromosome synapsis (Weiner and Kleckner, 1994; Nag *et al.*, 1995) and implies that homologous chromosomes need to be brought together and aligned before recombination can take place, particularly in regions where the frequency of DSBs is reduced by DNA heterologies (Rocco and Nicolas, 1996; Xu and Kleckner, 1995). DSB formations can be affected by some heterologies, revealing the existence of an anti-initiation process sensing the presence of sequence non-homology between the homologous chromosomes (Rocco and Nicolai, 1996). There is evidence that the clustering of telomeres towards the nuclear envelope may have an effect on pairing, as this clustering occurs at the same time as pairing during meiosis. This telomere clustering might provide a mechanism for chromosome alignment that is conducive to homologous chromosomes finding one another. This assembly, termed the 'bouquet', is almost universal among sexually reproducing organisms, and has been extensively reviewed (Zickler and Kleckner, 1999; Bass, 2003).

1.2.2 Meiotic Recombination Is Initiated by Double Strand Breaks (DSB)

In *S. cerevisiae*, the formation of DSBs initiates recombination (Sun *et al.*, 1989), and it is believed that DSBs are initiators of meiotic recombination in most organisms (Lin and Smith, 1994; Dalganov *et al.*, 1996). There are many proteins involved in this multi-stage process. A non-random process of DSB formation happens in cluster sites of initiation (known as hotspots), which are usually located in promoters or in coding sequences (Lichten and Goldman, 1995; Bullard *et al.*, 1996; Baudat and Nicolas, 1997). There is no evidence of any specific sequence motifs that control

DSB, but they are instead scattered across a 50-200-nucleotide tract within nuclease hypersensitive regions (Liu *et al.*, 1995; Xu and Kleckner, 1995).

DSBs are formed by a topoisomerase-like transesterification which is catalysed by the Spo11 protein in *S. cerevisiae*, (Keeney *et al.*, 1997) and by Spo11 orthologues in other organisms such as *Arabidopsis*, mouse and humans (Keeney *et al.*, 1999; Shannon *et al.*, 1999; Hartung and Puchta, 2000). It starts by breaking both strands of a DNA molecule and covalently linking the 5' ends of the breaks to a tyrosine within itself (Keeney and Kleckner, 1995; Keeney *et al.*, 1997). Even though Spo11 is an essential protein for initiation, there are many other proteins involved in this process (Johzuka and Ogawa, 1995; Roeder, 1997).

RAD50, *MRE11* and *COM1/SAE2* are three genes fundamental for the resection process (Alani *et al.*, 1990; McKee and Kleckner, 1997; Nairz and Klein, 1997). Rad50 and Mre11 proteins are required not only for DSB induction, but also for processing of the broken strands. Moreover, the exonuclease involved is thought to be a complex made up of Rad50 and Mre11 (Johzuka and Ogawa, 1995; Trujillo and Sung, 2001). After double-strand cleavage, the 5' - attached Spo11 protein is removed by the Com1/Sae2 protein along with the Rad50/Mre11/Xrs2 complex (Rattray *et al.*, 2001). This prepares the chromosomes for strand invasion by leaving single tails with 3' - termini exposed by the Rad50/Mre11/Xrs2 complex (Cao *et al.*, 1990; Nairz and Klein, 1997). From this, exonucleolytic resection is initiated.

Following resection, strand invasion of the 3' tail into the unbroken duplex of the homologous chromosome requires strand invasion of four yeast proteins: Rad51, Dmc1, Rad55 and Rad57 (Schwacha and Kleckner, 1997); which are homologues of the bacterial recA strand exchange enzyme (Shinohara *et al.*, 1992). However, Rad51 is the catalyst for the invasion (Sung, 1994). The 3'-resected end invades the homologous chromosome to form structures known as Holliday junctions (Holliday, 1964).

In human cells, the Rad51 protein is required for both branch migration and Holliday junction resolution (Liu *et al.*, 2004). With different cleavage orientation (vertical or horizontal) of a Holliday junction, the DSB repair system can cause either crossover

or non-crossover products (Storlazzi *et al.*, 1995). However, a pathway without the involvement of a Holliday junction intermediate can also form non-crossover recombinants (Allers and Lichten, 2001).

1.2.2.1 Models of meiotic recombination

The first model is double-strand break repair (DSBR) (Szostak *et al.*, 1983). In DSBR the D loop (Figure 1-3) captures the second 3' single end and anneals to it via sequence complementarity. Ligation results in the generation of a double Holliday junction (Schwacha *et al.*, 1995). Whether the double Holliday junction resolves into a crossover or noncross-over product depends on the direction in which the Holliday junction is resolved; if both Holliday junctions are cleaved in the same orientation then no crossover will occur, but if they are cut in opposite orientations then crossing over will occur. The DSBR model is reinforced by the visualisation of branched intermediates that correspond to Holliday junctions (Schwacha *et al.*, 1997) (Figure 1-3).

A second model, called synthesis-dependent strand-annealing (SDSA), was first described in *D. melanogaster* while studying P-element induced gap repair (Nassif *et al.*, 1994). This model has the same initial steps as the DSBR model, in that it invades the homologous chromosome to displace the 3' strand and anneal it to the original chromatid from which it came. The SDSA model can explain gene conversion because the conversion events are only expected on the recipient chromosome (Paques *et al.*, 1999). The possible model for crossing over by the SDSA method has been suggested by Ferguson and Holloman (1996) and involves the formation of a D-loop and DNA synthesis, followed by re-annealing of the second 3' end to produce a single Holliday junction, and subsequent resolution. This model has since been adapted to incorporate a double Holliday junction, which can be cleaved to result in either a crossover or non-crossover (Paques *et al.*, 1998) (Figure 1-4).




Figure 1-3 Double strand break repair model (DSBR). Diagrammatic representation of the DSBR model of recombination (adapted from Pagues and Haber, 1999; and Petes, 2001). DSB formation is followed by a 5' to 3' exonuclease resection of the ends, to leave a 3' overhang. This 3' overhang invades the intact homologue and produces a D loop, which can be extended by new DNA synthesis. In the DSBR model the second 3' is captured and two Holliday Junctions (HJs) are formed; these can be resolved independently by cutting the crossed and non-crossed strands, resulting in crossover or non-crossover products.




Figure 1-4 The synthesis dependent strand annealing (SDSA) model. Above is a diagrammatic representation of the SDSA model (Adapted from Pagues and Haber, 1999; Petes, 2001). DSB formation, resection, single strand invasion and extension occur as in the DSBR model. However, the extended 3' end is then expelled from the homologue and anneals to the original chromatid to produce a non-exchange gene conversion event. If the second 3' end invades the heteroduplex, it allows the formation of a double HJ, which can be resolved either with or without crossover. The SDSA model predicts crossover and conversions.

1.2.2.2 D-loop nicking pathway in *S. pombe*

Despite similarity in the initiation step, where the Spo11 orthologue Rec12 is essential for the formation of DSBs; fission yeast (*Schizosaccharomyces pombe*) recombination models vary substantially from the models proposed for recombination in budding yeast (*Saccharomyces cerevisiae*) (Cervantes *et al.*, 2000). Inter-sister recombination is preferred over-homologue recombination, and not double HJs but instead single HJs are the predominant joint molecule in meiosis (Cromie *et al.*, 2006). A transient D-loop is nicked before it can form a double HJ (Cromie *et al.*, 2006).

Single HJ is cut by Mus81 that is a part of resolvase complex Mus81-Eme. In crosses involving fission yeast mutant for Mus81, which display kinetics and normal numbers

of DSB formation, the number of crossovers is greatly reduced with little effect on the number of non-exchange conversion events (Cromie *et al.*, 2006). In budding yeast, the corresponding complex of Mus81/mms4 is not the major meiotic HJ resolvase, and the crossover frequency is reduced modestly by mutations in mus81 (de los Santos *et al.*, 2003).

1.2.2.3 The crossover/ non-crossover decision

Producing a crossover or non-crossover decision occurs before or at the appearance of strand exchange intermediates (SEIs) (Börner *et al.*, 2004). Non-crossover products are seen in the presence of mutations that prevent resolution of HJs in yeast (Allers and Lichten, 2001). The level of crossover is reduced by meiotic recombination proteins including Zip1, Zip2, Zip3, Mer3, Msh4 and Msh5, but these proteins maintain high frequencies of non-exchange conversion (Börner *et al.*, 2004). This points to the non-crossover mechanism as the main repair mechanism in the absence of crossover formation.

In contrast, crossovers tend to be maintained at the expense of non-crossovers at a given DSB location when the number of DSBs is artificially reduced (Martini *et al.*, 2006). This points to a specific subset DSBs “deciding” to enter a pathway of inter-homologue crossover differentiation, with the remaining DSBs resolved primarily without reciprocal exchange of chromosomal arms, as non-crossovers.

1.2.3 The Synaptonemal Complex (SC) links homologous chromosomes

The SC is a meiosis-specific, chromatin-associated protein structure which is evolutionary conserved and found in many eukaryotes including *S.cerevisiae*, *D. melanogaster* and humans (Zickler and Olson, 1975; McKim *et al.*, 1998; Moses *et al.*, 1975). During leptotene, zygotene and pachytene, the SC, a tripartite ribbon-like structure, forms a physical link between homologous chromosomes.

During prophase I, an axial element (AE) develops between two sister chromatids of a single chromosome, and the SC is initially formed from AE. After formation of the SC, the AE is renamed as the lateral element (LE). During zygotene, synapsis begins

where transverse filaments form the SC structure and connect the AEs of two homologous chromosomes. Chromatin loops anchor the LE. The entire space encompassing the lateral and central elements is known as the central space (Zickler and Kleckner, 1999). Fewer crossovers are seen within larger loops (Roeder, 1995), with DSBs preferentially occurring in the middle of these chromatin loops (Blat *et al.*, 2002)

The Zip1 protein of *S. cerevisiae* is required for SC production and subsequent synapsis, and is also involved in chromosome interference (Sym *et al.*, 1993; Tung and Roeder, 1998; Sym and Roeder, 1994). Also, the CP1/Syn1 complex has been identified and characterised as protein components of the central element of the SC in mammals (Dobson *et al.*, 1994; Meuwissen *et al.*, 1997). Early studies using a *zip1* mutant in *S. cerevisiae* showed that the Zip1 protein is an essential structural element of the SC (Sym and Roeder, 1994). Moreover, chromosome synapsis is not necessarily required for recombination, as in some yeast mutants recombination can occur without the presence of a mature SC and hence synapsis. In *zip1* mutants, gene conversion occurs even in the absence of the SC (Roeder, 1995). The Zip1 protein was found to promote centromere coupling, to favour homologue pairing, and to serve as sites of synapsis initiation (Tsubouchi and Roeder, 2003). Recently, studies showed that the formation of the SC is a critical process in meiosis, although a positive correlation between crossovers and sites of synaptic initiation has been seen in some organisms (Henderson and Keeney, 2005).

1.2.4 Recombination Nodules mark the locations of recombination events

Recombination nodules (RNs) are electron-dense structures found within the SC and are visible with electron microscopy. Early RNs (ENs) form between the late leptotene or early zygotene and mid-pachytene phases, and are thought to mark the locations of recombination events. A second type of RN is the late RN (LN). LNs form in pachytene and sometimes in the diplotene phases. LNs are less frequent in most organisms (Zickler and Kleckner, 1999). Dmc1 and Rad51 are two RecA-like proteins thought essential in strand invasion and Holliday junction formation during DSBs (Anderson *et al.*, 1997). Components of LNs are thought to be mismatch repair

proteins. Msh4, Nad, and Mlh1 and linked to the stabilisation or resolution of Holliday junctions (Ross-Macdonald and Roeder, 1994).

1.2.5 Two homologous non-sister chromatids exchange genetic material during crossover at chiasmata

Chiasmata are the physical structures left by the process of recombination and serve to covalently attach a sister chromatid from one chromosome to a sister chromatid of the homologous chromosome, to ensure correct disjunction of recombinant chromosomes at meiosis I. For correct disjunction, at least one chiasma is required per chromosome. Chiasmata can be visualised due to the accumulation of Mlh1 in mice (Baker *et al.*, 1996) and humans (Tease *et al.*, 2002), and counts of crossovers made. The cleavage of Rec8 protein at metaphase/anaphase dissolves chiasmata, when homologous chromosomes are separated to opposite poles of the cell (Lee and Orr-Weaver, 2001).

1.2.6 The numbers and distribution of crossovers are controlled by interference

At least one crossover must occur in each chromosome for prevention of non-disjunction, and therefore the size of the chromosome is important. With this knock-on effect, smaller chromosomes have proportionally more crossovers per unit length than larger chromosomes (Kaback *et al.*, 1992). Moreover, if a large chromosome is split into two smaller chromosomes, the number of crossovers per unit length increases (Kaback *et al.*, 1992).

Yeast mutants of *zip1*, *zip2*, and *msh4* do not exhibit interference, possibly preventing the correct formation of the SC (Sym and Roeder, 1994; Novak *et al.*, 2001). Organisms that lack an SC, such as *S.pombe* and *Aspergillus nidulans* also do not exhibit interference (Egel-Mitani *et al.*, 1982; Kohli and Bahler, 1994). However, some organisms, yeast (Stahl *et al.* 2004), humans (Housworth and Stahl, 2003) and *Arabidopsis thaliana* (Copenhaver *et al.*, 2002), are thought to generate a few crossovers that lack interference, compared with the total number of crossovers generated. Other organisms, such as *Drosophila* and *Neurospora*, are thought to only generate crossovers that exhibit interference (Copenhaver *et al.*, 2002).

1.2.7 Mismatch repair proteins involved in recombination

During meiotic recombination, the correlation between heteroduplex DNA formation and the frequency of meiotic gene conversion indicates that mismatched base pairs are necessarily repaired by gene conversion after heteroduplex DNA is formed (Nag *et al.*, 1995). Mismatch repair (MMR) was first characterised in bacteria. MutS, MutL and MutH are three proteins in the family, and their orthologues are components of the MMR system in yeast and mammals. In yeast, MutS and MutL are orthologues, whilst in mammals they are Msh1-6 and Mlh1-3, Pms1 and Pms 2.

Mismatches are recognised by a heterodimer made up of the MutS homologues Msh2 and either Msh3 or Msh6 (Marsischky *et al.*, 1996), leading to recruitment of other heterodimers; Mlh1-Pms1 for the excision and synthesis of DNA (Prolla *et al.*, 1994; Svetlanov and Cohen, 2004) and Mlh1-Mlh3. Mlh1 and Mlh3 are essential for proper recombination as mutants defective in the *mlh1* and *mlh3* genes show decreased numbers or complete absence of crossovers in yeast (Hunter and Borts, 1997; Wang *et al.*, 1999). In mammals, MLH-1 and MLH-3 proteins are considered as markers for sites of recombination (Svetlanov and Cohen, 2004).

1.3 RECOMBINATION HOTSPOTS IN EXPERIMENTAL ORGANISMS

In most eukaryotic organisms, recombination has been observed in regions of either high or low activity (Lichten and Goldman 1995; Wahls 1998). Hotspots are generally relatively narrow regions of elevated recombination, whereas cold spots tend to be recombinationally inert (Petes, 2001). As a result, hotspots have been identified in model organisms, such as yeast, maize, mice etc.

1.3.1 Recombination Hotspots In Yeast

Most of the understanding behind the recombination processes involved in meiosis has come from studies of lower eukaryotes, in particular the yeast *S.cerevisiae*, in which recombination analysis is greatly helped by the ability to recover all four products from a single meiotic event.

At least ten meiotic recombination hotspots have been well characterised in yeast (Petes, 2001) including ARG4 (Sun *et al.*, 1991; Sun *et al.*, 1989), HIS4 (Fan *et al.*, 1995) and HIS4-LEU2 (Xu and Kleckner, 1995) in *S.cerevisiae* and ade6-M26 in *S.pombe* (Steiner *et al.*, 2002). *S.cerevisiae* and *S.pombe* separated from their common ancestor about 420 to 330 million years ago (Sipiczki, 2000). High levels of DSBs are associated with many regions of 50-100 bp containing recombination hotspots (Xu and Kleckner, 1995), although there is no evidence of consensus sequences among these hotspots. Hotspots in yeast are also associated with the promoter regions of genes, with DSB sites preferentially occurring at intergenic regions rather than within genes (Wu and Lichten, 1994; Gerton *et al.*, 2000).

Petes (2001) characterised hotspots in yeast into three classes; $\square$ -, $\square$ - and $\square$ -hotspots. $\square$ -hotspot activity depends on trans-acting transcription factors, but not on transcription itself – variation in $\square$ -hotspot activity may reflect the varying ability of different transcription factors to efficiently recruit the Spo11 endonuclease that initiates recombination by introducing a DSB. An example is the HIS4 hotspot, which is found within the promoter region of the *HIS4* gene, but studies using transcription factor mutants (Bas1, Bas2 and Rap1) show that hotspot activity is controlled by transcription factor binding (White *et al.*, 1993; Kirkpatrick *et al.*, 1999). Another example is *ade6-M26* hotspot activity in *S.pombe*, which is controlled by the binding of the heteromeric transcription factor Atf1/Pcr1 (Mts1/Mts2) (Kon *et al.*, 1997). $\square$ -hotspots such as HIS4LEU2 associate with only nuclease-sensitive sequences, and all DSB sites tend to fall in regions of DNaseI or micrococcal nuclease sensitivity (Wu and Lichten, 1994; Wu and Lichten, 1995; Fan and Petes, 1996). A sequence of 12 tandemly repeating CCGNN motifs stimulates recombination and transcription (Kirkpatrick *et al.*, 1999). However, there is no evidence that transcription factors bind to these tracts, which supports the idea that $\square$ -hotspots are controlled by an alternative mechanism to $\square$ -hotspots (Petes, 2001). A third category is the $\square$ -hotspots, which have been observed in regions with high GC content (Gerton *et al.*, 2000).

1.3.2 Maize Recombination Hotspots

In maize, there is a disproportionate frequency of crossing over in distal chromosomal regions (Dooner *et al.*, 1997). A sharper resolution of the variability of meiotic recombination in maize has been attained in studies of intragenic recombination at various loci. Dooner *et al.*, (1997) studied the *bronze* (Bz) gene locus as a recombinational hotspot in maize and meiotic recombination products between heteroallelic pairs of *bz* mutations with both the presence and absence of heterologies have been studied. These studies have revealed an extreme non-randomness in the distribution of recombination events, and although genes comprise a small fraction of the maize genome, they behave in general as recombination hotspots (Dooner, 1986).

1.3.3 Mouse Recombination Hotspots

The majority of hotspots characterised in the mouse have been in the major histocompatibility complex (MHC) region. Pedigree analysis in mice is more practical than parallel experiments in humans, as their breeding can be controlled and the number of offspring is greater than in humans.

The *Pmsb9* (*Lmp2*) hotspot was previously identified using pedigree analysis (Shiroishi *et al.*, 1995). This recombination hotspot is located close to the *Pmsb9* gene and has been demonstrated to be a site of recombination initiation (Baudat and de Massy, 2007). Baudat and de Massy, (2007) have analysed this hotspot in both male and female germlines and compared the level of recombination in different hybrid mice. *Trans*-acting elements were observed to increase the recombination activity at *Pmsb9* by 2,000-fold, while *cis*-acting elements were shown to repress the initiation of recombination. In addition, subtle variations in the frequency and distribution of recombination events were described between different strains and sexes. These findings suggest that most of the regulation observed acts at the level of initiation, and provide the first analysis of the control of the activity of a meiotic recombination hotspot in the mouse genome to reveal the interactions of elements located both in and outside the hotspot (Baudat and de Massy, 2007). A recombination hotspot has

also been characterised in detail at the E β gene in mice. It was initially analysed using inbred mouse pedigree methods, and subsequently by sperm typing (Yauk *et al.*, 2003). At least seven recombination hotspots are known to exist in the mouse MHC, however not all of these have been refined by sperm typing.

1.4 MEASURING RECOMBINATION RATES IN HUMANS

In yeast, recombination can be studied efficiently by analysis of the four spores (tetrad analysis) resulting from a single meiotic event. Based on the knowledge developed from lower eukaryotes, meiotic recombination studies in humans have been analysed using more indirect approaches. Ratios of genetic to physical distance predict recombination frequencies, and hotspot locations in the human genome can also be estimated by these methods.

1.4.1 Pedigree Analysis

Pedigree analysis has been efficiently used to study recombination hotspots, providing us with an approximate indication of where recombination hotspots may lie. It is difficult to obtain detailed analyses of recombination events in the human genome by traditional pedigree analysis because of the given low frequency of meiotic recombination events per unit physical distance (~ 1 cM/Mb) (Kong *et al.*, 2002). Polymorphic markers, for instance short tandem repeats in nuclear families with two to three generations, can be used for mapping (Kong *et al.*, 2002; Kong *et al.*, 2004). Recombination within the dystrophin gene has been shown to be approximately 4 times the expected value based on its length. Two hotspots have been identified from studies of minisatellite markers in CEPH families (Oudet *et al.*, 1992). Furthermore, pedigree studies have characterised hotspots in the MHC class II region: one in the TAP2 gene (Cullen *et al.*, 1995), one in the *DNA-RING3* region of the MHC, and one in the *DQB3-DQB1* region (Cullen *et al.*, 1997). Of the 30 recombinant sequences in the TAP2, *DNA-RING3* and *DQB3-DQB1* regions, 21 were maternally derived, indicating a higher rate of recombination in females than in males (Cullen *et al.*, 1997). One of the advantages of pedigree analysis is that both maternal and paternal meioses can be scored for crossovers.

Pedigree analysis of the phosphoglucosyltransferase 1 (*PGMT1*) gene, in Centre d'Etude du Polymorphisme Humain (CEPH) families have shown a region of increased recombination over a total of 58 kb, supported by additional linkage disequilibrium analysis which has marked the existence of two putative recombination hotspots in the region. Family data contributed to the discovery of two hotspots in the *PGMT1* gene region, by studying patterns of inheritance of markers in CEPH families (Yip *et al.*, 1999). A recent study of fine scale patterns of recombination with pedigree data used single nucleotide polymorphism data (SNP) in 725 Hutterites (364 male and 364 female gametes), whereas previous studies were done by microsatellite data, and so this was able to develop a higher resolution linkage map using a very small amount of offspring. Also, this study reveals that overall recombination hotspot usage is similar in males and females. Moreover, extensive and heritable variation among both males and females in the proportion of crossovers occurs in this population (Coop *et al.*, 2008).

1.4.2 Linkage Disequilibrium

Linkage disequilibrium (LD) is a term used for the non-random association of alleles at two or more loci. It describes a situation in which some combinations of alleles or genetic markers occur more or less frequently in a population than would be expected from a random formation of haplotypes from alleles based on their frequencies. LD can estimate the quantity and localisation of historical recombination in a region of interest.

LD estimations can help determine the location of recombination hotspots by estimating the association between alleles, for instance, if strong LD appears between alleles it can be inferred that little or no recombination has occurred historically between the markers. If weak LD appears between two markers, historical recombination can be inferred. LD can be used in association mapping by examining associations between an allele of interest and other alleles. There are many statistical measures of LD, with the most commonly used being D' (Lewontin, 1964).

D' values depend on the value of D . D can be calculated using the equation $D = x_{11} - p_1q_1$, where x_{11} is the observed frequency of haplotype AB, and p and q are the

expected frequency of alleles A and loci B. D is simple to calculate but its main disadvantage is its dependency on the frequency of the alleles inspected. There can be no D observed if any locus has an allele frequency 0 or 1, and it is maximal when frequencies are at 0.5. Lewontin (1964) suggested normalising D by dividing it with the theoretical maximum for the observed allele frequencies. Thus, $D' = D/D_{\max}$, with $D_{\max}$ being the maximum level of D possible given the observed haplotype frequencies. ($D_{\max} = \min [p_1 q_1, p_2 q_2]$ when $D < 0$, or, $D_{\max} = \min [p_1 q_2, p_2 q_1]$ when $D > 0$) (Lewontin, 1964). When $|D'|=1$, this means the markers are said to be in complete LD, and there is no evidence for historical recombination between the two markers. If $D'=0$, it suggests there is free association between the two markers and therefore it is likely that extensive historical recombination has occurred.

Measured LD values can be used to create an LD plot (Figure 1-5) for the target region. These LD plots can then be used to determine the location of putative recombination hotspots within a region of interest prior to high-resolution sperm typing.

Previous studies using LD analysis have led to the characterisation of a number of putative human meiotic recombination hotspots inferred from regions of local LD breakdown. This approach includes hotspots in the α -globin gene cluster (Chakravarti *et al.*, 1984), near the insulin gene (Chakravarti *et al.*, 1984) and at the *PGMI* gene (Yip *et al.*, 1999). Nevertheless, patterns of LD can be influenced not only by recombination rate but also by recurrent mutation (Jeffreys *et al.*, 2001), natural selection, genetic drift and admixture (Ardlie *et al.*, 2002).




Figure 1-5 Graphical representation of a hypothetical LD plot: Linkage disequilibrium (LD) in a hypothetical genomic region. LD is calculated for each pair of single nucleotide polymorphisms (SNPs) from a panel of genotyped individuals (shown as vertical bars on the axis of plot) and is plotted as a rectangle centred on each SNP. The statistical importance of these values is shown above the diagonal and $|D'|$ values are shown below the diagonal. They are represented by a colour code. A region of LD breakdown is apparent between markers 2 and 4 indicated by the arrow. However, the likelihood ratio (LR) shows that the odds of equilibrium are high and therefore does not statistically support the D' value. (Diagram taken from Kauppi *et al.*, (2004))

1.4.2.1 Linkage disequilibrium unit (LDU) maps

Allowing LD to be presented as a metric map called a Linkage Disequilibrium Unit (LDU) map is similar to a centimorgan map, but with additive distances. Describing the relationship between distance and LD (Collins and Morton, 1998) as in the Malecot model (Malecot, 1948) can be adapted to pairwise LD data. Time (in generations) and recombination frequency control the decay of LD.

In LDU maps, each marker is given a position on the resulting map. The most efficient metric is ρ (Morton *et al.*, 2001), which is equivalent to $\frac{D'}{D'_{\max}}$ (Collins and Morton, 1998). However, any pairwise metric can be used while constructing the LDU map. Showing large-scale correlation with pedigree-based linkage maps allows LDU maps to be used in increasing the resolution of pedigree maps (Zhang *et al.*, 2002; Tapper *et al.*, 2003). Comparing LDU maps with coalescent-based maps (described below) shows that they are different from each other. LDU maps reflect

the underlying LD structure, whereas coalescent maps reconstruct the underlying recombination rate with a particular demographic model.

In this thesis, LDU maps are used prevalently. In Chapter 4, these maps are used to confirm putative LD hotspots in a donor panel. Previously, 493,408 markers have been used to produce an LDU map of the genome (Tapper *et al.*, 2005). Recently, genomewide LD maps have been created using over 2 million SNPs and the LDMAP algorithm (<http://cedar.genetics.soton.ac.uk/pub/PROGRAMS/LDMAP>). These LD maps were used to determine LD hotspots which have been confirmed by high-resolution sperm crossover analysis (Webb *et al.*, 2008). In this thesis LD maps play a significant role for determining the putative hotspots.

1.4.3 Coalescent Analysis

Coalescent simulations are used to predict or infer historical recombination events from contemporary population genotype data, and for estimating recombination rates and locating hotspots (Fearnhead *et al.*, 2004). Thus, they differ from LD maps in that complete haplotypes are related to a single common haplotype under a coalescent model. When using this approach for estimating recombination rates and predicting the location of hotspots, results are generally confirmed by direct estimated sperm typing (Schneider *et al.*, 2002; McVean *et al.*, 2004) or population-based surveys (Smith *et al.*, 1998; Wall *et al.*, 2003).

$P = 4N_e r$ is the formula for calculation of the population scale recombination rate (P) using coalescent approaches. External estimates of the effective population size (N_e) can infer the per-generation recombination fraction (r).

However, using LD data, recombination hotspots in the NID/TM7HSF1 (206 kb) region on chromosome 1q42.3 were discovered by high-resolution sperm typing (Jeffreys *et al.*, 2005). Comparisons of coalescent analysis and sperm typing techniques in this region shows that there is a significant difference between sperm crossover frequencies and historical recombination rates. The reason could be that the hotspots may have evolved very recently.

1.5 MEASURING RECOMBINATION RATES IN HUMANS

Studying recombination in humans is more difficult than in lower eukaryotes. For example, the recombination rate in yeast is on average 1 cM per 3 kb (Petes, 2001), while the human sex-averaged rate is ~ 1.1 cM/Mb (Kong *et al.*, 2002).

The huge number of sperm available from males (typically 10^8 sperm per ejaculate) provides the possibility of high-resolution analysis and recombination studies from individual men (Li *et al.*, 1998). Sperm typing can be used instead of pedigree analysis to study recombination events in detail. There are two important methods of studying recombination in sperm DNA molecules. The first is to pick out and type individual sperm (Li *et al.*, 1988), and the second relies on the amplification of single recombinant molecules from pools or batches of sperm DNA of up to 50,000 molecules in size (Jeffreys *et al.*, 2000).

As with every method, sperm typing has drawbacks; firstly, sperm typing can only supply information on males and estimates of the male recombination frequency. Female recombination rates can only be estimated from family data, as obtaining eggs is far more difficult and would not provide the necessary number of gametes required for each study.

1.5.1 Single Sperm Typing Technique

Single sperm typing relies on the ability to isolate individual sperm. Each individual sperm can then be analysed by whole-genome amplification, followed by the polymerase chain reaction (PCR) to amplify markers of interest. Single sperm typing has led to the identification of putative recombination hotspots in a 208-kb-long DNA segment near the Huntington disease locus (Hubert *et al.*, 1994) and allowed recombination frequency analysis within the pseudoautosomal region PAR1 (Lien *et al.*, 2000). This technique is suitable for studying large genomic regions, however the resolution of single sperm typing studies has been restricted by low marker density and especially by the limited number of sperm that can be typed, typically in the region of a few hundred per study. Even the largest study to date, within the MHC, yielded only 325 recombinants from 20,031 sperm typed (Cullen *et al.*, 2002)

1.5.2 Recombination Detection Using High-Resolution Sperm Typing (Batch Sperm Typing)

An alternative method for the detection of recombination events in DNA molecules has been developed to allow batches of sperm DNA rather than single sperm to be used. This method is termed High Resolution Sperm Typing and is capable of producing a high resolution of analysis of sperm molecules (0.0001 cM or less). Linkage Disequilibrium (LD) patterns are analysed by comparing identified single nucleotide polymorphism (SNP) markers and a target region for the analysis can be established where a breakdown in LD occurs; this indicates historical recombination and the presence of a putative hotspot. Initially, a target region spanning the LD breakdown in suitable donors is selected and amplified in a round of allele-specific PCR directed to alleles in repulsion phase at the outermost SNP sites, followed by a second round of allele-specific PCR directed to sites internal to the primary PCR sites. If a crossover product can be picked up after secondary PCR, a tertiary PCR can be performed using internal universal primers and the PCR product dot blotted to type SNPs by Allele-Specific Oligos (ASOs). The point of exchange is then determined for each crossover (Figure 1-6).

Both these methods were first developed to search and characterise the relationship between meiotic crossover and tandem repeat DNA instability in the germline (Jeffreys *et al.*, 1998a). With the high-resolution sperm typing method not only can hotspots be determined, but gene conversions can also be obtained (Guillon and de Massy, 2002; Jeffreys and May, 2004). Indeed, the first human crossover hotspot (MS32) to be characterised at the molecular level was identified through the detection and analysis of crossovers at the MS32 minisatellite (Jeffreys *et al.*, 1998b) on chromosome 1. Approximately 40 allelic recombination hotspots have been identified in humans (Jeffreys *et al.*, 1998a; Jeffreys *et al.*, 2001; Jeffreys and Neumann, 2002; May *et al.*, 2002; Kauppi *et al.*, 2004; Jeffreys *et al.*, 2005; Holloway *et al.*, 2006; Webb *et al.*, 2008).




Figure 1-6 The high-resolution sperm typing approach for recovering crossover molecules directly from human sperm DNA. SNPs are identified in the chosen target region, followed by genotyping in a panel of semen donors. LD mapping allows the identification of LD blocks and can give clues about historical recombination events. Such regions of LD breakdown are putative recombination hotspots. The second stage starts with identifying a suitable semen donor. Two rounds of repulsion phase allele-specific PCR (allele-specific primers are shown by black arrowheads) and tertiary polymerase chain reaction (PCR) are used to selectively amplify recombinant molecules from sperm DNA; cross-over breakpoints are mapped by typing internal SNPs. Reciprocal crossovers (*red-blue, blue-red*) can be recovered separately using appropriate primer combinations.

1.6 HUMAN RECOMBINATION HOTSPOTS

Direct analysis of the fine-scale distribution of recombination events is not feasible using pedigree analysis but is possible using single molecule PCR methods to recover recombinant DNA molecules directly from sperm DNA (Jeffreys *et al.*, 2000; Jeffreys *et al.*, 2001).

The first human recombination hotspot associated with minisatellite MS32 on chromosome 1 was characterised using sperm typing and LD analysis (Jeffreys *et al.*, 1998b), and it was the discovery of this hotspot that provided the first clear indication that human meiotic crossovers generally concentrate into very narrow (1-2-kb) hotspots interspersed with recombinationally inert DNA (Jeffreys *et al.*, 2000). Other examples near minisatellite MS32 are the *NID1* recombination hotspot, which is located 58 kb upstream from minisatellite MS32. Several hotspots within the human major histocompatibility complex (MHC) class II region (Jeffreys *et al.*, 2001), and two loci within the *SHOX* gene in the Xp/Yp pseudoautosomal region of the short arms of the sex chromosomes have been characterised (May *et al.*, 2002). A near-continuous 103-kb region on chromosome 21 (Tiemann-Boege *et al.*, 2006), a recombination hotspot at β -globin (Holloway *et al.*, 2006), and 21 LD hotspots have been identified using sperm techniques (Webb *et al.*, 2008; Jeffreys and Neumann, 2009). Table 1-1 presents the hotspots in the MHC region, the MS32 region, *SHOX* and β -globin.

Region	Hotspot	Chr	95% width activity (kb)	Activity cM	Peak activity (cM/Mb)	Location	References
MHC	DPA1	6	1.7	0.028	27	intergenic	(Kauppi <i>et al.</i> , 2005)
	DNA1	6	1.9	0.0005	0.4	<i>HLA-DOA</i> promoter	(Jeffreys <i>et al.</i> , 2001)
	DNA2	6	1.3	0.0037	8	Intergenic, Alu	(Jeffreys <i>et al.</i> , 2001)
	DNA3	6	1.2	0.13	100	Intergenic, Alu	(Jeffreys <i>et al.</i> , 2001)
	DMB1	6	1.8	0.0027	5	exon/intron boundary	(Jeffreys <i>et al.</i> , 2001)
	DMB2	6	1.2	0.026	45	Intergenic	(Jeffreys <i>et al.</i> , 2001)
	TAP2	6	1	0.0058	8	<i>TAP2</i> intron	(Jeffreys <i>et al.</i> , 2000; Jeffreys <i>et al.</i> , 2001)
MS32	NID3	1	2	0.096	70	intergenic, Alu	(Jeffreys <i>et al.</i> , 2005)
	NID2a	1	1.4	0.0085	10	Intron	(Jeffreys <i>et al.</i> , 2005)
	NID2b	1	1.1	0.003	4	Intron	(Jeffreys <i>et al.</i> , 2005)
	NID1	1	1.5	0.05	70	Intron, Alu	(Jeffreys <i>et al.</i> , 2005)
	MS32	1	1.5	0.039	40	Intergenic, in RTLVLTR	(Jeffreys <i>et al.</i> 1998a; Jeffreys <i>et al.</i> , 2005)
	MSTM1a	1	1.6	0.001	9	Intergenic	(Jeffreys <i>et al.</i> , 2005; Neumann and Jeffreys, 2006)
	MSTM1b	1	2.1	0.009	16	Intergenic	(Jeffreys <i>et al.</i> , 2005; Neumann and Jeffreys, 2006)
	MSTM2	1	1.3	0.0007	0.9	Intergenic	(Jeffreys <i>et al.</i> , 2005)
PAR1	<i>SHOX</i>	X/Y	2	0.3	300	Exon	(May <i>et al.</i> , 2002)
β -globin	β -globin	11	1.2	0.15	200	Intergenic	(Holloway <i>et al.</i> , 2006)

Table 1-1 Human recombination hotspots analysed by high resolution sperm typing.

1.6.1 Hotspots Within The Major Histocompatibility Complex (MHC) Region

Seven hotspots called *DPA1*, *DNA1*, *DNA2*, *DNA3*, *DMB1*, *DMB2*, and *TAP2* were identified in the class II major histocompatibility complex (MHC) (Kauppi *et al.*, 2005; Jeffreys *et al.*, 2000; Jeffreys *et al.*, 2001). Family studies gave the first clue of a putative hotspot in the *TAP2* gene (Cullen *et al.*, 1995; Cullen *et al.*, 1997), using a sperm typing technique to identify the 1-kb hotspot (Jeffreys *et al.*, 2000). The activity of the crossover hotspot in female meiosis was shown by pedigree studies (Cullen *et al.*, 1995). There are two more regions of LD breakdown occurring near the *TAP2* gene: the *DNA* locus and the *DMB* gene. Five crossover hotspots, three at the *DNA* locus (*DNA1*, *DNA2*, *DNA3*) and two in the *DMB* locus (*DMB1*, *DMB2*) have been characterised using crossover assay analyses at the region of *DNA* and *DMB* LD breakdown, with all showing 1-2 kb width. Referring to the observations of the pattern of LD blocks and associated hotspots in the MHC region, the other haplotype patterns in the human genome are traced (Jeffreys *et al.*, 2001).

1.6.2 The MS32 Region

Sperm typing around the GC-rich minisatellite MS32 on chromosome 1q42.3 revealed the first human crossover hotspot to be defined at high resolution (Jeffreys *et al.*, 1998a). This hotspot is centred 200 bp upstream of the minisatellite, with a peak activity of 40 cM/Mb and a width of 1.5 kb within which 95% of the crossovers occur (Jeffreys *et al.*, 1998a). It appears that this hotspot is responsible for driving repeat instability at MS32 (Jeffreys *et al.*, 1998a). Surprisingly, SNP markers around this active hotspot are in strong LD. Analysis of 206 kb surrounding MS32 revealed a block-like pattern of LD, as seen in the MHC, with five intervals of LD breakdown near the *NID* gene and upstream of *TM7SF1*, that might signal the presence of crossover hotspots (Jeffreys *et al.*, 2005). Sperm typing showed that all were genuine hotspots of 1-2 kb width, though with activities that correlated poorly with historical activity as estimated by coalescent analysis. Two of these hotspots proved to be doublets, with each showing an additional hotspot in a region of intense LD. This indicates that regions of strong marker association are not necessarily recombinationally inactive and might point to these hotspots being too young to have

left a mark on haplotype diversity. Also, one of these hotspots displays an on/off polymorphism, with only some men showing hotspot activity (Neumann and Jeffreys 2006). Surprisingly, active and inactive men can share the same hotspot haplotypes, suggesting that distal or *trans*-acting factors are involved in regulating hotspot activity.

1.6.3 Recombination Hotspot in the β -globin Region

Pedigree studies (Smith *et al.*, 1998), LD analyses (Antonarakis *et al.*, 1982; Chakravarti *et al.*, 1984; Wall *et al.*, 2003), coalescent analyses (Wall *et al.*, 2003), single sperm typing analyses (Schneider *et al.*, 2002), and high resolution sperm typing analyses (Holloway *et al.*, 2006) are all techniques used with β -globin recombination hotspots.

1.6.4 *SHOX* Hotspot In The Xp/Yp Pseudoautosomal Region

It is known that the most of human Y chromosome does not undergo recombination. Male meiosis is restricted to the terminal pseudoautosomal regions PAR1 and PAR2. The first region, PAR1, spans 2.6 Mb of the Xp/Yp terminus (Brown, 1988; Petit *et al.*, 1988). An obligate recombination event occurs, creating a male-specific recombination hot domain with a recombination rate ~ 20 fold higher than the genome average (Lien *et al.*, 2000). The 320-kb PAR2 is located at the end of Xq/Yq; its overall recombination rate is lower than that PAR1, though still six-fold higher than the genome average (Freije *et al.*, 1992; Li and Hamer, 1995). In females, recombination can take place along the entire X chromosome, but the recombination rate is lower at a genome average 1.5 cM/Mb (Henke *et al.*, 1993). The *SHOX* gene, in the PAR1 region, is located ~ 500 kb from the Xp/Yp telomere (Rao *et al.*, 1997), showing high male recombination in LD patterns, which can be assayed by sperm typing studies. In the *SHOX* gene, as with the MHC region, crossovers were not randomly distributed but instead crossover assays within a 9.9-kb sub-region revealed a recombination hotspot with a peak activity between 190- 300 cM/MB in a 2-kb-wide hotspot (May *et al.*, 2002). Previous studies revealed that recombination in this

region is static, and recombination does not occur along the PAR1 (Baird *et al.*, 1995).

1.7 HOTSPOT EVOLUTION AND GENE CONVERSION IN HUMANS

Evolution of Hotspots

Comparisons of DNA diversity in humans and chimpanzees have revealed remarkably divergent LD landscapes at orthologous loci despite ~99% identity at the DNA sequence level (Wall *et al.*, 2003; Ptak *et al.*, 2005; Winckler *et al.*, 2005). This information suggests that the turnover of recombination hotspots occurred within the last six million years and to an extent disproportionate to that of sequence divergence. Rapid hotspot turnover also increases the possibility of hotspot polymorphism within human populations, increasing from newly evolved hotspots. Extreme examples show a region of LD breakdown that is in fact recombinationally inert in sperm (Kauppi *et al.*, 2005) and a recombination hotspot that is yet to have an impact on the LD landscape (Jeffreys *et al.*, 2005). There is also evidence of hotspots that do not result in a discernible breakdown of LD, yet appear to have recombination rates similar to those leaving a crisp breakdown in LD, which is not predicted by the coalescent model (Jeffreys *et al.*, 2005). These ‘invisible’ hotspots may be young hotspots that have not yet made an impression on LD patterns.

In contrast to most other hotspots, in the MS32, *DNA2* and *NIDI* hotspots both haplotypes show different exchange frequencies; asymmetric locations of exchange points were identified in the same men (Jeffreys *et al.*, 1998a; Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005). Crossover asymmetry is caused by a heterozygous SNP at the centre of the hotspot; with one allele initiating the crossover and promoting biased gene conversion with over transmission of the recombination allele. As estimated in the DSB repair model, recombinational meiotic drive of a suppressing allele can eradicate the hotspots, resulting in the “hotspot paradox”, as fortified by these findings (Boulton *et al.*, 1997; Pineda-Krch and Redfield, 2005).

Gene Conversion

As in yeast, gene conversion at human crossover hotspots has been observed (Jeffreys and May, 2004; Jeffreys and Neumann, 2005). Human gene conversions have been examined at the *DNA3*, *DMB2*, *SHOX*, *NID1*, *S1* and *S2* hotspots (Jeffreys *et al.*, 2001; May *et al.*, 2002; Jeffreys *et al.*, 2005; Jeffreys and Neumann 2009). These studies indicated that the same recombination can trigger both crossovers and gene conversions, although gene conversion events show more variation between hotspots compared to crossovers (Jeffreys and May, 2004; Holloway *et al.*, 2006). Moreover, according to the short tract of conversion events, difficulties in detecting them from LD data and the affects of a few SNPs is thus highly localised within recombination hotspots. A lack of gene conversions in LD regions may have serious consequences for association studies. Thus it is essential for LD to be characterised at a high resolution to identify these conversions. Crossover rate and marker density restrict the high-resolution comparisons of crossover and conversion at recombination hotspots. More research is essential in this area, because little is known about the distribution of conversion events.

1.8 THE HAPMAP PROJECT

In October 2002, the international HapMap project (a haplotype map of the human genome; www.hapmap.org) was established with the aim of producing a freely available single nucleotide polymorphism (SNP) haplotype map of the human genome to facilitate tagSNP selection. A tagSNP is a representative SNP in a region of the genome with high linkage disequilibrium. Such SNPs are useful in genome-wide association studies in which hundreds of thousands of SNPs across the entire genome are genotyped. For this reason, the International HapMap Project aimed to use tag SNPs to discover genes responsible for certain disorders. In identifying such SNPs, the project was successful in aiding researchers to identify genes that underlie the susceptibility of the carrier to common diseases. Initially, the project analysed DNA from 269 individuals from four populations, namely the Yoruba people of the Ibadan region in Nigeria (YRI), the Japanese of Tokyo (JPT), the Han Chinese of

Beijing (CHB), and the Centre d'Etude du Polymorphisme Humain in Utah (CEPH), USA. CEPH residents have ancestry from northern and western Europe (CEU).

October 2005 heralded the completion of the first phase of the project, yielding data on more than one million validated SNPs with an average density of 1 per 5 kb (The International HapMap Consortium, 2005). This was followed in July 2006 by HapMap with a further ~4.6 million SNPs showing a density of 1 per kb being released in phase II of the project data (International HapMap Consortium 2005). These markers provide the resources to produce a highly detailed LD map of the human genome. Recently, in HapMap Phase III, 7 more populations of African ancestry have been completed: in the south-western USA (ASW); Chinese in metropolitan Denver, Colorado, USA (CHD); Gujarati Indians in Houston, Texas, USA (GIH); Luhya in Webuye, Kenya (LWK); Maasai in Kinyawa, Kenya (MKK); Mexican ancestry in Los Angeles, California, USA (MXL); and Tuscans in Italy (Toscani in Italia, TSI) are included (International HapMap 3 Consortium, 2010). As a result, 1.6 million common SNPs in 1,184 reference individuals from 11 global populations have been genotyped.

Furthermore, 10 million common DNA variants have been identified by The Human Genome Project (International Human Genome Sequencing Consortium, 2001) the SNP Consortium (The International SNP Map Working Group, 2001) and the International HapMap Project (The International HapMap Consortium, 2007). This information along with linkage disequilibrium patterns allows an understanding of genome-wide association studies. In this thesis, the international HapMap Phase II data is used for identifying the SNPs for regions of interest.

1.8.1 Confirming Human Hotspots from LD Data by High-Resolution Sperm Crossover Analysis

Using coalescent analyses genomewide LD landscapes were determined by the International HapMap Project (The International HapMap Consortium, 2005, The International HapMap Consortium, 2007), revealing kilobase level resolution of hotspots. Additionally, fewer than 20 human meiotic hotspots were identified in sperm surveys that equal 0.6 Mb of human DNA to date, and they have shown good harmony between the location of LD hotspots and sperm hotspots (Webb *et al.*, 2008). According to previous studies, and to clarify whether LD landscape can accurately predict and locate hotspots or correctly estimate their historical activity, hotspots which show the most extreme LD breakdown in HapMap genotypes have been analysed by sperm crossover assays, and the repertoire of human crossover hotspots has been doubled with hotspots A, B, C1, C2, D, E, F, G1, G2, H, J1, J2, K, L, M, N, P, Q, R, S1, S2 (Webb *et al.*, 2008, Jeffreys and Neumann 2009). These studies revealed that comparisons of LD patterns with crossover profiles show that population diversity data are excellent predictors of hotspots and can generally locate them with accuracy but are poor at predicting hotspot intensity (Webb *et al.*, 2008).

1.9 DNA SEQUENCE MOTIFS ASSOCIATED WITH RECOMBINATION HOTSPOTS

Previous studies have shown that many sequences in the human genome are associated with enhanced recombination through their close proximity to recombination hotspots. Only two factors stand out as being strong and consistent correlators of recombination rate: GC content and the location of the motif most strongly associated with hotspots (Myers *et al.* 2006). Sequence motifs promoting crossover activity have been previously found in several organisms, for example a single eukaryotic hotspot, M26 in *S.pombe* (Fox *et al.*, 2000). Studies in *S.cerevisiae*, have also shown that there is a strong association between recombination rate and sequence motifs (Myers *et al.*, 2006).

Recent studies have shown that fine-scale coalescent analysis show peaks that are highly related in rate, most likely due to recombination hotspots, with about 80% of

all recombination events occurring within one-fifth of the genome sequence (Myers *et al.*, 2005). HapMap Phase II data (22,699 autosomal and 608 chromosome X hotspots mapped to within 5 kb) revealed in excess of 30,000 hotspots in the human genome with an average density of around 1 per 50-100 kb (Myers *et al.*, 2005; Myers *et al.*, 2008). To investigate particular repeat sequences and simple sequence motifs associated with hotspots, Myers *et al.*, (2005) compared hotspot regions with regions of the same size and SNP density which showed no evidence of recombination activity; they named these matched regions “coldspots”. Hotspots and coldspots show different frequencies of particular sequences (Myers *et al.*, 2005). DNA sequences which can move around to different positions within the genome of a single cell, the long terminal repeats of the THE1A and THE1B retrovirus-like transposons, along with CT-rich and GA-rich repeats were over-represented in hotspots. GC-rich repeats, certain L1 elements and (TA)_n repeats, were significantly under-represented (Myers *et al.*, 2005).

The strongest correlation of all was seen with a seven-nucleotide oligomer CCTCCCT that aligns to the positions of 261 to 267 in the THE1B consensus (Myers *et al.*, 2005). THE1B in hotspots occurs more frequently in hotspots when compared to coldspots. Chromosomes active at the hotspot contain the motif CCTCCCT, with the “suppressor” mutation being a change from T to C in its third position. Suppressor alleles disrupt the hotspot activity of motifs. At most, this motif accounts for 11% of the 25,000 hotspots examined (Myers *et al.*, 2005). The latest studies show a 13bp hotspot motif CCNCCNTNNCCNC, a 6 bp extension of CCTCCCT motifs that determines the location of at least 40% of ~30,000 human crossover hotspots (Myers *et al.*, 2008). These motifs are found in hypervariable minisatellites, clusters in the breakpoint regions of disease-causing non allelic homologous recombination hotspots, common mitochondrial deletion hotspots, and it is assumed that it drives genome instability. In addition, a nine nucleotide long motif CCCCACCCC is enriched amongst HapMap hotspots. The hotspots *DNA2* and *NIDI* (Jeffreys *et al.*, 2002, Jeffreys *et al.*, 2005), characterised by sperm typing and crossover rate polymorphism data contain the motifs CCTCCCT and CCCCACCCC at their centre. These polymorphisms may be determined by recombination frequency (RF) measurements in sperm by analysis of differences in crossover distributions in the reciprocal products of crossing-over (Jeffreys *et al.*, 2002). SNPs are located in one of the

hotspot motifs, with the lower activity allele being the derived state and disrupting the motif (Myers *et al.*, 2005). Consequently, hotspot activity can be influenced by local sequence determinants. Jeffreys *et al.*, (2002) have shown that the recombination-suppressing allele is over-transmitted to recombinant progeny due to biased repair processes operating during recombination. A recent study found DNA sequence motifs associated with recombination in G-quadruplex DNA, and the co-occurrence of potential G4 DNA within 7 short sequence elements (SES) that are associated with recombinogenic regions (Mani *et al.*, 2009). This finding is interesting because most organisms' DNA is in the double stranded formation (B-DNA) (Mani *et al.*, 2009). In this thesis the argument for association of a 13-bp DNA sequence motif with recombination hotspots will be discussed.

1.10 TRANS-REGULATOR EFFECTS ON RECOMBINATION HOTSPOTS

Little is known about the location of the elements associated with hotspot activity, despite the determination of the recombination landscape. The direct molecular detection of DSBs allows mapping of initiation sites in *S. cerevisiae* and *S. pombe* (Kon *et al.*, 1997; Keeney, 2008). Previous studies in yeast and mammals show that some DNA sequences determine the location of hotspots (Kon *et al.*, 1997; Shiroishi *et al.*, 1991; Neumann and Jeffreys, 2006). For instance, the loci *Dsbc1* and *Rcr1* are *trans*-acting loci that control the activation of specific hotspots. These loci are located in overlapping 5.4 Mb and 6.3 Mb regions on mouse chromosome 17 (Parvanov *et al.*, 2009; Grey *et al.*, 2009). Additionally, the trimethylation of lysine 4 of histone H3 (H3K4me3) is known as a common chromatin feature that also defines yeast and mouse initiation sites (Borde *et al.*, 2009; Buard *et al.*, 2009). Moreover, *in silico* studies show that LD-based hotspots were found highly associated with a 13-bp motif (Myers *et al.*, 2008), and sperm-typing analysis illustrates associations with variation of hotspot activity in *cis* (Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005).

PRDM9, PR domain-containing 9, is a meiosis-specific histone H3 methyltransferase with a C-terminal tandem-repeat C2H2 zinc finger (ZnF) domain encoded by a minisatellite (Hayashi *et al.*, 2005). It is uniquely expressed during early meiosis in both males and females (Parvanov *et al.*, 2010). Recent studies revealed that, depending on the carried *PRDM9* alleles, the recombination profiles and crossover

hotspot activity showed variation in mouse subspecies hybrids (Parvanov *et al.*, 2010). In humans, according to computational analyses (Myers *et al.*, 2010), PRDM9 has been identified as a human ZnF protein that recognizes the 13-bp CCNCCNTNNCCNC motif. This motif might also serve as a binding site for the ZnF protein (Myers *et al.*, 2010; Myers *et al.*, 2008). Nevertheless, an allele of *PRDM9* is the most common allele that binds *in vitro* (Baudat *et al.*, 2010), but the *PRDM9* allele 'I' cannot bind to this motif (Baudat *et al.*, 2010).

Previous studies in the Jeffreys laboratory have investigated the influence of variation in the PRDM9 ZnF array (Berg *et al.*, 2010). The results demonstrate that crossover activity at individual human recombination hotspots and genome instability both at minisatellites and at pathological non-allelic homologous recombination (NAHR) rearrangements, are all influenced by PRDM9 variation. Sixteen different forms of PRDM9 containing between 8 and 18 zinc fingers have been found in 74 African and 156 European semen donors (Berg *et al.*, 2010) (Table 1.2). Ten active hotspots (including 5 hotspots with the sequence motif) were examined, and the results showed that all 10 hotspots showed activity dependent on PRDM9, and were generally activated by the common allele 'A'. This study implies that PRDM9 operates across a much longer track than the 13-bp sequence motif (Berg *et al.*, 2010). The most recent study shows that the activation of PRDM9 variants that are common in Africans but rare in Europeans reveals second-class hotspots, and these hotspots act differently even in the same populations (Berg *et al.*, 2011).

active		motif match
A		8
B		8
suppressed		
L13		8
L20		7
L7		7
L22		6
C		5
L4		5
L6		5
L14		5
L16		5
L17		5
L18		5
L19		5
E		4



Table 1.2 Activating and non-activating *PRDM9* alleles. Allele structures are coded as in Berg *et al.*, 2010, with predicted DNA binding sequences and best motif matches shown. (This figure is adapted from Berg *et al.*, 2010)

Transgenic mouse studies showed that the hotspot activity (as inferred by histone H3 lysine 4 trimethylation (H3K4me3) levels, and chromosome-wide distribution of crossovers) is changed by a sole modification of *PRDM9* zinc fingers (Grey *et al.*, 2011). Also, this study demonstrated with an *in vitro* assay that the three tested hotspots are activated when a *PRDM9* variant binds specifically to DNA sequences located at the hotspot centre (Grey *et al.*, 2011). Thus, mutations in *cis* located at the hotspot centre and associated with a decrease of hotspot activity can affect *PRDM9* binding. In this study, *PRDM9* is presented as a master regulator of hotspot localisation through the DNA binding specificity of its zinc finger array, and that binding of *PRDM9* at hotspots promotes local H3K4me3 enrichment (Grey *et al.*, 2011) (Figure 1.7).




Figure 1.7 Model for hotspot specification by PRDM9. a) The DNA and several nucleosomes are shown. A DNA sequence motif recognised by PRDM9 is represented in light green. b) PRDM9 binds to its target DNA motif through the zinc finger array and catalyses H3K4me3 (orange). c) A protein partner of PRDM9 may catalyse another post-translational histone modification (grey), allowing for the formation of a hotspot-specific signature. d) PRDM9, a partner, or other component of the chromatin may recruit the recombination initiation complex containing SPO11 or may create a favorable chromatin environment allowing access of SPO11 to the DNA. e) A DSB is formed by SPO11 and triggers the phosphorylation of histone H2Ax (yellow) in the surrounding nucleosomes. Then, homologous recombination is repaired by the DSB and gives a crossover or non-crossover. (This figure is adapted from Grey *et al.*, 2011).

Single nucleotide polymorphisms (SNPs) from whole-genome resequencing and genotyping studies have been used to estimate recombination rates across the mouse genome (Brunschwig *et al.*, 2012). This analysis identified 47,068 historical hotspots - an average of over 2477 per chromosome. The positions of historical hotspots were identified by simulation in inbred mouse strains (Brunschwig *et al.*, 2012), and considering the predicted binding sequences for different alleles of the PRDM9 protein enriched the location of recombination hotspots. Recombination rates were on average lower near transcription start sites. This study suggests that characterising and studying the dynamics of historical hotspots can be done in inbred strains, and also strengthens previous findings on mouse recombination hotspots, and specifically the impact of sequence variants in *Prdm9* (Brunschwig *et al.*, 2012).

Finally, the *SPRY3* hotspot in the PAR2 region was studied by Sarbajna *et al.*, (2012), and this revealed that PRDM9 strongly modulates both crossovers (COs) and non-exchange gene conversions (non-crossovers, NOs) in *trans*. Additionally, a SNP located at the hotspot centre that appears to influence recombination initiation, causes biased gene conversion in *cis*. This study showed that recombination initiation frequencies vary between haplotypes but are not mediated by a *cis*-effect. Also, through subsequent processing, they have the potential to significantly intensify the meiotic drive of hotspot-suppressing alleles (Sarbajna *et al.*, 2012).

1.11 WORK IN THIS THESIS

Recombination is an important evolutionary force in shaping the human genome and creating human diversity. In humans, at least one recombination event per chromosome is required for proper segregation of chromosomes, and in cases of non-disjunction (when chromosomes fail to separate normally into the daughter cells), genetic disorders such as Down's syndrome (three copies of chromosome 21) may result. The recombination event may be resolved as a crossover, where information is reciprocally exchanged between chromosomes, or a non-exchange gene conversion event. Recombination events have mostly been studied in yeast and mice. The reciprocal exchange that takes place during meiotic division can occur nearly anywhere along a chromosome. However, meiotic recombination occurs more

frequently in some regions of the genome called hotspots, which arise in 1-2 kb intervals across the human genome (Jeffreys *et al.*, 2000). Hotspot analysis has focussed on the description of crossover profiles, but at the beginning of this work little was known about the factors that influence the localisation and frequency of human crossover hotspots.

Furthermore, our knowledge about regulating factors of the human recombination machinery is very limited. Recombination hotspots could be influenced by single base changes known as single nucleotide polymorphisms (SNPs). The International HapMap Project, established in 2002, (www.hapmap.org) is a multinational effort to identify and catalogue genetic similarities and differences in human beings. This project has helped and will continue to help the discovery of uncharacterised inherited genetic variation in human disease by establishing a SNP map of the human genome. Approximately 4.6 million SNPs have been characterised in four different populations in this project so far. This data can also help us to identify putative localised crossover hotspots. Sperm typing has been used most successfully to identify hotspots in humans. The first characterised hotspot using sperm typing was the MS32 hotspot on chromosome 1 (Jeffreys *et al.*, 2000). Biased gene conversion had been found responsible for over-transmitting alleles, and therefore implicated in hotspot silencing. Could hotspots be affected by a DNA sequence motif? DNA sequence motif composition is thought to play an important role in recombination, and many sequence components have an effect on recombination rates. The aim of this thesis is to identify hotspots with the DNA sequence motif and which include a motif-disrupting SNP to test whether the disrupting allele influences the crossover frequency and distribution. Or are there any other regulatory factors (*cis*- or *trans*-) that influence hotspot activity? This work aims to gain insights into these interesting questions.

Chapter 3 investigates four previously identified LD hotspots by Donnelly and his colleagues from low-resolution HapMap Phase II data. These LD hotspots based on having a 13-bp CCNCCNTNNCCNC motif with a disrupting SNP and a good historical activity. To confirm the presence of these LD hotspots and whether the disrupting SNP within the motif located at the centre of the hotspots, high-resolution genotyping techniques used for genotype out European semen donor panel. This

chapter shows and prove by LDU mapping that the motif disrupting SNP within the 13-bp motif is located at the centre of only one LD hotspot.

Chapter 4 includes the recovery of recombinant DNA molecules, the analysis of recombination rate and distribution, and determination of the hotspot centre of Hotspot DA. Crossover frequencies and distributions were compared with previously established parameters. Also, this chapter characterises biased gene conversion by comparing recombination frequencies and distributions in both reciprocal orientations. Interestingly, the results show the highest observed transmission distortion ratio. Furthermore, it was tested whether crossovers and non-crossovers are influenced by the same biases. For better understanding of the effect of *cis*-regulation on the studied hotspot, the analysis was expanded to more men to allow the identification of DNA sequence motifs that carry the disrupting SNP to control hotspot activation. This chapter shows for the first time an example of strong *cis*-regulatory control on a human crossover hotspot.

Chapter 5 investigates the important question remaining, as to the effect of the *trans*-regulator factor PRDM9 on the activity of Hotspot DA. Therefore, in this chapter, more men with variant PRDM9 genotypes were analysed to explore possible influences of PRDM9 status on crossover frequencies. This chapter shows for the first time whether *cis*-regulation is more effective than the *trans*-regulator factor PRDM9.

CHAPTER 2: MATERIAL AND METHODS

2.1 MATERIALS

2.1.1 Suppliers

ABgene (Epsom, UK), Applied Biosystems (Warrington, UK), Bio-Rad (Hemel Hempstead, UK), Cecil Instruments (Cambridge, UK), Clare Chemical Research (Delores, USA), Eppendorf Scientific (Hamburg, Germany), Fisher Scientific (Loughborough, UK), Fisons (Beverley, USA), Flowgen (Ashby-de-la-Zouch, UK), FMC Bioproducts (Rockland, USA), GE Healthcare (Little Chalfont, UK), Hybaid (Teddington, UK), Invitrogen (Paisley, UK), MJ Research (Waltham, USA), New Brunswick Scientific Co. (New Jersey, USA), PerkinElmer (Cambridge, UK), Qiagen Ltd. (Crawley, UK), Serva (Heilderberg, Germany), Sigma-Aldrich (Poole, UK), Sysngene (Cambridge, UK), Thermo Scientific (Pittsburg, USA), USB Corporation (Cleveland, USA), UVP Life Sciences (Cambridge, UK).

2.1.2 Chemical Reagents

2.1.2.1 Enzymes

T4 polynucleotide kinase and Exonuclease I was supplied by New England Biolabs and Fermentas. *Pfu* polymerase was obtained from Gibco-BRL and *Taq* polymerase was obtained from Abgene and Kapa *Taq* from Kapa biosystems. Shrimp Alkaline Phosphatase (SAP) was obtained from Roche.

2.1.2.2 Molecular Weight Markers

λ DNA digested with *Hind*III and ϕ X174 RF digested with *Hae*III was supplied by ABgene.

2.1.2.3 Oligonucleotides

Three suppliers have been used for synthesising oligonucleotides; The Protein and Nucleic Acid Chemistry Laboratory (PNACL), University of Leicester, UK; Invitrogen (Paisley, UK); Sigma-Genosys (Haverhill, UK).

2.1.2.4 Human DNA

Semen, and in some cases blood were collected from 200 men of North European decent with approval from the Leicestershire Health Authority Research Ethics Committee, and with informed consent. Most of the semen samples were from anonymous donors attending fertility clinics, which were provided by J. Blower (Leicester Royal Infirmary, Leicester, UK). Additional blood and semen samples, donated by volunteers from the Department of Genetics, University of Leicester, UK, were anonymised before use. Blood and sperm DNA samples were prepared under high containment to minimize the risk of contamination; in a class II laminar flow hood using designated pipettes. All solutions used for DNA preparation were UV treated to disable the amplifiability of any potential contaminating DNA.

A.J. Jeffreys (Department of Genetics, University of Leicester, UK) extracted sperm and blood DNA as described in Kauppi *et al.*, 2009. The North-European donor panel was built from those men showing highest sperm DNA yield. As positive controls and referencing samples, four donors were included twice, thus generating 100 samples from 96 North-European men. Additional sperm DNA from 174 Afro-Caribbean and Zimbabwean (donated by A.D Nakomo and S.B. Kanoyangwa, Forensic Science Laboratory, Causeway, Zimbabwe) men were prepared, giving in total genomic sperm DNA from 270 donors available for analysis. Donor-panel master-plates containing whole-genome multiple displacement amplified (MDA) DNA were generated by R. Neumann (Department of Genetics, University of Leicester, UK) using the GenomiPhi Amplification kit (GE Healthcare). All studies were granted Local Ethical Committee approval.

2.1.2.5 Standard solutions

20x sodium chloride-sodium citrate (SSC) buffer and 10x Tris-borate/EDTA (TBE) electrophoresis buffer, were as described by Sambrook *et al.*, (1989), and were supplied by the kitchen, Department of Genetics, University of Leicester, UK.

2.1.2.6 Preparing 11.1 X PCR buffer

Typically 10 ng of DNA was amplified using an MJ tetrad PCR machine PTC 250 (supplied by GRI, Braintree, Essex, UK) and unless otherwise stated, was in a 10 μ l total reaction volume. All reagents and plasticware were PCR clean, all pipettes dedicated to PCR only and all reactions were carried out in a category II laminar flow hood to limit contamination.

11.1 x PCR buffer (Jeffreys *et al.*, 1990) was prepared by Rita Neumann (Department of Genetics, University of Leicester, UK) as indicated below. dNTPs and BSA were supplied by GE Healthcare.

Component	Concentration of Stock Solution	Volume (arbitrary units)	Final Concentration (in PCR)
Tris/HCl pH 8.8	2M	167	45 mM
Ammonium Sulphate	1M	83	11 mM
MgCl ₂	1M	33.5	4.5 mM
2-mercaptethanol	100%	3.6	6.7 mM
EDTA pH 8.0	10mM	3.4	4.4 μ M
dATP	100mM	75	1 mM
dCTP	100mM	75	1 mM
dGTP	100mM	75	1 mM
dTTP	100mM	75	1 mM
BSA	10mg/ml	85	113 μ g/ml
Total Volume		676	

For amplicon sizes of less than 2 kb, no Tris base or *Pfu* were added. For long-PCR these reagents help amplification. *Pfu* is a proofreading 3' to 5' polymerase, which removes base mismatches that can cause *Taq* polymerase to stall during amplification, resulting in shorter products or PCR jumping. Tris base was added to raise the pH of the reaction, thus reducing the risk of template depurination at high temperatures and allowing denaturation at lower temperatures.

In reactions where the input of template DNA was below 5 ng carrier herring sperm DNA was added to the PCR reaction at 1µg/ml to coat the inside of the PCR tubes and prevent the target DNA being sequestered as DNA binds to certain types of plasticware.

Cycling conditions for PCR varied according to amplicon length. Typically the reaction conditions were as follows: denaturing for 2 min at 94°C, followed by 25-32 cycles of 94°C for 20 sec, 54-66 °C for 30 sec, and 66°C for 4-15 min and finally a soak at 15°C. Small numbers of PCRs, typically less than 50, were carried out in 200 µl PCR tubes, with larger numbers of PCRs carried out in PCR plates and sealed with self-adhesive PCR film (ABgene).

2.1.2.7 Whole Genome Amplification by Multiple Displacement Amplification (MDA)

Whole genome amplification was carried out as described by Dean *et al.*, 2002. Reagents for a 50 µl reaction were as follows Table 2-1:

Reagent	Stock concentration	Final concentration	Volume (μl)	Added
Tris-HCl pH 7.5	2 M	37 mM	0.925	
Potassium chloride	2 M	50 mM	1.25	
Magnesium chloride	1 M	10 mM	0.5	
Ammonium sulphate	1 M	5 mM	0.25	
dATP	100 mM	1 mM	0.5	
dCTP	100 mM	1 mM	0.5	
dGTP	100 mM	1 mM	0.5	
dTTP	100 mM	1 mM	0.5	
Thiophosphate modified random hexamer primer	1m M	50 μ M	2.5	
Yeast pyrophosphatase	200 u/ml	1 u/ml	0.25	
ϕ 29DNA polymerase	unknown	800 u/ml	0.5	

Table 2-1 Reagents used in whole genome amplification reaction.

The reagents were added to 40 ng of good quality PCR clean DNA and the reaction volume made up to 50 μ l with PCR clean water. After 30°C for 18 hours incubations and then 65°C 3 minutes to stop the reaction, samples are ready to use. MDA DNAs were prepared by A.J. Jeffreys (Department of Genetics, University of Leicester, UK).

2.1.3 Computers

Data and images were stored and processed using the software packages AutoAssembler, Papers for Mac, Factura, Chroma, Microsoft Office and Cricket

Graph. Images either tranfered to .jpg via Mac Preview or using the Epson Perfection 1250 Photosmart scanner.

LDU plots were generated from un-phased diploid genotyping data using LD mapping software modified by Adam J. Webb (University of Leicester, UK) from version 1.5 of LDMAP (Maniatis *et al.*, 2002). Historical recombination rates (coalescent analysis) were estimated using data with the LDhat program version 2.0, available from www.stats.ox.ac.uk/~mcvean/LDhat/ (McVean *et al.*, 2004).

Maximum-likelihood Poisson-approximation, two-sample confidence-interval simulation, and least squares best-fit normal distribution analysis were each determined using bespoke simulation programs written by A.J Jeffreys (Department of Genetics, University of Leicester, UK) in True Basic 4.1 in the Classic set-up of Mac OS9 (all are available from A.J. Jeffreys upon request). Basic statistics were calculated using software available at <http://faculty.vassar.edu/lowry/VassarStats.html> T-test performed on Poisson means were calculated using available at <http://www.quantitativeskills.com/sisa/statistics/t-test.htm>. Again, Mann Whitney U test performed on Poisson means were calculated using available at <http://vassarstats.net/utest.html>

Plotting and this thesis was produced on a MacBook Pro and PC running Microsoft Windows XP. Word processor used was Microsoft Word (2007) and 2008 (Mac). Citation manager was Paper2 (Mac). Graphs were produced in Microsoft Excel 2007 (PC), Microsoft Power Point 2008 (Mac), Cricket (Mac). Internet searches were performed using Safari. DNA sequences were analysed on Autoassembler and Factura (Mac) and Chrome (PC).

2.2 METHODS

2.2.1 DNA Extraction from Semen

DNA extraction was carried out in a category II laminar flow hood. Frozen semen samples were slow thawed on ice for 1 hour and an aliquot of 200 µl removed and transferred to a screw-top Eppendorf tube. 1 ml of 1 x SSC was added to the tube, the

contents mixed and then centrifuged at 13,000 rpm for 2 min. The pellet was resuspended in 1ml of 1 x SSC and SDS added to 0.2% (w/v) to lyse non-sperm cells. The contents was mixed gently by flicking and centrifuged at 13,000rpm for 2 min. The supernatant was removed, the pellet re-suspended in 1ml of 1 x SSC and SDS added to 0.2% (w/v). The contents were centrifuged for 2 min, the supernatant removed and the pellet re-suspended in 800 µl of 1 x SSC. The transparent pellet was resuspended in 450 µl 0.2 x SSC. Sperm heads were lysed by the addition of SDS to a final concentration of 1% and 2-mercaptoethanol to a final concentration of 1M and the sample incubated at room temperature for 5 min. Proteinase K was added to a concentration of 200 µg/ml and this was incubated for 45 mins-1 hour at 37°C, mixing occasionally. Proteins were removed by addition of 300 µl phenol/chloroform (with gentle mixing for 5-10 min to allow emulsification, and then centrifuged for 2 min at 13,000 rpm. The organic layer was re-extracted with 1 x SSC and 1% (w/v) SDS. DNA was ethanol precipitated with 2 volumes of 100% (v/v) ethanol and gentle swirling. After centrifuging, the supernatant was removed and the pellet washed with 1ml of 80% (v/v) ethanol, and dried. The pellet was dissolved in distilled water and 0.1 volumes of sodium acetate (pH7.0) were added, followed by 2 volumes of 100% (v/v) ethanol and centrifuged for 1 minute. The supernatant was removed and the pellet air-dried and dissolved in 5mM Tris-HCl pH 7.5.

2.2.2 DNA Extraction from Blood

Venous blood samples (delivered into equal volumes of 1x SSC and stored at -80°C) were thawed at 37°C and 500 µl was transferred to a 1.5 ml screw-topped eppendorf tube. 800 µl of 1x SSC was added gently mixed and then centrifuged for 2 min. The supernatant was removed and the cell pellet washed twice with 1x SSC and centrifuging. The pellet was resuspended in 300 µl 0.2x SSC and cells were lysed by adding 30 µl 10% (w/v) SDS and incubated at room temperature for 5 min. Proteinase K was added to a final concentration of 200 µg/ml and was incubated at 37°C for 1 hour, with occasional mixing. Trace proteins were removed by addition of phenol/chloroform, with gentle mixing to allow emulsification and then centrifuged for 3 min. The organic layer was re-extracted twice with 1x SSC and 0.2% (w/v) SDS. The DNA was ethanol precipitated, dried and diluted as for the sperm DNA.

2.2.3 Measuring DNA Concentration

DNA concentrations were estimated by visual comparisons of signal intensity against DNA of known concentration following agarose gel electrophoresis in the presence of ethidium bromide. The DNA concentration was then estimated by measuring optical density at a wavelength of 260nm (OD_{260}) at a dilution of 1 in 200, or if very concentrated 1 in 1000, using a Cecil Instruments CE 202 Ultraviolet Spectrophotometer at wavelength. Two aliquots of each sample were measured and the average taken. This was then used to calculate the concentration of DNA by using the equation $(\text{dilution factor} \times OD_{260}) / 0.02$ with 0.02 being the weight given to double-stranded DNA measured at 260nm. Oligonucleotide concentrations were also estimated in this way, however 0.024 was substituted for 0.02.

2.2.4 Gel Electrophoresis

SeaKem LE agarose (Cambrex) was used to make gels at a concentration of 0.8-1.2% (w/v) and sizes 20 cm x 20 cm. PCR products were run using a horizontal submarine format with 0.5xTBE (44.5 mM Tris-borate (pH 8.3), 1 mM EDTA) buffer containing 0.5 $\mu\text{g/ml}$ ethidium bromide. $\frac{1}{4}$ volume of loading dye (30% glycerol, 0.5 x TBE, bromophenol blue to colour) was added to each sample prior to loading between 1-5 μl into the well. The samples were electrophoresed along side markers of known size. DNA bands was visualised using a GeneGenius system (Syngene). Photographic records were acquired using the GeneGenius (Syngene) and printed using a Sony digital graphics printer UP-D895 (Syngene). Electrophoresis tanks were manufactured in-house, and power supplies were provided by Bio-Rad.

2.2.5 PCR Amplification

Generally, polymerase chain reaction (PCR) DNA amplification was carried in 10 μl total reaction volumes in 200 μl tubes or 96-well plates sealed with self-adhesive film on an a MJ Tetrad PCR machine PTC 250 (supplied by GRI, Braintree, Essex, UK) and Veriti Thermal Cycler (Applied Biosystems, Warrington, UK). All PCR reactions were carried out in a category II laminar flow hood to limit contamination;

moreover all reagents and plastic ware were PCR clean and all pipettes dedicated to PCR clean. To amplify 5-10 ng DNA template, 0.9 µl of 11.1 x PCR buffer (described above), 12.5 mM Tris base, 0.2 µM of each primer, 0.05 U/µl *Taq* polymerase, 0.005 U/µl *Pfu* polymerase were mixed for per reaction. For accurate *Pfu* activity, which is a 3' to 5' proofreading exonuclease that removes mismatches, is helped by Tris base that raises the pH. These possible mismatches may cause *Taq* to stall during primer extension.

2.2.6 PCR Cleanup by Exonuclease I and Shrimp Alkaline Phosphatase (SAP) Purification

Amplified DNA (PCRs) that produces a single clean PCR product can be treated with Exonuclease 1 (20U/µl) and SAP (1 U/µL) before resequencing or reamplification. Excess primers and single-stranded DNA can be digested by Exonuclease 1 while excess dNTPs are removed by SAP. 1 µl of 20U/µl Exonuclease 1 and 3 µl of 1 U/µl SAP were added into 10µl PCR product. An MJ Tetrad PCR machine was used to hold tubes with the following conditions: 37°C 1 hour; 80°C 15 minutes to inactivate enzymes.

2.2.7 Automated DNA Sequencing

ABI PRISM BigDye™ Terminator Cycle sequencing reaction Kit, version 3.1 was used for an automatic sequencing. 20-30 ng per kilobase of template DNA, 4 µl Big Dye mix and 3.2 pmol of sequencing primer were prepared in 10 µl reaction. An MJ Tetrad PCR machine was used to cycle tubes 25 times with the following conditions: 96°C 10 sec, 50°C 5 sec, 60°C 4 min. The second step is adding 10 µl H₂O and 2 µl Sodium Dodecyl Sulphate (SDS) (10% w/v). After that tubes were held at 98°C for 5 minutes followed by 25°C for 10 minutes. The Qiagen DyeEx 2 sequencing cleanup kit (Qiagen) was used to clean up the sequencing following the manufacturer's protocol. Sequencing was carried out on an Applied Biosystems 3730 sequencer at the Protein and Nucleic Acid Chemistry Laboratory, University of Leicester. Sequences were analysed by eye using Factura (Mac) and assembled using AutoAssembler (Mac) and Chroma (PC).

2.2.8 Dot Blots

3-100 ng per kilobase DNA was available per reaction after PCR amplification; ¼-loading dye (30% [v/v] glycerol, 0.5x TBE, bromophenol blue to colour) was added to 20 µl of PCR product followed by at least 5x volume of denaturing mix (0.5 M NaOH, 2M NaCl, 25mM EDTA) was added to provide at least 30 µl per filter. A vacuum was applied to the assembled 96 well dotblot manifold harbouring one sheet of HybondTM-N^{fp} (Amersham) nylon membrane (pre-soaked in 2x SSC [100 ml distilled water, 17.6 g of sodium chloride and 8.9 g of tri-sodium citrate, pH 7.0]), and two sheets of Whatman 3mm chromatography paper to act as a backing. 30µl of the denatured DNA was loaded into each well for each replica filter. Each well was then washed with 150 µl 2x SSC to neutralise the sample. The filters were dried at 80°C for 10 min and the DNA covalently linked to the membrane by 7×10^4 J/cm² of UV light in an RPN 2500 ultraviolet crosslinker (GE Healthcare).

2.2.9 Dot Blot Hybridization

18mer Allele-specific oligonucleotides (ASOs) were designed and ordered from Sigma, with the SNP site as position 8 from the 5' end of the oligo. 8 ng of each Allele-Specific Oligonucleotide was labelled in a 10 µl reaction containing in 1µl 10 x Kinase mix (700mM Tris-HCl pH 7.5, 100mM MgCl₂, 50mM spermidine trichloride, 20mM dithiothreitol) 0.35 U/µl of T4 polynucleotide kinase, 7.8 µl water and 0.12 µl 10mCi/ml γ-³²P-ATP) for 45 min-5 hr at 37°C. Following incubation 20 µl of kinase stop solution (25 mM diNa EDTA, 0.1% SDS, 10 µM ATP) was added to the labelling reaction. Dot blot filters were soaked in 3x SSC and pre-hybridised in 2ml hybridisation solution [3M TMAC (tetramethylammonium chloride, Sigma), 0.6% (w/v) SDS, 1 mM diNa EDTA (pH 8.0), 10 mM sodium phosphate (pH 6.8), 0.1% (w/v) Ficoll 400, 0.1% polyvinylpyrrolidone, 0.1% (w/v) BSA, 0.4 µg 10mg/ml yeast RNA] at 48.5°C for 5 min (10 min if the signal was likely to be low due to low DNA yield) in a mini hybridisation oven. The hybridisation solution was discarded and 2.5ml of fresh hybridisation solution was added. This was hybridised for 5 min at 48.5°C. Prior to adding the [γ-³²P]-labelled oligo and unlabelled 160-320 ng


competitor ASO (e.g. opposite allele) and hybridising for 1-2 hr at 48.5°C. The hybridisation solution was discarded, and the filters washed in TMAC wash solution (3M TMAC, 0.6% [w/v] SDS, 1 mM EDTA (pH 8.0), 10 mM sodium phosphate, (pH 6.8)) for 2x 10 min and 1x 15 min, using a fresh aliquot of 2.5ml of wash solution each time. The filters were then rinsed in 3x SSC at room temperature, blot dried and wrapped in Saran wrap before exposure to Fuji RX100 X-ray film at -80°C with an intensifier screen from 3 hours to overnight, depending on the strength of the signal. Screens were scanned using Typhoon 9400 variable mode imager (GE Healthcare). Images analysed using imageQuant TL v2005 (GE Healthcare).

2.2.10 Probe Removal from Membrane

Probes on membrane were removed by washing in boiling 0.1% (w/v) SDS. The washing was continued (4-5 changes) and monitored by a Geiger counter until probe removal was complete. Membranes were rinsed in 2x SSC and stored damp at 4°C.

2.2.11 Crossover (Recombination) Assay


Design and execution of recombination assays was an extremely complicated and time-consuming process, with many stages. A simplified version of the steps involved in designing and performing the assay is shown in figure 2.1. Each stage is described in more detail below.



(Figure 2.1 continues on the next page)


↓ Optimisation of ASPs

PCR performed using a forward ASP in conjunction with reverse universal primer, or a forward universal primer in conjunction with a reverse ASP on donor homozygous for the allele in the primer and those homozygous for the opposite allele



↓ Establishing linkage phase

Amplify DNA from chosen suitable donor using a forward ASP (i.e SNP G/C is used for designing ASP G/C) in conjunction with a reverse ASP (i.e SNP A/T is used for designing ASP T/C), use all four combinations of primers in separate reaction. Those ASPs directed to alleles in coupling phase will produce a product (✓), those in repulsion phase will not (X). The outermost forward primer should never be used in conjunction with the outer reverse ASP, to eliminate any chance of introducing false recombinants to future experiments.



↓ Pilot recombination assay

Nested repulsion phase allele-specific PCRs performed on pools of sperm DNA and blood DNA to selectively amplify recombinant sperm molecules only. Pool sizes typically range from 300-9600 molecules



↓ Large scale recombination assay and mapping of recombinant products

The large scale assay is performed in pool sizes depending on the optimum pool size determined from the pilot assay that maximises the number of recombinants recovered, while limiting the amount of mixed reactions. Mixed reactions occur when more than one recombinant molecule is present in a single PCR reaction. These reactions are impossible to identify from gel electrophoresis of the products and can only be seen when the internal SNPs are mapped. The mixed reactions show up as a mix of alleles at a SNP site. Typing of internal SNPs is done in the presence of progenitor haplotype PCRs.




Figure 2.1 Steps involved in design and implementation of a recombination assay. The figure shows a flow chart of steps that need to be taken when designing and carrying out a recombination assay. Re-sequencing and SNP discovery is performed on a subset of the DNA donors. All SNPs genotyped by ASO hybridisation in every donor and LD analysis performed on the genotype data. LD analysis allows identification of a target region for the crossover assay. By examining the genotype data, it is necessary to select a semen donor on which to perform the recombination assay. The criteria for this are for the individual to be heterozygous at a number of SNP sites within and flanking the target region identified by the LD analysis and they are heterozygous at potential primer sites. Allele-specific primers (APSS) are designed at suitable SNP sites, away from the target region. Usually two forward and two reverse allele-specific primers are designed and used in nested primary and secondary PCRs, as well as one forward and one reverse universal primer (a primer that can amplify both haplotypes). ASPs are optimised using donors homozygous for each SNP allele. Each donor is amplified using a forward ASP in conjunction with a reverse universal primer at several different temperatures and the optimum temperature determined. Reverse ASPs are optimised with the forward universal primer. Linkage phase of the donor selected needs to be established in order to perform the recombination assay. DNA from this donor is amplified using forward ASPs in conjunction with reverse ASPs. The four possible combinations of forward and reverse ASPs are used in separate reactions. If the reaction produces a PCR product, the alleles in the ASPs are said to be in coupling phase. If the PCR is unsuccessful the alleles are said to be in recombinant phase. A pilot recombination assay is performed, using primary ASPs that are in recombinant phase and nested secondary primers that are also in recombinant phase on differing pool sizes of semen DNA. The pilot assay is used to determine the optimum pool size of sperm DNA molecules. Blood DNA is used as a control. A large scale assay is performed using the pool size(s) determined from the pilot assay. Recombinant products are amplified in a tertiary reaction using the two universal primers and the products dot blotted and hybridised with ASOs to map each crossover to a SNP interval.

2.2.11.1 Allele Specific Primers (ASPs)

Allele specific primers (ASPs) 17-19 bases in length, depending on the GC content of the sequence, were designed with the differential alleles at the 3' end of the oligo for amplifying DNAs. Each primer was optimised, in conjunction with a primer that will prime from both haplotypes (universal), using a donor homozygous for the allele and a donor homozygous for the opposite allele. Optimisation was initially performed at 56°C, 59°C, 62°C and 65°C for the annealing step of the PCR. Specificity usually improved with increasing temperature, while efficiency normally decreased. The primers used as forward primers in the PCR had to be both efficient and specific at

the same conditions as the reverse primers, to ensure they would be both efficient and specific at the same reaction conditions. Allele specific PCRs were set up as in section 2.2.2. Inputs and conditions are given in chapters 3, 4, 5 and 6.

2.2.11.2 Primary PCR

Allele Specific PCRs were set up as in section 2.2.2. Inputs and conditions are given in chapters 3, 4, 5 and 6.

2.2.11.3 Secondary PCR

Immediately following primary PCR was halted by addition of 40 µl of dilution buffer (10 mM Tris-HCl pH 7.5, 2 µg/ml salmon DNA). Arbitrarily, samples can be stored at 4°C before use in secondary PCR. 0.6 µl of diluted primary PCR product can be added in 9.4 µl per reaction for secondary PCR set up as in section 2.2.9.3. Conditions are given in Chapters 3, 4, 5 and 6.

2.2.11.4 Tertiary PCR

Once positive secondary PCR results had been confirmed, 0.5 µl from the secondary PCR was added in to a tertiary PCR. Universal tertiary primers were situated internally to the secondary primers. Conditions are given in Chapters 4, 5 and 6.

2.2.11.4 Mapping crossovers to SNP intervals

Tertiary PCR products were denatured, dotblotted and then sequentially hybridised for all informative SNPs in the target region (see section 2.2.8 and 2.2.9), first with one allele then with the opposite allele. Progenitor haplotype PCRs generated during phasing experiments were hybridised in parallel to establish the progenitor haplotypes (Figure 2.2). The same theoretical results have been used in this section to explain the procedure.




Figure 2.2 Typing of hypothetical informative SNPs in a recombination assay interval by dot blot hybridisation. Each rectangle represents a dot blot hybridisation for one allele of the SNP. The dots are arranged in rows A-E, top to bottom, and columns 1-12 left to right. The SNPs are numbered 1-8, with the allele hybridised shown next to each blot. Rows A-D represent 48 x reactions performed. Black circles show PCR product to which the probe allele has bound, white circles show PCR product to which the probe has not bound. SNPs arranged sequentially 5' to 3'. Row E 1 represents haplotype 1 progenitor PCR (green haplotype), row E 2 represents haplotype 2 progenitors PCR (red haplotype).

Each haplotype was assigned a colour, either red or green. In this theoretical case haplotype 1 was green and haplotype 2 was red. Therefore this assay was detecting crossovers from green to red haplotypes. Every SNP was typed for each reaction, and the genotype of that SNP put into the corresponding column and colour coded for the progenitor haplotype it belonged to. The results of this can be seen in Figure 2.3.

Reaction	SNP1	SNP2	SNP3	SNP4	SNP5	SNP6	SNP7	SNP8
Progenitor 1	C	A	G	A	C	T	A	G
Progenitor 2	T	G	A	T	T	C	G	T
A1	C	A	G	A	T	C	G	T
A2	C	A	G	A	C	T	G	T
A3	C	A	G	A	T	C	G	T
A4	C	A	G	M	M	M	G	T
A5	C	A	G	A	T	C	G	T
A6	C	A	G	A	C	C	G	T
A7	C	A	G	A	T	C	G	T
A8	C	A	G	A	C	C	G	T
A9	C	A	G	A	T	C	G	T
A10	C	A	G	A	T	C	G	T
A11	C	A	G	A	M	M	G	T
A12	C	A	G	A	C	T	G	T
B1	C	A	G	T	T	C	G	T
B2	C	A	G	A	T	C	G	T
B3	C	A	G	T	T	C	G	T
B4	C	A	G	A	C	T	G	T
B5	C	A	G	A	C	C	G	T
B6	C	A	G	A	T	C	G	T
B7	C	A	G	A	T	C	G	T
B8	C	A	G	A	C	C	G	T
B9	C	A	G	A	C	C	G	T
B10	C	A	G	A	T	C	G	T
B11	C	A	A	T	T	C	G	T
B12	C	A	G	A	C	C	G	T
C1	C	A	G	A	C	C	G	T
C2	C	A	G	A	T	C	G	T
C3	C	A	G	A	T	C	G	T
C4	C	A	G	A	T	C	G	T
C5	C	A	G	A	M	C	G	T
C6	C	A	G	A	C	C	G	T
C7	C	A	G	A	C	C	G	T
C8	C	A	G	T	T	C	G	T
C9	C	A	G	A	C	T	G	T
C10	C	A	G	A	C	C	G	T
C11	C	A	G	A	T	C	G	T
C12	C	A	G	A	T	C	G	T

D1	C	A	G	A	T	C	G	T
D2	C	A	G	A	C	T	G	T
D3	C	A	G	A	M	C	G	T
D4	C	A	G	A	T	C	G	T
D5	C	A	G	A	T	C	G	T
D6	C	A	G	A	C	C	G	T
D7	C	A	G	T	T	C	G	T
D8	C	A	G	A	C	C	G	T
D9	C	A	G	A	T	C	G	T
D10	C	A	G	A	T	C	G	T
D11	C	A	G	A	C	C	G	T
D12	C	A	G	A	T	C	G	TD

Crossovers sorted and mixtures resolved

Reaction	SNP1	SNP2	SNP3	SNP4	SNP5	SNP6	SNP7	SNP8
Progenitor 1	C	A	G	A	C	T	A	G
Progenitor 2	T	G	A	T	T	C	G	T
B11	C	A	A	T	T	C	G	T
A4a	C	A	G	T	T	C	G	T
B1	C	A	G	T	T	C	G	T
B3	C	A	G	T	T	C	G	T
C8	C	A	G	T	T	C	G	T
D7	C	A	G	T	T	C	G	T
A1	C	A	G	A	T	C	G	T
A3	C	A	G	A	T	C	G	T
A5	C	A	G	A	T	C	G	T
A7	C	A	G	A	T	C	G	T
A9	C	A	G	A	T	C	G	T
A10	C	A	G	A	T	C	G	T
A11a	C	A	G	A	T	C	G	T
B2	C	A	G	A	T	C	G	T
B6	C	A	G	A	T	C	G	T
B7	C	A	G	A	T	C	G	T
B10	C	A	G	A	T	C	G	T
C2	C	A	G	A	T	C	G	T
C3	C	A	G	A	T	C	G	T
C4	C	A	G	A	T	C	G	T
C5a	C	A	G	A	T	C	G	T
C11	C	A	G	A	T	C	G	T
C12	C	A	G	A	T	C	G	T
D1	C	A	G	A	T	C	G	T
D3a	C	A	G	A	T	C	G	T
D4	C	A	G	A	T	C	G	T
D5	C	A	G	A	T	C	G	T
D9	C	A	G	A	T	C	G	T
D10	C	A	G	A	T	C	G	T
D12	C	A	G	A	T	C	G	T
A6	C	A	G	A	C	C	G	T

A8	C	A	G	A	C	C	G	T
B5	C	A	G	A	C	C	G	T
B8	C	A	G	A	C	C	G	T
B9	C	A	G	A	C	C	G	T
B12	C	A	G	A	C	C	G	T
C1	C	A	G	A	C	C	G	T
C5b	C	A	G	A	C	C	G	T
C6	C	A	G	A	C	C	G	T
C7	C	A	G	A	C	C	G	T
C10	C	A	G	A	C	C	G	T
D3b	C	A	G	A	C	C	G	T
D6	C	A	G	A	C	C	G	T
D8	C	A	G	A	C	C	G	T
D11	C	A	G	A	C	C	G	T
A2	C	A	G	A	C	T	G	T
A4b	C	A	G	A	C	T	G	T
A11b	C	A	G	A	C	T	G	T
A12	C	A	G	A	C	T	G	T
B4	C	A	G	A	C	T	G	T
C9	C	A	G	A	C	T	G	T
D2	C	A	G	A	C	T	G	T

crossovers	SNP1	SNP2	SNP3	SNP4	SNP5	SNP6	SNP7	SNP8
No. positive	0	1	5	24	15	7	0	
No. negative	80	79	75	55	63	73	80	
No. unscorable	0	0	0	1	2	0	0	
No. of Poisson corrected crossovers	0	1	5	28	17	7	0	

Figure 2.3 Hypothetical crossover mapping results. Progenitor haplotypes were colour coded either red or blue. Each SNP was typed and assigned to a haplotype. SNPs belonging to red haplotype were coloured red and those belonging to the blue haplotype were coloured blue. SNPs that showed mixed results for a particular reaction, ie. both alleles at a SNP site showed positive hybridisation, are coded as **M** (mixed). A crossover has occurred between the marker SNPs that change from the green to red haplotype. In the case of mixed sites the crossovers needed to be resolved, so that one was counted before the mixed sites and one after. If more than one mixture was present, as in the case of reaction A4, still only 2 crossovers could definitely be accounted for, one between SNP3 and SNP 4 and one between SNP6 and SNP7. Any crossovers occurring between SNP4 and SNP6 would be masked by the other crossovers. This was corrected when estimating crossover rates (see below). The resolved mixed crossovers, as in the case of A4, were called A4a and A4b. Once all of the mixtures were resolved and the crossovers sorted into order, the number of crossovers in each SNP interval was counted. The numbers of negative, positive and unscorable reactions for each SNP interval are shown at the bottom of the table with unscorable referring to any interval that were between two mixed sites. These sites, such as interval SNP4-SNP5 in sample A4, cannot be counted as either negative or positive for a crossover occurring as any crossover would be masked by the crossovers in both the preceding

and following SNP intervals. These numbers were used to estimate the Poisson corrected numbers of crossovers.

Once the mixtures have been resolved and sorted, maximum likelihood methods were used to estimate mean frequency of crossovers in each interval, taking into account the number of input molecules. Where more than one mixed site was observed, the intervening intervals were excluded from the analysis, because a crossover in these intervals could not be discounted. For each interval, the Poisson estimate of recombination frequency was multiplied by the number of input molecules screened in the interval, to yield the Poisson corrected number of crossovers. Once the Poisson corrected numbers of crossovers was known, it could be used to calculate the recombination activity for each SNP interval in cM/Mb. This was done by initially calculating the recombination activity in cM by dividing the number of Poisson corrected crossovers by the total number of molecules screened and multiplying the answer by 100. The activity in cM was converted to cM/Mb by dividing the recombination fraction in cM by the length of the SNP interval in base pairs and multiplying by 1 million.

CHAPTER 3:

HIGH-RESOLUTION LINKAGE DISEQUILIBRIUM ANALYSIS OF PUTATIVE HOTSPOTS CONTAINING A MOTIF-DISRUPTING SNP

3.1 INTRODUCTION

Donnelly and colleagues have identified more than 30,000 putative hotspots from localised linkage disequilibrium (LD) breakdown, and carried out an exhaustive search of short (5- to 9-mer) motifs for enrichment in those historical hot spots (Myers *et al.*, 2005). They identified two motifs, CCTCCCT and CCCCACCCC, which were strongly overrepresented in a small fraction (~10%) of human hot spots (Myers *et al.*, 2005). The first of these motifs, CCTCCCT, is found in THE1A/B retro-transposons and is over-represented (five to sixfold) in THE1A/B elements within the hotspots (Myers *et al.*, 2005). Previous polymorphic hotspot studies have reported the role of these motifs in hotspot activity where single nucleotide variants disrupting the centrally located motifs CCTCCCT and CCCCACCCC reduce crossover activity in *cis* at hotspots DNA2 (Jeffreys and Neumann, 2002) and NID1 (Jeffreys and Neumann, 2005) respectively. Additionally, Myers et al. (2008) used the power of HapMap Phase 2 data (22,699 autosomal and 608 chromosome X hotspots mapped to 5 kb resolution), to identify classes of repeat elements that are over-represented in hotspots. According to low-resolution HapMap Phase II data, Donnelly and colleagues drew up a shortlist of the four best candidate LD hotspots based on having a motif with a disrupting SNP and a good historical activity (personal communication with A.J Jeffreys, University of Leicester, UK). Subsequently, they searched for motifs that are independently associated with hotspots on multiple repeat-family backgrounds. This approach revealed a common 13-bp motif CCNCCNTNNCCNC, which is a 6-bp extension of the previous CCTCCCT sequence motif (Myers *et al.*, 2008). Additionally, this study showed how well the presence of the motif predicts hotspots; for example the presence of CCTCCCTNNCCAC in a THE1A background resulted in the detection of a hotspot 73% of the time, whereas in unique DNA it led to detection of hotspots only 10% of the time. The sequence context of the repeat element in THE1A leads to the presence of the most

recombinogenic nucleotides outside of the motif. Additionally, the DNA3 hotspot in the HLA class II region (Jeffreys *et al.*, 2001) and the MS32 hotspot (Jeffreys *et al.*, 1998b) contained the 13-mer motif within a few base pairs of the estimated centre.

The study of Myers *et al.* (2005) implicates the 13-mer motif in allelic crossover activity during meiosis. This raises the question of whether the nature of the motif offers any clues for understanding the molecular basis for recombination hotspots (Myers *et al.*, 2008). The four best candidate putative hotspots, their motif-disrupting SNPs, the 13-bp motif and their locations, are all listed in Table 3.1 for further analysis. The aim of this thesis is to identify hotspots with the 13-bp motif and which include a motif-disrupting SNP to test whether the disrupting allele influences the crossover frequency and distribution. In this chapter, four identified LD hotspots from low-resolution HapMap Phase II data were genotyped by high-resolution genotyping techniques in our European semen donor panel and tested to see if the motif-disrupting SNP lay within the motif at the centre of the hotspot by linkage disequilibrium (LD) and linkage disequilibrium unit (LDU) mapping.

LD Hotspots	SNP	Motif	Location
DA	rs7036542	MCNCCNTNNCCNC	Chr 9 p22.9
DB	rs6035457	CCWCCNTNNCCNC	Chr 20 p19.70
DC	rs6578087	CMNCCNTNNCCNC	Chr 8 q24.3
DD	rs1982437	YCNCCNTNNCCNC	Chr 11 q21

Table 3.1 Candidate SNPs and the locations of these SNPs within the motif. The table shows the four candidate SNPs in hotspots identified by Donnelly (personal communication with A.J Jeffreys, University of Leicester, UK) and their chromosomal location. Also, the table shows the single base changes (labelled in red) inside the motif (M: C, A; W: T, A; Y: C, T).

3.2 FOUR SELECTED LD HOTSPOTS

The first LD hotspot to be studied was Hotspot DA. This hotspot contains an intergenic SNP (rs7036542), which is located on the short arm of chromosome 9 in its sub terminal region (Figure 3.1a), and within a well-localised putative hotspot within a THE1B element. This SNP changes the 13-bp motif from CCNCCNTNNCCNC to ACNCCNTNNCCNC. The ancestral SNP allele is C (or complementary G). In addition, downstream of the CCTCCCT motif was a sequence, CCTCCCTAGCCT that is overrepresented in the hotspot THE1B elements. This suggests that the presence of this downstream sequence is also helpful in promoting hotspots. Interestingly, previous evidence from genome-wide statistical comparisons shows that ACNCCNTNNCCNC is associated with a lowered hotspot activity (Myers *et al.*, 2005). The ancestral SNP allele is C, and the allele frequency is 0.58/0.34 (C/A) in CEU population.

The second LD hotspot, Hotspot DB, has an intergenic SNP (rs6035457) that is located on the short arm of chromosome 20 (Figure 3.1b). This SNP is outside of any repeat elements, and changes the sequence CCTCCCNTNNCCNC to CCACCNTNNCCNC. The analysis of Donnelly and colleagues (personal communication with A.J Jeffreys, University of Leicester, UK) did not give an especially precise localisation for this hotspot, but the hotspot did localise exactly to the SNP location based on HapMap Phase II LD patterns. The downstream sequence CCTCCT..CCAC is found 3.5 times more frequently than expected by chance in narrow hotspots. The ancestral SNP allele is T, and the allele frequency is 0.36/0.64 (T/A) in CEU population.

Hotspot DC is the third LD hotspot, and SNP rs6578087 is a very well localised intronic SNP that locates to the long arm of chromosome 8 (Figure 3.1c). This SNP is in a LINE/L1 element and changes CCNCCNTNNCCNC to CANCCNTNNCCNC. This change shows strong genome-wide evidence of less activity (personal communication with A.J Jeffreys, University of Leicester, UK). The downstream sequence CCTCCCTGACCCC is two times enhanced in well-localised hotspots. The allele frequency in the CEU population is 0.633/0.367 (C/A, C is the ancestral allele)

The last LD hotspot, Hotspot DD, has an intergenic SNP (rs1982437) on the long arm of chromosome 11 (Figure 3.1d). This SNP is in a SINE/MIR retrotransposon element and changes CCNCCNTNNCCNC to TCNCCNTNNCCNC. The downstream sequence CCTCCCTGACCTC is 2.1 times enhanced in well-localised hotspots. The allele frequency of the SNP in the CEU population is 0.701/0.299 (C/T).

3.2.1 SNP Discovery and Annotation

For each putative hotspot containing a SNP within a CCNCCNTNNCCNC motif, a 15 kb interval of DNA sequence centring on the target SNP (the hotspot) was downloaded from ENSEMBL (www.ensembl.org). The sequence was annotated to include all SNPs and repeat sequences (LINEs, Alus etc) using information gained from Phase II HapMap data, dbSNP data and Repeat Masker (Appendix I). This was carried out so that Alu elements, with their high genomic copy number, could be taken into consideration while designing PCR primers and Allele Specific Oligos (ASOs). In summary, 88, 77, 70 and 69 SNPs were characterised using HapMap Phase II and dbSNP data at 15 kb intervals for LD Hotspots DA, DB, DC and DD respectively. The sequences are shown in Appendix 3.1.




Figure 3.1 shows the location of disrupting SNPs on the chromosomes for each target. Additionally, the figure shows the location of the SNPs (red) in the sequence and the matches within the 13-bp sequence motif. (W: A/T, M: C/A, Y: C/T) (Adapted from www.ensembl.org)

3.2.2. Typing SNPs In Semen Donors by Allele Specific Oligo (ASO) Hybridisation

All identified SNPs were genotyped using Allele Specific Oligo (ASO) hybridisation (see Materials and Methods) (Figure 3.2) and these genotypes were used for LD and LDU mapping, and coalescent analysis to test for the presence of historical hotspots. The 15-kb interval of DNA sequence that centred on each LD hotspot was divided into 3 overlapping 4-6 kb amplicons. These amplicons were amplified using nested PCR on whole-genome amplified (MDA) sperm DNA; MDA DNAs were used to save genomic DNA.

Initially, sperm DNA from 92 semen donors was whole-genome amplified (PCR conditions and primers are shown in Appendix II). The PCR products used for SNP genotyping were used in ASO hybridization (all ASOs are shown in Appendix III). Depending on the number of SNPs in each amplicon, 2-6 replicates of each amplicon for donors 1-96 (there are three donors who are duplicated in the panel: donor 19 and donor 49, donor 30 and donor 33, donor 31 and donor 86 and donor 50 and donor 95) were produced, with a single membrane being hybridised sequentially, first with one allele ASO and then with the opposite allele ASO. The resulting genotypes were normally unambiguous, although if the PCR products were weak then it was necessary to assume an unknown result.

In total, 39 SNPs were typed in 92 donors for Hotspot DA. A further 49 SNPs were either non-validated by HapMap or did not have a frequency in the CEU population and were therefore discarded. The data from all 38 SNPs typed is shown in Table 3.2 (donors 1-50) and Table 3.3 (donors 50-96). For the other LD hotspots, a total of 30, 31 and 23 SNPs were typed in 93 donors out of 77, 70 and 69 annotated SNPs for Hotspots DB, Hotspot DC and Hotspot DD respectively. Tables 3.4 - 3.9 show genotyped SNPs in our donor panel for Hotspots DB, DC and DD. These genotypes were used for LD, LDU and coalescent analysis.




Figure 3.2 An example of SNP genotyping from ASO hybridisation for Hotspot DA markers. PCR products from 92 men were loaded onto membranes. Blots are probed with radiolabelled ASOs, one membrane with one allele and the other membrane with the other allele. Genotypes can thus be determined. For example, donor 2 for SNP rs7036542 (DA7.5T/G) is homozygous (G/G), donor 1 for SNP rs56293504 (DA7.6A/C) is heterozygous (A/C) and donor 1 for SNP rs17472622 (DA8.4G/A) is homozygote (G/G). (Donors 1 and 2 are coloured in red)

		donor																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
SNP	location	1	2	3	4	5	6	7	8	9	0	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	4	4	4	4	4	4	5	6	7	8	9	0																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
DA2.4-/+	2368	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Table 3.2 SNP genotypes from semen donors 1-50 for the 39 SNPs for Hotspot DA. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DA7.5T/G is highlighted in red.

SNP	location	donor																			
		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
DA2.4-/+	2368	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DA2.6G/C	2593	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	-
DA3.5T/G	3489	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T
DA3.7T/G	3667	G	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	T
DA4.0C/T	4005	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA4.0aG/A	4044	A	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	A
DA4.8A/C	4777	A	A	A	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	A
DA5.0T/C	5112	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	T
DA5.3A/T	5368	A	A	A	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	A
DA6.0A/G	6057	A	A	A	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	A
DA6.1C/T	6139	C	H	H	C	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	C
DA6.1aA/G	6171	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	A
DA6.3T/C	6335	H	H	H	H	C	C	T	T	T	T	T	T	T	T	T	T	T	T	T	H
DA6.3aA/T	6352	H	H	H	H	T	H	A	A	A	A	A	A	A	A	A	A	A	A	A	H
DA7.0A/G	7025	H	H	H	A	A	H	H	G	A	H	H	A	A	A	A	A	A	A	A	H
DA7.0a-/+	7049	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
DA7.0bT/G	7140	H	H	H	G	H	T	T	T	G	H	T	T	T	T	T	T	T	T	T	H
DA7.4A/C	7481	H	A	A	C	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DA7.5T/G	7501	H	H	H	G	G	H	H	T	T	H	H	H	H	H	H	H	H	H	H	H
DA7.5aT/C	7542	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA7.6A/C	7631	H	C	C	A	H	C	C	C	H	H	C	C	C	C	C	C	C	C	C	C
DA8.2G/A	8229	G	H	G	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DA8.4G/A	8413	G	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DA8.5C/G	8590	H	C	C	C	H	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C
DA9.5C/T	9580	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DA10.0G/A	10126	C	T	T	H	C	T	H	C	H	C	H	C	H	C	H	C	H	C	H	C
DA10.2C/T	10203	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DA10.6G/A	10563	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA10.6aA/C	10604	C	A	H	C	A	H	C	A	H	C	A	H	C	A	H	C	A	H	C	A
DA10.6bC/A	10614	C	A	H	C	A	H	C	A	H	C	A	H	C	A	H	C	A	H	C	A
DA11.5C/T	11543	H	C	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA12.0C/T	12063	H	C	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA13.4A/G	13364	H	A	A	A	G	A	A	H	A	A	H	A	A	H	A	A	H	A	A	H
DA13.4a-/+	13384	H	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DA13.4bC/T	13388	H	C	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DA13.5T/C	13559	H	T	T	C	T	T	H	H	H	H	H	H	H	H	H	H	H	H	H	H
DA13.8aG/A	13798	A	G	H	G	A	G	H	A	H	H	A	H	H	A	G	A	A	A	A	A
DA13.8bC/T	13858	C	T	H	H	C	C	C	T	H	H	C	C	C	C	C	C	C	C	C	C
DA14.4T/C	14479	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T

Table 3.3 SNP genotypes from semen donors 50-96 for the 39 SNPs for Hotspot DA. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DA7.5T/G is highlighted in red.

SNP	location	donor																														
		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
DB2.2T/C	2286	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	
DB2.3G/C	2390	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	
DB2.4G/A	2448	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	
DB2.5T/C	2612	C	H	C	C	C	T	H	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DB2.7T/C	2704	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	
DB2.7aC/G	2747	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DB3.7A/G	3777	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	
DB3.9G/C	3927	G	G	G	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	
DB4.1C/A	4152	C	C	C	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DB4.1bA/G	4191	A	A	A	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	
DB4.2A/G	4222	G	G	G	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	
DB4.3C/G	4406	H	H	G	H	G	G	C	H	G	C	H	H	H	G	C	H	H	H	H	G	C	H	H	G	G	H	H	H	H	H	H
DB4.3aA/G	4413	A	A	A	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	
DB4.5A/G	4517	A	A	A	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	
DB5.4G/A	5448	H	H	A	H	A	A	H	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	H	H	H	H	
DB6.6A/G	6689	G	H	G	H	G	G	A	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	
DB7.0T/C	7058	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DB7.0aC/A	7077	H	C	C	C	H	A	H	A	H	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	
DB7.1G/T	7155	G	H	G	H	T	H	G	G	G	G	H	T	T	H	G	H	G	H	G	H	T	T	T	T	T	T	T	T	T	T	
DB7.2T/C	7301	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	
DB7.5T/A	7501	A	H	H	T	A	H	A	T	A	H	H	A	H	A	H	A	H	T	T	T	T	T	T	T	T	T	T	T	T	T	
DB7.6C/T	7712	H	C	T	H	C	H	C	T	H	C	H	C	H	C	T	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	
DB7.8T/C	7889	H	H	T	T	H	H	C	H	T	T	C	H	H	C	H	T	T	C	H	H	C	H	C	H	C	H	C	H	C	H	
DB7.9T/A	7921	H	H	H	T	H	H	A	T	H	T	A	C	H	H	A	T	H	T	H	H	A	T	A	T	A	T	A	T	A	T	
DB9.0C/T	9048	H	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DB9.2G/A	9267	H	G	G	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	
DB10.5A/G	10502	G	H	A	A	H	H	G	A	H	H	G	H	G	A	H	H	G	H	G	A	H	H	G	H	G	H	G	H	G	H	
DB12.3T/A	12339	T	T	T	T	H	T	T	T	H	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	
DB13.5G/A	13520	H	H	G	G	H	H	A	G	G	H	H	A	G	G	A	H	A	G	G	A	H	A	G	G	A	H	A	G	G	A	
DB14.3G/C	14400	G	H	G	G	G	H	H	G	G	H	H	G	G	H	H	G	G	G	H	H	G	G	H	H	G	H	H	G	H	G	

Table 3.4 SNP genotypes from semen donors 1-50 for the 30 SNPs for Hotspot DB. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DB7.5T/A is highlighted in red.

[illegible]

Table 3.5 SNP genotypes from semen donors 51-96 for the 30 SNPs for Hotspot DB. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DB7.5T/A is highlighted in red.

SNP	location	donor																																			
		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	
DC3.0G/A	3105	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DC5.4C/T	5645	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DC5.8T/-	5847	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T
DC6.1C/T	6231	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DC6.7G/A	6746	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DC6.7aG/A	6798	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DC6.8A/G	6849	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DC6.8aT/C	6860	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	
DC7.1T/C	7192	C	H	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC7.2C/T	7312	H	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC7.4G/A	7481	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DC7.5C/A	7501	A	H	A	H	C	C	A	H	H	C	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	C
DC7.5a-/C	7508	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
DC7.5bC/T	7510	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C		
DC7.5cC/T	7538	H	C	C	H	C	C	H	T	C	C	T	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
DC7.6C/T	7673	T	C	C	C	H	T	C	H	C	H	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC7.7C/T	7765	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC8.2C/T	8326	C	T	C	C	H	C	C	H	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC8.7G/A	8708	G	A	G	G	H	H	G	H	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DC9.1A/G	9203	G	H	G	G	H	H	G	H	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DC9.6G/A	9622	G	A	G	G	H	H	G	H	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DC9.9C/G	9940	C	G	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	H	C	C	C	
DC11.1C	11105	C	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC11.2G/A	11251	G	A	G	G	H	H	G	H	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DC12.1G/C	12162	G	G	G	G	H	H	G	H	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G	H	G
DC13.0A/G	13140	A	A	A	A	H	H	A	H	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A
DC13.3C/T	13337	C	T	C	T	H	H	C	H	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
DC13.4T/C	13459	T	C	T	T	H	H	T	T	H	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T
DC13.9A/G	13923	A	A	G	A	A	H	H	A	H	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	A
DC13.9aC/T	13927	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
DC14.4A/G	14451	A	A	G	A	A	H	H	A	H	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	H	A	A

Table 3.6 SNP genotypes from semen donors 1-50 for the 31 SNPs for Hotspot DC. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DC7.5C/A is highlighted in red.

[illegible]

Table 3.7 SNP genotypes from semen donors 51-96 for the 31 SNPs for Hotspot DC. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting SNP DC7.5C/A is highlighted in red.

donor	location																						
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3
DD 2.2T/C	T	T	H	H	H	T	T	H	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T
DD 2.7G/A	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 4.0T/C	H	C	H	T	T	H	T	T	C	T	H	T	T	T	T	T	T	T	T	T	T	T	T
DD 5.7T/A	T	T	H	H	H	T	T	H	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T
DD 5.7aG/A	G	G	H	H	G	G	H	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 7.3C/A	C	C	H	H	H	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DD 7.5G/A	G	H	H	H	G	H	H	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 7.5aC/T	C	H	H	H	C	H	H	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DD 7.6C/T	C	C	C	H	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DD 7.8A/G	A	A	H	H	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DD 8.4G/T	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 8.5A/G	A	A	H	H	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DD 8.5aG/A	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 8.5bA/G	A	A	H	H	A	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DD 8.6C/G	C	C	H	H	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DD 10.9G/C	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 11.0G/A	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 11.5G/A	H	A	G	H	G	A	H	H	G	G	H	H	H	H	H	H	H	H	H	H	H	H	H
DD 11.9A/G	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 12.0C/T	C	C	T	H	C	C	C	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C
DD 12.1G/A	G	G	H	H	G	G	H	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G	G
DD 12.4A/G	A	A	H	H	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
DD 12.6A/G	A	A	H	H	A	A	H	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A

Table 3.8 SNP genotypes from semen donors 51-96 for the 23 SNPs for Hotspot DD. SNP names are listed down the left and donor number across the top. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). Motif disrupting DD7.5G/A is highlighted in red.

3.2.3 Linkage Disequilibrium (LD) and Linkage Disequilibrium Unit (LDU) Mapping, and Coalescent Analysis

As part of the high-resolution study of meiotic recombination, LD analysis is used to define regions that potentially contain a recombination hotspot. Previously, Donnelly and colleagues (Myers *et al.*, 2005; Myers *et al.*, 2008) screened this target region DA on low-resolution Phase II HapMap data, and it was one of the best candidate LD hotspots based on having a motif with a disrupting SNP and due to its historical activity, as inferred by its strong LD breakdown. Genotyped SNPs in our donor panel were used to determine haplotype frequencies across the 15-kb target region, via a maximum likelihood approach (software written using TrueBASIC 4.1 by A. Jeffreys). Firstly, allele frequencies for each SNP were calculated and the most likely haplotypes for each pairwise comparison of SNPs were calculated from the genotype data. The analysis program calculates the most likely haplotypes from all the genotype data in a similar manner. Therefore, the D' value was calculated for the genotype data from the target region of DA. This identified the approximate position of a change from a region of free association to strong LD. In our analysis pairwise D' values were assigned a colour, with red representing high D' and black representing low D' (explained in detail in Chapter 1). For example, the D' value is red ($= 1$) and the corresponding odds of linkage equilibrium are also red, with a value of <0.0001 indicating that the statistical significance of the association between the two markers is high. Conversely, if it is blue then this indicates that the value of D' between these two sites is between 0.4-0.6. This would suggest substantial LD. However, the statistical significance ($LR>0.05$) shows that the odds of equilibrium are high and therefore it does not statistically support the D' value. Figure 3.3 shows higher-resolution LD mapping for the target region DA. LD breakdown was reproducible in these European donors and the Hotspot DA was narrow and flanked by regions of strong LD. LD plots showed evidence for localised LD breakdown but with some SNP pairs showing strong LD across a putative hotspot.




Figure 3.3 Linkage disequilibrium breakdown across the target region DA. All analyses were based on genotyped SNP typed data for Hotspot DA in our donor panel. Maximum likelihood haplotype frequencies for each pair of SNPs were determined and used to estimate $|D'|$ levels of LD (lower right), plus the associated likelihood ratio (LR, odds of LD) versus free association (upper left), and are colour-coded as indicated. Only SNPs with minor allele frequencies (MAFs) ≥ 0.15 were included in the analysis. The locations of the SNPs are shown below and to the right of the plot, with positions centred on the middle of DA at co-ordinate 0. The LD block is shown in black below the plot, and the position and the approximate width of the LD hotspot DA is indicated by the red arrow.

Linkage Disequilibrium Unit (LDU) mapping:

Before testing the importance of the disrupting SNPs within the motif and carrying out crossover assays to estimate the recombination rate, all the genotyped targets (DA, DB, DC, and DD) were LDU mapped to confirm the presence of the putative hotspots, and compared with HapMap CEU data (Figure 3.4). In this analysis, the disrupting SNPs had to be within the motif localised at the centre of the hotspots. All putative hotspots show a big similarity with HapMap Phase II CEU data and with having 1-2-kb hotspot intervals. This reflected the normal concentration of human meiotic recombination hotspots (Jeffreys *et al.*, 2000). LD hotspot target DA was an excellent candidate, with strong and narrow LDU steps and a central SNP with a

disrupting allele affecting a key motif base. LD hotspot target DB showed the same features as target DA, but the disrupting SNP base change (T/A) did not affect a key base in the 13-bp motif. LD hotspot target DC clearly showed a very narrow LDU step, but a key SNP disrupts the motif at the boundary of the LD hotspot and not in the centre. Therefore, this target was a poor candidate for a crossover assay. This information was not given in the results of Donnelly and colleagues, presumably because this LD hotspot was mapped at lower resolution using Phase II HapMap Data (Myers *et al.*, 2005). LD hotspot target DD was not a clearly localised LD hotspot, with LD weakly decaying over an interval of at least 4 kb. This LD hotspot was thus a very poor candidate and was rejected as a LD hotspot.




Figure 3.4 LDU maps of targets DA, DB, DC and DD. In the figure, LDU (B) maps confirmed the putative hotspots with 1-2 kb intervals, apart from target DD; also, each putative hotspot was compared with the LDU of CEU data from HapMap (A) (minor allele frequency > 0.3). The disrupting SNP within the motif is shown with red arrows. In targets DA and DB, the disrupting SNPs are localised close to the centre; therefore, both putative hotspots are eligible for crossover assays for testing the recombination rate of the hotspot. However, the disrupting SNP is localised very far away at target DC. Target DD showed only a very weak LDU step, and thus targets DC and DD were eliminated from this study.

Coalescent analyses

Comparing LDU maps with coalescent-based maps shows how different they are. LDU maps reflect the underlying LD structure, whilst coalescent maps reconstruct the underlying recombination rate with a particular demographic model (Fearnhead *et al.*, 2004). Coalescent analyses were used for estimating recombination rates and predicting the location of hotspots as generally confirmed by direct estimates from sperm typing (Schneider *et al.*, 2002; McVean *et al.*, 2004). According to low-resolution analysis from HapMap Phase II data, these targets showed good historical activity. Coalescent analyses were carried out on genotyped SNPs for each target LD hotspot in our donor panel (Figure 3.5). Coalescent analysis of Hotspot DA suggested a highest peak of activity of ~ 50 cM/Mb crossover rate in all four LD hotspots, with an approximate historical recombination frequency (RF) of $\sim 5 \times 10^{-4}$. This RF is typical for crossover hotspots analysed by sperm typing. Hotspots analysed by sperm typing vary widely in crossover activity, with RF values ranging from 5×10^{-6} to 3×10^{-3} for currently characterised hotspots. This range of nearly three orders of magnitude almost certainly reflects widely differing rates of recombination initiation. The LD hotspots DB and DC showed a similar peak activity of ~ 32 cM/Mb and a crossover rate of $\sim 3.2 \times 10^{-4}$. These results defined hotspots with >2 kb resolution. This width is more than previously observed hotspot intervals (Jeffreys *et al.*, 2000), and moreover these hotspots do not show typical coalescent mapping for a normal hotspot. The lesser peak activity (~ 14 cM/Mb) for the LD Hotspot DD was reported along with a very narrow hotspot width (< 0.4 kb). Therefore, according to coalescent analysis, we confirmed the LDU results for all four LD hotspots.




Figure 3.5 Coalescent analyses of four LD hotspots (DA, DB, DC and DD). Coalescent mapping gives clues about historical recombination and recombination frequency. For example, Hotspot DA showed a highest peak activity of ~ 50 cM/Mb crossover rate in all four LD hotspots ($RF \sim 5 \times 10^{-4}$.) The width of Hotspot DA was ~ 1.4 kb. Despite not having any good coalescent mapping, Hotspots DB and DC suggested a similar peak activity of ~ 32 cM/Mb with a very broad hotspot width of >2 kb. The lesser peak activity (~ 14 cM/Mb) suggested for Hotspot DD came with a very narrow hotspot width (<0.4 kb). Therefore, LDU maps were confirmed by coalescent analyses for these LD hotspots. Also, red arrows show the location of the disrupting SNP within the motif in each LD hotspot.

3.4 DISCUSSION

According to our knowledge, 40% of human recombination hotspots have a 13-bp CCNCCNTNNCCNC sequence motif that determines activity in the hotspots (Myers *et al.*, 2008). The work of previous studies (Jeffreys *et al.*, 2002; Jeffreys *et al.*, 2005) has shown that CCTCCCT and CCCCACCCC motifs are present at the centre of hotspots *DNA2* and *NIDI* (Jeffreys and Neumann, 2002; Jeffreys *et al.*, 2005). Furthermore, SNPs in both the two motifs disrupt hotspot activity, with the non-reference SNP base acting as a recombination-suppressing allele (Myers *et al.*, 2005). The four best candidate SNPs within the 13-bp CCNCCNTNNCCNC motif theoretically locate to the middle of four hotspots and have been analysed to confirm the presence of the putative hotspot in our donor panel by LDU mapping. Confirming these hotspots with LDU mapping is crucial because it establishes the existence of the hotspot in our donor panel and the location of disrupting SNPs within the motif, and also the size of the hotspot can be estimated. Therefore, further analysis with a reciprocal crossover assay (Jeffreys *et al.*, 2002) can be carried out according to LDU mapping, genotyping of the target regions, and the availability of genomic DNA in our stocks.

Thirty-nine SNPs have been genotyped using ASO hybridisation for the putative hotspot DA. LDU mapping confirmed 1-2 kb intervals (Jeffreys *et al.*, 2000) with the disrupting SNP in the middle, and estimated the historical recombination frequency to be $\sim 5 \times 10^{-4}$. This RF shows that the hotspot is an ordinary hotspot, but the exact RF should be deduced and more information from the crossover assay should be collected. Following the genotyping of 30 and 23 SNPs in the regions of the second and fourth putative hotspots DB and DD respectively, LDU maps confirmed the location of the disrupting SNP to be close to the centre of both hotspots. However, for the 31 SNPs genotyped for target DC, the LDU map showed the disrupting SNP to be outside of the centre. Thus, target DC cannot be studied for this project because it does not fit into the objectives of this thesis.

In summary, given our knowledge about putative hotspot DA, good heterozygosity of donors in our panel and the availability of genomic DNA, this is the best candidate for further crossover assay analysis. Chapter 4 describes its detailed study. Putative

hotspot DB is also quite promising for the future study of crossover activity. Even though the disrupting SNP is localised at the centre of the putative hotspot DD, the heterozygosity of the donors does not allow us to conduct further analyses. Given the location of the disrupting SNP in target DC and the lack of good donors in our donor panel for target DD, SNPs in these putative hotspots were deemed unsuitable for study in this thesis.

CHAPTER 4: FREQUENCY AND DISTRIBUTION OF RECOMBINATION EVENTS AT HOTSPOT DA

4.1 INTRODUCTION

Intergenic SNP rs703642, which is located on the short arm of chromosome 9, disrupts the 13-bp CCNCCNTNNCCNC motif at the first base of the motif sequence (SNP rs703642: **C**CNCCNTNNCCNC → **T**CNCCNTNNCCNC). Previously, LD plots from HapMap phase II genotype data (Stephens and Donnelly, 2003) have confirmed the presence of the hotspot in four different populations, Utah residents with ancestry from northern and western Europe (CEU), Yoruba in Ibadan, Nigeria (YRI), Japanese in Tokyo, Japan (JPT) and Han Chinese in Beijing, China (CHB). Additionally, Donnelly and colleagues drew up a shortlist of the four best candidate LD hotspots based on having a motif with disrupting SNP accompanied by high historical crossover activity based on low-resolution HapMap Phase II data (Myers *et al.*, 2005) (Chapter 3). In Chapter 3, the 15-kb interval region of Hotspot DA was genotyped using ASO hybridization for a 92-donor panel, testing for the presence of the hotspot. LD and LDU map analysis confirmed the presence of the hotspot (1-2-kb interval) (Figure 3.3 and 3.4).

This Chapter discusses the optimisation of the allele-specific PCRs, identification of appropriate semen donors for the assay, recovery of recombinant DNA molecules, the analysis of recombination rate and distribution, and determination of the hotspot centre of Hotspot DA.

4.2 THE CROSSOVER ASSAY STRATEGY FOR HOTSPOT DA

The recombination rates and distributions of crossovers at recombination hotspots were measured using repulsion-phase allele-specific PCR of recombinant molecules from genomic sperm DNA. The strategy behind this method was that selective PCR recovers recombinant molecules from batches of genomic DNA, if necessary allowing millions of molecules to be rapidly screened. In Chapter 2, the reagents and methods of recovering crossovers and the estimation of recombination frequency are discussed.

4.3 SELECTION OF SEMEN DONORS FROM THE DONOR PANEL

It was necessary to have blood controls, as well as the sperm reactions while recovering crossover molecules, in order to test for meiotic specificity of putative crossovers and to check for production of PCR artefacts during the reaction. As only a small proportion of the semen donor panel also donated blood samples, it was necessary to optimise the assay on one of these donors first.

4.4 OPTIMISATION FOR RECOMBINATION ASSAY

When performing crossover assays, it helps to keep the amplified fragment as short as possible, while still including multiple informative heterozygous SNPs. Targets of recombination assays are generally ~4 - 7 kb long (Jeffreys *et al.*, 1998a; Jeffreys *et al.*, 2000; Jeffreys *et al.*, 2001; May *et al.*, 2002; Jeffreys and Neumann, 2005; Kauppi *et al.*, 2009). Heterozygous SNPs were used as selector sites for allele-specific amplification, and heterozygous SNPs in the intervening region acted as markers to map crossover breakpoints. Possible allele-specific PCR selector sites were selected based on their proximity to the target region, and the requirement for them to be present in the heterozygous state in a number of semen donors. However, for testing the effect of the disrupting SNP on the hotspot initiation activity, also both homozygote donors for motif disrupting SNPs were analysed (Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005; Neumann and Jeffreys 2006). Two possible forward and two reverse allele-specific primers were designed, and the annealing temperature of each primer optimised on DNA from semen donors homozygous for one or other allele at the locus. These optimisation experiments were necessary to achieve efficient and highly selective amplification of crossover molecules.

4.4.1 Recombination Assay for Hotspot DA

4.4.1.1 Optimisation of forward Allele-Specific Primers (ASPs)

The three SNPs chosen for the forward primer selector sites were DA2.6, DA3.7 and DA4.0a (Appendix II), as most of the semen donors that possessed these SNPs in the heterozygous state also had informative SNPs within the target region. There are several selection criteria for any SNP site to be used in recovery of crossovers; the SNP site must be within the LD block well away from the putative hotspot, sites must be within single-copy DNA (important for primary selector sites, but not absolutely necessary for secondary selector sites) and they must have a relatively high GC content (~60%).

In the optimisation experiments, MDA DNAs from donor 50 and donor 51 were used, as these donors were homozygous for all three SNPs; donor 50 had the alleles G, T and G for DA2.6, DA3.7 and DA4.0a, respectively and donor 51 had C, G and A. These donors were used for the entirety of the forward primer optimisation.

Universal primers (those which prime from either haplotype) were designed at internal positions to the allele-specific primers, within the target region. One forward and one reverse primer were designed; these primers were 20-24 bases in length, and roughly 65% GC rich. They were designed for three reasons: to ensure amplification was possible across the entire target region, to use in conjunction with allele-specific primers during optimisation, and to use in the recombination assay to increase yield of the crossover PCR products. Optimisation PCRs for each of the allele-specific primers were performed on semen donors' MDA DNA, homozygous either for the allele being tested (+) or for the opposite allele (-), using the forward universal primer (DA5.9aR) at temperatures shown in Appendix II. The PCR products were electrophoresed on an agarose gel (Figure 4-1).




Figure 4-1 Optimisation of forward allele-specific primers on ethidium-bromide-stained agarose gels (presented as negatives). Three forward ASP pairs were optimised: DA2.6FG/C, DA3.FT/G and DA4.0aFG/A from donors homozygous for either the allele being tested or the opposite allele amplified using MDA DNA. DA5.9aR was used as a reverse universal primer. PCRs using each primer were performed at four different annealing temperatures 56°C, 59°C, 62°C and 65°C. DNA inputs were 10ng per 10µl PCR. (M: marker λ HindIII and ϕ XHaeIII).

All primers worked, and showed similar efficiency and specificity. All primers at 62°C showed specificity. It was preferred to amplify the all-forward ASPs at an annealing temperature greater than 59°C. However, the optimum temperature for the PCRs could not be decided until the reverse primers were optimised.

4.4.1.2 Optimisation of reverse Allele-Specific Primers (ASPs)

The four SNPs chosen for the reverse primer selector sites were DA10.6RG/A, DA10.6aRA/C, DA10.6bRC/A and DA12.0RC/T (Appendix II). In the optimisation experiments, MDA DNA from donor 4, donor 5, donor 34 and donor 38 were used, as these donors were homozygous for all four SNPs. Donor 4 had the alleles A, C, C and C for DA10.6, DA10.6a, DA10.6b and DA12.0, respectively, donor 5 had G, A, C

and C, donor 34 had G, C, A and C and donor 38 had G, C, C, T. Optimisation of primers directed to 3' SNPs was more difficult than for the forward primers. ASP DA10.6RG/A had to be redesigned, and was named DA10.6RG2/A2. DA9.9aF has been designed as a forward universal primer (PCR profile and primers are shown in Appendix II). Figure 4-2 shows the electrophoresed PCR products at different annealing temperatures.




Figure 4-1 Optimisation of reverse allele-specific primers on ethidium-bromide-stained agarose gels. Four reverse ASPs were optimised: DA10.6RG2/A2, DA10.6aRA/C, DA10.6bRC/A and DA12.0RC/T, from donors homozygous for either the allele being tested or the opposite allele amplified. DA9.9aF was used for universal forward primer. PCRs using each primer were performed at four different annealing temperatures 56°C, 59°C, 62°C and 65°C. DNA inputs were 10ng per 10µl PCR/ reaction. (M: marker λ HindIII and ϕ XHaeIII).

As with all forward allele-specific primers, all reverse allele-specific primers worked, but with varying degrees of efficiency and specificity.

4.4.1.3 Linkage phasing of donors

Donors were selected on the basis of having multiple heterozygous SNP sites both flanking and within the target hotspot region, which were identified by genotyping analysis and their locations in the LDU map. Donors required heterozygous sites at

two forward ASP sites and two reverse ASP sites. In order to characterise the distribution of crossovers within the hotspot, it was necessary to choose donors with as many informative SNP sites as possible within the interval of LD breakdown. Therefore, primarily 13 donors have been selected from the donor panel. Linkage phase of each donor was determined by PCR amplifications using different combinations of secondary forward and reverse ASP selector sites (Figure 4.3) (PCR conditions and primers are shown in Appendix II).

After linkage phasing, the availability of sperm and blood DNA in the available stock was the other elimination criteria for donor selection. Donor 7 was heterozygous for all of the primer sites and had 11 informative sites (including disrupting SNP within the motif) within the region. Compared with other 12 donors, donor 7 was the best option when these criteria were considered. Also, more importantly, blood DNA from this donor was available, and this donor's sperm DNA was used to optimise the recombination assay. Linkage phasing results for donor 7 and the other donors (those having the same secondary ASP selector site genotypes) are given in Figure 4.3b.




Figure 4.3 Designing linkage phasing assay for suitable donors for crossover assay. a) Shows four different combinations of internal allele-specific primers (ASPs). Internal allele-specific primers used for designing the linkage-phasing assay. The phasing of two forward ASPs and two reverse ASPs were done using linkage mapping. b) PCR results of 13 selected donors. Electrophoresis results give us information on the phasing for each donor; for example, donor 7 showed positive PCR reaction on A and D. Thus, the haplotype phasing of donor 7 is G – G, A-A). (M: marker λ HindIII and ϕ XHaeIII).

4.4.1.4 Performing the recombination assay on donor 7

The reciprocal crossover asymmetry test is a powerful rate-independent test that examines the distributions of exchange points to test whether reciprocal exchanges are distributed differently across a hotspot, and can be used to detect even minor variation in crossover activity. The reciprocal crossover asymmetry test also allows recombination proficiency at the level of individual haplotypes to be analysed (Jeffreys and Neumann, 2002). A pilot experiment using a crossover assay strategy consisting of two rounds of repulsion-phase allele-specific PCR was performed on sperm DNA from donor 7. Each reaction had a number of amplifiable molecules varying from 300 to 9600; using DA2.6FG and DA10.6bRC in the primary PCR and DA4.0aFG and DA10.6A2 in the secondary PCR (PCR conditions and primers are shown in Appendix II). Additionally, blood DNA of donor 7 was used for negative controls with the number of molecules in each reaction varying from 4800 to 9600.

In detail, in the pilot assay 12 x 300 molecules, 12 x 600 molecules, 12 x 1200 molecules, 12 x 2400 molecules, 12 x 4800 molecules and 12 x 9600 molecules from sperm DNA (a total of 2.27×10^5 amplifiable sperm DNA molecules for each haplotype); and 12 x 4800 molecules and 12 x 9600 molecules blood DNA controls (a total of 1.7×10^5 amplifiable blood DNA molecules for each haplotype) were used. A total of 22 positive reactions were seen. The numbers of amplifiable crossover molecules are lower than the true numbers of molecules, since some molecules are non-amplifiable due to nicking or other damage; numbers were calculated using the Poisson distribution programme written by Alec J. Jeffreys, University of Leicester, UK. Poisson-correction was used for each analysed men for estimating the number of crossover molecules from the proportion of PCR that were negative; maximum-likelihood software This programme uses a mathematical model to determine the probability of a negative reaction (P_0) using the equation, $P_0 = e^{-m}$, where m is the mean number of amplifiable molecules per PCR. In the pilot assay, the recombination frequency (RF) was found to be 1.15×10^{-4} (95% CI: 0.6×10^{-4} - 2.24×10^{-4}) The recombination frequency (RF) is given as the number of crossovers per input molecule (Figure 4.4).




Figure 4.4 Pilot assay results for donor 7. This pilot assay has genomic DNA pool sizes covering a wide range of inputs (300, 600, 1200, 2400, 4800, and 9600 molecules per reaction). Blood DNA was used as a negative control in pool sizes of 4800 and 9600. Positive controls (donor 8) including sperm DNA from a man with primers in coupling phase is indicated by (+) with respectively, 0.24 ng sperm DNA input. (M: marker λ HindIII and ϕ XHaeIII).

The large-scale assay is performed in pool sizes depending upon on the optimum pool size determined from the pilot assay that maximises the number of recombinants recovered, while limiting the amount of mixed reactions. Mixed reactions occur when more than one recombinant molecule is present in a single PCR. The recombination assay was based on the two repulsion-phase PCRs and tertiary PCR using universal primers. However, when amplified with universal primers (DAXOF + DA10.4R) (Appendix II) these products formed a visible band when electrophoresed on an agarose gel and stained with ethidium bromide. Four pool sizes were used for the recombination assays for both orientation A and B (Figure 4.5), including; 24 x 4200, 24 x 5830, 24 x 8400 and 24 x 11670 molecules per pool (a total of 7.22×10^5 amplifiable molecules for each haplotype), and amplified to select for recombinants (PCR profile and primers are shown in Appendix II). Universal primers were used for

tertiary PCR and total of 60 positive reactions for orientation A, and 73 positive reactions for orientation B were observed. Therefore, in total approximately 723,000 molecules were used for both orientations A and B.




Figure 4.5 Illustrates the design of a recombination assay for both orientations for donor 7 according to linkage phasing and genotyping. a) 15 intervals are shown with an approximately 1.5-kb region of LDU breakdown. b) Two forward and two reverse allele-specific primers for each haplotype are shown with heterozygous selector sites. c) Both orientation A and B have been designed for crossover assay.




Figure 4.6 Secondary crossover assay PCR results of both orientation A (a) and B (b). a) Shows the result of the orientation A crossover assay. Sperm DNAs were amplified in different concentrations consisting of 4200 molecules, 5830 molecules, 8400 molecules and 11670 molecules respectively. A total of 60 positive reactions were observed. b) Shows result of orientation B crossover assay. Sperm DNAs were amplified in different concentrations as orientation A. A total of 73 positive reactions were observed. (M: marker λ HindIII and ϕ XHaeIII).

4.4.1.5 Mapping recombinant PCR products

The tertiary PCR products from recombination assays for donor 7 (both orientations A and B) were then dot blotted and hybridised sequentially with first one allele for a given SNP and then the opposite allele (Figure 4.7b). All informative SNPs within the amplified target were typed (PCR conditions and primers are shown in Appendix II). Hybridising PCR products with allele-specific oligo (ASO) probes is necessary, so that the recombination rate, distribution and the centre of the hotspots can be calculated by crossover mapping by ASO hybridisation. The results of hybridisations for crossover recombinants for donor 7 are shown in figure 4.7. In orientation A, recombination frequency was calculated as 1.1×10^{-4} (95% CI: $0.6 \times 10^{-4} - 2.4 \times 10^{-4}$) or 1 crossover in 9100 molecules and for orientation B 1.5×10^{-4} (95% CI: $0.7 \times 10^{-4} - 2.5 \times 10^{-4}$) or 1 crossover in 6700 molecules was used to combine data across all input pool sizes.




Figure 4.7 Mapping of crossover products in donor 7. a) Schematic representation of layout of dotblots. PCR products from orientation A (red) and from orientation B (yellow) are shown. Progenitor sites determine the haplotypes for SNP alleles. Progenitors for orientation A (red square) and B (yellow square) are also shown. b) Constituent haplotypes in donor 7 are shown on either side, with informative SNPs indicated. PCR products from crossover assay were sequentially hybridised with one allele of an informative SNP, followed by the opposite allele. The progenitor haplotypes were hybridised at the same time, and can be seen with each blot. The motif-disrupting SNP is DA7.5G/T.

4.5 DISTRIBUTION OF CROSSOVERS WITHIN HOTSPOTS DA

4.5.1 Calculating Crossover Activity

The crossover activity is calculated by as (inter-marker crossovers / total number of molecules) / inter-marker distance x 100 (cM) x 1000000 (Mb), and is given in cM/Mb (table 4.1). Each PCR was examined to determine in which SNP interval the crossover breakpoint lies, the numbers of total crossovers for each interval were determined, and the numbers of reactions positive for crossover were subjected to Poisson correction. This accounts for any crossovers that have occurred in mixed reactions (sometimes one crossover reaction might contain two molecules) that cannot be identified by SNP typing (see Materials and Methods). Table 4.1 shows a summary of crossover data obtained for donor 7, in both orientations, and the numbers of crossovers typed for each.

Donor 7

SNP	location	distance (bp)	No. A COs	No. B COs	cM/Mb, A COs	cM/Mb, B COs
DA5.O	5112		0	0		
DA6.1a	6171	1058	0	0	0.0	0.0
DA6.3	6335	163	0	0	0.0	0.0
DA6.3a	6352	16	0	0	0.0	0.0
DA7.0a	7049	696	15.6	0	3.2	0.0
DA7.4	7481	431	38	3.2	12.5	0.5
DA7.5	7501	19	3.2	2.2	23.8	7.8
DA7.5a	7542	40	10.8	18.8	38.2	31.8
DA8.4	8413	870	10	230.7	1.6	18.0
DA10.0	10126	1712	0	1.5	0.0	0.1
DA10.2	10203	76	0	0.5	0.0	0.4
DA10.6	10563	359	0	0	0.0	0.0
Poisson corrected total COs			76.6	259.8		

Table 4.1 Distribution of crossovers in the Hotspot DA. The name of each informative SNP site in the target interval for each donor, their locations and their distance (bp) to next marker, number of crossovers (No. A COs) for orientation A, number of crossovers for orientation B (No. B COs), calculated recombination activity in cM/Mb for orientation A (A COs) and orientation B (B COs) (separately) and Poisson corrected number of crossovers for both orientation A and B are also shown. Number of crossovers and estimated recombination activity (cM/Mb) are given between two markers, for example 15.6 crossovers observed in orientation A between SNP DA7.0A and DA7.4. The numbers of crossovers are different in both orientations. This means that mixed PCRs were observed in some crossovers, containing more than one molecule.

When the peak activity was plotted against the size of SNP intervals, the hotspot was clear, and the width was estimated at around 1.2 kb (Figure 4.8).

The centre point of the hotspot for donor 7 was estimated at position 7601 and the width within which 95% of crossovers took place was estimated at approximately 1.6 kb. The same program was used to generate values for a best-fit normal distribution curve, and for a best fit cumulative frequency curve. The graphs of cumulative frequency values are shown in Figure 4.9.




Figure 4.8 Crossover distributions in donor 7 in hotspot DA. Crossovers were scored for each SNP interval, and the peak activity calculated in cM/Mb. This value was plotted against the distance, with each column in the graph representing the width of the SNP interval. Informative SNP positions are shown as short lines above each graph. a) orientation A. b) orientation B. c) orientation A+B. The black arrow indicates the centre point of the hotspot for donor 7.

4.5.2 Distribution of Crossovers and the Centre of the Hotspot

The position of the centre point of the hotspot was estimated by the programme that written by Alec J. Jeffreys, University of Leicester, UK. The centre point for donor 7 was estimated at position 7601, and the width within which 95% of crossovers took place was estimated at approximately 1.6 kb. Analysis of cumulative crossover frequency distributions across the target interval (Figure 4.9) showed that hotspot DA was active in donor 7. Also, the cumulative frequencies of orientations A, B and combined A+B crossovers for donor 7 are shown in Figure 4.8. The A+B distributions define a typical narrow crossover hotspot ~1.4 kb wide. The separate A and B crossovers show major asymmetry in donors 7, with A and B cumulative distributions shifted by 330 bp. Thus, one allele of the motif-disrupting SNP suppressed the hotspot activity.




Figure 4.9 This figure explains how recombination breakpoint asymmetry around the hotspot arises as a consequence of donor/recipient asymmetry. The cumulative frequency values for orientation A (red), and B (blue) for each donor are shown. The fit curve for orientations A+B (black) are shown for each donor. The curves for both donors show a similar shape. Cumulative distributions shifted by 330 bp for A and B crossovers for donor 7.

4.5.3 Biased Gene Conversion in Crossover Progeny

Markers within the hotspot showed massive over-transmission (Figure 4.10) with central markers (DA7.5G/T and DA7.5aC/T) showing 90:10 transmission ratios into crossover progeny in donor 7. This biased gene conversion is maximal for the motif-disrupting SNP located just 90 bp from the hotspot centre. Donor 7 over-transmitted the disrupting allele T into crossovers, consistent with motif disruption down-regulating crossover initiation.




Figure 4.10 Transmission of alleles from one haplotype into crossover progeny in donor 7. Massive over-transmission was observed for the markers within the hotspot. Central markers (DA7.5G/T and DA7.5aC/T) showed 90:10 transmission ratios into crossover progeny in donor 7. This biased gene conversion is maximal for the motif-disrupting SNP located just 90 bp from the hotspot centre (the location of the motif-disrupting SNP DA7.5G/T is shown by the green line).


4.6 RECOMBINATION ASSAY IN MORE INFORMATIVE DONORS

For further information about the role of the disrupting SNP within the motif at the centre of the hotspot, more donors who were heterozygous or homozygous for the disrupting SNP were assayed at Hotspot DA.

4.6.1 Recombination Assay Performed on Sperm DNA of Donor 6

Four more donors were selected for the recombination assay for Hotspot DA. As with donor 7, donor 6 was heterozygous (G/T) for the disrupting SNP 7.5 within the motif. In addition to this donor, two homozygous donors (donor 33 and donor 67) for the G-

allele and one homozygous donor (donor 44) for the T-allele at the disrupting SNP DA7.5 were selected. Linkage phasing was required for donors 6 and 67. Four different combinations of forward allele-specific primers DA4.0aFG/A and reverse allele-specific primers DA10.6bC/A were used for linkage phasing (PCR conditions and primers are shown in Appendix II) (Figure 4.11).



- A) DA4.0aFG + DA10.6bRC
- B) DA4.0aFG + DA10.6bRA
- C) DA4.0aFA + DA10.6bRC
- D) DA4.0aFA + DA10.6bRA

Figure 4.11 Linkage phasing electrophoresis results for donors 6 and 67. Four combinations of allele-specific primers are shown above. Electrophoresis results give us information on the phasing for each donor; for example, donor 6 showed positive PCR reaction on B and C. Thus, the haplotype phasing of donor 6 is G – A, A-C). (M: marker λ HindIII and ϕ XHaeIII).

The first informative heterozygous marker within the interval was SNP DA7.0. There was 300 bp between the second forward selector site DA4.0a and first SNP heterozygote marker DA7.0. Possible positive crossovers would be missed out. Therefore, ASP DA4.0a was included as an informative heterozygote marker and previously optimized ASPs DA3.7FG1/T1 were selected as a second forward allele-specific primer. There was strong linkage between SNP DA3.7 and SNP 4.0a, thus linkage-phasing results considered while designing the crossover assay. Sperm DNA from donor 6 was amplified for both orientations A and B, that consisted of 24 x 1320 molecules, 24 x 1890 molecules, 24 x 2450 molecules and 24 x 3400 molecules, using

allele-specific primers, DA2.6FG and DA12.0RT for primary PCR and DA3.7FT1 and DA10.6bRC for secondary PCR for orientation A. And, for orientation B; DA2.6FC and DA12.0RC for primary PCR and DA3.7FG1 and 10.6bRA allele-specific primers were used. 66 positive molecules from orientation A and 60 positive molecules from orientation B have been detected in a total of 217,000 for both orientations. According to the secondary PCR gel results, the estimated recombination rates for orientation A and B, respectively were 8.0×10^{-4} (95% CI: $5.0 \times 10^{-4} - 13.0 \times 10^{-4}$) and 6.0×10^{-4} (95% CI: $4.0 \times 10^{-4} - 13.0 \times 10^{-4}$) recombinants per molecule, or 1 crossover in 1200 molecules for orientation A and 1 crossover in 1700 molecules for orientation B (these recombination frequencies were calculated and Poisson-corrected after crossover mapping) (Figure 4.12). The PCR products were then sequentially hybridised, first one allele then the opposite allele, for all informative SNPs in the target interval.




Figure 4.12 Recombination assay carried out on donor 6. Recombinant molecules were amplified in repulsion phase using allele-specific primers. Reactions were carried out on sperm DNA in pools of 24 x 1320 molecules, 24 x 1890 molecules, 24 x 2450 molecules and 24 x 3400 molecules for both orientations. Respectively a) shows the gel results from orientation A, and b) shows the gel results of orientation B. (M: marker λ HindIII and ϕ XHaeIII).

It was necessary to confirm whether the recombination activity seen at the hotspot DA was fully reciprocal, as well as crossovers occurring from one haplotype to the other haplotype (orientation B), and *vice versa*.

4.6.2 Recombination Assay Performed on Other Semen Donors

The best way to understand the effect of disrupting SNP within the motif of the Hotspot DA is to undertake a crossover asymmetry assay. If the disrupting SNP is present in both the active and suppressed allele (i.e. G/T) for Hotspot DA, mapping of crossover assays after dot blot hybridization should show crossover asymmetry. However, to confirm the contribution of the disrupting SNP to hotspot activation/inactivation, donors that are homozygous for the G and T alleles for the motif disrupting SNP were picked. Since previous studies (Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005; Jeffreys and Neumann, 2009) showed that homozygote alleles for cis-regulator SNPs, for the hotspot activation, did not show crossover asymmetry, thus, recombination assay was performed on homozygote donors 33, 67, 44 and 55 for the motif disrupting SNP.

Donor 33 was homozygous for the disrupting G-allele at SNP DA7.5 within the motif, this donor had 10 nicely spread informative SNP sites in the target interval. Both recombinant phases were amplified, using primary PCR primers DA2.6FG and DA10.6aRA and secondary primers DA4.0aFG and DA10.6RG2 for orientation A; and primary PCR primers DA2.6FC and DA10.6aRC and secondary primers DA4.0aFA and DA10.6RA2 for orientation B. Input pool sizes were 24 x 373 molecules, 24 x 561 molecules, 24 x 831 molecules and 24 x 1246 molecules for both orientations. All secondary products were re-amplified with tertiary universal primers. The rate of orientation A crossovers calculated from the number of putative crossover positive PCRs and the number of negative PCRs is approximately 1.3×10^{-3} (95% CI: $0.7 \times 10^{-3} - 2.4 \times 10^{-3}$) crossovers per molecule, or 1 crossover in 770 molecules. The rate of orientation B crossovers, also calculated from the number of putative crossover positive and negative PCRs is 1.0×10^{-3} (95% CI: $0.5 \times 10^{-3} - 2.2 \times 10^{-3}$) crossover per molecule or 1 crossover in 980 molecules.

As well as donor 33, second donor 67 was homozygote for allele G for disrupting SNP DA7.5. Donor 67, was also performed with 7 informative SNP markers in the target interval. For orientation A, DA2.6FG and DA10.6bRC as primary ASP primers and DA4.0aFG and DA10.6aRA as secondary ASP primers were used. Additionally, ASP primers DA2.6FC and DA10.6bRA for primary PCRs and ASP primers

DA4.0aDA and DA10.6aRC for secondary PCR were used for orientation B. 24 x 473 molecules, 24 x 710 molecules, 24 x 1050 molecules and 24 x 1575 molecules were the pool sizes for both orientations. Recombination frequencies were calculated for orientation A and B respectively, 1.4×10^{-3} (95% CI: $0.7 \times 10^{-3} - 2.7 \times 10^{-3}$) and 1.6×10^{-3} (95% CI: $0.8 \times 10^{-3} - 3.0 \times 10^{-3}$) or 1 crossover in 675 molecules for orientation A and 1 crossover in 620 molecules for B.

Donor 44 was homozygous for allele T for disrupting SNP. He was the best possible donor to perform for this assay among all European donor panels. Donor 44 had 9 informative SNP sites in the target interval. Both recombinant phases were amplified, one using primary PCR primers DA2.6FG and DA12.0RC and secondary primers DA4.0aFG and DA10.6RA2 for orientation A and primary PCR primers DA2.6FC and DA10.20RT and secondary primers DA4.0aFA and DA10.6RG2 for orientation B. Input pool size was 48 x 5200 molecules for both orientation A and B. There were no recombinant molecules observed in both orientations. In this manner, donor 44, that homozygote for allele T for disrupting SNP turned off the hotspot activity at the Hotspot DA. And, the highest recombination rates were estimated from donors 33 and 67 (G/G homozygous). Thus, G allele is an active allele for disrupting SNP DA7.5G/T and initiates the hotspot activity. Allele T is a suppressed allele and turns off the hotspot activity. Figure 4.13 shows active and suppressed haplotypes for hotspot DA. All PCR products resulting from the tertiary PCRs were applied to eight replica membranes and sequentially hybridised with both alleles of all informative SNPs (PCR conditions and all primers are shown in Appendix II)




Figure 4.13 All haplotypes of four donors. According to reciprocal crossover assay; Donors 7 and 6, heterozygous (G/T) for the motif disrupting SNP had one active and one suppressed haplotype. The donors (33 and 67) were homozygous (G/G) for the motif disrupting SNP had two active allele, and additionally donor 44 that homozygous (T/T) for the motif disrupting SNP had two suppressed haplotypes.

4.6.3 Calculating Crossover Activity

Table 4.2 shows a summary of recombination assays performed on donors 6, 33 and 67, in both orientations, and the numbers of crossovers typed for each orientation. The recombination assay data is not shown for donor 44, because there was no single positive reaction in the assays.

Donor 6

SNP	location	distance (bp)	No. A XOs	No. B XOs	cM/Mb, AXOs	cM/Mb, BXOs
DA4.0a	4044		0	0		
DA7.0	7025	2980	21.3	0	3.1	0.0
DA7.0a	7049	23	0	0	0.0	0.0
DA7.4	7481	431	108.4	4.4	109.3	4.4
DA7.5	7501	19	6.3	0	144.1	0.0
DA7.5a	7542	40	27.3	2.2	296.6	23.9
DA7.6	7631	88	12.9	15.5	63.7	76.5
DA8.2	8229	597	7.4	114	5.4	83.0
DA9.5	9580	1350	0	0	0.0	0.0
DA10.2	10203	622	0	0	0.0	0.0
DA10.6b	10614	410	1	0	1.1	0.0
Poisson corrected total COs			184.6	136.1		

Donor 67

SNP	location	distance (bp)	No. A XOs	No. B XOs	cM/Mb, AXOs	cM/Mb, BXOs
DA 5.0	5112		0.0	0.0		
DA 6.1a	6171	1058	0.0	0.0	0.0	0.0
DA 7.0b	7140	968	5.4	15	6.1	16.9
DA 7.4	7481	340	20.3	33.4	65.4	107.8
DA 7.6	7631	149	20.5	43	150.6	316
DA 8.2	8229	597	53	45.3	97.2	83
DA 10.2	10203	1973	0.0	0.0	0.0	0.0
DA 10.6a	10604	400	0.0	0.0	0.0	0.0
Poisson corrected total COs			99.2	136.7		

Donor 33

SNP	location	distance (bp)	No. A XOs	No. B XOs	cM/Mb, AXOs	cM/Mb, BXOs
DA6.1a	6171		0.0	0.0		
DA6.3	6335	163	0.0	0.0	0.0	0.0
DA6.3a	6352	16	0.0	0.0	0.0	0.0
DA7.0a	7049	966	7	5	10.2	10
DA7.0b	7140	90	0.0	0.0	0.0	0.0
DA7.4	7481	340	24	17	97.6	69
DA7.5a	7542	60	19	13	438	300
DA7.6	7631	88	29	26	456	409
DA10.0	10126	2494	15	12	8.4	7.0
DA10.6	10563	436	0.0	0.0	0.0	0.0
DA10.6a	10604	40	0.0	0.0	0.0	0.0
Poisson corrected total COs			94	73		

Table 4.2 Distribution of crossovers in the Hotspot DA. The name of each informative SNP site in the target interval for each donor, their locations and their distance (bp) to next marker, number of crossovers for orientation A, number of crossover for orientation B, calculated recombination activity in cM/Mb for orientation A and orientation B (separately) and Poisson corrected number of crossovers for both orientation A and B are also shown above. The number of crossover showed differences between orientation A and B in some donors. This means, mixture PCR reactions were observed in some crossovers and these mixture reactions carried more than one molecules.

4.6.4 Distribution of Crossover and The Centre of The Hotspot

Table 4.3 shows the summary of the centre point of the hotspot for four donors. The centre of the hotspot was calculated by the programme written by Alec Jeffreys, University of Leicester, UK.

Donors	Centre of the Hotspot (bp)	95% CI, width (kb)
7	7601	1.6
6	7583	1.3
67	7597	1.0
33	7532	1.0

Table 4.3 The summary of the centre of the hotspot for four donors. All four donors showed very similar centres; the small differences could result from sampling differences.

Analysis of cumulative crossover frequency distributions across the target interval (Figure 4.14) showed that hotspot DA was active in all four donors, but not in donor 44, who is homozygous (T/T) for the motif-disrupting SNP. Moreover, these donors (7. 6. 67 and 33) showed varying crossover frequencies. Also, the cumulative frequencies of orientations A, B and combined A+B crossovers for each donor are shown in Figure 4.14. The A+B distributions are very similar in all four donors and define a typical narrow crossover hotspot 1.4 kb wide.




Figure 4.14 Cumulative frequency of crossovers for Hotspot DA. The cumulative frequency values for orientation A (red), and B (blue) for each donor are shown. The best fit curve for orientations A+B (black) is shown for each donor. The curves for all four donors show a similar shape. Cumulative distributions shifted by 330-450 bp for A and B crossovers for donors 7 and 6. The crossover asymmetry was not observed at donors 67 and 33.

The separate A and B crossovers show major asymmetry in the heterozygous donors 7 and 6, with A and B cumulative distributions shifted by 330-450 bp. This asymmetry is not present in the homozygous donors 67 and 33, and therefore appears to result from heterozygosity for an intact and disrupted 13-bp sequence motif, consistent with a major reduction in recombination initiation efficiency triggered by motif disruption.

4.6.5 Biased Gene Conversion In Crossover Progeny

Markers within the hotspot showed massive over-transmission (figure 4.15) with central markers (DA7.5G/T and DA7.5aC/T) showing 90:10 transmission ratios into crossover progeny in donor 7 and donor 6. A two-tailed Fisher exact test was performed to check if the numbers were significantly different from the 50:50 (Mendelian transmission) ratio and is showed statistically extremely significant ($P = 0.0001$). This biased gene conversion is maximal for the motif-disrupting SNP located just 90 bp from the hotspot centre. Donor 7 and donor 6 both over-transmit the disrupting T-allele into crossovers, consistent with motif disruption down-regulating crossover initiation. Transmission distortion in donor 33 is much less marked, with central marker (DA7.5aC/T) showing at most a 53:47 transmission ratio ($P = 0.7773$, statistically not significant), donor 67 showed 51:49 ($P = 1.000$) transmission ratio at the central markers (DA7.4A/C and DA7.6C/A).




Figure 4.15 Transmission of alleles from one haplotype into crossover progeny. Central Markers (DA7.5G/T and DA7.5aC/T) showed 90:10 transmission ratios into crossover progeny in donor 7 and donor 6. This biased gene conversion is maximal for the motif-disrupting SNP located just 90 bp from the hotspot centre. However, transmission distortion in donor 33 and donor 67 is much less marked, with central markers showing at most respectively 53:47 and 51:49 transmission ratios. The location of the disrupting SNP DA7.5G/T is shown by the green line.

4.7 GENE CONVERSION AT THE HOTSPOT DA

A non-exchange gene conversion assay for Hotspot DA was carried out by Alec Jeffreys, University of Leicester, UK, while this thesis was being written up.

4.7.1 Strategy of Recovering Crossovers and Non-crossovers

The strategy for detecting crossovers (COs) and non-exchange gene conversions (NCOs) is summarised in Figure 4.16. Donor 6 and donor 55 were the best candidates for this assay, since both tested donors were heterozygous for SNPs DA7.4 and DA7.5. Also, these SNPs are located close to the hotspot centre and should show the highest frequency of conversion compared with markers further from the hotspot centre. However, given the relatively low crossover frequency at hotspot DA, it is not possible to detect conversions at just one of these sites using the half-crossover assay approach.

SNPs DA7.4 and DA7.5 are separated by only 19 bp and should therefore co-convert in the majority of NCO events that span at least one of these sites. The strategy was therefore to identify and map DA7.4/DA7.5 co-conversion events in pools of sperm DNA using nested allele-specific PCR. This approach will miss conversion tracts that include only one of these SNPs, as well as tracts that do not include either site, so NCO frequencies will be under-estimated; this is however true for all NCO assays, since markerless tracts will always go undetected.




Figure 4.16 The strategy for detecting crossovers (COs) and non-exchange gene conversions (NCOs) at Hotspot DA. **a**) Progenitor haplotypes in the two donors (6 and 55) tested. Both showed the same linkage phase for SNPs DA2.6, DA3.7 and DA10.6b used to separate COs and NCOs, and also for SNPs DA7.4 and DA7.5 used to detect NCO events spanning these sites. Universal (non-allele-specific primers) also used in this analysis are shown as black arrows. **b**) Two separate primary PCRs were used on multiple pools of sperm DNA containing DNA inputs ranging from 150 to 1500 amplifiable molecules of each haplotype, and also on blood DNA from donor 6, across two 96-well plates per man per orientation. 63,000 sperm molecules were scored in each orientation for donor 6, and 156,000 molecules for donor 55. These primary PCRs used one or other allele-specific primer directed to SNP DA2.6 in combination with a downstream universal primer. PCR products will be enriched for one or other type of non-recombinant progenitor haplotype molecules (NR) plus different types of any COs and NCOs present, depending on the SNP DA2.6 primer used. All further analyses were carried out on these primary PCR products. **c**) Re-amplification with nested allele-specific primers in repulsion

phase, as in a regular crossover assay, selectively amplified CO molecules. The specificity of ASPs used for SNP 10.6b was good enough for CO molecules to be detected and mapped directly by ASO hybridisation to these secondary PCR products, exactly as for regular CO mapping. d) Re-amplification of the same primary PCRs with nested allele-specific primers in coupling phase resulted in NR and NCO molecules being amplified and CO molecules being eliminated. e,f) NCOs with switches at SNPs DA7.4 and DA7.5 were selectively amplified from these coupling-phase secondary PCRs by nested PCR using DA7.4 plus DA7.5 ASPs in combination with universal primers as indicated. Forward ASPs selectively amplified the 3' end of NCO molecules, while reverse ASPs amplified the 5' end of the same molecules. Thus each NCO was recovered in two pieces. Conversion tracts were then mapped by ASO hybridisation of these two pieces. This approach gave good specificity and yielded NCOs, detectable by agarose gel electrophoresis, from sperm DNA but not from blood DNA (no events seen in 63,000 blood molecules screened from donor 6), providing good evidence that these NCOs are genuine and of meiotic origin. Note that COs and NCOs were analysed in the same primary PCRs (b) and were, as expected, distributed across PCRs independently of each other. (Figure drawn by Alec jeffreys, University of Leicester, UK).

4.7.2 Crossover and Non-crossover Frequencies

The crossover frequency for donor 6 was higher than previously measured (0.152% vs. 0.070%), reflecting maybe variation in DNA quality and/or quantity, or primer efficiency. However the crossover frequency for donor 55 showed average (0.062%) frequency for Hosspot DA (Table 4.4).

NCO frequencies were low (Table 4.4), at about 10% of the CO frequency in both donors. Previously, studies showed a wide range of NCO: CO ratios, with typical values of ~1:3 at other hotspots. The NCO frequency at hotspot DA seems unusually low, though this might well reflect missing NCOs since only those that had co-converted at SNP DA7.4 and DA7.5 were scored. There is no significant difference between the two donors in the ratio of NCOs to COs (Fisher exact test, $P = 0.14$).

Donors	Sperm molecules screened	Number of COs	CO frequencies, %	Number of NCOs	NCO frequencies, %	NCOs:COs
6	126,000	192	0.152	15	0.0119	1: 12.8
55	312,000	193	0.062	26	0.0083	1: 7.4

Table 4.4 Poisson-corrected numbers of recombination eventx for donors 6 and 55 are shown above.

4.7.3 Reciprocal Crossover and Conversion Asymmetry

The centre point of the hotspot for donor 6 was estimated at position 7564 and the width within which 95% of crossovers took place was estimated at approximately 0.8 kb (previously the centre of donor 6 was estimated at position 7583 and the width was 1.3 kb). The sampling differences caused only minor differences in centre point location (19 bp) and width (0.5 kb) . However, the centre point for donor 55 was at position 7523 and the width 1.5 kb. Marker DA5.7G/T has transmitted the T allele and showed 80:20 for donor 6 and 86:14 for donor 55 statistically extremely significant (respectively, $P = 0.0001$, two-tailed Fisher exact test and $P = 0.0001$, two-tailed Fisher exact test) transmission ratios into crossover progeny. Marker DA7.5aC/T showed the highest transmission ratio (91:9) ($P = 0.0001$, two-tailed Fisher exact test) for donor 6 in both crossover assays. While donor 55 seems to have a broader distribution of crossover breakpoints, the basic features are much as observed in terms of hotspot centre, the strong over-transmission of allele DA7.5T (Figure 4.17). These transmission ratios confirmed previous results (Figure 4.15).




Figure 4.17 Cumulative frequencies of crossovers (a), and transmission of alleles from one haplotype into crossover progeny (b) in donors 6 and 55. a) The cumulative frequency values for orientation A (red), and B (blue) for donors are shown. The best fit curve for orientations A+B (black) are shown for each donor. The curves for both donors show a similar shape. Cumulative distributions are shifted by 380 bp for donor 6 and 495 bp for donor 55 for A and B crossovers. b) Transmission of alleles from one haplotype into crossover progeny in those donors normalised to equal frequencies of A and B orientations. Massive over-transmission was observed the markers within the hotspot. Central Marker DA7.5G/T showed 80:20 (donor6) and 86:14 (donor 55) over-transmission ratios into crossover progeny (the location of disrupting SNP DA7.5G/T is shown by a green line).

Conversion asymmetry

The non-crossovers showed complete bias, with all 41 NCOs (34 events before Poisson correction) resulting in the transfer of DA7.5T to the DA7.5G haplotype, and with no instances of G>T transfers. This extreme bias is highly significant ($P = 1.2 \times 10^{-10}$) and is in the same direction as the bias seen in crossovers. Table 4.5 compares the transmission distortion seen in COs and NCOs:

	d6	d55	d6+d55
COs with 7.5G *	34	26	60
COs with 7.5T *	130	156	286
Observed NCOs with 7.5G	0	0	0
Observed NCOs with 7.5T	14	20	34
<i>P</i> bias in COs and NCOs same	0.075	0.083	0.0049
Poisson-corrected NCOs with 7.5G	0	0	0
Poisson-corrected NCOs with 7.5T	15	26	41
<i>P</i> bias in COs and NCOs same	0.078	0.051	0.0010

Table 4.5 Comparison of the transmission distortion seen in crossovers (COs) and non-crossovers (NCOs) in both donors 6 and 55. The table respectively shows the number of COs with alleles 7.5G and 7.5T, the number of observed NCOs with alleles 7.5G and 7.5T and *P* values of bias in COs and NCOs at the direction as crossovers, the number of Poisson-corrected NCOs with haplotypes 7.5G and 7.5T and *P* values (after Poisson correction) of bias in COs and NCOs for each donors 6 and 55, 6+55. (*Numbers normalised to equal numbers of A and B crossovers.)

For both donors 6 and 55, the strength of distortion is greater in NCOs than in COs. For each donor, this disparity is not significant (Fisher exact tests on numbers of 7.5G- and T-containing COs vs. numbers of G- and T-containing NCOs). However, it is significant for data from both donors combined, even on raw counts of numbers of NCOs before Poisson correction. It therefore appears that NCOs show a significantly stronger bias towards acquiring 7.5T compared with COs.

4.7.4 Conversion Tract Lengths

40-48% of NCOs show co-conversion of one or more flanking markers, most particularly at SNP DA7.5a that lies just 41 bp away from SNP DA7.5. There are examples of quite long conversion tracts incorporating 5-6 SNPs in each donor, with minimum tract lengths of 607 and 583 bp in donor 6 and donor 55 respectively, though they could be much longer since there are not sufficient markers to narrow the location (e.g. the tract with minimum length 583 bp could be as long as 2237 bp).

The conversion data were selected for NCOs showing conversion at SNPs DA7.4 plus DA7.5, and could not be used to determine an overall conversion profile across the hotspot. SNP DA7.5a is of particular interest, as it seems to map closer to the centre

of the hotspot and might show a higher NCO activity. Nevertheless, the data can be used to determine the likelihood that a flanking SNP is co-converted in those NCO molecules known to have converted at DA7.4 plus DA7.5. These data, with 95% confidence intervals, are shown below for both donors; the locations of SNPs DA7.4 and DA7.5 are shown by dotted lines (Figure 4.18).




Figure 4.18 Probability of co-conversions. (This graph was drawn by Alec Jeffreys, University of Leicester, UK)

While the sample sizes are small, there is clear evidence for a very steep gradient, with the likelihood of co-conversion declining rapidly as one moves away from the selected sites DA7.4 and DA7.5. This fits with previous studies of NCO distributions in human hotspots (Sarbjana *et al.*, 2012).

4.7 DISCUSSION

A 15-kb target interval around Hotspot DA which was centred on the motif-disrupting SNP 7.5 within the 13-bp hotspot sequence motif was assayed for recombination activity in a total of six men. The crossover rates showed Hotspot DA to be a regular hotspot with an average crossover rate among hotspots assayed on autosomal chromosomes. Hotspot DA provides strong evidence that the motif is likely involved in promoting the initiation of recombination. Five assayed donors (6, 7, 33, 55 and 67) showed very similar hotspot locations for orientation A + B crossovers combined. This centre is displaced 3' to DA7.5 by about 50-70 bp. The numbers of crossovers mapping 5' and 3' of DA7.5 were normalised to equal numbers of A and B crossovers, and a Fisher test was performed to check if the numbers were significantly

different from the 50:50 ratio predicted if DA.7.5 is located exactly at the centre. Donors 6, 7, 33 and 67 showed statistically significant crossovers mapping of DA7.5 was; the only exception was donor 55 where the shift was of borderline significance ($P = 0.054$, two-tailed Fisher exact test). Thus, DA7.5 and the motif were not located at the centre of hotspot DA. Sperm crossovers in men heterozygous for a motif-disrupting variant show the greatest transmission distortion ratio (~ 90:10) ever seen in a human crossover hotspot (Jeffreys and Neumann, 2002; Neumann and Jeffreys, 2006).

The transmission frequency results showed that the asymmetries in three heterozygous donors (donors 6, 7 and 55) for the motif disrupting SNP DA7.5G/T were very similar in terms of the transmission of DA7.5T to crossover progeny (90:10 transmission ratio) and in terms of the displacement of orientation A versus orientation B crossover distributions. Donors (33 and 67) that carried the active G-allele showed the highest recombination frequency respectively of 0.115% and 0.155% among analysed 6 donors. Donors 6 and 55 are both heterozygous for the disrupting SNP and showed similar recombination frequencies (0.07% and 0.06%). However another heterozygous for the disrupting SNP, donor 7 showed markedly different crossover frequencies (0.013%) than donors 6 and 55. This shows that there might be other affects (*cis*- or *trans*- factors) for this donor for the hotspot activity.

The direction of biased gene conversion indicates that the chromosome carrying the disrupting allele was suppressed for crossover initiation. This was supported by donor 44, who is homozygous for suppressing allele for the motif disrupting SNP (T/T). There were no single recombinant molecules observed in the crossover assay. The strength of biased conversion in favour of the suppressing allele, combined with the high activity of the hotspot, was sufficient to ensure its eventual population fixation, highlighting the necessarily ephemeral nature of recombination hotspots.

Gene conversion assays carried out on two donors (6 and 55) showed biased non-crossover frequencies to be low, at about 10% of the crossover frequency in both cases. However to date, observed relative rates of NCO: CO showed major variation between human hotspots (Holloway *et al.*, 2006). However, those studied hotspots showed a wide range of NCO: CO ratios were typically ~1:3 (Holloway *et al.*, 2006;

Sarbajna *et al.*, 2012). The non-crossover frequency at hotspot DA seems unusually low, though this might well reflect missing non-crossovers since we only scored those that had co-converted at SNP 7.4 and 7.5. There was no significant difference between the two donors in the ratio of non-crossovers to crossovers (Fisher exact test, $P = 0.14$). Nevertheless, the data can be used to determine the likelihood that a flanking SNP is co-converted in those non-crossover molecules known to have converted at 7.4 plus 7.5. While the sample sizes are small, there was clear evidence for a very steep gradient, with the likelihood of co-conversion declining rapidly as one moves away from the selected sites 7.4 and 7.5. This fits with previous studies of non-crossover distributions in human hotspots.

This suggests perhaps two different pathways for generating NCOs and COs, as seen in yeast and mice. The NCO pathway (maybe the SDSA model, (Petes, 2001)) would require that SNP 7.5 is always incorporated into a G/T heteroduplex in G/T heterozygotes and is always repaired in favour of the T-allele during e.g. early mismatch repair. The CO pathway would have to be different, either in terms of a lower likelihood that a G/T heteroduplex is generated, or in terms of a lower visibility of the heteroduplex to mismatch repair or a lower strength of bias in favour of T during repair. Also, a similar story is seen at a PAR2 hotspot (Sarbajna *et al.*, 2012). Gene conversion that favors the transmission of GC-alleles over AT-alleles, was not observed at Hotspot DA.

To sum up, Hotspot DA is the unique example to date of strongly direct *cis*-regulation for hotspot on/off polymorphism in which a disrupting SNP is located close to its centre. This is confirmed by our reciprocal crossover asymmetry and non-exchange bias gene conversion assays.

CHAPTER 5: EFFECT OF TRANS-REGULATOR FACTOR PRDM9 ON HOTSPOT DA

5.1 INTRODUCTION

In Chapter 4, variation in the crossover frequencies between men heterozygous for the disrupting SNP (DA7.5G/T) within the motif was observed using crossover assays. In particular, a low recombination frequency was observed for one of the heterozygous men. This result was unexpected, because of the high sequence similarity between all heterozygous men showing higher and lower crossover frequencies. This suggests that there might be other factors that affect the hotspot activity besides the *cis*-regulator SNP (DA7.5G/T). The question thus remained: are there any other elements within Hotspot DA that could influence hotspot initiation? Or, based on recent studies (Baudat *et al.*, 2010; Myers *et al.*, 2010; Berg *et al.*, 2010) are there any *trans*-regulators that may be responsible instead?

The *trans*-regulator factor PRDM9 has been identified as a regulator of hotspot usage in mice and humans (Baudat *et al.*, 2010; Myers *et al.*, 2010; Berg *et al.*, 2010). The protein encoded by the *PRDM9* gene consists of an N-terminal KRAB domain and a SET domain encoding a histone methyl-transferase followed by a tandem repeat zinc finger domain. The PRDM9 variant A has 13 C2H2 zinc-fingers (ZnF), each encoded by an 84 bp repeat of a minisatellite (Hayashi *et al.*, 2005), and is the most common variant in Europeans and Africans (Baudat *et al.*, 2010, Berg *et al.*, 2010). At positions -1, 2, 3 and 6 of the α -helix domain, every ZnF has four predicted DNA contact residues (Baudat *et al.*, 2010). Based on these residues, the last six ZnFs of the variant PRDM9 allele A are predicted to be responsible for binding to eight non-degenerate bases of the 13-mer CCNCCNTNNCCNC hotspot motif (Baudat *et al.*, 2010, Myers *et al.*, 2010, Berg *et al.*, 2010). This hotspot motif can be found in about 40% of human recombination hotspots (Myers *et al.*, 2008; Myers *et al.*, 2010).

The first direct evidence for *PRDM9* regulation in humans came from Hutterite individuals in a single pedigree carrying the variant PRDM9 allele I, which encodes a

ZnF array that cannot bind to this motif (Baudat *et al.*, 2010). This study used linkage analysis to show a genome-wide shift in hotspots activity (Baudat *et al.*, 2010).

PRDM9 alleles have been genotyped in our semen donors by A. Jeffreys, R. Neumann and I. Berg (University of Leicester, Leicester/ UK) as described in (Berg *et al.*, 2010). *PRDM9* variability was limited in Europeans, therefore ZnF alleles in a panel of 74 African semen donors and 156 European donors based on the number of ZnF repeats (8-18 ZnFs) were sequenced in our laboratory (Berg *et al.*, 2010). All reported *PRDM9* alleles (A-E), except variant *PRDM9* allele I, that were seen in the Hutterite population (Baudat *et al.*, 2010), were also present within our European semen donor panel. In addition, 24 new *PRDM9* alleles (L1-L24) was identified (Berg *et al.*, 2010). *PRDM9* variability was much higher in the African donor panel. Additionally, the classification of alleles according to the predicted ability of the resulting protein variants to recognise the hotspot motif showed that nearly half of these variants should result in impaired binding relative to the common A allele as shown in Figure 5.1 (Berg *et al.*, 2010).




Figure 5.1 *PRDM9* variants A and L1, with examples of tandem repeats encoding the ZnF array with variant repeat units coloured differently (modified from Berg *et al.*, 2010). The predicted binding sequence is shown above, with dots indicating weakly predicted bases and uppercase letters indicating the most strongly predicted bases, and aligned with the hotspot motif CCNCCNTNCCNC (Myers *et al.*, 2008). The binding sequence for the variant *PRDM9* allele A matches all eight specified bases in the motif, while allele L1 matches at best only six of the eight bases.

Recent studies indicated that the *trans*-regulator *PRDM9* has a strong effect on the activity of human sperm hotspots (Berg *et al.*, 2010, Berg *et al.*, 2011) and mouse hotspots (Baudat *et al.*, 2010, Parvanov *et al.*, 2010, Grey *et al.*, 2011, Brunshwig *et al.*, 2012), and even at hotspots lacking the sequence motif (Berg *et al.*, 2010). The changes within the ZnF can create hotspot non-activating or enhancing variants and

can even trigger the appearance of a new hotspot. Therefore, PRDM9 is a major global regulator of hotspots in mammals (Berg *et al.*, 2010, Berg *et al.*, 2011, Grey *et al.*, 2011, Brunschwig *et al.*, 2012). In chapter 4, *cis*-regulation was studied for hotspot DA; this hotspot has a disrupting SNP (DA7.5G/T) within its motif sequence close to the centre of the hotspot, and strong *cis* influences were observed. According to recent studies, the question remained: what is the effect of the *trans*-regulator PRDM9 on the activity of Hotspot DA? Therefore, in this chapter, more men with variant PRDM9 genotypes were analysed to explore possible influences of PRDM9 status on crossover frequencies.

5.2 DESIGNING THE CROSSOVER ASSAYS

To test whether the *trans*-regulator PRDM9 has any influence on crossover frequencies at Hotspot DA, a more efficient crossover assay was used to analyse crossover frequencies. The crossover assay relies on nested repulsion-phase allele-specific PCR to selectively amplify crossovers from sperm DNA. The principle of the crossover assay has been explained in detail in the Materials and Methods chapter, but in summary, two sets of heterozygous selector sites located within LD blocks flanking both sides of the hotspot are identified and optimised for primers to allow for efficient crossover detection in as many men as possible. The crossover frequency results of multiple men would give clues about the factors that influence hotspot activation in *cis* and in *trans*. To allow as many PRDM9 variants as possible to be tested, 74 Afro-Caribbean and Zimbabwean (African) and 156 European men were investigated.

5.2.1 SNP Discovery and Annotation for the African Panel

As explained in Chapter 3, a 15-kb interval of DNA sequence spanning Hotspot DA was downloaded from ENSEMBL (www.ensembl.org). The sequence was annotated to include all SNPs (including both European and African) and repeat sequences (LINEs, Alus etc) (Appendix I) using information gained from Phase II HapMap data, dbSNP data and Repeat Masker. All identified 38 SNPs were genotyped using Allele Specific Oligo (ASO) hybridisation (see Materials and Methods for more details) (Table 5.1). 74 African semen donors were amplified on DA amplicons (PCR conditions and primers are shown in Appendix II).

[illegible]

Table 5.1 SNP genotypes from the African semen donor panel. 38 SNPs for Hotspot DA were genotyped. SNP names and their locations and donor number are shown. Each genotype is depicted as either a homozygote (A, C, G, T, +, -) or heterozygote (H). The motif disrupting SNP DA.7.5T/G is highlighted in red.

5.2.2 LDU Mapping for African Panel

Using this genotype data, metric LD analysis (LDU) was performed (Figure 5.2) to see if the African population showed a historical hotspot as well as the Europeans (Chapter 3).




Figure 5.2 LDU map as established from the genotyped African panel. The length of ticks in the bottom panel represents the minor allele frequencies (MAFs) of the SNPs within the population tested. The location of the disrupting SNP DA7.5G/T within the 13-bp motif is shown with a black arrow.

The LDU map across Hotspot DA showed an increase of LD across the target interval in the African population, implying that historical recombination has taken place. The LDU step of the African population was reduced two-fold compared to the European population (see Figure 3.4). However, historical recombination has not necessarily influenced LD to a similar extent in both populations.

5.2.3 Allele-Specific Primers (ASPs) and Optimisation of Selector Sites


It was important to analyse as many men as possible. According to genotype LDU maps of both European and African populations, several sites became apparent as potential selector sites, located outside of Hotspot DA. Additional to previously designed and tested ASPs (see Chapter 4), 16 forward ASPs and 12 reverse ASPs were designed. Universal reverse primer DA10.3R was used for optimising forward ASPs at four different annealing temperatures respectively: 56°C, 59°C, 62°C and 65°C (Figure 5.3a). ASP DA4.8FA did not work with the chosen annealing temperatures. Additionally, ASPs DA5.3FA and DA7.0FA did not show any specificity. ASPs DA4.8FC, DA5.0RC, DA5.3FA, DA5.3FT, DA7.0bFG and DA7.4FC and DA5.0RC, DA6.1FC and DA7.0bFT showed optimal efficiency and specificity (respectively, 56-65+ °C and 59-65+ °C). Moreover, ASPs DA7.0FG and DA7.4FA showed efficiency and specificity between 56°C and 62°C, and ASPs DA6.0FG and DA6.1FT showed between 62°C and 65°C. Finally, ASP DA5.0FT showed specificity at 65°C.

DA5.2F and DA9.9aF were used as forward universal primers for the optimisation of reverse allele-specific primers. The optimised temperatures for ASPs DA10.0RG/A and DA10.2RC/T were 50°C, 53°C, 56°C and 59°C, however for ASPs DA13.4R-/+, DA13.4RA/G, DA13.5RT1/C1 and DA13.8aRA/G were 56°C, 59°C, 62°C and 65°C (Figure 5.3b). ASP DA10.0RA did not show any specificity at these temperatures. ASPs DA13.5RC1 and DA13.8aFG showed very good efficiency and specificity at the temperatures between 56-65°C. ASPs DA10.2RC, DA10.2RT and DA13.4RA showed their specificity at 59°C. ASP DA10.0RG worked efficiently between 50 °C and 59 °C. The other ASPs DA10.2RC, DA13.4R-/+, DA13.4RG, DA13.5RT1 and DA13.8aFA showed specificity at annealing temperatures of 50-59°C, 56°C, 62-65°C, 56-59°C and 56-62°C respectively.

DA 4.8F



DA10.2R



DA13.4R




Figure 5.3 Optimisations of forward and reverse allele-specific primers. a) Eight forward ASP pairs were optimised: DA4.8FA/C, DA5.0FT/C, DA5.3FA/T, DA6.0FA/G, DA6.1FC/T, DA7.0FA/T and DA7.4FA/C (DA7.0bFT/G is not shown in the figure) from donors homozygous for either the allele being tested or the opposite allele amplified from MDA DNA. DA10.3R was used as a reverse universal primer. PCRs using each primer were performed at four different annealing temperatures 56 °C, 59 °C, 62 °C and 65 °C. b) Six reverse ASP pairs were optimised: DA10.0RG/A, DA10.2RC/T with optimisation temperatures 50 °C, 53 °C, 56 °C and 59 °C respectively. ASPs DA13.4R-/, DA13.4RA/G, DA13.5RT1/C1 and DA13.8aRA/G, which are not shown on the figure, annealing temperatures were 56 °C, 59 °C, 62 °C and 65 °C respectively. Universal forward primer DA5.2F was used for DA10.RG/A and DA10.2RC/T, and universal primer DA9.9aF was used for the rest of the reverse ASPs. DNA inputs were 10ng MDA DNA (previously measured and stored by Rita Neumann and Alec Jeffreys, University of Leicester, UK) per 10µl PCR/ reaction. (M: marker λ HindIII and ϕ XHaeIII).

5.2.4 Phasing of Selector Alleles

Analysis of population LD had revealed that forward and reverse sets of alleles were in strong LD in Europeans and Africans. But haplotypes needed to be determined. To solve this problem, the designing of linkage phasing are illustrated in Figure 5.4a. The linkage phase of forward and reverse selector sites, as well as between two forward and two reverse alleles, had to be determined experimentally in each donor selected for crossover assay. In Figure 5.3b the linkage phasing results for d232 are shown with the two haplotypes of d232 as determined by linkage phasing. 28 donors were selected for crossover assay.




Figure 5.4 Phasing of selector alleles. Linkage is represented by the line, with SNP alleles represented by circles, and the allele indicated above each circle. a) Strategy for phasing and determining the haplotypes. The forward selector sites 3.7 and 4.0a and two reverse selector site 10.2 and 10.6b were selected for donor 232. 12 possible reactions were designed for determining the haplotypes. b) Agarose gel results for donor 232. Positive reactions determined the two haplotypes of donor 232. (M: marker λ HindIII and ϕ XHaeIII).

5.2.5 The Crossover Assays

Crossover assays were set up with forward and reverse primers in repulsion-phase (see Chapters 2 and 4). Primary PCR amplification of pools of sperm DNA used outside ASPs and secondary amplification of the primary PCR product was performed using inside nested ASPs to improve specificity and PCR yield. Crossover assays were carried out on 28 men, with each assay testing only one orientation of recombination. Four different pool sizes of sperm DNA molecules were set up for

each man. According to a previous estimate of crossover frequency for men homozygous for the disrupting SNP DA7.5G/T and assuming the crossover frequency is ~0.13 % for this hotspot, the pool sizes were adjusted so that they contained 0.6, 1.2, 2.4 and 4.8 crossover molecules, respectively (Table 5.2).

A universal PCR master-mix was made up for two plates to minimise variation in amplification results. Two men were analysed on the same PCR plate (in total ~1 µg sperm DNA was used for each donor), using twelve aliquots for each pool size, except for the smallest pool size. For both of the men, the first and second samples were replaced with genomic DNA from a man with selector SNPs in coupling phase in amounts of 0.1 ng and 1 ng respectively, to function as a positive control.

Donor	Population	1 st pool size	2 nd pool size	3 rd pool size	4 th pool size	Primary PCR ASPs	Secondary PCR ASPs
8	British	482	964	1929	3858	DA2.6FC + DA10.6bRC	DA3.7FG1 + DA10.6RG2
12	French	381	762	1525	3092	DA2.6FG + DA10.6bRC	DA3.7FG1 + DA10.6RA2
17	British	473	946	1892	3784	DA2.6FG + DA12.0RC	DA3.7FT1 + DA10.6bRA
26	British	309	618	1236	2472	DA2.6FC + DA10.6bRC	DA3.7FG1 + DA10.6aRA
31	British	411	849	1672	3345	DA2.6FG + DA12.0RT	DA3.7FT + DA10.6bRC
73	British	469	938	1875	3750	DA2.6FG + DA10.6bRC	DA3.7FT1 + DA10.6aRA
178	Afro-Caribbean	440	880	1760	3520	DA4.8FC + DA13.5RC1	DA5.3FT + DA13.4RaR1-
180	Afro-Caribbean	369	739	1479	2958	DA2.6FG + DA12.0RT	DA3.7FT1 + DA10.6aRA
181	Afro-Caribbean	440	880	1760	3520	DA6.1FT + DA13.8aRG	DA7.0FG + DA13.5RT1
184	Afro-Caribbean	461	922	1845	3691	DA6.1FT + DA13.8aRA	DA7.0FG + DA13.5RC1
185	Afro-Caribbean	514	1029	2047	4117	DA2.6FG + DA12.0RT	DA3.7FT1 + DA10.2C1
186	African	461	922	1845	3691	DA4.8FC + DA13.8aRG	DA5.3FT + DA13.4aR1-
211	British	464	927	1854	3708	DA2.6FG + DA10.6bRC	DA4.0aFG + DA10.2RC
232	British	477	954	1907	3820	DA2.6FC + DA12.0RC	DA3.7FG1 + DA10.6bRA
236	Zimbabwean	311	622	1244	2487	DA3.7FT + DA10.6bRC	DA4.0aFG + DA10.2RC
238	Zimbabwean	369	738	1476	2953	DA3.7FT + DA10.6bRC	DA4.0aFG + DA10.2RC
243	Zimbabwean	461	922	1845	3691	DA6.1FC + DA13.8aRA	DA7.4FA + DA13.4aR1+
244	Zimbabwean	460	920	1840	3680	DA7.0FG + DA13.4R1-	DA7.0bFT + DA10.2RC
247	Zimbabwean	413	827	1654	3300	DA2.6FG + DA10.6bRC	DA3.7FG1 + DA10.6aRA
251	Zimbabwean	312	624	1247	2495	DA3.7FT + DA10.6bRC	DA4.0aFG + DA10.2RC
253	Zimbabwean	470	941	1882	3764	DA2.6FG + DA12.0RT	DA3.7FT1 + DA10.6RG2
256	Zimbabwean	369	739	1479	2958	DA2.6FG + DA12.0RC	DA3.7FT1 + DA10.2C1
259	Zimbabwean	462	924	1849	3699	DA7.0FG + DA13.4R1-	DA7.4FC + DA10.2RC
261	Zimbabwean	440	880	1760	3520	DA4.8FC + DA13.5RC1	DA5.3FT + DA10.6bRA
269	Zimbabwean	366	732	1464	2927	DA2.6FG + DA12.0RT	DA3.7FT1 + DA10.6aRA
272	Zimbabwean	465	930	1860	3720	DA6.1FC + DA13.8aRA	DA13.4aR+ + DA7.0bFG
279	Zimbabwean	462	925	1850	3701	DA7.0bFT + DA13.8aRA	DA7.4FA + DA13.4aR+
280	Zimbabwean	369	739	1479	2958	DA2.6FG + DA12.0RT	DA3.7FT1 + DA10.2T1

Table 5.2 Crossover assay designs for all possible donors. The Table illustrates respectively, donors, the population to which he belongs, the pool sizes for recombination assays, and primary and secondary PCR primers. Only one orientation was used for each donor, with orientation A coloured in blue and B marked in green. All PCR profiles and primers are shown in Appendix II.

5.2.6 Determining Crossover Frequencies

Crossover frequencies were calculated from the pooled number of positive and negative results as seen from PCR products and detected by ethidium bromide staining after gel-electrophoresis. Positive PCRs indicated the presence of at least one crossover molecule in the original pool of sperm DNA. In Figure 5.5 an example of a recombinant molecule detection is shown. Pools containing fewer molecules were less likely to be positive for crossovers, while pools containing more molecules were more likely to be positive for recombinants. Poisson-correction was used for each of the analysed men to estimate the number of crossover molecules from the proportion of PCRs that were negative. A maximum-likelihood software (written by Alec Jeffreys, University of Leicester, Leicester, UK) was used to combine data across all input pool sizes.




Figure 5.5 Crossover detection after repulsion-phase allele-specific PCR. Secondary PCR products of a crossover assay for d185 (homozygous (T/T) for disrupting SNP DA7.5) and d236 (heterozygous (G/T) for disrupting SNP DA7.5) men were analysed by agarose gel electrophoresis followed by ethidium bromide staining. For all four of the analysed pool sizes, the number of amplifiable molecules of each progenitor haplotype in the respective pools is shown for each man. Positive recombinants appeared as black bands. Positive controls, including sperm DNA from a man with primers in coupling phase, is indicated by (+) with respectively, 0.1 ng and 1 ng sperm DNA input. There were no recombinant molecules observed for donor 185. The reason might lay with either *cis*-regulation or *trans*-regulation or both (Berg *et al.*, 2010). (M: marker λ HindIII and ϕ XHaeIII).

A crossover assay was carried out for donors 185 (homozygous (T/T)) for disrupting SNP DA7.5) and 236 (heterozygous (G/T)) for disrupting SNP DA7.5) in Figure 5.5. There were no crossover molecules observed for donor 185, and moreover the recombination frequency of donor 236 (RF: ~0.016%) was lower than the previously estimated recombination rate for this hotspot. To understand the variation of the RFs and their regulatory effects on Hotspot DA, crossover assays for 28 donors were carried out as in Table 5.3.

Donor	Population	DA7.5G/T	RF %	lower 95% CI	upper 95% CI
8	British	G	0.196	0.012	0.336
12	French	G	0.203	0.011	0.346
17	British	H	0.032	0.017	0.06
26	British	G	0.361	0.204	0.625
31	British	H	0.045	0.024	0.077
73	British	H	0.02	0.001	0.039
178	Afro-Caribbean	T	0.000	0.000	0.000
180	Afro-Caribbean	T	0.008	0.002	0.019
181	Afro-Caribbean	T	0.000	0.000	0.000
184	Afro-Caribbean	T	0.000	0.000	0.000
185	Afro-Caribbean	T	0.000	0.000	0.000
186	African	T	0.000	0.000	0.000
211	British	H	0.000	0.000	0.000
232	British	H	0.026	0.013	0.046
236	Zimbabwean	H	0.016	0.008	0.043
238	Zimbabwean	H	0.09	0.053	0.146
243	Zimbabwean	T	0.000	0.000	0.000
244	Zimbabwean	T	0.000	0.000	0.000
247	Zimbabwean	H	0.063	0.035	0.104
251	Zimbabwean	H	0.036	0.017	0.07
253	Zimbabwean	T	0.000	0.000	0.000
256	Zimbabwean	T	0.006	0.001	0.017
259	Zimbabwean	T	0.000	0.000	0.000
261	Zimbabwean	T	0.000	0.000	0.000
269	Zimbabwean	H	0.014	0.008	0.022
272	Zimbabwean	T	0.007	0.000	0.010
279	Zimbabwean	T	0.000	0.000	0.000
280	Zimbabwean	G	0.042	0.023	0.071

Table 5.3 Crossover frequencies as estimated for assayed donors. 28 men were assayed for crossovers. The Table shows respectively donors, the populations of the donors to which they belong, the genotype of each man for the motif disrupting SNP7.5G/T, and recombination frequencies with lower and upper 95% confidence intervals (CI), as determined by a Poisson-correction. For example, donor 8 (G/G, homozygous for the active allele of the disrupting SNP DA7.5) showed a higher recombination rate than donor 17 (G/T (H), heterozygous for the active allele for disrupting SNP DA7.5), and moreover, donor 17 showed a higher recombination frequency than donor 178 (T/T, homozygote for the suppressed allele for disrupting SNP DA7.5)

As shown in Table 5.3, different variations of crossover frequency were seen between men. It is clear that *cis*-regulation has a major effect on Hotspot DA activity. For example, donors who are homozygous for active allele (G/G) for the disrupting SNP DA7.5 showed the highest recombination rates, and as a contrast, those homozygote for the suppressing allele (T/T) for disrupting SNP DA7.5 showed the lowest frequencies with most cases showing no crossovers. As expected, the recombination frequencies of heterozygous (G/T) donors are located in the middle. However, donors sharing the same genotype at the disrupting SNP showed substantial differences. For example, donors 26 and 280 are homozygous (G/G) for disrupting allele DA7.5 with RFs of 0.361 and 0.042 respectively, or the RFs of donors 238 and 236 heterozygous (G/T) for disrupting SNP7.5 are 0.090 and 0.016 respectively. According to recent studies, Hotspot DA has a 13-bp sequence motif that is recognised and regulated by PRDM9 (Myers *et al.*, 2010, Baudat *et al.*, 2010, Berg *et al.*, 2010).

In Figure 5.6 the association between crossover frequencies and their disrupting SNP (DA7.5) status for the analysed men is shown for Hotspot DA. The classification for their disrupting SNP (DA7.5) status was men homozygous for active allele (G/G), suppressed allele (T/T) and heterozygous (G/T). The median frequencies were also determined for each group and compared between groups. Men homozygous for the active allele (G/G) showed the highest crossover frequencies, and men homozygous for the suppressed allele (T/T) showed no crossover activity. Therefore, *cis*-regulator SNP DA7.5 has a major impact on Hotspot DA activity. Despite strong *cis* regulation on Hotspot DA, variation between crossover frequencies in the groups also indicates the effect of *trans* regulation.




Figure 5.6 Variation in crossover activity between men at Hotspot DA, indicating their status for the disrupting SNP DA7.5. Individuals were grouped to their status as men homozygous for the active allele (G/G, shown in red) and suppressed allele (T/T, shown in purple), and heterozygous (G/T, shown in blue) for the disrupting SNP DA7.5. 95% Confidence intervals (CI) were estimated using a Poisson correction. Dashed lines indicate the median crossover frequencies observed within each group.

5.2.7 Tertiary PCR Carried Out Men That Homozygous for Suppressed Allele (T/T) for The Motif Disrupting SNP DA7.5

After repulsion-phase allele-specific PCR and according to secondary gel results, crossover frequencies were estimated. Donors that were homozygous for the suppressed allele (T/T) for the disrupting SNP and that have PRDM9 A-allele variants did not show any positive crossovers. Therefore, tertiary PCR was carried out for 15 men that were homozygous for the suppressed allele (T/T) for the 13-bp motif-disrupting SNP DA7.5, in order to determine if those negative crossovers were real. The secondary PCR agarose gel results were confirmed by the tertiary PCR agarose gel results, giving all negative crossovers for men homozygous (T/T) for SNP DA7.5. Thus, the suppressing allele T turned off crossover initiation in the studied men for Hotspot DA (Figure 5.7).




Figure 5.7 Two different PCR cycles of tertiary PCRs ethidium-bromide-stained agarose gel electrophoresis of donors 244 and 256 are shown above. All four analysed pool sizes are shown for each man. Positive controls, including sperm DNA men with primers in coupling phase, are indicated by (+) with respectively, 0.1 ng and 1 ng sperm DNA input. DA7.4F and DA10.0R were used as universal primers. There were no recombinant molecules observed in the donors. (M: marker λ HindIII and ϕ XHaeIII).

5.2.8 Effect of *Trans*-Regulator PRDM9 on Hotspot DA

Table 5.4 shows the PRDM9 status of crossovers assayed in a total of 33 men (28 new donors and 5 previously analysed men (donors 6, 7, 33, 44 and 67, as studied in Chapter 4)). The men that did not carry an A-allele of *PRDM9* displayed the lowest crossover frequencies, and of the men who did carry an A-allele of *PRDM9*, those who were also homozygous for the suppressed allele (T/T) for the disrupting SNP DA7.5 within the motif showed the lowest recombination frequencies. In contrast, donors homozygous for the active allele for the disrupting SNP DA7.5 and who carried the *PRDM9* A allele showed the highest recombination rate. Moreover, the man (donor 236) who is heterozygous for the disrupting SNP DA 7.5 and carrying a non-A allele for *PRDM9* had a recombination rate of % 0.016 , whilst the other men (four men homozygous (T/T) and one man heterozygous (G/T) for the disrupting allele SNP DA7.5) who carried a non-A allele for *PRDM9* did not show any recombination.

donor	population	PRDM9 allele 1	PRDM9 allele 2	DA7.5G/T	RF %	lower 95% CI	upper 95% CI
44	British	A	A	T	0.000	0.000	0.000
256	Zimbabwean	A	B	T	0.006	0.001	0.017
272	Zimbabwean	A	B	T	0.007	0.000	0.010
73	British	A	A	H	0.020	0.001	0.039
31	British	A	A	H	0.045	0.024	0.077
247	Zimbabwean	A	A	H	0.063	0.035	0.104
6	British/Indian	A	A	H	0.069	0.004	0.135
238	Zimbabwean	A	A	H	0.090	0.053	0.146
67	British	A	A	G	0.155	0.007	0.302
8	British	A	A	G	0.196	0.012	0.336
12	British	A	B	G	0.203	0.011	0.346
26	British	A	A	G	0.361	0.204	0.625
261	Zimbabwean	L21	A	T	0.000	0.000	0.000
181	Afro-Caribbean	A	L11	T	0.000	0.000	0.000
243	Zimbabwean	B	L15	T	0.000	0.000	0.000
256	Zimbabwean	A	L12	T	0.000	0.000	0.000
244	Zimbabwean	L22	A	T	0.000	0.000	0.000
178	Afro-Caribbean	C	A	T	0.000	0.000	0.000
184	Afro-Caribbean	A	L7	T	0.000	0.000	0.000
180	Afro-Caribbean	L4	A	T	0.008	0.002	0.019
7	British	A	E	H	0.013	0.007	0.025
269	Zimbabwean	A	L11	H	0.014	0.008	0.022
232	British	A	E	H	0.026	0.013	0.046
17	British	A	L20	H	0.032	0.017	0.060
251	Zimbabwean	A	L16	H	0.036	0.017	0.070
280	Zimbabwean	L4	A	G	0.042	0.023	0.071
33	British	A	L2	G	0.115	0.060	0.224
186	African	L6	L13	T	0.000	0.000	0.000
253	Zimbabwean	C	C	T	0.000	0.000	0.000
185	Afro-Caribbean	C	L12	T	0.000	0.000	0.000
279	Zimbabwean	L6	C	T	0.000	0.000	0.000
211	British	L20	E	H	0.000	0.000	0.000
236	Zimbabwean	L4	L22	H	0.016	0.008	0.043

Table 5.4 Sperm crossover frequencies and their relationship with *PRDM9* status. Men were ranked with recombination frequencies (RFs), and 95% confidence intervals were determined by a Poisson-correction. *PRDM9* variants and SNP information for each man for the motif disrupting SNP7.5G/T are also shown above. The *PRDM9* variant allele B acts like allele A (Berg *et al.*, 2010). The other variant alleles of *PRDM9* are indicated in blue.

To test the association status with crossover frequencies further, *PRDM9* allele classification was firstly simplified to A or N (non-A). With this classification, individuals could either be carrying A/A alleles, A/N alleles or N/N alleles. Individuals were then grouped according to their *PRDM9* status, and median crossover frequencies were determined for each group and compared between groups (Figure 5.6).




Figure 5.8 Variation in crossover activity between men at Hotspot DA. Individuals were grouped by their status into men carrying two A-alleles (A/A shown in red), one A-allele (A/N shown in blue) or non-A alleles (N/N shown in purple). 95% Confidence intervals (CI) were estimated using a Poisson-correction. Dashed lines indicate the median crossover frequencies observed within each group.

The difference between crossover frequencies of men homozygous A/A compared to the frequency of men without A alleles is significant (one-tailed t-test, $P=0.035$; one-tailed Mann Whitney test $P=0.0045$), however when men who carry the suppressed allele T for the disrupting motif were excluded from the group, *PRDM9* status became insignificant ($P=0.0741$). This was probably due to the small number of men with N/N genotypes for *PRDM9*. The higher crossover frequencies of men with an A/A *PRDM9* status compared to men with an A/N status is of marginal significance (one-tailed Mann Whitney Test, $P=0.0029$; one-tailed t-test, $P=0.0034$). However, when the men homozygous for the suppressed allele (T/T) for the disrupting SNP DA7.5 were excluded from the group, the frequencies observed in the A/A men were significantly higher than those in the A/N men (one-tailed t-test, $P=0.0224$). Additionally, the higher crossover frequencies of men with A/A *PRDM9* status compared to men with A/N and N/N statuses are extremely significant (one-tailed Mann Whitney test, $P=0.0006$; one-tailed t-test $P=0.0007$). Moreover, when the men carrying the suppressed allele (T/T) were excluded, the compared frequencies between A/A versus A/N and N/N stayed significant (one-tailed t-test, $P=0.0081$). These findings established the *PRDM9* variant allele A as an activating variant, while *PRDM9* variants L2 and L4 were found to be non-activating in men carrying the active G allele at the disrupting SNP DA7.5.

5.2.9 Re-Sequencing of Donors

14 crossover-assayed donors were re-sequenced for Hotspot DA to search for any other potential *cis*-regulators of hotspot activity. Separate haplotypes were generated using allele-specific primers and universal primers (DA7.3F and DA7.6R) to amplify the approximate 1.5-kb interval centred around the motif disrupting SNP (PCR conditions and primers are shown in Appendix II). In Table 5.5 the re-sequencing results are summarised (for full re-sequencing data, see Appendix IV). Two haplotypes of 14 men were re-sequenced and four new SNPs (7.5b, 7.5c, 7.6a and 7.7) close to the hotspot centre were identified. These SNPs were genotyped in both our European and African panels. SNPs 7.5b and 7.7 were donor-specific SNPs. SNP 7.5c was observed in only four donors in the European panel, but in the African panel this SNP is normally distributed. SNP 7.6a was also picked up in both panels. Table

5.5 shows a list of the active and suppressed haplotypes for Hotspot DA. Active haplotypes were identified as both the haplotypes found in each active man where crossovers have been mapped and there was no asymmetry, and also as the haplotypes in each man showing strong asymmetry that corresponds to the inactive haplotypes. Inactive haplotypes were identified in men carrying a *PRDM9* A variant (in practice, these are all T/T men), and in active men where mapping showed strong asymmetry. Comparing the two sets of haplotypes showed that only the G allele for SNP DA7.5, and no other variant, was found within the active haplotype group. To sum up, the re-sequencing results demonstrated that the *cis* effect is mediated by the motif disrupting SNP DA7.5 and no other sequences had an effect.

	SNP	DA7.0	DA7.0a	DA7.0b	DA7.4	DA7.5	DA7.5a	DA7.5b	DA7.5c	DA7.6	DA7.6a	DA7.7	DA8.2
	locations	7025	7049	7140	7481	7501	7542	7551	7573	7631	7661	7768	8229
Donors													
Suppressed haplotypes													
6		G	+	T	A	T	C	C	G	C	G	T	G
7		A	+	G	C	T	T	C	G	A	G	G	G
44		A	+	T	A	T	C	C	G	C	G	G	G
44		A	+	G	A	T	C	C	G	A	G	G	G
73		A	-	T	A	T	C	C	G	A	G	G	G
180		G	-	T	A	T	C	C	G	A	G	G	A
180		A	-	G	A	T	T	C	G	A	G	G	G
185		G	+	T	A	T	C	C	G	C	G	G	?
185		G	-	T	A	T	C	C	G	A	G	G	?
211		G	+	T	A	T	C	C	G	C	G	G	G
232		A	-	T	A	T	T	C	G	A	G	G	G
238		G	+	G	C	T	T	C	G	A	G	G	A
251		G	+	G	C	T	T	C	G	A	G	G	A
253		G	+	G	C	T	C	C	T	A	G	G	G
253		A	-	T	A	T	C	C	G	C	G	G	G
Active Haplotypes													
6		A	-	T	C	G	T	C	G	A	G	G	A
7		A	-	G	A	G	C	C	G	A	G	G	A
12		A	+	G	A	G	C	C	G	A	C	G	G
12		A	-	G	A	G	C	C	G	A	G	G	A
67		A	-	T	A	G	C	C	G	C	C	G	G
67		A	-	G	C	G	C	T	G	A	G	G	G
73		G	+	G	C	G	C	C	G	C	C	G	G
211		A	-	G	C	G	C	C	G	A	G	G	G
232		A	-	G	C	G	C	C	G	C	G	G	A
238		G	-	G	C	G	C	C	T	C	G	G	G
251		G	-	G	C	G	C	C	T	C	G	G	G
280		G	-	G	A	G	C	C	G	C	G	G	G
280		A	-	G	C	G	C	C	G	A	G	G	G

Table 5.5 Re-sequencing results. The active and suppressed haplotypes of 14 men are shown above. The locations and names of the SNPs are shown in the table. Newly identified SNPs 7.5b, 7.5c, 7.6a and 7.7 were typed and are coloured in pink. Donors that were heterozygous for each SNP are shown in red and blue letters. The motif disrupting SNP 7.5 is coloured in yellow. According to the active and suppressed haplotypes, the motif disrupting SNP DA7.5 is the only *cis* regulator that can effect hotspot activity for Hotspot DA.

5.3 DISCUSSION

Cis-regulator SNP DA7.5 is the main factor that influences hotspot activation on Hotspot DA, however the *trans*-regulator factor *PRDM9* also has an important impact. Both regulators showed a good correlation with each other. Hotspot DA was inactive in men that had the A-allele of *PRDM9* and were also homozygous for the suppressed allele (T/T) for the motif disrupting SNP. The crossover frequencies were higher in men that had the A-allele of *PRDM9* and who were also homozygous for the active allele (G/G) for the disrupting motif SNP. Moreover, men that had one A-allele for *PRDM9* showed variation in their crossover frequencies according to both their carried *PRDM9* alleles, and their disrupting SNP genotypes. Berg *et al.*, (2010) studied 5 hotspots that lack the 13-bp hotspot motif proposed to be the *in vitro* binding site for the protein encoded by the *PRDM9* A-allele. Additionally, *PRDM9* regulates hotspots with or without the hotspot motif to the same extent (Berg *et al.*, 2010), but in Hotspot DA the *cis*-regulatory effect is very significant.

Twelve men who were homozygous for the suppressed allele (T/T) of the disrupting SNP DA7.5 and who had different *PRDM9* non-activating variants (C, E, L4, L6, L7, L11, L12, L13, L15, L21, L22) were studied to see whether any of the *PRDM9* variants can rescue the suppression caused by the suppressed T SNP allele acting in *cis*. The *PRDM9* variant L4 generally binds five of the exact 8 bases (Berg *et al.*, 2010) of the 13-bp motif, but one of its exact bases is the disrupting SNP, so L4 (donor 236) variants only bind to four exact bases of the motif and so rescued only a few crossovers (~1-10 positive crossover reactions in 100,000 molecules). Interesting results come with the men carrying A and L4 variants (donors 180 and 280). These men had different disrupting SNP genotypes (donor 180 (T/T) and donor 280 (G/G)), and it was the men homozygous for the active allele (G/G) of the disrupting SNP who showed higher recombination frequencies. However, d280 and d236 were both homozygous for the suppressed allele (T/T) of the disrupting SNP, and showed very low hotspot activity when compared to the other men who were homozygous for the suppressed allele. Previously, the L20 variant had been observed to be non-activating at Super-hotspots F and U (Berg *et al.*, 2010). Conversely, L20

has been shown to activate the hotspot MSTM1b. The PRDM9 variant L20 therefore has entirely different activation profiles between different super-hotspots (Berg *et al.*, 2010). Even though it is not that strong, perhaps the PRDM9 L4 variant has an activation effect on Hotspot DA. Recently, a hotspot activated by C variants of PRDM9 was studied by Berg *et al.*, 2011. The C variant of PRDM9 totally inactivates Hotspot DA.

Despite a significant association of PRDM9 status with crossover frequencies, a large degree of variation can be observed between men with the same PRDM9 status. Men who carry A/A alleles show variation according to their disrupting SNP genotype, and when considering that the *cis*-effect of the variation was as large as 60-fold between donors 26 (G/G) and d256 (T/T). However, the same disrupting SNP genotypes showed a very small, ~3-fold difference between donors d26 (G/G) and donor 67 (G/G), and 4.5-fold between donors 238 (G/T) and donor 73 (G/T).

However, a comparison of recombination rates between A/A men and A/N men that were heterozygous for the motif-disrupting SNP is significant (one-tailed t-test, $P=0.0153$). Thus, the *trans*-regulator PRDM9 has a significant effect on hotspot initiation in Hotspot DA.

To conclude, both the *trans*-regulator PRDM9 and the *cis*-regulatory disrupting SNP DA7.5 within the 13-bp motif close to the centre of the hotspot, have major influences on hotspot initiation in Hotspot DA. Hotspot DA is the only human crossover hotspot in which the disrupting SNP within the motif has a very strong *cis* effect for the hotspot turn on/off polymorphism, and this *cis*-regulation of the disrupting SNP was confirmed by re-sequencing.

CHAPTER 6: DISCUSSION

There are three main techniques used to investigate recombination frequency in humans: cytological analysis, pedigree or sperm analysis to observe the segregation of markers, and population genetics approaches. The simplest method for measuring recombination is pedigree analysis, but this can only give a low resolution due to the combination of the low numbers of informative meioses observed and the low average recombination rate per unit of physical distance along DNA in humans. An alternative method, sperm analysis, allows male recombination rates to be estimated directly, but assays are restricted to short intervals (typically up to 10 kb) and are practically very challenging to design and optimise. In contrast, population LD analyses allow recombination to be estimated indirectly by inferring historical recombination events to explain haplotype structure. About 33,000 hotspots were estimated to be present in the human genome from historical LD block boundaries (Myers *et al.*, 2005), corresponding to about one in every 50 to 100 kb of sequence. To date, only ~40 hotspots have been directly characterised in individuals by sperm typing (Jeffreys *et al.*, 1998a; Jeffreys *et al.*, 2001; Jeffreys and Neumann, 2002; May *et al.*, 2002; Kauppi *et al.*, 2004; Jeffreys *et al.*, 2005; Holloway *et al.*, 2006; Webb *et al.*, 2008).

In addition to this ~40% of human recombination hotspots have a 13-bp CCNCCNTNNCCNC sequence motif that determines hotspot activity (Myers *et al.* 2008). Previous studies have reported the role of these motifs in hotspot activity where single nucleotide variants disrupting the centrally located motifs CCTCCCT and CCCCACCCC reduce crossover initiation activity in *cis* at hotspots DNA2 (Jeffreys and Neumann, 2002) and NID1 (Jeffreys and Neumann, 2005) respectively.

6.1 HIGH-RESOLUTION LINKAGE DISEQUILIBRIUM ANALYSIS OF PUTATIVE HOTSPOTS CONTAINING A MITF-DISTURPTING SNP

Using low-resolution HapMap Phase II data, Donnelly and colleagues drew up a shortlist of the four best candidate LD hotspots (DA, DB, DC and DD) based on

having the 13-bp CCNCCNTNNCCNC motif with a disrupting SNP and good historical activity (Donnelly, personal communication). This raised the question of whether the nature of the motif offers any clues for understanding the molecular basis of recombination hotspots. In Chapter 3 these four LD hotspots were genotyped using high-resolution genotyping techniques in our European semen donor panel and tested to see if the motif-disrupting SNP lay at the centre of the hotspot as defined by LDU mapping. Confirming these hotspots with LDU mapping is crucial because it confirms the existence of the LD hotspot in our donor panel, the location of the motif with the disrupting SNPs, and it also allows the width of the hotspot to be estimated. LDU mapping confirmed all four putative LD hotspots (DA, DB, DC and DD) to have a width of 1-2 kb which is characteristic of hotspots (Jeffreys *et al.* 2000). According to the LDU map, the motif disrupting SNP was at the centre of Hotspot DA, and this hotspot had an estimated historical recombination frequency of $\sim 5 \times 10^{-4}$. Hotspot DA was thus a very promising candidate for further analysis. The second hotspot, Hotspot DB, had the disrupting SNP close to the centre of the hotspot, but crossover assays designed for Hotspot DB failed to detect any crossovers. This could be explained by various reasons. Firstly, the recombination frequency of Hotspot DB is very low, and therefore one explanation is that the assay could not pick up any positive crossovers in our European panel. Here, a higher DNA input would help give the answer, but unfortunately there was only a limited DNA stock for these selected men. The second explanation is that Hotspot DB does not exist anymore in the population, but we did not have enough time to explore this further.

For Hotspot DC the LDU map showed the disrupting SNP to be outside of the centre and so this hotspot did not fit with our hypothesis and was eliminated. With Hotspot DD the disrupting SNP was localised close to its centre, but the heterozygosity of the donors did not allow us to conduct further analyses. For these reasons Hotspots DB, DC and DD were not studied for this thesis, and instead further analysis was carried out on only Hotspot DA.

6.2 DETERMINING THE RECOMBINATION RATE AND HOTSPOT POLYMORPHISM IN HOTSPOT DA

Previously, major variation in crossover frequencies had been observed (Neumann and Jeffreys, 2006; Jeffreys and Neumann, 2005), and some of these variations were associated with specific hotspot sequence variants that influence the efficiency of crossover initiation between chromosomes (Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005; Jeffreys and Neumann, 2009). This manifests as reciprocal crossover asymmetry in heterozygotes, as higher initiation on one haplotype can lead to biased gene conversion tracts accompanying the crossover, with markers acquired from the less active homologue (Jeffreys and Neumann, 2002). In a previously characterised hotspot, both crossovers and non-crossovers indicated comparable biased transmission in both crossover and non-crossover exchange conversion products (Jeffreys and Neumann, 2005). Therefore, crossovers and non-crossovers were in general influenced by the same factors.

A 15-kb target interval around Hotspot DA that was centered on the motif-disrupting SNP DA7.5 within the 13-bp CCNCCNTNNCCNC hotspot sequence motif was assayed for recombination activity in six men. The crossover frequency showed Hotspot DA to be a regular hotspot with an average crossover rate ($\sim 8 \times 10^{-4}$) among hotspots assayed on autosomes.

Another factor potentially at play is meiotic drive. This is observed in sperm when a recombination suppressing haplotype is over-transmitted to progeny, both at crossovers and at gene conversions, without exchange of flanking markers. It suggests that changes within the hotspot could become attenuated in activity during evolution (Jeffreys and Neumann, 2002; Jeffreys and Neumann, 2005). Other factors besides the sequence within the hotspot of identical haplotypes could regulate the activity of a presence/absence hotspot polymorphism (Neumann and Jeffreys, 2006). Therefore, Hotspot DA provides evidence that the motif is likely to be involved in promoting the initiation of recombination. Five assayed donors showed very similar hotspot locations for orientation A and B crossovers. The centre of the hotspot is displaced 3'

to DA7.5 by ~80 bp. The numbers of crossovers mapping to the 5' and 3' ends of DA7.5 were normalised to equal numbers of A and B crossovers, and a Fisher test was performed to check if the numbers were significantly different from the predicted 50:50 Mendelian transmission ratio if DA7.5 is located exactly at the centre. Thus it was concluded that DA7.5 and the motif were not located at the centre of Hotspot DA. Sperm crossovers in men heterozygous for a motif-disrupting variant show the greatest transmission distortion ratio (~90:10, T: G) ever seen in human crossover progeny (Jeffreys and Neumann, 2002; Neumann and Jeffreys, 2006).

In humans (Jeffreys and Neumann, 2002; Neumann and Jeffreys, 2005), mice (Boulton *et al.*, 1997) and fungi (Nicolas *et al.*, 1989; Nicolas and Petes, 1994), different recombination initiation rates result in over-transmission of alleles from the suppressed haplotype into recombinant progeny (Neumann and Jeffreys 2006). The highest transmission distortion had been seen in hotspot MSTM1a (on average 72:28 versus 50:50 for Mendelian transmission) for markers nearest the centre of the hotspot, which is similar in intensity to that seen at the other mammalian hotspots showing distortion (Jeffreys and Neumann, 2002; Neumann and Jeffreys, 2005; Yauk *et al.*, 2003). These meiotic drives in favour of alleles from the suppressed haplotype allow the identification of the putative active haplotype in each of the analysed men (Neumann and Jeffreys, 2006). The transmission frequency results showed that the asymmetries in the three donors heterozygous for the disrupting SNP DA7.5G/T were very similar in terms of the transmission frequency of DA7.5G to crossover progeny (10:90, G:T transmission ratio) and in terms of the displacement of orientation A versus orientation B crossover distributions. Donors that are homozygous for the active G-allele showed the highest recombination rate among the other donors. The direction of biased gene conversion indicates that the chromosome carrying the disrupting allele was suppressed for crossover initiation. This is supported by donor 44, who is homozygous for the disrupting allele (T/T) and shows no recombination (RF = 0%). *Cis*-regulation has previously been seen and has reduced the hotspot activation at studied hotspots (Jeffreys and Neumann, 2002; Neumann and Jeffreys, 2005; Neumann and Jeffreys, 2006; Jeffreys and Neumann, 2009; Berg *et al.*, 2010, Sarbajna *et al.*, 2012), but the *cis*-regulation of Hotspot DA has provided the first strong evidence that *cis* factors have a direct influence on the turn on/off activity of

hotspots.

6.3 THE RELATIONSHIP BETWEEN CROSSOVERS AND NON-CROSSOVERS

Understanding the relationship between crossovers (COs) and non-crossovers (non-exchange gene conversions, NCOs) has been facilitated by examination of the large number of non-exchange events at several hotspots. This revealed that crossover and non-crossover frequencies were positively correlated (Berg *et al.*, 2011; Sarbajna *et al.*, 2012).

Hotspots with high recombination rates also tend to show high non-crossover frequencies. This correlation was seen either between men at a given hotspot or when compared between hotspots (Jeffreys and May, 2004, Jeffreys and Neumann, 2005) at a fairly stable CO:NCO ratio of 2:1. Previously, the CO:NCO ratio was estimated at 4:1 in Europeans and 1:1 in Africans by population genetics approaches (Ptak *et al.*, 2004). In these estimates the influence of gene conversion on LD, which can have detrimental effects in association studies, was ignored. The inflation of historical recombination on LD cannot be explained by crossover-based recombination rates alone (Ptak *et al.*, 2004). Another study by Ardlie *et al.* (2002) reported non-exchange conversion at a ratio of 3:1-10:1 in favour of non-exchange conversions, with 6:1 being the best estimate (Ardlie *et al.*, 2002). This showed incomplete LD that was not readily explained by the expected historical recombination rate based on crossovers alone. It is important to remember that COs are always detected by repulsion-phase PCR, but NCOs can only be detected when they occur in a region including an informative SNP. Therefore, many NCOs are missed, so the quoted ratio may be misleading.

A wide range of CO: NCO ratios have typical values of ~3:1 between men. In this work, the directly observed CO: NCO ratios varied between two analysed donors for Hotspot DA, but at the lower end of what would be expected (10:1). The non-crossover frequency at Hotspot DA seem unusually low, although this might well reflect missing non-crossovers since only those that had co-converted at SNPs 7.4 and 7.5 were scored. There was no significant difference between the two donors in the

ratio of non-crossovers to crossovers (Fisher exact test, $P = 0.14$). Nevertheless, the data can be used to determine the likelihood that a flanking SNP is co-converted in those non-crossover molecules known to have converted at both SNP7.4 and SNP7.5. While the sample sizes are small, there was clear evidence for a very steep gradient, with the likelihood of co-conversion declining rapidly as one moves away from the selected sites SNPs 7.4 and 7.5. This fits with previous studies of non-crossover distributions in human hotspots. In contrast, CO: NCO ratios showed a significant and very strong variation between 14 men at hotspot *SPRY3* (Sarbjana *et al.*, 2012). Hotspot *SPRY3* is located in the minor human pseudoautosomal region (PAR2) and may behave differently to Hotspot DA because either PAR1 or PAR2 must engage in a crossover event at any given meiosis to prevent non-disjunction. Therefore, factors influencing the CO/NCO decision may be functioning differently between pseudoautosomal and autosomal hotspots. Alternatively, it is equally possible that differences between men at a given hotspot have not yet been detected at autosomal hotspots.

When reciprocal transmission rates of markers in crossovers and non-crossovers were compared for Hotspot DA, the non-crossovers showed complete bias resulting in the transfer of DA7.5T to the DA7.5G haplotype, and with no instances of G>T transfers. This extreme bias is highly significant ($P = 1.2 \times 10^{-10}$) and is in the same direction as the bias seen in crossovers. For both donors 6 and 55 the strength of the distortion is greater in NCOs than in COs. For each donor, this disparity is not significant (Fisher exact tests on numbers of 7.5G- and T-containing COs versus numbers of G- and T-containing NCOs). However, it is significant for data from both donors combined, even on raw counts of numbers of NCOs before Poisson correction. It therefore appears that NCOs show a significantly stronger bias towards acquiring 7.5T compared with COs.

6.4 THE PATHWAYS FOR GENERATING CROSSOVERS AND NON-CROSSOVERS

Hotspot DA is an example of a hotspot with both types of biased gene conversion operating within the same hotspot. Biased gene conversion into crossovers and also non-crossovers was observed at SNP DA7.5, located ~80 bp away from the centre of

Hotspot DA. Significantly distorted transmission ratios were observed for all men that were heterozygous at this marker.

Mechanistically, human recombination hotspots can be explained for all observations of recombination events by the single canonical double-strand repair model of recombination (DSBR).

Biased gene conversions in COs and NCOs are influenced to the same degree, if COs and NCOs are generated as alternative products of the same double Holliday Junction (dHJ) molecule. Heteroduplex DNA within a dHJ intermediate is subjected to mismatch repair (MMR), with repair being directional from the invaded to the invading CO. This was seen as transmission distortion in favour of CG at Hotspot *DNA2* (Jeffreys and Neumann, 2002) and *SPRY3* (Sarbjana *et al.*, 2012), as well as AT alleles at Super-hotspot S2 (Jeffreys and Neumann, 2009) and *NID1* (Jeffreys and Neumann, 2005). This observation is consistent with early mismatch repair being biased towards repairing from the invaded duplex to the invading strand.

The canonical DSBR model has the potential to explain both biases within the same intermediates. In the DSBR model of recombination, both COs and NCOs are produced from the same recombination intermediate and a dHJ by resolution in different planes. Therefore, the intermediates destined to become crossover and non-crossover molecules are perhaps sensed and processed differently by the MMR process, resulting in gene conversion with different degrees of bias. This may be manifested by differences in MMR recognising the heteroduplex and/ or differences in the strength of the bias in the lower of T during repair. Alternatively, the extent of resection of the Spo11-induced DSB may differ between molecules destined to become COs and NCOs such that there may be a difference in the likelihood that a G/T heteroduplex is generated at SNP DA7.5.

Two pathways that generate non-crossover recombinants have been proposed in *S. cerevisiae* recombination, with the DSBR pathway mainly responsible for crossover formation and the SDSA pathway responsible for non-crossover generation (Allers and Lichten, 2001). Evidence for two pathways of non-crossover generation in the human genome comes from the observations of Sarbjana *et al.* (2012) at the minor

pseudoautosomal hotspot SPRY3. They observed at least a proportion of non-exchange conversions being generated via a second, perhaps SDSA pathway (Sarbjana *et al.*, 2012). This SDSA pathway could be applicable to Hotspot DA. This pathway would require that SNP 7.5 is always incorporated into a G/T heteroduplex in G/T heterozygotes, and is always repaired in favour of the T-allele during, for example, early mismatch repair. Also, meiotic drive in favour of T will lead to hotspot extinction, and not just modest down-regulation as seen at most hotspots.

6.5 PRDM9 REGULATION ON HOTSPOT DA

At the beginning of this work, knowledge about the factors regulating the human recombination machinery was limited. Early findings of initiation biases that resulted in reciprocal crossover asymmetry pointed to *cis*-acting factors regulating hotspot activity. High variation in crossover frequencies between men had also been observed independent of specific sequence variation at two closely linked hotspots (Neumann and Jeffreys, 2006). These findings prompted the investigation of a *trans*-regulatory factor, which has recently been identified as PRDM9 (Baudat *et al.*, 2010, Myers *et al.*, 2010, Berg *et al.*, 2010).

The identification of PRDM9 as the major *trans*-regulatory factor for specifying and regulating hotspot activity (Berg *et al.*, 2010, Berg *et al.*, 2011), has dramatically increased our understanding as to what controls human crossover hotspots.

Variant *PRDM9* allele A is the most common allele in the European population, and it binds to a 13-bp motif in human LD hotspots identified using European HapMap data (Myers *et al.* 2010). Berg *et al.* (2010) provided evidence for PRDM9 affecting crossover activities in sperm independently of a hotspot motif that had been identified to be the PRDM9 binding site *in vitro* (Baudat *et al.* 2010). Moreover, additional data addressing PRDM9 regulation and the relationship with the hotspot motif came from the investigation of recombination hotspots tuned to *PRDM9* Ct variants, which are more common in Africans (Berg *et al.* 2011). However, the LD Hotspot DA was shown to be activated by the *PRDM9* A-variant, and only in men that are homozygous for the active allele (G/G) and heterozygous (G/T) for the disrupting SNP DA7.5 within the motif. Additionally, the men homozygous for the suppressed allele (T/T) of

the disrupting SNP DA7.5 showed either no or extremely low recombination rates in the presence of the *PRDM9* allele A. Men homozygous for the active allele (G/G) of the disrupting SNP and who carried a non-A *PRDM9* variant need to be studied to prove the direct influence of the T allele on the hotspot turn on/off status, but unfortunately, there were no suitable donors in our panel.

6.5.1 The Protein Encoded by *PRDM9* Binds to a 13-bp Motif

The data presented in this thesis is the only evidence for human crossover hotspot regulation by a very strong *cis*-regulatory disrupting SNP. However, the *trans*-regulator *PRDM9* has a secondary effect. Sperm crossover activity was highly dependent up on *cis*-regulation in Hotspot DA. However, men who carried different *PRDM9* variants showed variable crossover frequencies depending on their disrupting SNP genotypes and *PRDM9* status. In contrast, at some Super-hotspots independent of the presence of the hotspot motif (Berg *et al.*, 2010), sperm crossover activity was highly dependent on specific *PRDM9* variants. Moreover, a motif-strengthening SNP at Hotspot 5A was associated with a suppressed haplotype (Berg *et al.*, 2011), and it appears that the presence of a motif is not sufficient for recombination either, as the motif is common and can be seen in recombination cold sequence outside of a hotspot (Berg *et al.*, 2010). However, a motif-disrupting SNP was found to be associated with the suppressed haplotype at hotspot NID1 (Jeffreys and Neumann, 2005; Myers *et al.*, 2005; Myers *et al.*, 2008), which is opposite to Hotspot 5A, where a better-matched motif associated with the suppressed haplotype (Berg *et al.*, 2011).

Men homozygous for the motif-suppressing allele T at SNP DA7.5 showed no recombination or extremely low recombination frequency. In contrast men homozygous (G/G) and heterozygous (G/T) for SNP DA7.5 showed regular hotspot crossover frequencies depending on their *PRDM9* status. T/T men completely turned off their recombination activity regardless of the presence of the variant *PRMD9* A allele. Therefore, *cis*-regulation is a major factor that controls the hotspot activity in Hotspot DA.

Subtle changes in ZnF arrays between *PRDM9* variants can have a strong effect on recombination activity. The *PRDM9* variant L20 has been shown to activate the

hotspot MSTM1b, and show an entirely different activation profile between Super-hotspots (Berg *et al.*, 2010). Also, the C variant of *PRDM9* showed hotspot activation (Berg *et al.*, 2011). Additionally, men with variants that have identical binding predictions to the hotspot motif can display variation in crossover frequencies as strong as activation/non-activation (Berg *et al.*, 2010). Hence, *PRDM9* binding to a specific recognition site would be the most ready explanation for how subtle changes between alleles created non-activating variants incapable of recombination (Berg *et al.*, 2010). In Hotspot DA, non-activating *PRDM9* variant L4 binds five of the exact 8 bases of the 13-bp motif, including the SNP DA7.5. Therefore, in SNP DA7.5 T/T men, the *PRDM9* L4 variant is predicted to bind to 4 bases for the 13-bp motifs and activate hotspots with extremely low recombination frequency.

Finally, all active and suppressed haplotypes were determined for Hotspot DA, and the disrupting SNP DA7.5 within the 13-bp motif sequence was found to be the only *cis*-regulator and major factor for hotspot activation in this hotspot.

6.6 FINAL REMARKS

Hotspot generation and constant biased gene conversion extinction contribute to the regulation of recombination in the human genome, and this appears to be extremely dynamic. New *PRDM9* variants might create young recombination hotspots, which are then silenced over time through mutation and biased gene conversion. Hotspots would not have to persist given that they are silenced by biased gene conversion, but instead new locations could be activated as recombination hotspots by the generation of new *PRDM9* ZnF arrays (Berg *et al.*, 2010).

Intensive biased gene conversion, both in to crossovers and non-crossovers, has been found at Hotspot DA. Biased gene conversion that influences crossover and non-crossover activated hotspot activity correlates with *PRDM9* allele A. In Hotspot DA, the lifetime of the hotspot mostly depends on the *cis*-regulatory disrupting SNP DA7.5, and on the *trans*-regulatory factor *PRDM9*. Recent studies showed that a neutral system of recombination landscape evolution could only be achieved if *PRDM9* could evolve at an equal rate or more rapidly than the time it takes for a motif to be completely depleted (Ponting, 2011).

6.7 FUTURE WORK

Apart from PRDM9, no other protein is known to have a profound influence on recombination activity in humans. The factors that influence PRDM9 binding *in vivo* are still unknown. It also remains to be understood how a large ZnF array behaves *in vivo*, and whether more than the initially proposed five ZnFs are involved in DNA binding. The other important issue is whether determination of PRDM9 specifically depends on local hotspot-specific chromatin complexes. Grey *et al.* (2011) enriched for hotspots in mouse for H3K4 tri-methylation patterns, and it still remains to be understood where these arise through direct interactions with PRDM9.

Positive selection, insertion, deletion and gene conversion affect human PRDM9 ZnFs (Ponting, 2011). Finally, the influence of PRDM9 ZnF variants on minisatellite instability is intriguing, given that these variants themselves are encoded by a minisatellite (Berg *et al.*, 2010). If *PRDM9* influences its own evolution by generating alleles that affect meiotic instability at the *PRDM9* minisatellite and promote the generation of new alleles, a whole raft of new *PRDM9* alleles could be generated whenever an interaction allele appears in a population, implying a potential chaotic mode of hotspot evolution (Berg *et al.*, 2010). So, a number of questions in the future will need to be answered. Firstly, how does the ZnF array specify hotspots and what are the rules governing PRDM9/DNA interactions? There is a poor correlation between hotspot sequence and *in silico* predicted binding motifs, in part due to problems with *in silico* predictions. Evidence came from the study of Grey and his colleagues (2011) that mouse *Prdm9* variants bind to their cognate hotspot centres *in vitro* on naked DNA, despite a lack of obviously strong motifs. This study had a limited dataset, but is really important and needs testing in humans by examining interactions between known *PRDM9* variants and known hotspots. A key question is whether *in vitro* binding can identify hotspots, and if so, what exactly does PRDM9 bind to or whether chromatin imposes an additional layer of rules controlling PRDM9/hotspot interactions. On the other hand, how does PRDM9 activate a hotspot? Does it active either indirectly via histone modifications, or directly by interacting with components of the recombination machinery? How does *PRDM9* itself evolve and how does its rate of evolution compare with the rate of hotspot loss from the genome? All evidence so far says that *PRDM9* evolves rapidly, and

considerably faster than the hotspot loss, so that PRDM9 actually influences its own instability (personal communication with Alec J. Jeffreys).

APPENDIX I: DNA SEQUENCES OF TARGET HOTSPOTS

A 15-kb interval of DNA sequences for Target DA, DB, DC and DD, centred on the target SNP, was downloaded from ENSEMBL. SNPs have been characterised from Hapmap and dbSNP data. (SNPs in red are validated and genotyped SNPs, polymorphic in Europeans and Africans, SNPs in cyan are putative but not-genotyped SNPs, and SNPs in scratch-through cyan are SNPs genotyped but fixed in Europeans.) 13-bp sequence motif (black) is shown with matches to sequence.

TARGET DA

```

                                rs16938276
1      CAGGGGCACCAGTTACATTGTATTCTTTGTGAACGGCCATTCCTGGAGTTTTGTAATGCT
                                C 0.062
61     GTGGCCCTTTTTTCAAGCAAGGCCTTATGAGGACTTCAGGTCTCTAGGAAAAATCTGGTA
                                rs10811785
121    GAAGGATATGGGGCAGCACCAGTAGAGGAAAAGTGGCTTGAGGGGCGAGCCTCTGGAAGCT
                                A 0.250
181    CTCTTGGCTCTGCTGAACTTTGGTGTGTTGGGTAAAAGGTCTGAAGCTTGCTTCATGGCC
                                rs16938278
241    TGGTGAGAACTCACAGAGCTGCCAAGAAGGGCCTGGCATCAGAAATAAGCAACTACCAAG
                                C 0.062
301    GACAGGAAAGTCAACAACAAATGCCAGCCATGAGCATCAGATGATAAACTTCATGCCACG
                                rs35119837
361    AGGCCAGGTGAAATTGTCAGAATTGGCAAATGCCAATCCTGAGATCAGATCGACCCCCA
                                rs7853650      _+G
421    TGCCAGGTTGGCAGAGAGGGGCAGTACCCAGGCCAGCTTTCTCTCACCACCTCAACCCCC
                                G 0.000
481    TTCTATGTCTCCACTCCCCCAGTTATCAGAAAATACCCCTCAAGCTTTCACCTCCACCCAG
                                rs11999827      rs34504242
541    AAGCCATCTTGAAAAGCAGGAAGAAGACGGGGGTAAACAGCTCTGTTCAAAGAGTTTAAG
                                T 0.049      _+T
601    TTAAAATTATATGAATGTTTGTTCCCAAAAAAGCATTGAATATGTAGATACTATTAATT
661    TCCAAATTCTGCCCTTATTCTCACCCCATCTCCCTACTATCTAGCAAGATTGGGAGGGAG
721    ACTGGCAGTTAATAAGGAAGACTGGATCAGTTAAAGACTATAAAGAAGCTTGTATTTTGT
781    TTTGTTTTGTTTTTGCCAGCTTAGTGAAGTATGCATTTGCAATCCTGTTCTACCATGTTG
841    GTGCATAGCTCTTAGTCCTTTAGACAAACAGCTCTTAAACAATTCTACTGTGATTTGTCT
901    GAGATTCCTAGAAATCTCCTACCTTCCAAGTAAGGAAGGGATTAATGGCTGAGTACACAC
961    ACTCTGGGATGGAGTTAAAGCATCAGACTCTTGGGGCTGGAGCCATCTGGGAGACCATCT
1021   CATTAATGAAAGGTTTTATTTTCAGACAGAAAACTGCAACCCAAGAAGCTTCTACTTCTT
1081   GTCTTCTGAACTCTATCTGGGGTCTCTGAGTTGCTGAAAAGAAGCCTGACTACCCACCT
                                MLT1H1#LTR/Ma ->
1141   ACACATGCTAGAGAACATCTAGACACTCCATTCCCACCAATGTGTTAAACATTGAGTGAG
1201   CTGTCTTAGACCATACTTACTCATTCACCCAGATGAATTCCACCTAGTGACTTCAGTTTAT
1261   ATCACGTGAAGAAGAAAAATTGCCAACCTGAGCCCTTCCGAATTCCTGATCCAAAATCA
1321   TTAGATAAAAATAAAATGCCAGTTGTTTTAACTGGTTACAGTTTGGGATGGTCTGCTATCC
1381   AGCCATAGGCAACTAGTGTAGTAGAAAAGAAAGTGCAATAGAGTGTTAGAAAAGAAGAAAT
1441   TAATGCTAATTTGGGAGATCTCTGGGATAGGGGGAGGTAGGGTATAAGTATAGCTTTAGA
1501   AATGGCCAGACCTTGGGCAAGTGGTGATGGTGAGAGGCATGGAGAGGAGAGTAAGAAAGC

1561   TGTGGAAGTGGAAGCACATAGAGAATGTTCTGAGCTTGCCCAGAGTGACTGGAGTGAGGC
1621   TGGCATGAATGGGAGCAGCAACAGGGAGAGATTTTGGAAAAAGTCACTGGTTAATGCCA
1681   AGACTGTGCATGACATTAAGGATGCTTGTTACTACCAAAAAGGAAGTTTAAAGTGAAAG

```

~~rs16938284~~
1741 CCTTGTCTC ~~C~~GGTTATTGCTCCAGTGT CAGAAGCTGTCTATTGAAATATGTCACAGTGAT
 Φ 0.000
DA1.9-/+ rs34951391
1801 AAACAAC TAGGTT CATGTG TTCAGCCTGAACCC TAATGTGAGT TTTCTTTCTCCAGTGGA
|+G
1861 AGTACTAAACTGTGGCTTACACTAAATCTATATGACCTTTGGGTGGTTCCCTGGTAAGGA
1921 GTTAAACCTAAAACCTACATCCTCAAAAGTCCCAGAAAGAAATCTGATTACCCCTT ~~TAT~~
THE1D#LTR/MaL ->
1981 CAGTCTATTCTCACACTGCTATAAAAGATACAATCTGAGACTGGGTAATTTCTAAACTAAA
rs7030775
2041 CAAAAGAGTTT TTAATTGATT CACAGT TCTGCATGGCTGGAGAGGCCCTCAGGAACTTACA
G
2101 ATCATGGCAGAAGGCAAAGGGGAAGCAAGGCACATCTTACACGGCAGCAGGAGAGACCGA
2161 GCAAGCACGAGGAAGTGCCACACTTTTAAACCATCAAGATCTCAGGAACTCCCTCACT
2221 GTCATGAGAACAGCATGGAAGAAACCATCCCCATGATCCAATCACCTCCCACCAGGTCTC
2281 TCCCTCAACATGTGGGGATTACAATTCAAGATGAGAGTTGGGTGGGGACATAGAGCCAAA
DA2.4-/+ rs34397119
2341 CCATATCAGAACCCCTTGGTTAATCTCC ~~C~~TGCAACATAGGGATGGCCATTCC TAGAGTTGT
|+C
2401 GCAATTTGTGCAATTCTGAAATTCAGCTATGTGTGTAATTCTGAAATTCCTGTATTAAAT
2461 GGCCCTTCCTTTTTCAGGTTTTCAGAAATCCCCCTATTAAATCGTCACCATTCTGCTCATTTA
2521 TTTGTTTAAACAAATGTTTCTTGATGGCCTACTCTATATGCCAGGCACAGCTTTAGATACT
DA2.6G/C rs9777039
2581 TCCCAACATTGAGTAAGATAGACAAGCCTGTGGTTCTGGGAGGAACACCATTGGAGGAAA
C 0.342
2641 CCAATGGTAAACAAGTAAACAAGCAAGCACACAGGATAATTGCAGGAGGTATAAGAAAAG
2701 AAAC TAGCACATGTAACACAAAACAGCACATGTGGAAAGAGAGTGTGGAATAGTGAGTG
rs17406823
2761 AAAGGGGGACAGTCAGAA ~~C~~AGATCAGAGAGTCAGGCAGTGTTGGCCATGGAAAGTCTGTG
G 0.042
2821 GGGCCTGGGCAGAAGCTGGTTTTTCATTTCAAGCGTAGAGGGAAGCAGTAGGAGAGAGCAT
2881 GAGTAGGTTTATTTTAAAGCAGATCTTTGGCTGATGAAATGAATTGTCAATATTAGTTAT
2941 GAAGTTACTGGGGATTCAAC ~~C~~AGAGGTTGGCAGACTTGTTTTCTGTAAAAGGCCAGAGAG
3001 TAAATATTTTAGGCTTTGGGGCAATTTAGTCTCTGTTGCAACTACTCAATTCGCCTCAC
3061 AAAAGCAGCCACACACAAGATGTGTAACTTTAGTTACAAAAACAGGTGGTGGACTAGATT
<- MER58A#DNA/ME
3121 TGTCCCAAGGGCTGTAGTTTGGAGACCCTATATTGGATAATGGGGTGTGGGAAAAGTAG
3181 GCAGTTGAGTGCACCAAGCAGAGTGGGGATGTATGGTTAGTGGGAGCATGGAGAATTCTA
3241 AGAGGCAAGGCCACAGGCTCTGAGAGAAAAGGCAGGTGGAGGAGAAGGATGTCAGTGACA
3301 GATTCTGCATTTTCTAATTTTCGCAAGGGCTGACCCCATGAGCACGTGTGTGCATGCTGTG
3361 CGTTCAGCCTGGTGGCAACATGGACCAAAGGCTCTGGTGTACTGGGGTGGCT ~~GGTTTTGT~~
3421 GGGCCATGAAACCTAACAATATGGGAGTGCTCTTTAAGAAAGTGAGTATAAAATTACAAA
DA3.5T/G rs12554219 rs7850124 rs7850134
3481 TACAAAAT ~~T~~GAGGACAGGGCCTTGGAAGAAACGTAGGCAAGTGACAGGCCGTGAAGCGTG
0.102 G A <- MER69A#DNA/Ti Φ 0.000
3541 AGGCTTATTAGCTCCAGGGTAAATTTACCTCTGCTTGTGTATACCTACTCTCTCCCCACA
3601 AGCTCACAGCAACAATCTGAGCCTCATTAAGTCAGACTGTTTCAAATAAAACCTCTTTTA
DA3.7T/G rs10965506
3661 GTGACATCTGGTGCATGATCGATACTTCGAAACACTCAGAATCCTAAACAAGGAAAAGGG
G 0.342
3721 CACCTGCTCTGGGTCTGCTGTGTCTGATTTGTCATCACCAGGGTGCAGGTGCTCAGGCC
3781 TCGCCCCACCCCGCTGTCTTTAGCAACACAAAACAGCAGTAACTGGAAGCCACACTGCAGC
rs7869518
3841 TTGTGTGGCTGATGTTTGCTTTATGTCTTCATACTTCTATTGCTGGAAATGACACTGGAA
G
3901 CCCAGAAAGAATGTATGCTGGTGCTTTAGGTCATGAAATGGGAGAAATTTTGTGGATTGT
DA4.0C/T rs7851589 rs10811799
3961 GTTTATTCTATCTTATCCTGAAAAATTTTGTCTGTGAGACAGCC ~~C~~CTCCT ~~C~~TGGATTCCA
0.078 T G
DA4.0aG/A rs10965510
4021 CAGATCTGTACGGGGAAAATACT ~~G~~TAATAAGCACCTGCAGTGGGAGCTCAGTCTCCAGTG
~~rs4740673~~ A 0.331

4081 CATCTAGGCATGAGTGGAACTGCCCTGTGGAAGGTTGGAGGAGAGGGTGTGCTTGGTAGC
± 0.000

4141 TTAGGAGAAAGAGAGAGAGGTAAGGGCAAGGGGGAGAGAGGGATGGAGCCAGTGGATGGT
4201 GAAAGGCCCTTGCCCTCTGCAGTGTGAGCTCCCTTCAAATCTCTGCTCTGTCTCTTCCCTA
4261 TTATGCAAATTGTCAGTTAAATTTATGAAGTCAAGGAAGGAAGGAATGAGGGACATAAAG
4321 TGCTTGATGCACATGATTTTTCTTTAGAAACAATAGAAGTAGCTGAATTCCTCAGCAAGCA
4381 TGTGGAGGAGGATGTTGGAAGTGGGTGAGTGGTAAGCAAAATGGATAAGGAGGATGGAAAG
4441 CCATGGAAACTCGTGGGAATTGTGCGGGAGGCTTAGGTTGCCACAGCTCTGGATTTAAGG
4501 TTGGTTCCAAATTTAACCACATCTATGAAATACAGAGGGGGCCCTGCCTGAGAGCTCTGGT
4561 GGTGCAGATGGCAGTGCCTGGGTGCGACAGCAGCAGCAGCAGCCTGTTGATGAG
4621 CACATGTGAGACATCCCTTTTAGGCCTCCAGAAACATTGGGCAATTTAGCAAGGGGCTGAT
4681 TTTCTGTGTGAGTAGATGGGTCTATGGAAATCAATGAGATGTGGGTATAAAAAGTCCTGTG
DA4.8A/C rs7020468

4741 ACCTCATTGGAGACCACAGGGGAGAGAGGCCTGGGGACATTTAGGCTGCCATGGGTTGCA
C

4801 TATCTACCTACATCACCTGATGTAAAGTTACTGAGACCACAAACCTTGTCTTATTCATTG
L2b#LINE/L2 ->

4861 TCATAACTCTTCCTGTCCCCCAATCACCTTTCCCAACTTACCCAGTGCCTAGCATAAACCC
4921 CTGGCATATATGGTATTCACTCAGTGAATATATGTGCAATGAATAAATGAATAAAGAATG
DA5.OT/C rs13292475

4981 CATGAATAAAACACTCTTATGCAGGAGTCTGTACCCTGGCCCATGCTATCCTTCAGGCTT
C 0.625

5041 GATCAACTCTAGCTTCTTCCTGGACTTTTGGTCTCTATCTGCCATGAGAGAATTAATGGT
5101 GCTATCACAGCATCATTACAGGCTGACACTTAGAATTAGAATGGCAGAGCTGGAAAGGA
5161 CCCTAGAGCAGAGTCCAATGCTTTTGATGAAATCTGAGCCCTTAAAAAGAAAAGCCAAGTG
5221 ACTTCCATTTATCTGAAATCAAAACAAGCAAGAAATGCGAATGACTAGAATATTTTTTAT
5281 ACACCCTATTTATAAGAATACCTTATATATGTGAAGGTTTTTATGGGATATCAAGTTCTC
DA5.3A/T rs7021249

5341 TCACTTACATTATCTCACTGGATTTTCTATAGTATATTTTTAAGTAGTCATTGATCTCCGT
rs7035418 T 0.093

5401 TTTAGAAAGGCTGAGTGACTTAACCCAGATCATTACAGCTGGCTAATGACAGCCGGTGTTC
± 0.000

5461 AAAGTGGTTGCTTTAGTTCTTTCTCACACAGCTACAAAGAACTACCTGAGACGGGTAAAT
5521 AATGAAGAAAAGAGGTTTAATTGGCTCACAGTTTTACAGGTTGTACAGGAGGCATTGCTA
5581 GGGAGGCGTCAGGAAACTTACAATCATAGTGAAGGTGAAGTAGAAGCAAGCAGCTCTTC
5641 ACATGGCTGGCAGGAGAGAGAGAGGGGAGGGGAGGGGAGGGGAGAGAGAGAGAGACC
5701 AGAGAGAGAGAGAGAGAAGGGGGAGGTGAGACACACTTAAACAACCGACCTCATGAGGG
5761 AACTCTATCATGAGACAGCACTAGGGAATGGTGCTAAACCATTAGAAACCACCCCCGTGA
5821 TCCAGTCACCTCCCACCGAGGCCACCTCCAACACTGGGAATTACAATTCAGCATAAAGCT
← MSTA#LTR/MaLR

5881 TTGGGTGGGGACACAGAGCAAAACCTTATCAGTGGTCTACCGATTCCAGGTCCAATGTGA
5941 TATCCACCATCTGGCAGGAAGCTTACCAGTTCATGGATAACAAATAGGCAAACCTGATCTC
DA6.0A/G rs12684262

6001 AAGCATCTCCTTGGTAAGAAACACAGCTTCTAGGTGCTCTCAGTCTCCTATTTCTTAGAT
G 0.102

6061 AACTCCAGAGCTATATGGCAAAATTCTAGATAAAAGACACATGCTGTTCCACTAATTCG
DA6.1C/T rs10965522 DA6.1aA/G rs13294267

6121 CCAAGCTGTGAGAGAGTCGAGTTTCCCATGCCCCGTGAACAAATTACCAAACTTAA
T 0.267 G

6181 TGTTTTGGATGTCTTATGTTCTGGAAGTCACATGTCGAAATGAGTTGTACAAGGCTAA
6241 AATCGAAGTGTGAGCAGGGTATATTTCTTCTGCAGCTCTCAAAGGGGAATCTGTTCTTT
DA6.3T/C rs13298799 DA6.3aA/T rs13294613

6301 CTCCTTTCAGCTTCTAGAAGTTGCTGGCATTCTTGGCTGTAGCCCTCTCACTCCAATC
C 0.250 T 0.255

6361 TCTGCTTCTGTCCTCACATAGCTTTCTCCCCTGACTCTCTGACTCCTCCTGCATTCCCTT
6421 TATAAGGACTATTGTGATTACATTAGGCCCAGAATAATCCAGGATAACCTCCCCATTTC
6481 AGATCCTTGATTTAACCATCTTGACAAAGACCCTTTCGCCATGTAAGGTTAAATTCACAG
← MLT1D#LTR/MaLR

6541 GGTCTGGAATTAGAGCATGAACATATTTAGGGGATATTATTCAGCCTACCACAGGAAGA
6601 ATTTTACTTTTATAATGTGTCAGGTTTCAGCAGTTTTCAAAGAAATATTTAAAAATATAC
6661 TTGCCAAAGGGTTTATCTGAGAAGAGAATGGGAAGATTATGGTATATAAAGCCACTGTACT
6721 CCCAACAATGAGGAAGAAGCTATCTTCTCAATTTCTCTAGGGCATGGACTGTCTCTCCCA

6781 TGTACCCCTCCTTAGTCTCTGAGTTCAGAGTATGAGATGGAGGTAGCCAGACTGGTATCTAT
rs35084082

6841 GAATAGAGAAAAATTTTTTCAGTCTTGGCTTTTGAGCCTCTACTACCTATAGGTATGAGT
|+A

6901 GCCAAATGCCAGTATTTACATGCATATTAATCAGTCTTTGGTATCAATGTGTTTTTCAGT
6961 GTGAGGTTGTGGGTCTCAGCTTGAGAACCTGGGCTGTCTCTATCCTAGGATTTAAACCTG
DA7.0A/G rs10119429 DA7.0a-/ + rs34814746

7021 TCTGAGCATGTCCAGAGGGCCAGCAAAACCTCTTGCCTGTGGGACCCAGGAGCCTGC
G 0.276 |+GA

7081 AAGATGAGACAAAAAGAGCACGGAAGCTGCGTGCTTGGAGCAAAAAAAGTCTAAAGGCAT
DA7.0bT/G rs7032999
G 0.400

7141 TGGAGAACAAGGGCCATGTCTCTCACTAAGAGTACCCCTTGCTCCAGCTCTATAGGCTCA
rs12002333
G 0.000

7201 TAGCCAACAAAGTTAAACAATGAGTACAAGCTAAAAGGTCTGTTTCTCTAAAATCCCTGG
7261 GGGACATTGAGAAATGCAGAAAAGCCTTCACTGACTTGGCAGCATGATGCTGCTGGTTTGA
7321 GCAGCAACAGGAAATGTAATAGGCAGCTTTTATAGTGGCACCTCATGCTTTTTTAGGGTTT
7381 AGAAGGCAGTTAGTAGGTGTATTAGTCCATTTTCATACTGCTATGAAGAAATACCTGAGA
DA7.4A/C rs7033234

7441 CTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACAGCTCCACAGGGCTAGGGAG
C I I I I I I I I I I I
GNGGN NANGNGN

DA7.5T/G rs7036542 DA7.5aT/C rs7036558 DA7.5bC/T
7501 TCCTCAGTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACGGTGGCAGG
G
G 0.658 C 0.871 T

rs56278769 DA7.5cG/T
7561 CAAGAGGGTGTGGGCGGGGAACCTGCACTTTATAAAACCATCAGATCTCATGAGACTTAT
T
DA7.6A/C rs7033398 rs58914976 rs56293504 DA7.6aG/C
7621 TCACGTGCATAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCTCCACAG
C
7681 AGTCCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATTTGGGTGG
← THE1B#LTR/MaL
DA7.7G/T
7741 GGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACATTTTAGAAT
rs77873223 T

7801 TCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCTTGAAATT
C

7861 GCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTTTAAATATTAACAG
7921 GAATCATAAATTTCCATTATTTTCTATTACCCCTGTAATCCCATGACCCATTTTTGTTC
rs75105607

7981 AAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATTACAACAG
C

8041 CAGAATAAAGGCTTTGAGTTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCATAAACAGT
8101 AGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACTAGAAAAAG
8161 ATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGAGGAATAAAGG
DA8.2G/A rs1324202 rs1324203 rs1324204

8221 GGAAGCCAATAATGAATGTATGAGTGGATTGGGGGAAGAGGATATGGGAGTTTATTCCA
A 0.158 0.000 TA 0.000

8281 TTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATTTCGATTAGGGATAT
8341 CTGAGAACAAAGATCCCTTGAGCTCCCTGTCCTAAGTAGCTCCCTAGGAAAGAGACTAC
DA8.4G/A rs17472622

8401 ACCCCACACTACGCTCCTGCATGTTGTTTTGGTACATGGGGTTCTACACAGCCTTGTGGA
A 0.042

8461 TCTTACCATGGCTCAGCGTGGTGTGGGAGCCACAGAATTGTGCCCCGTCCCTCAGTGGA
8521 GCATGGCAGTAGGCATGAAGGACAACCCAGTGATTGTTTTTCATGTGCAATTGATGTACTG
DA8.5C/G rs10117864

8581 TTGGAAATACGAATGTCTCAAAGGATGTTGATCTGGAGAGACGATGACATAGAGTGCCCTC
 G 0.975 DA8.6 rs10117889
 8641 CTTCTCACAAATGATACCACTTAAACCCCCCTCCCAGACTTACACACAATCCCAGGGAAAA
 P 0.000
 0.308 (AFRICAN)
 8701 GGTAATCCAAAATAGAATGTGATTGATCTATGCTATTTTGGCATAAAGGGAAATCAAA
 8761 ATAGAAATCATATTGTTGAGTTGCAGAAAAATAAATACAATCGTACTTTGTTGACATCTG
 rs16931305 rs13288842
 8821 AGTGAGGGGACCACACTTTGCATTCTCTACATTCTGTAGTTGCATTTGCAGGTGACCTGA
 E 0.000 rs13290069 P 0.000
 8881 AACTCCCTGGTGTATAGCAAGGTACCATTTTGATGAGGCAAGAATTTCAATCCTTCACGT
 P 0.000
 8941 ATGGTAATGAGATATTTATCTGAAATGTGCTTCTATTTGATCAGCAGCATCTCAGTGTTG
 9001 CTCTTGCAATGAAGTTACTCTCAGTGAGGGTCTGAGCAGATTACATAAAATTTAATTTT
 9061 TATTTACCTAATATATTGCCAGGACTTGGGGGAATGTGATCACAGCAAATTTCTATGCTG
 9121 TAATGATTTTGTAAATCTGAATATTTGGAACAGCTTTGGGATATATTTAAGTCATTTGTG
 rs10123974
 9181 ATGTTTGATCTCTTCAAAAATTGATCAGCAGTAGAGAATATTTAGAGAAAATAGATTATT
 P 0.000
 DA9.2+/- rs34794098
 9241 TTTTGAATGTGTTATGCAAAGTTTGAACATATCCCAAATAAGAGAGAACAGTATAATGT
 -
 9301 TCCCCATGTTCCCATTTCCCAGCTTCAACTATTAATATTCTGCCAATCTGAAAATACAG
 9361 AATTTTAAATGGCAAATGCTTCATTTGAAAAGTGAGGAAACAGAGGGGAGGGGTACAAG
 9421 GGATCTTTCCAGTCACACATCAGTGACCTTTCTGCTCTGAAGTGAATAAAATTATGCACT
 9481 AATCAATATTTAATAGCCATCATATTTTCATAGTTCAGCCATTCTGAATATATGGGAGATT
 DA9.5C/T rs17472664
 9541 GCCCCCAAATCTTGATTGAGCCTGAATCCTCTGCAATTTCTGAAGAACTCCCAAAGTGAA
 T 0.188
 9601 GGTGGTTAAGCACAGGGTTGCCAAACACTGGGACTAAGCTTAGGCAGTGAGGCACCTAGG
 9661 ACACAACATTTAAGGGGCCCTGAGTCTCAGGTTACCCATACACAGGGCCAGCACCTCAT
 9721 TCACTCCATCCCATCCCCTGGGCTACCACATGCTCATTTCCAATTTCTGACTCATATTAAC
 9781 CCCAGGATCCCCAAACTAGCTGCTCAACCGCCTTGACTCTTGGGATCACACACTTTTGTG
 9841 AGAAGAGGTGGTCGACAAGGCACGACTGACTCCTCCTGCACTCACAAATTCATTTGATGT
 9901 GAAGTGACTCCTGGATGCCAGAAATGAGGCTAGATGCCTGGTGTGAAGATAAGTCAATGG
 9961 CCTTGACTTTGAGGACATTGCAGTCTGCTAGGGATTCTCTCTAAATGGTTTATTTTCCA
 10021 TTTGCATTTGAAGCAGTAAACTCTAAACCAGTATTAATTCAGGGAGCACATGGACTATG
 DA10.0G/A rs10965543
 10081 GCTGAATGGAAACTATTTATTCCTGGCAATTTAGAGGATGCTGGAGGGGGTAGTAGT
 A 0.239
 10141 TGACAATACATTTTTTCCTATAGTTGTTTATACTTGATTCTCACAGCAATTCTATGAGATG
 DA10.2C/T rs7026913
 10201 GGCATTATTTTCAATCTTTTAGAATTGACAAAATGTTGGCTTAGCAGTATTGAGTAATTTG
 T 0.358
 10261 CAAAGATCCAGCAACAAATGTTTCCCATTTGGGATCTGAACGCTAGCCTAGTGCCTCAAA
 10321 TTAAATGTCTTATGACATGATAACTACAACAGTCAAAAAGTCCCCACTAGAAATGACAAA
 10381 GGAATATTGCAAAACTGGGGACTTGGGAAGGAACATGTTACAAAGCAGCTACCAAGGTGGT
 10441 GAGAGAGGCCCTCGGGATGGCACAGACACGCCCAAATTTCTCATCCTCACCTGCAGTTCTT
 rs9987957
 10501 CCCTCGCCATCCTCAGATTATGATCCATAAAGCCTCTCTGAAGAGGCAGCCGACAGCCCT
 A 0.000
 DA10.6G/A rs1981006 DA10.6aA/C rs2376221 DA10.6bC/A rs9987682
 10561 GTGCTTGCTAACAACCTGCGTATCCTCTGAATAGTATCTCCATACTCTCCTGCAATGGG
 A 0.229 C A 0.438
 10621 GAGTTCTGTACTGTCTGCTGTTAGAGGCAGGAAGCCACAGAAGAGAATGGCTTCTTCC
 10681 TAGCTTGAATGCTTCAGTTCCATAATGGAGCTGACTTCCAGGCACTGATGGGGCTTGGGC
 10741 TAAGAAGCAGTGTGGAGTGGGGACTCTTTCCAGGAGGCAAAGGATGCTGGGATTTTCATAT
 10801 TTGAAAGTGAATTCATCCCAGCGTCACTGATGACTAGTAAAAAACCAATTTTGGGA
 DA10.8-/+ rs35200569
 10861 GTCTACTGGGTTGGAAGGGTGGGACAGTCCCTCACACTCTTGTGGAGCCCTGAGTTTGGTG
 |+T
 10921 TCAGAGATCTCTGAATGAGATCAGACATAAAGCCATAGGGGTATGCTAGCAGACTCAGAG
 10981 GAAGGCTATCATACAGCTCTAACCTGCATCCACATTGTTTGTGGTGCCCTGTGAATTAAA

11041 AATACATAGAACTCTGTGTCTTTAAAAATAGCACAGATATGTGTATACTGTAACTTTAA
11101 AAATAGCAATATTTACTGCATTTTGTACCTTCTTTTGACATTTCTTCATTTTAACTTTC
11161 AGAAGCATCAAAATGTGAAATTGGTCTTTTATGACATCTGAAGGTCTTGCCCTAGCCTTAA
11221 TTTTTTAGGAGGCCTAGTCCCAAGAAAAAGATATTGTTTCATAAGCCACTGATGTGTTC
11281 GGGTCTAGATTTTATTTAACGTCTTCAAACCATCAAGAAATTACTTAATAAGCTGTGT
11341 CTACCACCGCAGAGTGACTTTGAAGAGTTTGAGGCAGTTGCCCTGAGTTATTATAGTCCTA
11401 AAAGCTGTTTCATCTCAAATATGCAGGTAGTAGACACAAGGATGACTTCACCTTTATCTGG
11461 GTAATTGTATCAATTGCCCTGTAAATCACAGTAAATCAATGTATTATATAGGTGTGTATG
DA11.5C/T rs10811811 AluSx ->
11521 TATAACACTATAAAATATATAACATGGCCTGGCTCAGTGGCTCACACCTGTAATCCTAGT
rs2039352 T 0.229
11581 ACTTTGGGAGTCTGAGGCGGGAAATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCA
C
11641 ACATGGTGAAACCCCATCTCTACTAAAAATACAAAAAAATTAGCTGGGCGTGGTGGCGGA
11701 TGCCTGTAATCCCATCTACTCAAGAGGCTGAGGCAGGAGAATCGCTTGAACCTGAGAGGC
11761 GGAGGTTGCCGTGAGCCTAGATAAAGCCACCACACTCCAGCCTGGGCAACAGAGTGAGAC
rs35199905
11821 TCTGTCTCAAAAAAAAAAAAAAAAATTATATATATATATGTATATAAAACATTGAATAAA
--
11881 ATATTTTTTATACTTTAGTACTCATGTTCAATCAGTTCTTAACGTTTAAAAAATAATGC
Rs9987427
11941 ATTGTAGGTTATATAAACATTTCTCCTACTTTTCGTTTACATCCTGTTTTCCTAGTCAACGT
A 0.000
12001 CTTCTTGTTTGGTTGTTTAACTTTGGAACATGTGCTTTGTTGGTTTCAGTTTCAGGATTCA
DA12.0C/T rs13287382
12061 CGCGCCAGTACCTAACCTAGTCATGCAGTGATGTGTCACAGTTTCTACATCTAGGTCCC
T
12121 TGTGATGGTCCTTGGTGCTGTTCCACCAGCTATTTCCAGGCATTTCCCTGTTTGCCTTGTGT
12181 TGGGGAGGCCATGTGACTTTCTCTGGCTGAATTTTAAAGTGGAAGCACATGTTCCCTAGGCC
12241 AGACCATTTAACTCCTGACATAATACCTCTGGAGCTTTCTTTGCCATTTCTGGGGTAACC
12301 AGGAATCTTGCAGACTATGGCTGCTCCATCAGCTTAAAGTGTGGAGTTAAGATGATCTGG
12361 AACATAAAAGAGAAATAAACTTTTGTGTATTAAGCATCTGAGATCCTTTTTTCCCAT
12421 AACATAGCCTACTCCATCTTGACCAGTAGAGAATGTACTACATTTCTTTTAAATTTTTTAA
rs10965555
12481 AAAACATTTTTATTTTGTGGATACATAGTAGGTGTACGTATTTAGGGGGTACATGCGATA
C
12541 TTTTGGCACAGGCATGCAATGTGAAATAATGGTATTATGGAAAATGGGTATCCATCCCCT
rs2039353 rs2039354
12601 CAAGCATTTATCCTTTGTGTTACAAACAATCCAATTATACACTTTTAGTTGTTTTAAAT
G G
12661 GTGCAATAACATTATTATTGTTATTATAGTCTCTCTGTTGTGCTATCAAATAGTAGGCCT
12721 TATTTATTCAATTCTAGCTATTTTTTTTTTGTACCCATTAGCCATCCCCACCTTCCCAGCAA
12781 GGCTCCCTTCCCAATACATTTCCAGCCTGTGGTAACCATCCTTCTACTCTCTATCTCC
12841 ATGGGTCAATTGTTTAAATTTTCAGATCCCACAAATAAGTGAGAACATGCAATATCTGTT
12901 TTTCTGTGCCTGGCTTATTTCACTTAACATGATGATCTCCAGTTCCATTTCGTTGTTGTC
12961 AAATGTTCCAAATGACTGAATCTCATTTCTTTTTTATGGCTGAATAGTAATCCATCCGTGT
13021 ACAAGGACCACAGTTTTTTTAAATCCATTCATTTGTTGATGGACACTTAGGTTGCTTCCAAA
13081 TCTTGGCTATTGTGAACAGACCTGCAAGAAACAAGGGACTGAAGACATCTCTCAGTATA
13141 CTGATTTTCTTTCTTTTGGGTATACCCAGCAGTAAAATTGCTGGATTGTATGGTAGCT
13201 CTATTTTTTATTTGCATTTCTCTGATAATCATTGATATTGAGCATGTTTTTCATATGCTTG
13261 TTTAGCATTTGTATGTCTTATTTTGAAGAAATGTCTATTCAAATCTTTTGCCTCATTTATTA
rs12003624 DA13.4A/G rs10811818
13321 ATCAGATTAGATTTTTTCTGTAGTGTGTTTGTAGCTCTTTGTATATTCTAGTTATGAAT
G G 0.500
DA13.4a-/+ rs34370591 DA13.4bC/T rs34775873
13381 CCCCTATCAGATGGGTAGTTTGCAAAATTTTCTCTTATTCTGTGGGTGTCTCTTCATT
+T T
13441 TTGTTGATTGTTTCCTTTGCTGTGCAGAAGCTTTTTAACTTGATGTGATCCCATTTGTCT
DA13.5T/C rs7859510 rs10965560
13501 ATTTTTGCTTTTGTGCTTGTGCTTGTGGGGTATTACTCAAGAAATCATTGCCAGATTG
0.550 CA
13561 TTGTCTTGAGAGTTTCCCAATGTTTTCTTGTAGTAGTTTTATAGTTTGAGGTCTTAGT
13621 TTTAAGTCTTTAATCCATTTTAAATTTGATTTTAGCATATATCAAGAGACAGGGTCTAGT

13681 TTTATTCTTCTAGGTATGGATATCTGGTTTTCTCAGCACCATTAATTGAAGAGGCTGTCT
DA13.8-/+ rs35857441 DA13.8aG/A rs7869886
13741 TTTCCCAGTGTGTGTCTTGGCACCTTTGTCAAAAATGTTTGTGTAAGTGTGGGTT
|+C A 0.617
DA13.8bC/T rs10965562
13801 TGTTTATGGATTTTCTATTGTGTTCATTGGTCTATGTGTCTATTTTATGCCACTACCA
rs34158483 T 0.284
13861 TTCTGTTTGGTTACTATAGCTCAGTAGTATAATTTGAAGTCAGGTAATGTGATTCTTTTC
C
13921 AATTTTCTTCTTTTTTGCTTAGGATAGCTTTGGCTATTCTGGGACTTACGTGGTTTCATAT
13981 AAATTTTAGGATAGGTTTTTTTCTATGTCTGTGAATAATGTCATTGGTATTTTGATAGGG
14041 ATTGCATCAAATCTGTAGATTGCTTTGGGAAGTGTGGATGTTTAAACAATATTTATTATT
14101 CCAATCCATGAACATGAAATATTTTCTATTTTACTGTCTCTTCAATTTCTTTTATT
14161 AGTATTTTATAGTTTTCATTATAGAGATCTTTCACCTCTTTGGTTAATTTCTAGGTATTT
rs10965564
14221 AATTTTATGTGTGGCTCTTGAAAAATAGGATTACATTTTTTATTTATTTTTCAGACTGTTTC
± 0.000
14281 CCTGTTGACATATGAAAAATGGTATTGATTTTTGAATGCTGAGTTTATGTCCTGCAACTTT
14341 ACTGAATTTGTTTATCAGTTCTAACAGTTTTTGGTGGAGTATATAGGTTTTTCCAAATA
Rs10811819
14401 TAGGATCATAACATCTGCAAACAAGGATAATTTGACTTCTTCCTTTCCAATTTGGATACG
DA14.4T/C rs11531720 € 0.000
14461 CTTTATACCTTTCTCTTGCTGATTGCTCTAGCTAGGACTTCCAGTACTATTTTGAATAA
C
14521 TAGTGGTGAAAGTGGGCATTCTTACTGTGTTTCAGATCTTAGAGGAAAAGCTTTTCAGTTT
14581 TTCCCCCATTCAGCTGTGGGCCTGTTGTATATGGCCTTTATTATGTTGAATATGTTTCCTT
14641 CTATATACAGTTTTTTGAGGGATTTTATCATGAAGGGATGTTGAATTTTATCAAATGCTC
14701 TTCAGTATCAATTAAAATGATCATATGGATTTTGTCCCTTCATTCCTTTGATATGATGTAT
rs12377063 rs34900306
14761 CACATTGATTGATTTACATATGTTGAACCATCCATGCATCCCTGGGATAAGTCCCATTG
T A
14821 GTTATGATGAATAATCTTTTTAATGTGTTGTTGAGTTTGGTTTGCTAGTATTTTCTGAGG
14881 TTTTGCATCAATATTTATCAGTGATATTGGCCTATAGTTGTTTTGCTTTTGTGTTGTT
<- L1
14941 GTTTGATGTGTCCTTTGTCTGGTTTGGGTATCATGGTAATACTGACCTCACTGAGTTTGG

TARGET DB

LINE/LA#L1P3 ->

```

1   TTTATGGCTGCATAGTATTCCATGGCATATATGTGCCACATTTTCTTTATCCAGTCTATC
61  ATTGATGGGCATTTGGGCTGGTTCCAAGTCTTTGCTATTGTGAATAGTGCTGCAATAAAC
121 ATACATGTGCATGTGTCTTTATAGTAGAATGAGTTATAATCCTTTGGGTATATACCCAGT
181 AATGGGATTGCTGGGTCAAATAGTATTTCTAGTTCTAGATCCTTGAGGAATTGCCACATT
                                     rs6046364
241 GTCTTCCACGATGGTTGAACTAATTTACACTCCCACCAACAGTGTAAGCTTTTCCTATT
                                     G
301 TCTCCACATCCTCTCCAGCATCTGTTGTTTCCTGACTTTTTTAATGATCACCATTCTAACT
361 GGTGTGAGATGGTATCTCATTTGTGGTTTTGATTTGCATCTCTCTTATGACCAGTGATGAT
421 GAGCTTTTTTTTCATATGTTTGTGGCCACATAAAATGTCTTCTTTTGAGAAGTGTCTGTT
481 CATACCTTCCACCTACTTTTTGATTTTTTTTTTTTTTTGTAATTTGTTTAAAGTTCTTGT
541 AGATTCTGGATATTAGCCCTTTGTCAGATGGATAGATTGCAAAAATTTTCTCCCATTTCTA
601 TAGGTTGCCTGTTCACTCTGATGATAGTTTCTTTTGCTGTGCAGAAGCTCTTTAGTTTAA
                                     rs7346766 (rs6035456)
661 TTAGATCCCATTTGTCTATTTTGGCTTTTGTGGCCATTGCTTTTGGTGTTTTAGTCATGA
                                     C
                                     rs7343771 (rs6046365 )
721 AGTCTTTGCCCATGCCTATGTCCCTGAATTGTATTGCCTAGGTTTTATTCTAATGTTTTCA
                                     T
781 TGGTTTTAGGTCTTATGTTTAAAGTCTTTAATTCATCTTGAGTTAATTTCTGTATAAGGTT
841 TATGAAAGGGGTCCAGTTTCAGTTTTCTGCATATGGCTAGCCAGTTTTCCCAACATCATT
901 TATTAAATAGGGAATCCTTTCCCATTTGCTTTGTTTTTGTGAGGTTTGTCAAAGATCAGAT
961 GGTGTAGATGTGTGGCGTTACTTCTGAGGGCTCTGTTCTGTTCCATTGGTCTATCTACC
1021 TGTTTTGGTACCATTACTGTGCTGTTTTTGGTTACTGTAGCCTTGTAGTATAGTTTGAAGT
                                     rs6081767
1081 CAGGTAGTGTGATGCCTCCAGCTTTGTTCTTTTTTGCTTAGGATTGTCTTGGCTATACGGG
                                     A
1141 CTCTTTTTTGGTTCCATATGAAATTTAAAGTAGTTCTTTCTAATTGTGTGAAGAAAGTCA
1201 ATGGTAGCTTGATGGGGATAACATTAATCTATAAATTACTTTGGGTAGTATGGCCATTT
                                     rs12479740
1261 TCACGATATTGATTCTTCCTATCCATGAGCATGGAATGTTTTTCCATTTGTTTGTGTCCC
                                     T
1321 CCTCTTATTTCCCTTGAGTAGTGGTTTGTAGTTCTTGAAGAAGTCCTTCACATCCCTTGTA
1381 AGTTGGATTCCTAGGTATTTTATTCTCTTTATAGCAATTGTGAATGGGAGTTCACATCATG
1441 ATTTGGCTCTCTATTATTGGTGTATAGGAATGTGTGTGATTTTTGCACATTGGTTTTGTA
                                     rs6112609
1501 TCTTGAGACTTTGCTGAAGTTGCTGATCAGCTTAAGGAGATTTTGGGCTGAGACGGTGGG
                                     G
1561 GTTTTCTAAATATACAATCATGTGCATCTGCAACACAGACTATTTGATTTCCCTCTCTTCC
1621 TATTTGAATATGCTTTATTTCTTTCTCTTGCCCTGATTGGCCAGCCAGAAGTTCCAATAC

1681 TATGTTGAACAGGAGTGGTGAGAGAGGACATCCTTGTCCTTGTCGCCGTTTTTCAAAGGGAA

1741 TGCTTCCAGTTTTTTGCCCATTCAGTATGATATTGGCTGTGGGTTTTGTCATGAATAGAGAT
                                     DNA/MER1_type#MER102a ->
1801 AGCACCTTCTTCTATGGGCAGGGGCACCAGTTACTCCATCCAGCCTACCATAATTACCTG

1861 AGAATACAGGACCTGTGCTCACAGACCTTTTGATTTTTTCAAAAGACAACAGAAATCCAGA
1921 TTTGTAAAGTAGTATCTCTTAATTTTTTGAACATTAGCAACTATTCCATTTTTCTTTTGTTT
1981 ATCTCTTTTTGTAATATTGGGCAGACCAAAATTAATTTACTGTTTTGCCCTGCAGTCAAC
2041 ATTGTTTTGTCACTGAATAGGATAATGGCACAGCTGAGTTGCTGAAGATCCTCTTGAGGG
2101 ATGCTCATTGATTCCTTTTTTGCTTTTTTATCCTTCATCTGAAGCATTTAGCATTTGTTTG
2161 CAGTTTTCATGTAATTTTTCCCTTAGTGAAAGTCCAAAGGGTTTTGATGCTCATCAGCTC
2221 ACTCTACCCTTGCTCATAAACTGTCAGTTTAGGCCACAGTTCCTTACTCTTCATCCCTG

DB 2.2T/C rs17300552
2281 AGATAAGTTACTACTAAGTGTTGTAGGATTTCTCAGGGTGGTTTTGAAAATTCACATTTT
                                     C 0.125
                                     DB 2.3G/C rs6106142

```

2341 AAAGAATCAGGAAAGCTTATGCATAAACGTGCATGCAGTTAAAAGGGAGGTGCCTAGACT
 C 0.025
 DB 2.4 G/A rs6112610
 2401 GGCAGTGGGCTCAACAAGAGGGTAGAGGTGCTGCCACTTCAGCTTCCGGAGACCCAGAGG
 DNA/MER1_type#MER33 -> A 0.025
 2461 GGGTTCTAGAAAGTGTGGCACCCAGCACAGTAGTCCCAGAATACATGGCAGTGTCCAGCAC
 2521 TTGACGTGTGGCTTGTGTGAACTGAGATGTGCAATCAGTGTAAAATACATACCAGATTTA
 DB 2.5T/C rs9789825
 2581 GAAACATAATGAAAAAGAGATAAAATATCTCATTTTTTGAATTTGGTTACATATTTAAGTG
 C 0.759
 2641 GCATTTTATAGATATATTGGGAAATTAAATAGTATTAAAATTAATTTTACCTGTCTAATCTT
 DB 2.7T/C rs6112612 DB 2.7aC/G rs6106143
 2701 ACTTTTAAATCTGGTTACTAGAAAAATTTAACATTATGACTGTGAGTCGCATTATATTCTA
 C 0.042 DNA/MER1_type#MER58A -> rs6136857 G 0.025
 2761 CTGATCAGTTCTGCTCTAGAACAGGGAGGGGCCATAAACTTTTTTCTGTAGAGATCCAC
 rs8118681 G 0.000
 2821 AGAGTAACTTTTTTAAGCTCCACAGGCCATATGGTCCTTGTGCAAACATTCACTCCACC
 G 0.000
 2881 ATTCCAGTACAAAAAGCAACCATGGATGAGATGTAAATGAATGAGCAGGGCTGTGTTCCAA
 2941 TAAAACTTTATTTGCTAAAAATAGGCAGGGGCCAGATTTGCTGACTCCTGCCTGATGAGAA
 LINE/L1#L1ME3A ->
 3001 AATAAAAGCAAGGGGGAGGGAGGGGACATTGAGGTGTTGGTGGCATTCTGTTTCTTGATC
 rs8118912
 3061 TTAATGCTAGTTAAGTGGTGTACTTTTTGAAAATCCATCGAGCTACAGTTATATGATATG
 A 0.000
 3121 TGTACTTTTCATGTACACATTATACTTCAATAAAAAAGTTGACTTAAAAAGAGCAGGGTCT
 SINE/Alu#AluSc ->
 3181 CGGCCAGACAAGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGTGG
 DB 3.2T/C rs8125637 DB 3.2aC/T rs6081768
 3241 ATCATGAGGTCAGGAGATCGAGACCATCCTGGCCAACATGGTGAAACCCTGCTTTACTA
 C T
 DB 3.3C/A rs8120208 DB 3.3aG/A rs8120277 DB 3.3bA/C rs7352938
 3301 AAAACACACAAAAAATTAGCTGGGCGTGGTGGTGTGTGCCTGTAATCCCAGCTACTTGGG
 A A C
 DB 3.4A/G rs6046366 DB 3.4aC/A rs8120249
 3361 AGGCTGAGGCAGGAGAATCACTTGAACCAGGGAGTCGGAGGTTGCAGTGAGCTGAGATCA
 G A
 rs11480038 rs11352724
 3421 CACCACAGCACTTCAGCCTGGTGACAGAGCAAGACTCCATCTCAAAAAAATAAAAAA
 -/A -/A
 rs35673192
 3481 AAAAAAGAGTGGGGTCTCTTCTGGAAGATCTGACTAAAAGAAAAAAGCCGGAGATGTACA
 -/A in/del
 rs35276535
 3541 TCTGCTCTTATTAATCAGTAACAATCCTCTTCCCGGTTTAAGAATGAAACAGTTTTTTTT
 rs8120352 -/T in/del
 3601 TCACAGTACATAGCAGTTATTTATTTAAATACCTTGAAAAGGTTGATGATGGAATAATAG
 T 0.000
 3661 GTTTATCGTGAGTTTATATCCATTCGATTTATTTTATCATTTAAAAAACTACTGCCTCTA
 DB 3.7A/G rs6106144
 3721 GGTTATTCTAGCCTGACATAGAACACTTTTGACACCTGCAGTTACTGTAATATACTATAA
 G 0.200
 3781 TAGACACAGCCATTATAGAAATGATTTCCACTTGGGAGGAAATTCAACAGTAGTAAGGATG
 3841 ACTCTTTATTTAAACTAAAAATCATTTTTCTAATTCTCTACCATCAGTCGGCCATTTAGTT
 DB 3.9G/C rs1737277
 3901 GTCCAAACTCATCTGGCTTTCCTCAGTCTCTGTACATCCATTCGGTACAATGGTCACTA
 C 0.042
 3961 CCTTTGTGAGAATTGCACTGGGACAAAATTCAAGCTATTGGCCATTTGGGGAGTAGTAAG
 4021 GGGATAGAATTCACTGGATATCAAAAAGCCTAAACTGTATTAAAGTTGTGTAGACTTAAAC
 4081 CACCAGATTTTGCAAAATTAATAAAAAAAAAAATTCGGTTCCCTGTGAGCTCATCCTGTGCA
 DB 4.1C/A rs6112615 DB 4.1a-/G rs34729041 DB 4.1bA/G rs6132237
 4141 GAATGAATATGCAGGTTTTACTATTTTGCCATCTGAATATAGACAGACAGAAAAGTATGA

A 0.075 -/G G 0.061
DB 4.2A/G rs6081769
4201 CTTTTCCTTCTAGACCTCGATACTGACCAACTATCAAGACACTTGCTCAGGCCTGCTCAG
G 0.058
4261 ACAGAAATGAGAAAGCGTGGAAACCGGGGCCGAGGTAGAGAACAGGACAGCCATGGACA
4321 CAGGCTCCCAAGGTCAGGGCATGGAAGTGCCAGACCCAGCAGGGTCTTGGTAGCTGCGAG
DB 4.3C/G rs3950057 DB 4.3aA/G rs34634068
4381 AGCATCGTTCTACCCGACTCTGCTCCTGCTCAGCAGCAAAGTTGCAGAGAGAGAGAGCT
G 0.028
4441 TCCAGAAGTGGAAAGATTTTTAAATAAGTCTTTTAACTTTTTGCCTGTGGATACAGCTGC
DB 4.5A/G rs34181998
4501 GTTGACACAAAGCCACAATTGAGGCATGATGTCTCGGAAGCCTGGCACCACGGACTGTTT
G 0.028
4561 TTCTACTGGGACCCATAATTGCTGCCTTTTAAAGAGGTGTCTGTGTTACGTTTTATCAAT
4621 GTGGTGCTTGAACCGGACTTTTCAGCTGACTCCCAAAAGGAAATAGTTTTTAAAGGAAGAA
4681 TTTTAAAGTCTGCCAAGAGCCAGATAATGGCATTAGCACAGAGAAAAAGCCAGGGTTTTGTGG
4741 TTTGTATATTTAAATACAAAGTCTCTTAATGCCTCAAAACAGCAGCCTCCAGAAAAATGGGA
4801 AGTTTAAATAGATGAGGCTAGAGAAAGCAGTTTTTAAAGATCGAAATTTTCCCTCTTTGTTT
4861 CTTGTGATTTACCCGAAAGGAACAAGTTCCCTTTCTCTGAACCTCCTCTATGTCTATTT
4921 TTGGTTTTTATACAAGTGACTGTTCTCATTAAGTAAATCTCAAAGTGCTCTGAAAATGTC
4981 CATGCTGGGCTGCCGGCTCACGCCAGGAGCTTTTGGCTGGACACTCTGCAAAAATG
5041 TGTCTGAGGACAAAGGCCATTAACATTTGGTTAATCTAACATCATAAATTACTTTTTCCC
5101 ATAAATTACTATTAAACAGACCTCCCTCCATACTTTTTCTGAGTGCTGTCTTGCCGTTTTT
5161 AACCTCCCTTACATTTCCACCCTTTTGCCCAACACAGAATCACATGAGAGCCCTGGAGG
rs6112617
5221 ACACGGGGGAGGGGTGGGTTCAGCTGTTGTCTTAGCACAGTCTGCAGCTCCTCCGTGCAG
DB 5.2G/A rs34367386 rs6112618 A 0.000
5281 GCTGTTGTTTTCCCTGACAGTAATCATCTGTCAAGAGAAATGTTACGTATCCCATCATCA
A A 0.000
DB 5.3G/A rs17300678
5341 GTGTGGACTCTGGCTGGACTCTAGACAATGCACAGAACCATCAGCCATGGTCTCACAAA
A 0.042
rs6081770 DB 5.4G/A rs941736 DB 5.4aG/A rs6112619
5401 CCACTTGGCCACTATTGTCTTCTTACCTTCTGTTTGTAGCAGTCACTGCAATAGGTTGGG
G 0.000 0.490 A A
5461 CCAGGGGACAGCAGAGGAGGTTTTGGGGATGCCTGAATTCAACTGGAATGCCACCTACACT
5521 TGTATTATCCAACACATGCCCCCTGGTGCAGTGATTTTGGTTTTTAAACCAGTTTTTAAACG
SINE/Alu#AluSq ->
5581 GATGCACATTGTGGTTAGAAATGGCAGACCAAGCTGGGTGCAGTGGCTCATGCCTGTAAT
5641 CCCAGCACTTTGGAAGGCCGAGGCTGGTGGATCATTTGGGGTCAGGAGTTCAAGACCAGC
5701 CTGACCAACATGGTGAAACCTGTCTCCTAAAAATACAAACAAAAACCAAAATTAGCCT
5761 GGCATGTTGGCACATGCCCTGTAATCTCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCT
5821 TGAACCTGGGATGCAGAAATTCAGTAAGCCAAGATCGTGCCACTGCACTCCAGCCTGGG
Simple_repeat#(GGAA)n ->
5881 CAACAAAAGCAAGACTCTGTCAAAAAAAGAAAGGGAGAAAAAGGAAGGAAGGAAGGA
DB 5.9A rs114757 rs3966681 (-/A/AGAAAGA/G)
DB 5.9aGAAG/-rs35906767 (rs11467912)
5941 AGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGA
DB 6.0T/A rs6046369 SINE/Alu#AluSq -> -/del -/del - in/del
6001 GGAAGGAAGGAAGGTAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGA
A
6061 TGCCTAACCTGCAGTCTGACACTGATCTCTAGGCATGCTGGGTGCTGGGAAGTGGGGTGA
6121 TGGAGGGGGTCAGTGGCAAAGAGAAAAACCTTGGGGCAGGTGAGATGATGCTGGGGAAGGG
6181 ACCCCAGTGGTGTGGATGTGACACTAGGCCATAGAGGACTCAATCAATAAGAAAGGAAGG
6241 ATTTGCAGTGTGAGGGTTCCAGACACAGGTGAATCTTGAAGCCAGGTACAGATGAAGGA
rs16981220
6301 GATTGGGAAAAGTTTCCAGCCAAGTGGGTAGGCCAACCCAGGTGCCAGGGACAAAGAACCT
SINE/Alu#AluJo -> T 0.017 (0.100 AFR)
6361 TGGTCTTGGGGCTGGGCATGATGGCTCAAGCCTGTAATCCCAGCACTTAAGGAGGCTGAG
6421 GCAGGAAGATGCTTGGAGCCAGAGTTCTTGAGATCAGCCTGTGCAACATAACGAGACT
6481 TCATCTCTACAAAAACAAAAATCAGCTGGGCTTGGTGGTGTGTGCCGCTGGTCCCAGCT
6541 ACTCAGAGGCTAAGGTGGGAAGATCGCTTAAGCCTAGGAGGTGCAGGAATGCAGTGAGTTA

6601 TGATTGTGCTACTACACTCCAACCTGGGCAATAGAAATAGAACTCTCTTCTCTTGGGCTCC
 DB 6.6A/G [rs4814910](#)
 6661 CAAGAGCTCTAGCGGGGAGTGACCACACATGGTTGCTGAGCACTGTGACAGCTGCCATGA
 G 0.792
 LTR/MaLR#MLT1H ->
 6721 GACCGGCTGAAAAGAGGTATTAGTTAGCTATAGTCCCAGTAGAACTACCTAACAAGGCAC
 6781 CCCCAACTCAGAGGTATACAACAACAAGCACTTCTTTCTCACACTTACGTATGCAGGCT
 6841 GGCTGAAGTCCAGCTGATCTAGGCTGGGCAGGCTGGGCTCATCTGGGCTCAACTAGGCTT
 6901 GGCTGCAAGTCTGTGGATTGGTTTCAGGGCTACTCCATATGTCTTTTCGTCTTCCCTGGCATC
 6961 TCTGACACATGTTCTCAGGGCCGTGGCAGAAGCACCAGAGCACAAGCCCAGCACAGAAA
 LTR/MaLR#MLT1H ->DB 7.0T/C[rs4813375](#) DB 7.0aC/A [rs7263747](#)
 7021 CACTTTTTAGAGCCAGTGCTCATGGCATTATTCTATTGGGCAATGCAGGTCATGCCGTG
 0.892 C A 0.525
[rs6136858](#)
 7081 AAACCCACATCAAAGGGCAGGGAATATGCTCTGCCTCTACGTGGGGAAGTGC AAAGCC
 DB 7.1G/T [rs7263900](#) 0.000
 7141 ACATGGCAAAGGGTGTTGGATAAATAGAAGGGTAAAGAATTGAAGGTGGGTAACATGACCA
 T 0.379 Unknown#MamRep605->
 7201 AGGTGATTCTACCAGCATCTCCAGGTGGTGATGAAGGCTCCAGATGGACTCCCACTAATT
 DB 7.2T/C [rs13040206](#)
 7261 AAGCTCATGCAACTGATACTTAAACCAGAAAGTCACCTTATTGATCTGCAGCTAGAAATC
 C 0.051
 7321 TTAGTATATTGCAGACTAGAAAGCTCCTGTTCATCCGCTCAGTGTATTCTTTTCAGTAGGA
 7381 AATTAAATGTAGAACATCAAGTCATAATTCCAGCTTTGCTTATGAACATGGAGAGCAAGCA
 7441 AGAAGCATTGGTTGGGCGATCCTAAAGGCTTGAATTATCCAGGTCTCGTTGCCTGAGGCC
[rs6035457](#) DB 7.5T/A II
 CC
 7501 TCCCTTTCCACTACAGGAAAACACCTGCCAAAGGGATAGTGGGCAGGCTGCTCCCTTGT
 I I I I I I I I I I
 NCCNTNCCNC
 A 0.636
 7561 TAGGTAGAGACCTTGCCAAATTACTCTTTGTATGCTCTTTTCTAGCCTCCTCTCTGATCA
 7621 TTCTTAATCTACATTAGTCCCTTACATACAAGGTAATAATGAAATTATTATTCTGTGACT
 DB 7.6C/T [rs6136859](#)
 7681 ACAAGCCATATTGGGAATTAAGGTCTCTAAGATGCCACAGTCACCTAGTCACCTAAGACT
 T 0.448
 7741 GTCGCTTAGGATAAGGTGCTTTACATATTCATCAATATCTCTTAAATAGCAATGGATATC
 LINE/L1#L1PA5 ->
 7801 ATTTGCCATCCTTTTTTTTTTAATTATTATACTTTAAAGTTCTAGGGTACATGTGCACAAC
 DB 7.8 T/C [rs6046370](#)
 7861 GTGCAGGTTGTTACATATGTATACATGTGCCATGTTGGTGTGCTGCACCCATTAACTCG
[rs6046371](#) C
 DB 7.9 T/A [rs6035458](#) DB 7.9aT/C [rs6112620](#)
 7921 TCATTTACATTAGGTATATCTCCTAATGCTATGCCCTCCCCCTCCCCCACCCTCATGACAG
 G A C
 7981 GCCCCAGTGTGTGATGTTCCCTTCTCTGTGTCCATGTGTTCTCATTGTTCAATTCCCACC
 8041 TATGAGTGAGAAATATGCGGTGTTTGGTTTTTTGTCTTGCAGATAGTTTGTGAGAAATGAC
 8101 GGTTCACAGCTTCATCCATGTCCCTACAAAGGACATGAATCATCCTTTTTTATGGCTGC
 8161 ATAGTATTCCATGGTGTGTATGTGTACATTTTCTTAATCCAGTCTATCATTGATGGACA
 8221 TTTGGGTGTTTCCAAGTCTTTGCTATTGTGAATAATGCTGCAATAAACATACGTGTGCA
 8281 TGTGCTTTTATAGCAGCATGATTTTATACTCCTTTGGGTATATACCCAGTAATGGGATGGC
 8341 TGGGTCAAATGGTATTTCTAGTTCTAGATCCTTGAGGAATCACCACACTGTCTTCCACAA
 8401 TGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAGTGTTCCTGTTTCTCCACATCC
 8461 TCTCCAGCACCTGTTGTCTCCTGACTTTTTTAATGATCACCATTCTAAGTGGCATGAGATG
 8521 GTATCTCATTGTGGTTTTGATTTGCATTTCTCTGATGGCCAGTGACGATGAGCATTTTTT
 8581 CATGTGTCTGTTGGCTGCATAAATGTCTTCTTTTGGAGAAGTGTCTGTTTCATATCCTTTGC
 DB 8.6 C/T [rs6112621](#) ([rs7361979](#))
 8641 CCACTTTGTGATGGGGTTGTTTTTTTCTTGTAATTTCTTTGAGTTCTTCGTAGATTCTG
 T
 8701 GATATTAGCCCTTTGTTCAGATGAGTAGATTGCAAAAATTTTCTCCCATTTCTGTAGGTTGC
 8761 CTGTTCACTCTGATGATAGTTTCTTTTGGCTGTGCAGAAGCTCTTTAGTTTAAATTAGATCC
 8821 CATTTGTCAATTTTGGCTTTTGTGTCATTGCTTTTGGTGTTTTAGTCATGAAGTCGTTG

8881 CCCATGCCTATGTCCTGAATGGTATTGCCTAGGTTTTCTTCTAGGGTTTTGATGGTTTTTA
8941 GGTCTAACCTTTAAGTCTTTAATCCATCTTGAATTAATTTTTGTATAAGGTGTAAGGAAG
DB 9.0C/T rs6075582 (rs7352902)
9001 GGATCCAGTTTCAGCTTTCTACATATGGCTAGCCAGTTTTCCCAGCACCATTATATAAAT
T
9061 AGGGAATCCTTTCCCCATTTCTTGTTTTTGTCTAGGTTTGTCAAAGATCAGATGGTTGTAG
9121 ATGTGTGGTATTACTTCTGAGGGCTCTGTTCTGTTCCATTGGTCTATATCTCTGTTTTGG
9181 TACCAGTACCATGCTGTTTTGGTTACTGTAGCCTTGTAGTATAGTTTGAAGTCAGGTAGT
DB 9.2G/A rs6081771 (rs7352972)
9241 GTGATGCCCTCCAGCTTTGTTCTTTTGGCTTAGGATTGCCCTTGGCAATGCGGGCCCTTTTT
A
9301 TGGTTCATATGAACTTTAAAGTAGTTTTTCCCAATTCTGTGAAGAAAGTCATTGGTAGC
9361 TTGATGGGGATGGCATTGAATCTATAAATTTCCCTTGGGCAGTATGGCCATTTTCATGATA
9421 TTGATTCTTCCATCTATGAGCATGGAATGTTCTTCCATTTGTTTTGTGTCTCTTTTTGTT
9481 TCGTTGAGCAGTGGTTTGTAGTTCTCTCTTGAAGAGGTCCCTTACATCCCTTATAAATTGG
9541 ATTCTAGGTATTTTGTCTCTTTGAAGCAATAGTGAATGGTAGTTCACATCATGATTTGG
9601 CTCTCTGTTTGTCTGTTATTGGTGATAAGAATGCTTGTGATTTTTGCACATTGATTTTG
DB 9.6C/T rs7269719
9661 TATCCTGAGACTTTGCTGAAGTTGCTGATCAGCTTAAGGAGATTTTGGGCTGAGACGATG
T
9721 GGGTTTTCTAAATATATAATCATGTCTGCAAACAGGGACAATTTGACTTCCTCTTTT
9781 CCTAATTGAATACCCTTTATTTCTTTCTCCTGCCTGATTGCCCTGGCCAGAACTTCCAAG
DB 9.8C/- rs35363632
9841 GCTATGTTGAATAGGAGTGGTGAGAGAGGGCATCCCTGTCTTGTGCCAGTTTTCAAAGGG
-/C
9901 AATGCTTCCAGTTTTTGCCCATTCAGTATGATATTGGCTGTGGGTTTGTCTATAAATAGCT
9961 CTTATTATTTTGAGATACGTCCCATCAATACCTAATTTATTGAGAGTTTTTGGCATGAAG
10021 GGCTGTTGAATTTTCGTCAAAGGCCTTTTCTGCATCTATTGAGATAATCATGTGGTTTTTG
10081 TCTTTGGTTCTGTTTATATGCTGAATTACATTTATTGATTTGCGTATGTTGAACCAGCCT
10141 TGCATCCCAGGGATGAAGCCCACTTGATCTTGGTGGATAAGCTTTTTGATGTGCTGCTGG
10201 ATTCGGTTTGCCAGTATGTTATTGAGGACTTTTGCATCAATGTTTCATCAGGGATATTTGT
10261 CTAAAAATCACTTTTTTGTGTGTCTCTGTCAGGCTTTGGTATCAGGATGATGCTGGCC
10321 TCATAAAATGAATTAGGGAGGATTCCTCTTTTCTATTGATTGGAATAGTTTCAGAAGG
10381 AATGGTGCCAGCTCCTCCTCATACCTCTGGTAGAATTTCAGTTGTGAATCCGTCTGGTCTT
DNA/Tc2#Kangala ->
10441 GGACTTTTTCTGGTTGGTACATTTGCCATCCTTTTGATGGCAACTTACAACCCCTTCTGAC
rs6035459 DB 10.5A/G
10501 CATGTAGTCATCAAGTGGTTGTCAATTTCCCTGAATGTGTACAAGTTTGCAACTGGACATCC
G 0.578
10561 TGAAGTTTCCATCAACCAACCATTTAAGGAGCATTTAAGGAAGGAATATGAGTCTTTCAC
10621 TGACCTCTTCTGTAAAAATCAAGAAAAACCAACAAGAGACTGGCAAAACTGACACCGGAG
SINE/Alu#AluSg ->
10681 GCTTGGGGGAAAAAATCCCAGAGACAAAAATGAAACATCTTGGCCAGGCATGGTGGCTC
10741 ACGCTTGTAATCCTAGCACTTTGGGAGGCCAAGCGGGTGGATCACAAGGTCAGGAGTTC
DB 10.8T/C rs6081772
10801 GAGACCAGCCTGGCCAACATGGTGAAACCCTATCTCTACTAAAAATACAAAAATTAGCAG
C
10861 GGTATGGTGGCAGGCACCTGTGATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCT
10921 TGAACCTGAGAGGCGGAGGTTGCAGTGAGCAGAGATCGCACCATTGCGCTCCAGCCTGCG
DNA/Tc2#Kangala ->
10981 TGACACAGCAAGACTCCTTCTAGAACAAAAAAGAAGAAAAATCTTTTAAGAGACGCT
rs11907801 DB 11.0A/G rs6112622
11041 ACATCATGAATGTCCTTGAAAGATCATAACCTGTATATGAAAGAACTTTAGGGATATCTT
± 0.00 G
11101 AATTAATTAATTTTGTCTTTTATTTTCCCTTGTAATGCGCATGGGAAAAACTGTGCATGACG
11161 ACATTCTGTGTCTAAATATGATTTTAGGGTTTTAAGAGTTATTTCAATAAGATTAAAGTA
SINE/Alu#AluJo -> rs28722182 DB 11.2G/A
11221 AATTCTAAGAGATAAGAAAAATAAATTTCAGCCTGGTCAACATAGTGACAACCCATCTCTAC
A
11281 AAAATAAATTTAAAAAATAATTTTAATTAGCAGTAGTTGGGCATGGTGACATTTGCCTGT

11341 AGTCCAGCTACTCCAGAGGCTGAGGTGGGAGGATCGCTTGAGCCCAGGAGTTCAAGACT
11401 ACAATGAGTCACGATCATGTCACGTACTCCAGGCTGGGAGAGAGAGTGAGACTTTGTCT
Simple_repeat#(GGAA)n ->
11461 CAGAAAAAAAAAAAAAGAGAGAGGGAGAGAAAGGGAGGAAGGAAGGAAGGAAGGGAGGGGA
11521 GGGAGGATGGAAGAAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGGAGGGAGGGGA
DNA/Tc2#Kangala -> rs35771019
11581 GAGAGATATTGCCATGGTTTAATTGGCAATGTCTGTTTCATTAGATGATACATAAAATAA
rs6081773 rs6132238 I-/A
11641 TGATGTCCTTTACTATTGATGGAGGCTCAAAATGCTATTAAATTTTGTATTTCTCCACTGG
G 0.569 G-0.000
11701 AGCATTCCAGCGACTGGTCATCAGAAATGGAAC TAGCACCATGAGCGAGGTAGCTTTGGC
11761 TGTGAACTGATTCCAAATCTTGCAACGTGGCCAGTAGTAAAGAAACAAGATGAGAGGCCA
11821 CTTTTTATATGGCTTTTTTAAAGCCTTTATATATACATACTGGAATATCTTAGCCAGTATC
LINE/L1#L1ME3 ->
11881 CCCCCTCATTTTTTAAAACCTTAATTTTATTGAGATATAATTTGTATACAGCAAAGTGCA
rs6136860
11941 AAGTCTTAAGGTACAGCCCAGTGAACTTTAGGCAGAGACCCCGGTAGCCACCATCCAGA
P 0.000
12001 TCAAGGTCTAGAACATTTTCATTATCCCGGATGGTTTCCTGTCCCTTTTCCTAGTCAATGC
12061 CTCCCTAAACAAGAATACCCATTATTCTGTTTTCTATTAAATAGCAATGTAGATTAGTTTTT
12121 GCCTGTATTGATCTCCATATATATGGAATCAAAATGTATACACCTTTGTGACTGGCCTC
12181 TTTTGCTCAACATAATGTTTTGAGCAAATGCATCCACGTTGCTTCATATATCAGTAATTT
12241 GTTCCTTTTTGTTCCTGGGTACTTATCCATTGTATGAATAATACAATGGATTTCATTGTAT
DB 12.3T/A rs7268810
12301 TATTTTCATATTGATGGATATTTAAATTGTTTCTAGTCTGGACTATAATGAATAAAGCTG
A 0.237
12361 CAATGAACATTTCTGTACGTGTATCTTTTTGTAGACACATACATCCATTTATTTTGGATG
12421 TATAACTAAGAGTGAATTACTGGATTATAGAGCAAGCATAGATATTAGTAGATTATTCC
12481 AGCTTTCTAAGGTAGTTGGACCAATTTTTATTCCCACCAACACCATATGAGAGTTCCAGT
12541 TGCTAACACTTGGTATGATCAGTCTTTTAAATTTTACTTATTCCAGAGGGTGCATGGGAG
SINE/Alu#FLAM_A ->
12601 TGTCTCAATGTGGCTTTAATCTGGATTTTCCCTCACTGGATATGGTGGTACACACCTGGAA
12661 TCCCAGCTACTTGGGAGACTGAGGTGGGAAGATTGCTTGAGCCCAGGAATTTGAAGCCAG
Simple_repeat#(TAA)n -> LINE/L1L1M ->
12721 TCTGGGCAACAAAGTGAGACCTGTCTCTAATAATAATAATAATAATTTGGATTTTC
12781 CTGATGAGTAATAATGTTGAACAGTCTTTTGAATGTTTTAGGTTTGAATATTCTCTGTAG
12841 TGAAGGCTCCATTTAAGCCTTTTGTCTTTTGAATAATGTGTTTTGTCTTCTTATATATT
12901 CTAGCCAGAAGTTATTTGTCTTACATGTGCATTTCAAATATCTTCTCCTGCTCTATGTCT
12961 TATTCATTCACTTTTAAATGATGTGTTTTGTTGAACAAAAGCATTTAACTTTAATGAGGT
rs6035460
13021 CCAACTCATCCCTTTTTATGGTCTGTCTTTTTTTAAAAAAAATATTAAGATGGCTTGAG
A 0.444
DB 13.0C/A rs34800086
13081 TTTTTTATGTCCTGTTTAAGACATTTTTTGCCTACTCCTTGTTTTTCTGTCTTACAACCC
A
13141 TGTTTCTTTTGCCAGTTTAATTGCCTGCCCTTTTCTTGAGTGGGGAGAATAGGAATCAGG
13201 TCAGGCTACATCTGAGTGAGGAAGGAAGGGTGACAGAGTTAAATTAGGAAAGCGAGGCCA
13261 ACAAATTAGGGGAATAGATTGAAGCAGGAAGAGGCCCAACACTGTCTGATTTTTTGGTCTA
LINE/CR1#L3 ->
13321 AGGGACCTGAAAGCCTTTGAGTCTGGGTAACCTGATAACTGACTTCAGTGTGTCCAGCC
13381 CAAATATCTGCATTGCGTCTCTTAGAGTGTTTGGAGAAGCTTGTCAAATTTTATGAAATC
DB 13.4C/- rs34759328 DB 13.4aA/- rs35133530
13441 AACCTCTTCCGTGCTCACAGCCCTGATCTATTGCC TAGAAACATGAAAAAGTTAATGAAG
-/C -/A
DB 13.5G/A rs6081774
13501 TTCGTGTTTTAAGGACATCTGTGCTAATGTCTAGAGACCATCATTTTCCTTCTAAGTGCTC
A 0.438
13561 AAAAACCATCTTGATAATCCCTTCTTGACCATATCCAGGAAATGAAACCTCCATTTGGAA
13621 TAATATTTACTTATTCCTAATCCTCTGACTCCTTCCCCATTCTCCATAAGTTTTCTTAC
13681 TTACTAAAGATGTCAATAATTCCATGATCTCATCTGTCTTCTTACAATCAAGGGTAAATG
13741 TTTGGGTCTGCTTTTCATAAAGAGACCCTGGCAGGGCCTGAAC TGACCTGACCATGTAGT
13801 GGAGACCAGAACAAAGCAGGAGTTGGCAGGGGGCTCGGGACATGCAGGGAGAAGGCGGGA

13861 CTGCTGCAAACACGGTGGAGGACAGAATACATTTCTTAAAGTAGCTTCAGATTAGGTAGC
13921 AGCAACTGAGTTGAGATCCCTGGGCTCAGAAGATGGACTCTGGAGTCCATAGGGCTTTCT
13981 TGGGAAGATAAACAGCTCTACAGGGAGAAAATACCTCCATGCCAGGCCCTTCCAGGGGGT
14041 CATACTTAGAATGTTGGGACTACATTGATGAATCAGAGTCTCCTTAGAGGCACATAATTGG
14101 CAGGAACAAGATGGGGAGGAGCCATCCAACCTCCAGGGATGAGCTGGATGAGGGCAGGCA
SINE/MIR#MIRb ->
14161 GGATGTGGCTGCAGAGACGCCCCCTGGGCGTCCACCCTCAGGCACAGG**GAAAGGGAGTATG**
14221 **GTGTAATAGAAAGAGAGGACTGCTGGGATTCACACATTCCTGGTTCTAATCCTGACTCTA**
14281 **CCACTTATTAATTGTGTAACATTAGGCAAG**AATAGTGCTTCCATCCGAAGATTGACTAGA
DB 14.3G/C rs6081775
14341 GGGTCAAATAGGATACTGTGCATAAAATGCCAATTTCCCCATTTTCTCCCATTTCTTTG
LINE/L2#L2 -> C 0.237
14401 GCTCTTCCTTCTGGTTGCTCTACCCAACAGACAGCTTTCAATTCTTATCTTTCTTGCCCA
LINE/L2#L2 ->
14461 CTTTGAAGCACTGGCACCATTAAATAGTCACAAGGTCTTGAAATATAACTTTCCCTTGAC
14521 TTCCATGAAGATCCCATCTATTCCATGACAGTAGCTACCATGTGCATGCTGACAACCTCCC
14581 ACGTGACTATCTCCGCACATAACTCCTTCCTAAGAGCCAGATCCATTGATATACCTGCTT

14641 CCTGAACTTTCCACATGGATGTCCTACTGACAGCTCAAACCTCAACAATTCCAAATTCAGC
14701 TCATTATCTTTCCATAAAATCTTTCCCTTCCTCACCTGCGTTCTCTATATGGAGAATCCA
LTR/ERVL#LTR16C ->
14761 GTCATCAAGCCCCAAACTTGGGAGTCATGGATTCAAGTGCAAGTGGTTTATTTGGGAGAT
14821 GATCCCCAGAAGCATCACTGGGGGATCTTGGAAGTGAAACAAGGAAGGAAGGAAGCCAG
rs6046374
14881 TATAGAGTGTTTATCAAGCCTGGCACCCCTGTGGACAACCTGGAACCTGAATCCCACTGAA
C 0.000
14941 AAACCTGGAGATGCTGTAGAGAGCACAAGCTTCAGAGTCACTCATCCCAAGGTGCAAAGG
15001 A

TARGET DC

(AT) rich/ Low complexity ->

```

1 GCCTGGCAACAGTCCGAGACTCCATCTCAAAAAAATAAAATTAATAATTAAGAGATTTTA
61 AAAGACCCTTCATTTCAGAGTTCAGAAAGCAACACCAGATCCTCACAGCCAGACAGCTCTC
rs4736153
121 CCGTCTCTGAACTCAGGGTGTGGAACACTCGGCAGCCTTCAGCAGCGTGCCTTCCGTCCCT
A
181 CACTTGCTTAACGTATGCCAAGAAGCTGCTCTGACCAGGCCTCACTGCATACTGGGAAAG
241 GAGAGAGCACACGGCAGCTACGTGGGAGACTCAGGGAAGGATGAGCTCGAGCTCTGCCAC
301 CACAGGACATGGAGGGAGGGGACACTCAAGGGCTTGCAGGAGGGAGGGGCCGAGTGGGTT
361 GGCAGAAAAAGAGAGACGGACATTCCAGGTGGAGGGAAGAGCACAGATGAAGGGCATTTC
(GA)n/ simple repeat ->
421 ACAAAGGCCAGGGTACGGCATGCAAGGGCCCAGCAACACGAAGAGGCAGACAGAGAGAGA
481 GAGAGAGAGAGAGAGAGAGGGGAGACTGGGACCAGATTACATAGAGACTTAGACACCAAAG
rs28678828
541 TGAGGAGCCCATTTGTTTTGAGAAAAGTGTAAAGACACACCAGAAGATGGATTCAAGAGG
A
601 GCCAGGCTAGTGACAGCGAAAGAGTTAACTAGGCTCCCGTGAAGGCTCAGATAAAACGTG
661 TTTGGCATGTGTACCAAGGCAAAGAGGGAGAGAAGATGGAGGGATATTTAAGAGAAAGAA
721 CAGATGAGCCTTGGGGAAGAACGGATGGAATCCAGCGGTGAGAGAACCATCTGCAACAG
781 CCCCAGGACTCTTGCCGGCACTTCCCAGCAGATGATAATGGCTTTTGCCACCAAAGGAAA
841 CACAGAAAGGTGAGCCCGTCTGGAGAGAATGACAATCCATCAGAGTTTGAACAAGCTGAA
901 CTGGAGGTGTTTTCGGGGCTGCCAGGTGAAAAAGTCAGGAAGCCAGCTAAAAACATTGAC
rs7002644
961 ATGGAATTCAAGACCGGAAATAGACATTTTCAGAGTCATTACCATCATGTTAGAGCCTGTG
G 0.033
1021 AAATCATTTAGGAAAAATATAGTGTATGGTAAGTATTAAGGACAAAACGTGTTAGGAACAT
1081 CCATAGCTGGGGATGCAGCAGTGAAGCAGAGTCGGGAACAGTCAGTGTGGCACGGCACGG
rs6982187 rs34989198
1141 GCCAGGGGAGGGAAGCTCCCCACCTACAGGAGGACTGGCCAGTCACAGCGCTCTCCCAAG
A /T
1201 GATGAGTAAAGTGGCAACCACGGAGGGGGAGGGAGGTTAAAAGCCTGATTTCAATGGCGGA
1261 AAAGTACAGAAGGATGAAAAAGTGAAGGGGAAAAGAGTAAGGAGTAGCCAGAGAGAAACC
1321 CATGGTTTAGAAGAGGATTTGGGCATATCGGCTGAGGGACTGGTACAAAACCTGCTCAAAG
1381 CTTAGTGCGCAGAACCCCCCAGAGAATGGGTCAGAAACACAGATCGCAGCCACGCGCCA
1441 CAGAAAGGGATGTCTGAAGAGCTGGGTGGGCCGAGGAATCTGCGTTTTAGCAAGACACTT
1501 TGATGCAAGTGGTCCATGGGCCGTGACCTACAAAAACAAGGGCAAGTTCAAAAGACCAAA
1561 GAGAAAGGATACCTGATCCGGAACACAAGTCAGACGATTCACCTCTGATGAGAGGAGGAG
1621 CCCATCTTCCCTCTACAACGAAACAGATGGGAAAAACAAGTGTATCCAGAGGAAAAGAGGG
1681 GAAGCAGAGAAGGTTTCTGCCTGATGGCCTCTGTGGATCTTTGAAAAGAGACCATGTGCT
1741 GAGAGGAAGGGATACAAGAGTGGGGAAAAGCCTTAAAAAAGTGGCATGTTGACAACAGC
1801 TGAAACTAGGCACACACTTGCCCTGTGTTTTGATGAATGAATGTTTAGTGGGAGAGCCC
1861 TATGATACAGATAAGCATATTTTCCCCATGGTGTTCAAATTCATGGGATAAAATGGGCAC
1921 TACTACCAAAGTCAACCTGTCCCCTTCTCAAGATACAAAAGCAGCAGATGACTTAAAGG
1981 ACCAGGTTTGCCGCCCCTCTCTATTACCTCCTCTCTGACAAAGACAGGAAGATTCTCTT
2041 ACATGAACTGCTATCATATCCCCATTTTGA AAAAAGCAAGTCTCCATTGTGCCACCAGA
2101 ATTGTGACATTCACTTCCCAGCAAACCAGAAGTTTATAGGTACCACAAAGATGGACCTAG
DNA/MER1_type# MER1B ->
2161 AAATACTGTTCTGTTTGTTCCTAAGCGGGGGCCGCAACCCCTGGTGGCCTGTTAGGA
DC -2,2G/T rs4736154
2221 ACTGAGCCGCACAGCAGGAGGTGGGTGGCAGCCTAGCGAGCTTTCAGCCTGAGCTCTGC
T 0.042
2281 CTCCCGTCAGCTCAGCAGCGGCCTCAGGTTCTCACAGGAGTGCAAACCTCTATGTGACCT
2341 GTGCACACCAAGGATCTAGGTTGCACGCTCCTTATGAGAATCTAATGCCCTGATGATCTGA
2401 GGTGGAAGAGTTTCAACCCAAAACCATCCCCCTTGCCACCATGGTCCGCAGAAAACTGTC
2461 TTCCACAAAACCTGGTCTTGGTGGCCAAAGAGGTTGGGGACCGCTGCCCAAAGGGAAGGAA
2521 GGAGTGGATAACAGCAGGACAAGCTCCGCAGCAGGCAGGGCCCCCTGGTGTCTGTGTGA
2581 GGCCTTAGACAAATCATTCACCTTCCTGGGACTCAGGTTCTGTCTGTCAACCAAATT
rs10110957
2641 GATTAGCTGACATCTACCTCTCGTCTCATTTCTGTGATACTAGGGATCACTATTTCCCAT
A -0.000
2701 ACTGAAACTGAAATGCCACAGTTAATTATCATGTCTAACAGAACTGTCTAGCAGGGAAAG
AT_rich/Low complexity ->
2761 TTGACATTTCTCTTACAAAACCAAAAAGCCAAAAAGTACACAGAGAAAGAAAACCAATTA
2821 AATAATTAATTAATTGAAAAGGAAACCAAGCAGGTGATGCTTTTCATCCCACCGTCAAGA
2881 AACGGCAACCCAAAGGCAGTTTTTCATGTGACACATCAATCCCAATAAAATCAAAACACTA

```


DC 5.8 T/- rs10709306
5821 CTAGAATATGTCCCGCTCATTTCTAAGTCAAGATTCTCATGTATACAGTGTACCCATTTCAT
/-
5881 GCAACAGTTTCAAGGGTTTTTTTTTTTAAATTACAGAAAGTTTCTGTGAATTATAGTTTT
5941 TAACATGTTGTGGTTCCATTGTTTCCGTTTCCTTCTCTGGTGTCTCATAGCAGATATATG
6001 TATGTATATATGTATGCATGCATGCATGTACGTTAGATCTTCTTTGCCTAGCTTCTAAGT
6061 GTGTCACTTTCTCTTTAATCATCTTTCTCTCGATTCTTTTCTTCTCTCTTTTCATCTT
6121 CTGCTTCCCTTAATGTATCTGGCAGGTATATATAACTCACTAGAAACTACAATGCTGGAA
DC 6.1C/T rs6981937
6181 AAAAAAATTTATTCTATTACAAATTCTTTCCCTGAGTTATATCCATCTCATCTCTGAGTTT
T 0.033
6241 TTCTCATTCAGATTTATGTTATTCTTTTGTACTTCTTCTTCATGTCTTTTAGCTCATTAT
DC 6.3 T/A rs7005691
6301 GGGTTTTTGTAAATTTTATCAGCTTCTGAGCACGTTCTTCTATGTTATCTCGCTGCTTAT
A 0.034
6361 GTTTTCACTAGAACTCACTCTGCATAGAGTTTGGCCATGATCCTTTTCTGTGACCATCTT
6421 TACATGAACTAGTTTTCATGAATGTTTAGGAGAAATGATTCAAGATAGCTCTTCTAATT
6481 CTAGTAAATCTACACACTGTATTCTGTGTTTGGGGTGGTACTCAAGAATATAAGAAATT
6541 ACTTTCTAGACCACTTAACTCTGTTCTCCTCCCTAGTTTTCAGCCAGATCTTCTCTTTCC
6601 TTGCTTCTGCTATCCACCTCTGTTCCACGAGCTTCTCCACAGGTGAGGCTTTGTTCTA
6661 GAGGAATTATTTGCACTCATCTGCTACTGGAACATACAACTCCTCCACATTTTCAGCTGC
DC 6.7 G/A rs4422756
6721 TGTTCCTCAACTTGGCCCACTGAGCTGCCCAATGAGTACCTGCTGGCTGTGTGGGGATTCC
A 0.017
DC 6.7a G/A rs4422757
6781 TGGGTGTGTGTGTTTCCGCTTCTCTTGTGCAGACGGTGAAACCGTGTGTTATTAGTG
A
DC 6.8 A/G rs4307318 rs4409383 DC 6.8a T/C
6841 GTTTGTCCACATCTACTTATATTTTGGGGTCCGTGGGGATACTCTGGTAACTGGTTTTGC
G C 0.021 DC 6.8 F
6901 TATATATTTTGCCTATGGGTATTTGGTTTTTCTATTCTAGTTGTTTCAGTCTGTTTGACT
6961 GAATAGTTTCATATATTTCAAAACCTAAGACAGTTTGGCCACCATCTTCCAGGACTTCTAATT
7021 TTAAACATAAAAATTTCAAGAAATCAGAGATTTCAGATATTCAAGTATTATAAGGATCATAGGAAAAGA
7081 ATATACTATTTTGTGGGTGAAAAGTTGACTTCTCTTACCCTAGGCTAGTTATATGAAGAA
DC 7.1 T/C rs7010692
7141 GATAGATATCTGCCAAGAATTTGAAGATAAGGTAAATAAATTTGCTTTTCTGATGTTTCATT
C 0.008
7201 TAGAAACAATTTCTAAAATTCACCTTAGAAATCAAAATAATACATCCAAACAGTGCTCTAC
LINE/L1# L1MC4 -> DC 7.2 C/T rs6578086
7261 AAAATCTTTTCTTGTACTATTTTGAAGAAATATCGAGCCTACAGAAAAGTCAACAAGAA
LINE/L1# L1PA16 ->rs33992585 T 0.425
7321 TGAAGATCTATATCTCTTTATCTAAAGCCAACTTTTTTTTGTAATTTCAACTTTTATTTT
/-
7381 AGATTTAGCGGGTACGTGTTTCAGGTTTGTACATGAGTATACTGTGTGATGCTGAGGTTT
DC 7.4 G/A rs4736023
7441 GGGAAATGAGTGATTCTGTCTATCCGACAGTGAGCGTGCTGCCCAACAACGTTTTCCTC
DC 7.5 C/A rs12682161 DC 7.5b C/T A 0.150 I
rs6578087 rs11382806 DC 7.5a -/C rs4736024 DC 7.5c C/T C
7501 CTCCCTGACCCCTCACTCCCTGCCTTCTCGAGTAGCCCCCGTGTCTGTTGCTGCCACCTT
IIIIIIIIIIII
CNCCNTNNCCNC
A 0.367/CT T 0.292
7561 TATGTCTGTGAGGACTCAATGCATACCTCCACTTATATGTGAGAATATGCTGTATTTGC
DC 7.6 C/T rs4736155
7621 TTTTCTATTCTGCAATTCATTGGTTTAGGATAATGGCTTCCAGATGCATCCACGTTGCTG
T
7681 CAAAGGCCATGATTTTCATTCTGTTCTATGGCTGCATAGTCTTCCAGGGTGTATATGTACC
DC 7.7 C/T rs10110769
7741 ACATTTTCTTTATCCAATTCACACTGATGGCCACTTAGGTCGATTCCACATATTTGGTA
LINE/L1# L1MC4 -> T 0.110
7801 TTGTAATAGTTAAAGACACTTCTTTTAAATAATTTGACATTTTACTTTATTTCTCTCT
7861 AGATTACATTCACACTGTATTTTTTTTCCCTTACCCTATTAAAGTAAGTGAGGCAAAAT
rs35511380
rs34710276 rs10611493
rs11988522
SINE/Alu# AluY -> rs11988521
7921 CATCTTTCACCTTTTTTTTTTTTTTGTGAGATGGAGTCTCGCTCTGTCACC
DC 7.9 R C A /-
C
/-

7981 CAGGCTGGAGGGCAGTGGCGGATCTCGGCTCACTGCAAGCTCCGCCTCCCGGGTTCACG
8041 CCATTCTCCACCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACCCGCCACCACGCCCC
8101 GCTAATTTTGTGTTTTGTATTTTAGTAGAGACGGGGTTTACCATGTTAGCCAGGATGG
8161 TCTCAATCTCTGACCTCGTGATCCGCCACCTCGCCTCCCAAAGTGTGGGATTACAG
rs4736157 LINE/L1# L1MC4 ->
8221 GCGTGAGCCACCGTGCCGTGGCTGATCTTCACTCTTAAATGCTTCTGCATTTATTTCCCT
A DC8.2 C/T rs4236870
8281 AAGAACAAGAATTTTCTGCTACAATTTCAATTTCAATTATCATACTCGATATATTTGTCAT
T 0.125
8341 TGATACAATAATATTATAGTATTCAATTTCTTCAATTGTCCCAAAACAAAGTCTTCTTTT
8401 TTAAATCCAGGATACAATTAAGGATCATGCACGGCATTGATTGTTACAGCTCTTCAATC
8461 TCCTTTAATCTAGAACATTCTTCCACTTGCGTTTATAAAATGGGAATTACAACATTTAC
8521 TTTATAGAGTTTTTACAAAGATTAAATAGAAATAATGCCAGAAAAAAGTGCGTAGCCCA
8581 GTCTTTTATACACAACATGTGACAATGCTCAGTAAACATTAATTATCTTCCAGCTATCTAT
8641 GGCCGACACTGAATCCAGGATCCCGGTTTGTGCAACAGCTATCCAGGTTGCTGTGAATTT
DC8.7 G/A rs6992126
8701 TTTAAGCTCATTTTAACTTCAGTAACCATAATTAATGCGAGTCCATGCCTGAGAATCAAA
A 0.117
8761 TTGGATCCACACGTGGTCCCCCATTAGATGTCTCTGAGAATGTTAGACTGTGAGCTACAG
8821 GGGGTCGTCTCCAGTTCCAGAGGCCACAAATGAGCCTCTGCCACTGAGTTCACAGCCA
8881 CTTACATAAGGGCGCCGTGATTGTCTCGTGCTTCTCAGACTGAACTGCACGTAACAAG
8941 GCAGCCTCCATGGACCAAGCTCTGGGTGGTTCTTCTCGTGCCCTACCTTTTCTCCATAAAAC
9001 TTGACCTGGTTTCTGTTTCTTAAGGTAAACCTTACCTTAGAGATTGCTGTCTCTTT
9061 CTGCCACATACTATGTAAACAACCAGCCAGAGCTTCTATTAAGTGTATTAATAAAGGGG
9121 GCATCTCATGAGTAACCACTACGTGCCATGACCAGCAATCAGGCCAGCCTCACATTTACA
DC9.1 A/G rs7017431
9181 AACCACCTGGTGACCATAATTCAGGCCTGATTTGGTTTTGTTTTAAAGATAGAAGAAG
G 0.642
9241 GTATTCCCAGGCTACAAGTCCCAAATTGCAATTTTGCTCAATTTTCTCTCTGACCTTAG
9301 AAGGGCAGAGAGACTGCCCTAGTCCCTCTATAACAAAAGGCAGAAGCACAGCTATAACA
9361 GGACAAAATAGGTCTGCACTGAACATGCAAAATTCAAACAACCAAGCACAAAAGCCAAGC
9421 CTTCCACATGGAAGCCTTCCCACTGTTTCTCAGGAATAAGACGACCTGGCAGGCCATG
rs34882077
9481 GGAGAAACCACGGTCACCATTCCTCACTGCTAGCCTGGAGTCCACGTGCCAAGACATAG
/-
9541 CCCTGGGGTAATATCCAGTCCCAAGTGTTCCAGGGCAGGTGCTGGGCACCATTTATTCT
DC9.6 G/A rs4736158
9601 GCCAAACCCCTTCTTGGGAAAGAAGATCAGAACCTATGTAACCTCTGTCTACTGATT
A 0.125
9661 AAAAAGAAAAATGCAGTTCAGCGGGATAAAGCCGTTTACACACCAACCAAAAAATCCG
9721 TGTATCAGACATTTTTAAGTCTTGGTATAATTTGAAATCCTCTCACTTTTTTTCATTTT
9781 CTAATGTATCCAACCTAAATCTGTTTTTCTACATTTGTTAATAATATAAAAAGAATATT
9841 TTACCAATACCAGCACTATACAAGAAGCTCATGCTGACTATTTGAAGTGCAGAGGGTGC
LTR/MaLR# MLT1A -> DC9.9 C/G rs4736025
9901 AGACAGCAACTCTATGGAGGGCGTCTGTTAGGGACTGAGCTGCGTCCCCCTTCCCCAGC
G 0.125
9961 TGCATCTACTGAAGGCCTATCCCCAGTGGGACAGCTTTAGGAGGTGGGGCCTTTGGGAG
10021 GTAATTAGGGTTAGATGAAGCAATGGAGATGGAGCCCCCTCTATGAGATGAGTGCCTTG
10081 TAAGAAGGGGTGGACACCAGAGCTCCCTCTCTCCTCCAGTGGAGACGCAGCAGCAAGGT
10141 GGCCATCTGCAAGCCAGGAAGAGGGCCCTCCCTCACCAGAAAAACACCAGGCTGACAGT
rs35260714
10201 CTGATCTCAGACTCCAGTCTCCAGAGCTATGAGGAAATAAATCTTGGTTGTTAAGCTG
rs11782549 /T
10261 TTCTGTCTGTGGTATTTTGTGTAAGGGAGCCTGAGTTGACTGAAAGACTCCACACTGCCTC
A SINE/Alu# AluSx ->
10321 CAAATGAATGCTTCATAATTTGGCATAATTAATTTATGAAATCTTTTTTTTTTTTTTGAG
10381 ATGGAGTCTCACTGTGTTGCCAGGCTGGAGTGCAGTGGCGTGATCTCGACTCACTGCAA
10441 CCTCCGCTCCAGGTTCAAGCGATTCTCCTGCCCTCAGCCTCCTGAGTAGCTGGGATTA
10501 CAGGCATCGCCACCATGCCGACGAATTTTGTATTGTTAATAGAGACAGATTTACC
10561 ATGTTGTCCAGGCTGGTCTGAAAGTCTGGCCTCAGGTGATCCGCCCGCCTGGCCTCCC
10621 AGAGTGTGAGATTATAGGTGTGAGCCATCACACCCAGCCAAATCTATGAAATCTTATCTC
10681 TAATCAGTCTAATGTTACAACAAATATAAATTTCCATTTCTTCCACACTCCACCTCCTT
rs35936231
10741 ATAGATATCATCAGACTTTGAAGGAAAACTTTATCATCACAGCTAATTAGATGTCTAAAG
/C
10801 AATCACAGCAGTTATACTTGAAAAACGCAGTAATTCCTACATTCCACTAATTTAGAATG
10861 ACCTGCTGGTAAATGAGTACAAAATAAAGAGTGAGAATTAATCATTTAGATAAAAA
10921 GTACTTTTATTACTTTTCAGACACATACAGTAACACACTCTGTTAACAAGTGGCCAGGAG
10981 ATGTCTCAGGCAGCTTGAGTTAATGAATGACAAGTGAGTTACAAACAGCAACAGCAGGC
rs11986788

11041 ATCAAGGGATGGGGGTTGCTACACAGTATCTAGGACCCTGACGTGCTAATTAAAATTAGG
A 0.000

DC11.1 C/T rs11166964

11101 AAAGCGCTTACCATCACTGAGATCCTGCAGGAGATTCTCCTGGCAGGAGAAATCCAGCTT
T 0.085

11161 CACTTTGATGTTGATTGTGAACGTGGCCACCTTCCCAGGCTGCAAAGGGAAGTGGGCAAG
DC11.2 G/A rs11166965

11221 GGTTTCCTCTAGCTTCCAGCTCAAGAAGTCGCCATACAATTTTCTGTAATAATAACAAT
A 0.096

11281 GACAGTGATGAGGATGCTGTAACGTAGGCAGTATGGGACTTACCAATCCCCTAGAAAAATT
11341 CTGATGCATTCTCAAAAGCCAAGGAAAAAGAGCTTTTAAATGTGTAGATCAAAGT
11401 GACAAGAACATTCCAGAACCAAGAAGTGTGCAAGGCAATCACCCCTGTTTATGAAGGAG
11461 GCACAGGGAGGAGGAAGAACTGCTCATCTCTAGAGGCACCGAGCTCAAGCCAAGCCATCT
rs11166966 rs12334515

11521 TGACGCCTTAGTGAGCAACTCCTTCTCATTGACCAATAAATGCCGTTTTGCTCTTATAA
T A

11581 ACTAAATCAGAGTTAAACTAAATTTCTCCACAATGAATATTTTCTGTATTATATCACCTT
11641 AAAGAGAAACAGATCCAAGTGTAGTAGGGAAAGTGTATATTTAATATGAGACACCTCTTC
SINE/Alu# AluSx ->rs7821968

11701 ACAAAAAGAGAATAAAAAATCAAAACCCAAAGCAGGACGCTGTGGCTCACACTTATAATCC
G

11761 CAGCACTTTGAAAGGCTGAGGCAGGGTGAATCACTTGAGATCAGGAGTTCAGTCCAGCC
11821 TGGACAACATGGTGAACCCCATCTCTACAAAAAATACAAAATTTAGCCAGTGTGGCAG
11881 CGCGCCTCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGC
rs4736159 rs12543314

11941 AGGCAGAGGTTGCAATGAGCCAAATCATGCCACTGCACTCCAGCCTGGGCAACAGAGCA
rs7841395 T

12001 AGACTCCATCTCAAAAGAAAAAATCATCAAATCAAAGAATTAAGGACGGCACCTTGG
A

12061 GAAGGGCCTCCGGGGAGAGGTGTTTCCCTTGCTTTCTGGCAAATACACCATGGTCTTTAA
SINE/MIR# MIRc -> DC12.1 G/C rs7841647

12121 TAAAAAGTCTTGAATGTTAGAGTCACATGGCCTTGACTTTGGTGCCTTTTGGACACTGAC
C

12181 TAACTCGAGTGCCATGGAGAATAATGATCCCTTGAGTCAAGGTTTCTTCGTGTGTAATA
12241 TGGGGATAACAATTACTGCACCACAGGGTTATTTTACAGATTCAATAAAGTACTATCTGT
12301 AAAAGCACCAAGAAGACCACAGCACTGTAAGAACCTCAGGCAACACGGGAGGAAGGGGGA
12361 CAGGAAGGGGACATGGGGAGGCCACTGCTGGTGCCCGCTGAAGTAGCTGCGTCTCTCCAC
LTR/ERV1# LTR53 ->

12421 GGCTCCAGTTCTTAAACCCAGGCACAGTATGATATGCTGCCTTGACATCCGGCAAAACT
12481 GGGAGGGCCCCAAACGGCCTCACACAAAGTCCCCTCCTGACTCTGCTCCTGCAGATACAG
12541 GGTCCCTCAGCCAGGCAGGTTTCCAGGTGCGGAAAGCAGGTGCAGCCCTGTGTATCTTGG
12601 GCAGTGGGTGTGCTAGTTCCCTGCCAGCCTGGAAGGGACTGAAATAAGCCAGTCACATCCTC
rs6996327rs7013680

12661 CCTGGGGAGCCGGGGGAGCCCTCCCTCTCCATACCCCAAAGCCCGCTCCCCAGCCCC
GC

12721 TGGGCAGCTGCTCTCTGTTCCTGAGTGCAGCCACATGGCCCTACGTGGCATGGTATC
rs35027015

12781 CTCCTTCCCCAGCTGTGAGTGTCTGTGACCAATGAAGTGTGTCAGGTGCACATGCCCTG
/C

12841 TGCACATGCTAGGTCTCTGGCTGTCCCCACATGGTAGAACAAGAAACCCTCCTGACCAAC
12901 ACAGGGGACAGGAAGCCATGAGCACGGGGCCCTCCTCCTCCCAGGAAGGGCCAGCTTCC
12961 AGGCTCTGCAAAGTCTCTCTGCTGGTGCCTCCAGCCTAGGAGGCAGGAGCGACTTGC
rs36112566

13021 TGTTTTCCCACTATCCCCTTTCTGGGAACCAGTTTTTTTATGCTGAACGTCTTCGGTCTGA
T

DC13.0 A/G rs4736160

13081 ATAAGGAGACGGTTTTAGAGAGATGAAGTAACTTATCCATGGTCACCAACTATGGAATCA
rs4736161 G 0.121

13141 GTCTAGAAATCCTAGATCCAAATGATTCCAAAGTCACATTCACTTCTGTCATGAAGACATT
G

13201 TCATGGTGAAGTTCAAATGTAAAGTCTGGTCGGAAGACCCAGAAGTGAACCTCACAGGA
13261 GCTCAGGGGAAGACGGAGAGCTTGACCAAAATCCCCTATGAAAGAAAAAGATACGTGGTG
DC13.3 C/T rs4736026 rs7005324

13321 TGCTAACTCCAGAACAAGAGGACAAACTGAGCTGCAAAATAAGCAGACATATTCCTGGCC
T 0.125rs6980517 C

13381 GGAGGTGTGCTCGACCATGGCACGGTCTGCAGAACTGGCCAAGCTCCCTCTGGAGCACG
DC 13.4 T/C rs7005477 A-0.000

13441 TCTGACAGACGGCGTTTATGTCTCCATGTTTCTTAAAGAAGGATACTAACACAGAGAGA
C 0.125

13501 CAGATCCAGGGGACAGCGTCCTTGAAAAGTGTTTAGAAACCACATCACATTCATTTATTT
13561 ACTTAGTCATTACAGAACACCTCAAATGTGCCAGACACTCCACGTGTTACCTCACTTAA
13621 TCCTCCCAACAACCAGTGAAATCATGGAAGGAGGTTAGCATATGTAACAGGTCATTACAGC
13681 TGTCAGTGGAAGACTTGGCATATTATACATGTTTGATAAAATATTAGCTGCCCTTCAGCAT
13741 CACCCAGTCCACCACCTTGGATGGTGTTGAGATGCTTTGCAAACTGATACTATCACAGTA
13801 TTTTAGAATGATCTGGGAAAAGACAGATGGCTGGGAAAAGGATGATGGAATCGTTGAGCA
13861 GGCTGGTTCCTGGAAGTCAACTTTAACGACAGTCTGAGGAATGAATCCCTACATTCAGA
rs4078541 DC13.9A/G
DC13.9a C/T rs4475456 SINE/Alu# AluSx ->
13921 TGATTTTCGAGAAGCTGTGGACCGGGCGCAGTGACTCACACCTGTAATCCCAGCACTTTGG
0.125 G T 0.062
13981 GAGGCCAAGGCGGGCAGATCACCTGAGGCCAGGCGTTCGAGGCCAGCCTGGGCAACAGGG
14041 TGAAACCTGTCTCTACTAAAAATACAAAAATTAGCTGGGCATGGTGGCGCACACCTGTA
14101 GTCCTGGCTATTACAGGAGCCCAAGGCATGAGAGTCACTTGACCCAGGGAGGTGGAGGTTG
14161 CAGTGAGTCAAGGTCGCGCCACTACACTCCAGCCTGGGCAACAAAGCGAGACTCCGTCCC
14221 CAAAACAGAAGAAAGCTGTGGCTGTTGGATGAGATTCTTATAGGAATTTAGTGAAAAGGAA
14281 ATGGAGAATTGGAGGAAAGTATTATCCAAAACCTCAAAGTGGGAGATGGAATGGGTCAACA
14341 AGAATCACCTAAAGTCAAAGAAAGTGAATCATATCCAATTATAGCCACTCTAATTACAGG
DC14.4 A/G rs11778176
14401 ATAAAAATCTAAACACTTCAGTCAAGCTTTGGGGGCAAAGGGTACAAAACACTGGTCGCT
G 0.125
14461 TTGGTATTTTCATGATGACAACAGGCTACTGAATTCTCTGTCTGGAAACCCGCTTCAACAC
14521 ACAACATTTGGCCCTTGGCTGCTCAGGGGAATGTGTGGATACTCACATATATGATTTATC
14581 CTTTAGACGGTAAGTCACTCAGTCAGAGAAAGAACAAGATCTGTCTCCAAATGGGAAAA
14641 GAACTTCAAAGCCATCTTACAGGTGAGAAAGCAGAAGGAAAAGGAGAGTCTGACACAAAA
14701 TCACATCATCAATTGGGTGCGAGCTTTCTTCCACTCCTTCAGAAGGGTTCTGACGACAT
14761 CTTGGCTCATTAGTAAGGAAGGTAAGTACTGACTTTCTTCCCTCCACCTGCTCTCTCAAGCC
rs34455732
14821 ATGCCAGTTCTCTGCCTACTCGATGTGACCTCCTCCACGCAGGACCCCCTGGGCAGGCCCA
/-
14881 CCTGCTTCCGCTTGGTTGCCATTCTATGTGTATTCTGAGAATCTACCTCCCAAGACG
rs11778339
14941 CTGGAGTTCCTTTCCACTGTGCTCTTCTGTAGGTGCCGACACATCTGTGGGCAGCTGCAG
G 0.112
15001 A

TARGET DD

```

LTR/ERV# MER76-int ->
1 GGTGGTAGCCTAGAACCCAATTCCAGACAATATTATCTGTTTCCCCTTATCTTGGTGCCA
61 AGGGTTGTGGGAATCATAAGTCATTTGTGTACTGATCTCCAAAAGGCCCAAGAAGTACTA
121 GATCCCCCATCTCTCCATTGAGCTATGACCGTGAAGTAGGGTTTCTTGTCTCTTTGG
181 AGAGAGAAGGACCTCAGTCTAACTCTTTGTCTTGTGTTTATTGTGAATACTAAAAACCTG
241 GCAGAGGCTGGATGGACCATTTCAGCTCATCTTCAGGCCACGAGGAGGGTCAGAGGGATC
301 AGCACCATGTCACTCATAGGGACTGCCACCACTTGAATCCTCATGGGGTTGTCTGTTGA
361 GCCTCTCATGGCCTGGACCTGGCCACAAGTTCCTTGGCAGGGACCCCATCAGTCTCCTCC
421 TTGAGACCCATTATTGAGAGACAAGATTTCAGTGATCTTTCTGGAAGGCCCTTGCCAGG
481 ATGGTCCAGCAAAGGAGGCCCTGTTTACCCTCTCCAGCTGCTCTTTTGCCTAGTCAGACT
541 TTGATATCTTGGCAGTAGCCACTTTTTGCATGCCAGGAAATTTGTCAGTAAAGAGTCAGA
601 TTGTGTTGTGAAACAATGGGCCTGACTTCAAGCAGTGGCCTCAATAGCCATCAGGAGAGG
661 CATGAATAAACCTAGAAATCTGAGTCTATTAATGATCTTATCATGTACTGTTCCCACTAC
721 TTCACCTGATAGTCCAAGGGTGTGTTTGTAGGGCTGGCTTTGTGAGGGTGGTTCAAATATGTT
781 TGTGAGTGGCAAGGAATTTATCACCAGTGAGTCAGGTGTGCCAGAGCATAGCTGGTACCC
841 AACTGAGGAAGAAGAGGGTCTTAGATATGTGTACTGTCTCATTCACTCAATACCTTGCAC
901 CTCCTCTGTAGGCAGTCATGATTTATCAGGGTAGTCTGAAGAAGGGGTTTGTAGTGATGT
961 TCCTGTAAGGAACCACTCTCCTTCACTAAGTTTAAACAAGATGCTTGTTCATTATTGAGG
1021 CAAACTAACACATTCTCTCAGGCCTTTTTTGTGTTGCTGGGTGAAGTTATCCCTAAGTGCT
LTR/ERV# MER76 -> ENSNP10484456
1081 CTATGTTCTTTTTCTTGAAGGCACAAGTCTCAAGAATTGAGTTGAAGTGCAGAAAAAGT
C
1141 GTCTTCAAGTACCCCTCATAAAGAAGAGGTGCCTGAAAAATATTTTGGGTGAGGCCTCTG
1201 AATAGAGATGCCTAAGCTAAGAATGAAGCCATGCATATATGAGCATGGCTGGCTGGAATA
rs11219891
1261 GGCCTGAATCCCTGCCTGCAACTTCTTCCTGAGACTC CAATGCATTGGTTGTGCACCAAA
T
1321 TCTTTTGTGGGAAGGGCAGCTTTCCCTCCATGAGGCCTGCCAGGTAAAGTCTTTGGTAGA
LTR/ERV# ERVL-E-int -> rs11219899
1381 GCCTGAAAGATCACACATGAAATTTAGACCTGGGGCTGGACCAGTTGCACCTGGTCGATC
T
1441 GATTGATGTGGAAAGAGAAACAGCCTCAGTTAGGAATATGAAATAGCATATAGAAAATAA
rs7925506
1501 TAAATAACCTATTTGGCTGGTCAGTGGCACAGAAGTATTATAAAAAGATTAGAGGACTTG
G
1561 GGTCAAGGAGGTCTGGCGAAGAAGCATGAAGACTGACCTACTGAAGAGGGCATAAAGTGT
1621 GAAGGTATTTGTATTGTATGTTAATATTTCTCAGATAAAGTTCACCATGAAAGGAGCTCT
1681 AAAAATACATAATTTCAGTCAACTGATGTCAGCCAACATGCCATTGGCCATTCCAGTGTTG
1741 GCACAATGGGTAAATGAATTCAATAGACACTGGATCAGGGATGAAGCCTTTGTATATGCC
1801 CAACGATTAGGCTCCCCTCACCATGGTTGTTCCATCCTTGGTTTAAATTTTAAACAAAGA
1861 CCAACCTGAAGACCCAATATGGCACCATTTCATCTAAAATACCAAACAGCCACTTGGTTT
1921 CATGTTGTTATTGAATGCTTTCCATCCTTGAAGAGGCAGATATTCATCTTTTCTAAAATT
1981 GACTTAGACTTTGAGTGTGAGCTTACCTTACCTGCCTGTAGGACTGTAGCCAGAACTACT
2041 ATTTGGAATCTTGTGGAATGATAAATATTATAACCTGTGATCTTCAGAGAAAAGGAGAT
2101 GAGGGGATAAATACATAAAAATGGAGTCCATTGGTTTAAATCACATGCTATACAACCTCAGA
2161 AACCCTAGTCTTAATTGAGTTCTGGTGAAAGTATAGCCAAATATTAGTTTGGATATAAT
LTR/ERV# ERVL-E-int -> DD 2.2T/C rs11219948
2221 ACCCTAAGATTATGGGTGCCATTTTTCAGGATGCAGTGATATCTCCAAATCAATGACCAG
C 0.242 DD-2.3G/A rs35721278
2281 TATATAGTACTGTGCCTCCAAAAGGTAGAATTTAAAAAATGAGTCCAGAAACAAAGGGT
A
2341 ACATAAAATAACACTCCACTCACCATTATTTCTGTGACCGACTCATGAAATATGTGCTT
2401 GCCATCCCTACAGTTCTTGGATCTAGAGGTTTAGAGGTTTATTAGAAGTGTAGAAGAGA
Simple_repeat# +(TTA)n->rs34703815
2461 AATGCTTTTATTTTATTGTTATTATTATTGTTATTATTATTTTGAAGGACTAGGGCCTCA
G
2521 CTGGAGGAAGGTCTGCGTCATTCTACCAGGCAGGTCACCTTGGCCAGCAAAGGTTATCAT
2581 CAGAGATGAGGAATATGTAGAATAAAGTAAAAGAGTGAGATACTGCAGATCATTTGTGGA
2641 ATTGAGGGGTGACAGTTCATTCCACTAATTTTATCTGTCTCATAAATTTTCTTGAATAA
2701 AAGAGAAGCACCAGATTAGGAGTTGCTATCAGAATTTATATAAGACATGTAGATATAATG
LTR/ERV# LTR16A -> DD 2.7G/A rs35272776
2761 AATACAAAGTGGTAGATGTTAGTACATGTTTGTTCACCGGCCAAACCCCTACTACCTC
A
2821 AAGTAGGAGGCACTCATTATCTCAGCTGCTCAGAGTTGTCAGCTGACATCTTTTGGCTGA
2881 ATGCCTCTGGGGATTGGCGGGGAGTTAAAATGACCAAGACTATGCTCTTTTCTTGGGGCA

```

rs35547878
2941 GCCAATGACTAGTTGATGTAAAACTACAAAAAGCTAAGCCCACTTGCCCTACTGGAGAAT
T
3001 ACCTTTAAAGGATACCTCAGTTCCTGATCCCATTGTTGGGTTTGGCTGGAGCCTTTACTG
3061 CGAATTCATCTTTTCCCTTCACTCACTCATAGATATTAATAACTAGAGTATCTCCCAACA
3121 AGTTTCTTACACACAAATCTTACCTCAGTATCTTATCTCAGTATTTTCAATAGCAGCCTA
DD 3.1A/G ENSSNP10484457
3181 ACAATATTTCAAAAATTCCTTAACGGCAAATTTTATGCTTAGGAATCCATGTTATAGAAA
G
3241 TACTTGAACATGTTTCCAATAGTTGGTTGGTCCAAGACATTGGTCATCCTTAGTCATAGG
3301 GTTGAGACTCTCCAAAGTAGTGTCTATTCTTCAAACATCAATAAAACACAGTGGAATGC
3361 TCATCTCTAATCTGCCAAACCAATGCATTATGACGAGAATTCTCTGCTTTTCATCTTAAA
LINE/L1# L1ME4a -> rs35786280
3421 CTTATTAATAACTAGTCCAATGTTTATGGCTAAACATGTTTATTTTAGCACTGATTTTAA
-/T
3481 TTGGGTAAAATTTGGAATATTTAAATGTCCATCATTGTTGGGGAGGACTTAAATTTATGGTAT
3541 ATTCATAAAACTGAATGCTACTTAGCCATTTAAAAATGAGATCTTAAACACTAATTTGA
3601 AAAAAATATCTAAGGTCCATTATTAACGAATAAAGGAAAAATATAGAAAAATGTTTAAAT
3661 AGAATCCATTTGTTTAACTCTCTGATTTGTAGGTTTATTTTATTTTACTACACAGG
3721 CAGATGCAATTTGAGAGTATCAAGCATATAAATAACATCTGTTAAGTTTTCAGAGATTGT
3781 TTAAGAGTCATGTATAAAGCAACCAGAAATCAATCATTAGACTTTTTATTAGCCACACT
3841 GTGCATTAGACTACTATGGAACCATGTACTCAAAATCTTGAGAAAAAATTGTATTAAACAC
3901 ATAATTTTATACCTGGACAGTTTTTAATGACTGAAGTTTTTGCTATATTACAATAAATTA
Simple_repeat# (TA)n ->
3961 TGCCTGCAATATTACAGAATATATATGTAAGAGAATATATATATTATGTATATAGAATAT
rs36013891 rs10594066
4021 ATATATATTATGAGTGTATATATATATAATGTGTGTGTATATATATATATATATATAT
G -/TATATATA
4081 ATATAAAGAAAGAAAAAACCTGTGATATATATAGAATGAAAAAACCTGTAGATTATTA
LINE/L1# L1ME4a -> DD 4.0T/C rs34428483
4141 TATATATACCTAGACGTTATTGTGCTGATTAAATAGCAGCTATATTGGAGTCGTAGGACT
C
4201 ATGGGTGATTATGTTTTCTCTCAGTATTTTTTTCGTCTGATATTTTCCAATCCTCTACA
ENSSNP10484460 DNA/MER1_type# MER5A->
4261 AAGCATATTCAGAAAAAAAACACACATAGAAAACACTTAAGGTATGTTTCTTCATGGT
G
4321 CACCAGACTACTTGTCTGAATCAGTTAAGAGAAATAGACTTGTGAAACTCTATACCA
ENSSNP10484461
4381 GGCCCATTGAGTTAGAACTTTAGATGTTGGGCTTGGGATCCTGCACTTTAAATTAGCGC
T
4441 CCTTTGGTGGTACTTATATACTTTAAAGTTTAAAGATGAAATGCAGAGAATTCTCATTACA
4501 ATGCATTGGTTTGGCAGACTAGAGGTGAGTATTTCCATTGATGTTTGAAGATAGACACT
4561 ACTTTGCAGAGTCTCAAACCTACGACCAAGGAAGACCAATGTCATCTTTCAAATTGTTCC
4621 TGGGACCCCAACATTAAATACGCTTTTCTTTTAATTGCATTTCTATACAGTGTATGTTT
4681 TGAACCCAGCTACAGAAAAAGAACTTGACTTAGTCCACATTTTCATAGAAGATTTCTTT
4741 TGTAGCTGTTATCTACTAATTATTTGTCTCTTTTTTTTTTGTGTTTGGTCTACTCAATAAGC
4801 CATTTCCACTTGAAGATTAGTGCAGTGAACAATTTTTTCATAAAATGGTTTGTACTTAG
4861 GAAAATAAAGAACAAAGGAGTAAACCCCTACTAAAGAGTCTCTTGCTAGTTCAGCTCGTG
4921 ACACAAAGAATAGTTGAAAAATTAACACACCATAGAGTTAGTATTCAGAAATATCACAT
4981 CTTAACATTTCTGAGTATTAATGAAAGTAATGTTGGTTAAAGCAAGGCACGTAATAAA
5041 TGTGTTGTTGATTATCAAACTGAATGACTTTGCCAAATAAAATGACAAGTGATTGTCATA
5101 TAACTATTTTATAACAAGGGTAAATGATTTACAGATCCTTTTAATGAATAGTATTTTCAT
5161 TCTTAACAGTTCCTTCAACTGTCAGCAAAAGATTGCTCTCAACATTTTTTTCAGTCTGTTT
5221 TTTTTTAAAGAACTTTTCTCACTCAATTTGTCAACTCCTATGTGCATATTTGCTTAGCC
5281 TGTATTTTGGATATGAATTAACCACCAATAATTTAAAGTCCTTCTGCCCTTGGCTA
rs1452936
5341 GCAAGAAACAAAAAATGGCAAATGAGAAGGTGAAGCTACAACTATGTGCACCTTTGGTTCC
T 0.000
5401 CAAGTTACTCTGGTCCATTGCAGCTGCTGTGTTCCATTGTTAGGCTGTGCCACCTGGGA
rs7947133
5461 CAGAAGACAGAAATTAATAAGTTCAATTTTAAAAAATGCATATCTTAGGAAAAATGTT
G 0.000
5521 TAATATTATTTGCTCTTAAGAGAAGTTTTATTTATGAGCTATTAATTTCCCATGTGAAT
5581 AAGTTGTAATATAAATTCAGGAACCCAACTTTTCAGTCAGTTAAACCTTTAAACCTAAT
5641 GAGTTGAAACAATTGATTCTGCTCTTTCTCCTAGAGGGGTGGAAAAAATTCAGGATC
DD 5.7T/A rs1869267
5701 TTACGAAGAAAAATTTATTTTGTAAATTAAGGCACATTAATTAAGATGCTGTTAATTC
DD 5.7aG/A rs1869268 A
5761 AATAATGTTGCCTTTAAATGCATTTTTCATCTTTATTCTTTAAGGACAAATAAAGCAGT
A 0.217

5821 TATAAATCAGACATTCCCTTTAATGTAAGGTGTGACTAGGAAAATATATGATTCATAATCT
5881 GAGAGAAATGCTGATAAAAATAAATTTGCATTCACAATCCTTAGCCTAAATGATATTGAAT
5941 GTATTACAGCCAGGACTGGGCATAGGTTGAATTGTGAAATAGGCAAATTACATTTGTGGC
6001 CCCATTTTGGTCTCCTCTCTGTGGCTGTCTGCTTTCCGAAGTCTCATTCGATGCTA
6061 TCTGCTACAATTTCTTTGTACCTCCCAAGAGCAATTTTCAGAAAAATGGCACACATTAT
6121 CTTGGTGGGGTAAATAGTTTTCTGAGTTATGGAGAGAGACAAAGCTTTAGAAAAAATA
DNA/MER1_type# Charlie15a ->
6181 TCAGAGGGGCCACAAAGGGATATTGTGGGGCTATCAGTGAAGGTCCCTCTTTATGACTT
6241 CCTTCTCAACCAGATTAACTACATTCATGTCTATTTTACATTTGAGTTTCTCTGTGAGAT
6301 TTTGTTTGTATAAAAGTGTTCCTGTGGTAATGCAATCACAACCAACAAAAACAAAAA
6361 TGAACACAAAACCTTACAAAGTCTGAGAAGTGCTGTCTTAATGATAGGAATATAGGCTA
SINE/MIR# MIRb ->
6421 TGGATTTGGATTGAGTCCCTGACTCCAGCAATCATTGCTTAAGCAAATTAGGCTTTCTGA
6481 TTTTAATTCTCTTGATCCAAAAGCTTTAAAAATAATTATATATAAAGGACTGTTGTAATAA
6541 TTTAAAGAAAGACCTTAGTCAAACAACAATTATAGTGCTTAGCATATGGTAGGGATATAA
6601 AAAGCATAGTAGATTAGCATGGCTCTTTCTAAATTCCGCTCCTACTTTACTTACTTTCTT
DD-6.6A/G rs12575368
6661 TAGTAAGTAACTTGTGTGCTGTCTTTGTTATGTTGAGGTCACCTTGTAATCATTATTATTG
G
6721 GGTGTGGAGAGAGAAGCAAACGCAATGATGCTAATCAGTTGAGACTTAAGTTAGAGATT
6781 GATTGGAGATGGTGGAAAGACATCCTAAGCTCCTTGAAATGTGCCATCCACAGCCAAGGGC
rs7933883
6841 AAAATGCCACTCTTGGCGCTTCATAATCAATGTCATTGTCTTGTAAATGGTTCAGCAAGGA
A 0.000
6901 GAGAGACTTGCCCTGTTAAGTTAGTGCCCTTGAAACAAGTAGACACGAAGTAATGCTAAACA
6961 AAGGCCACTGAGTGTAATCTGTCCACAGCCGACTGTGTTTATTTTGGGGTGTGGAAAAA
7021 TAAGAAACCCCTGGCTTCCATTTCTTAGAAAGAAGCAGAGCCTGGATAGTCTTAAACACAG
7081 ACATGACAGCGTCAAAACAGCTTTTCCATCTGCCTCTCTTTTCATTTTCCAGAGTGGCCC
7141 AGCCCATTTAATGATGAGTGAGAGAAAATAGGACAGGGACTCACAAATCGTCTGTGTCAT
7201 GCTGCCAAGAGTGAGCATGAGTCAATCTGATCAGTGAGTAGGCTGAAATCCCTTAAAA
DD-7.2-/G rs34274486
7261 ATGTAGATTGTCCTAAATGGATTATCCAACCTCTAGCCTGTCTTCTTTTCACACTGCTA
DD 7.3C/A ENSSNP9202466 ENSSNP8950700 SINE/MIR# MIRc-> -/G
7321 TATACTTTTTATTGCTCTGAATAATTTTACTCTACAAAGAAATAAAATATTTCTATATT
A G
7381 TTTATATCATTGTATAGTTTGCAAAGCATTTCATGTTTATTATTTTCATGTGATCATTGCA
7441 TTAACTTTGTAAATATTATATTGTATTCTGATTTTTTTGTTTTTCCAAAGAGGAAAGGGAG
IIIIIIIIIIII
GNGGNNGGNG
DD 7.5G/A rs1982437 DD 7.5aC/T rs7928356
7501 GTGCAGAAAGGAGAAATGACTTAGAGCAAGTCTCCGCATGACCCAAATGCTAGCAAATAT
I
G
A 0.317 T 0.289
7561 ACAATTGCCCTGATTTTCGTTCCAGGTATCTTGGTAGTTAAACTGTGCTTCTTGCTATAT
7621 TTTAAACCTCTTCATGCCTCATAACACTAGCATATGTTTCAATTTGGCTGCATCCTCTTGTC
DD 7.6C/T rs17180923
7681 AGTTCTACTGGATGCTGGTCTGATCTTTTATTTGCTGTTTATTTTGGATAAGAATGAAGAA
T 0.104
7741 GCATGCACTGTTTTCTTTTCTTTTCTTTGATACTTGACTAAAAAACACTTTAAATTCACCTG
Low_complexity# AT-rich ->rs7937725 DD 7.8A/G rs17129665
7801 AATAATATTTTTTTTTTAAAAAGCCCTACAACCATTTTTTAACACCAATGCCTTTTGTG
A G 0.153
7861 GATACCTAATTAACATAAATGAGTAAGTGTTAAAGATTACTGCTCCCCATGGATCTGAG
rs17129666
7921 CAGAGTAAACTTTCTCTATTTAATTACATAGCATCATTTATCTTGAGGTGATTTGGGTA
A 0.000
7981 ACTATAAAAAGAGATTGATTATTCATGTCTTTCTATACCTTAGTTTCAAAATATCACACTC
8041 TGAATAATGTTTTTGAGATAATTAATTTTATTTTCACTCATGCTATCTGGTTTACTAATT
8101 TGTGAGAACTGTGATATTTAAGTATTGAATACTACACTCTTCAAGATTATGGACATTA
8161 TATGTTTATGGAAGAGTTATGCAGAAAACCCATACCTTAACTTTAAATAGTAGCTTAATT
8221 TAAAACTTTAAATAGTAGCTTAATTTAAATATCTGAGATTATTTACAATTACTTGACAG
8281 AAAGTACTTTTATTTTCTTTGAGAATGTCTTATCATTATAATTATCCAAAAGTATTGTA
8341 GCCCTTTTCCAAAAGTATTTTATGTTGGGTGGAATTTAGAATGTATTCAACAGATGTAT
Simple_repeat# (TA)n -> rs11220219 rs36093338
8401 TCGGTAAAGCATATGTGTACGTGTGTATGTTGTATATATAAGTGTATATGCGTATAC
rs5793824 A A
rs35572397LTR/ERV1# MER52A -> DD 8.4G/T rs34225368
8461 ATTTATATATATATATATATGCTTATGTGATGTGAGCTTTGAGGGTGTGTGTTTCTGGCC

```

      -/TA      -/AT      T
      DD 8.5A/G rs35030714DD 8.5aG/Ars35560250
8521 AGAAACCTCTGTGGTCAACAGTGCCTTTGCTGGGACCCACTGGGCTCTT
      DD 8.5ba/G rs35539924      G      A
8581 TCTGCCCTGCTTTGCCAGGCAGACTGCACCTTAGCTCATGCTATTGGCCTGGGTCCGTGCTT
      rs34124130      G      DD 8.6C/G rs34376453
8641 GCCAAGGGCAAATAGAGTGGTAAGGGGTGTGTGAGTGAGCAAGCATGGGGTCTGGCCACT
      G      G
8701 GTGCACAGCCAGGCACACTGGCTGCAGTGGGGCAGGCAGCTCCAGGCACCTGGTACAGGTG
8761 CCGGCTCCCTGTGAGGCTATAGCTGCACAAGGTGTTACAACGAGCAGCTTCCATGGCTGG
8821 CACTGGGAAATGCAGTGACACCTGGAAGCTTGGAGACACTAGGAACCACAGAGCCCCAAA
8881 GAGTGTGTACAGCTCTGGCTTGGGGAGCTCCTAGGTCTGGGTTCCTCCAAAAGGCCACAG
      rs35377089
8941 CTCTTCTTTCTCTTCTCTCTTTTCTTGTATCCGCAACATGGTGAGCAAGGGTCATGTTTG
      rs35860137 T
9001 AGCCCTGTTTGTGTTACAGCTCTTTTCCAGCCACCATTTCAGCAGGTCCCTGAGTTCTTTAC
      A
9061 CAGTGTCCAGGAAAAATGAGGTATGTGGACAAGTGGAGAGTGAGCAAGGTGAAGAGAAGC
9121 TTTAGTGAGTGACATAACAGCTCAGAGGAGACCCACAGTGGGTCACTACTCTCTGCAGGC
9181 AGGTTGTCCCAATGAGTGTTTCAGCTCTCAGCAGAGAGGAGACCCACAGTGGGTAGCTCTCT
rs34680366
9241 TTCTTTGGGTAGCTCTTCTCCACTACTGGTAGTCTGTATATCTGCTCAGCTCTCAGCAGA
      G
9301 GGGGAAACCTTGGCATAAGTAGCTCCTGTTCACAGGCAGGTCACTCCTGTATCTCTCTGA
9361 GTCTGGCTGAGTCTGGGGGTTTTATGGGCTTCAGAGGGGAGGAAGTGCATGCTGATTGGT
      rs35445893 rs2084911
9421 TCCTGGGTGGCCATGGGCAGCCCTGGAAGAGGCATCATAAGTTCTCATTCTGGTCCATGG
      C C
9481 AACTGACAGCCAGCCCCCAGGCTTCAGGCCACCCCTGGCTTGAAGGTGGGGCTTCACCA
9541 GGGACCCACCCCTTTCTATCCTGGAGCCTGTCTGCCTCCTGCCCTCATCCATGGCACTGA
9601 GGCTGTTCTTTGCCAAGGGGTGCCTGCAGGTCACTGTGTAGCTTCTCCGAGCATGCCCCGG
9661 GCCTCCCTCCCATCCTCGTCAGCACTCAAAGTCCAGAGTCAGCACTGTGTTGAGCGTGCA
9721 CACACCTGGCTGGGTGTGGCAGCACCCAGGCTTGGCCTCAATTTTACTCTGAGATTGGA
9781 GCAAGCACCAGGATCGGGGAGAGGCCAGGCAGCAGGAGCAGGCATATGCATACCTGTGGG
9841 GGAAGGAGGGCCTTCTCTGGCCCCCTGAGAGTGCAGAGATGTTTGGGTCTGCAGCTGCAGC
9901 TTGGGCAGCTGCAGCTGTAGGTGGGAGGGTGGAGGTCTGCTTACTCCCAGTCTCCAAGA
9961 GCAAAGGGGTGCCCAGGTCCAGAGCAGTGGCTGGGAAGCTGCAGCTGCACATGGGGAGTA
10021 TGAGGTTCCACCCCTGCCAGTTTCAAGAGGGTGCAGGGCTTCTGCCTATTCTGGCTCCCA
10081 CTGGCTCCATGGAGTGCACAACCCTGGCTGCACCTCCCCCATGGTAGCCAGCATCATGGC
      Simple_repeat# (TA)n ->
10141 AGCGGCCACTCCAGATGGGCCACCCTGCCATCACTTACACACACATACATATATGTG
10201 TATATATATGATTATGTAGAAAGAGTGTACTCTACCAATAACCTAACATTATCTGTCTT
10261 TCTCTTTTCCTAGCATAATAAATGTGTTTGTGTGAATTTTTCATATTCTCAGTTGTTTC
      SINE/MIR# MIRb ->
10321 CCTGTGTGACTAATAGCAAGGTTTGGAGAGACATATTGCTCATCTGAGGGTTGATTGGG
10381 CCTAAGTTTAAATCTCAGTTCTAACACTCTCAATAGCTATAGAATTGAGCTAAGTTCTCA
10441 GATTTTAGGCTTCTCTATCTGTGAATAATCCTTTTATAAGTTTAAAAAGGATTAAATGA
      rs35116437
10501 GATAATATATGTAATGTATGTAGTACAACGTCTGCCACAAATAGAAATTCAATAGATTTC
      A
10561 TTTTCTCTTTAATGAATCCTTTCTATTTTAAGGAGTTAAACAATCTACTGAAGAGGAA
10621 AAAGCTAAATAATGGCTAATCTAGTAGTCAAATATGCTCTTGAATTCCCTAGTACCTCTG
      rs35714742
10681 CATTTATTAAATAAGCTAGTCAACCAGAGTCTCCTCAAATAATCAACTTTTCATTAGAGATC
      -/AG
10741 AAGATTTTTGTTTTTCACTGAATCCACTAATTTTTTCATCATTTGAATAAAGCAACTGGTAT
10801 TTTCTGTAGTGGAACACATATGACTTCCATTTGAAACCATTTAAACTGAATACAGAGAT
      rs1452937
10861 CCAGGAAACAGACTGCAGTAGATCAGAGAGAATCCAGAACATTATTTTTTAAACATATG
      DD 10.9G/C rs1452938 A 0.000
10921 AAAGATACAGGTTTGAATATCAGAAGCACCTGGCTTCCCTTTATAGATAGATGCCAACCA
      C 0.102
10981 AATTAGGAATTCTTAGAAGAGAAGAGTTACATCATTAATAAAGGGTTTGGAGAAGAAAC
      DD 11.0G/A rs1452939 rs35234923
11041 TGCCTGGATTTTCAATGTTTCATCAACTATGGTTGTGCATATTTTACCAGTTGCATTTTA
      A 0.042      A
11101 TTTTCCTTATTCTTAAAAATATCTATGTAGTTTCTAAAAACATTAGGCTCCATTTGTGCC
11161 AAGGTTAAAGTTTCTTCTCTTCGCAAGAATTCTAATGGAAAAAGCTCCATGTAGTACATT
11221 CATTAGAGCAAATAAAAAATAGCAAAGTGTGCATTCCATTATGATTTCTGCATTTTCATT

```

11281 CTGTGAAATATTTAACTAAGTACTAACATAATTTTTGTATTGATAATGAGCTGATGTT
11341 TGTAAATCTATTTGTTTTCTTTGGGGAAGCAATGCTGAAGAACTCCTAGGCAGTGG
11401 GCTTTGGCAAGGACCTTTATTACATTTTGTACTGCTGTATACAGCCTTTTACATAAAT
11461 TATCTTTTCAAGAAAAGTAATTGATTTTTTGAGTAAGGAATGATAAAGCAACTACTAAAT
DD 11.5G/A **rs1452940**
11521 CTGATTTTTGTGCCATGCAAAAAGTAAAGCGCTTCTCCACTGGTCACACCTTCGCATTTA
A 0.568
11581 CCCACCCCAAGTCTAAATTTAATCCTGCTTGTGTGTACACCTATTACCTCTAGGTATTTT
11641 TACTCATAGCATTTGATGCATCGTGTTATCATGATTTACCTACCTCTGTTATGATTATA
11701 ATATTAATAGTATCCCCCTCATAGAAGTAACTTGTGTTATTATATTTTTGACGAAGAAC
11761 TAAACACAGTAGCTAGTGCCTAGAAGATGCTGCTGTACACAGGTTTATTGATTCAATGAA
11821 TGTTTTGCAACTCAACAAAACTCTTCCCTAAGAGGGAAAAATACAATGGTACTGGCTGCT
11881 TTACTCTTATGCCATCCCTAGCTTTAGTGTTTCAATTTTCACCAATCAATCCCTCCTAG
DD 11.9A/G **rs1901729** ~~rs12805681~~
11941 TTAATTATCTTGAGTTGAAAACATAACTAGAATAAAAATCTCCTGTCACTTACAATCAAT
DD 12.0C/T **rs1901730** ~~rs1901731~~ **G 0.042** ~~G 0.000~~
12001 ATTTACATGTATTCTCTGACTTCATAATTAATATTTAGATTTCTGTTTATGGACTTAGGC
T 0.095 ~~G 0.000~~
Simple_repeat# (TAGA)n ->
12061 CAAACGTCTTCATAACTTTATTATAGATATATATGTAGATAGATAGATACAGACAGAT
12121 **AAACAGATAGTAGATAGGTAGAT**GTTATCATTAAAGAAAGTATGATGTTAGTAATTTGTT
DD 12.1G/A **rs1901732**
12181 TATAATTTTGCTTCAATAATTACTTTGTCTTAACATTCTAGAATGAGTTTTCTTAAATC
A 0.085
12241 TGGTATTTTATGAAGGTAAATGGTTGAATTTGTGGTTCATTCACCTATGAGCTATGACAAA
LTR/ERV1# LTR80A ->
12301 GGGTCCAATTTTCAAATAATGCTCGTACTCTCAGCTCTTACCTGATGTTAAGGATACAAG
12361 **CAACCAAATGGGTGTAGGCACAGCAGAGAGAGGTCTTGGATATCCCATATGGCTTCCTAGG**
rs34690804
12421 **TCCTTCTTTCCTCATGAGACACATTTTGTGGCCTACAGTAACAGAAAAGGTTTGTAATCT**
DD 12.4A/G **rs17266200** **T**
12481 **AGGTATGCA**TGTCTCTTACAGTGTGAAGGCATTTAGATGATGAAAGGTCTGTAGTTTAT
G 0.042
12541 **GCCTAGAATATTCAACAGTTTTTCATGACATTTTCCAGGGGTATGTGCTTCATAATTTTCAT**
DD 12.6A/G **rs17129669**
12601 **AAATTCTAGTTTTATTTCCCATAAAGAAATCCTAAACCAAGGGCATCCTTTTAAGAACATT**
G 0.100
12661 **ACACAGATAAGCATTCCTTCTGCTAGCAAAACATTATTAGTCTGTTACCAAAAGTCCGTTA**
12721 **TTAGCAAGTTTATAAAGAAATTCATCTGGAACCTTTCCCTTCTTCCCTCTGGGATTGTT**
12781 **TTCCATTTTGGTACACTAGCAGATCTGGGGCAGTTCAGTAACCTTTTCTCCTATGTC**
12841 **CACCTTCTGACATCAGTTAATAAATATCCATCACATATTTTTCAGGTTTTAACATTTTTT**
12901 **TATCCTACAAAAATTTTTTGTGTTACTTAATGAAAAATGTAAGTACACTAACAGTCTAG**
12961 **TGGCCACCAGAATTTGAAGCATACAGTAGGGATAGAAAGCACCTTGTAAGCATATTAAT**
13021 **GACGTACATATCTCTTCAGGGATCTTATATCTTTAATCAGCTCAGTTACTCTTTTGTCT**
Low_complexity# AT_rich ->
13081 **CCATCCTCAGTTATTTGAAAACGTTAATGTGTGTTGGTGGAGAGGCTTAATTTAGTTTTA**
rs1349700 LINE/L1# L1PA16 ->
13141 **ATTTTTTTTACTTATTTTAAAGTTTCATTTTGTAACATTATAATAGACTTATGACCTTT**
G
13201 **ATTTTAATTCCAACTTTTATCTTGGATTTGGGGTATACATATGCAGGTTTGTAACATGAG**
13261 **TATATTGCATGATGCTGAGGTGTGGAATATGGATGATCCCATCAGCCAGGTAGTAAGCAT**
13321 **TGTACCCAAGGGGTAGTTTTTCAACCCGTTTCCTTTCCCTTCTTAGCCTCTAGTAG**
ENSSNP3991572
13381 **TCCTCAGTGCTTATTGTTCCCATCATTATGTCCGTGAGAACCCAGATTAGCTCCTACT**
G
13441 **TATAAGTGAGAATGTGTGGTGTCTGGTTTTCTGTTCCCTCATTAATTTGCTTGGGATAAT**
13501 **GGCCTCCAGCTACATCCATGTTGCTGCAAAGGACATGATTATTTCTTTATATGGCCATG**
13561 **TGGTATTCCGTGGTGTATGTACCACATTTCTTTTCCAGTCCATAATTTATGAACAC**
rs1349701 **rs1349702**
13621 **CTGGGTTGATTCATGTATTGTGCTATTGTGAATAATGCTAAGATAAACATATGTGTGCAT**
A **A**
13681 **GTGTCTTTTTGGTAGAACATTTATTTTCCCTTTGGGTATATATCCAGTAATGAGATTGCT**
13741 **GGGTCAAATGGTAATTGTGTTTTAAGTCTTTGAGAAATCTCTGAACACTTTCCACAGT**
rs12785351
13801 **GGCTGAACTAATTTGCATTCCCACAACTGTGTAAGTGTTCCCTTTCCCTTCGAGCCTTG**
T 0.000
13861 **CCAGCATCTGATATTTTTGACTTTTTTAATAATAGCCATTCTGTCTGGTGTGAGACAGTA**
13921 **TCTCACTGTGGTTTTGATTGCAATTTCCCTAATGGCTAGTGATATGGAGCATTTCTTCAT**
13981 **ATGTTTTATCAGCTAGTTGAATGTCTTCTTTTGAGAAGTGCTGTTTCATGTCCTTTGCCCA**
14041 **TTTTTTAAATGGGGTGTTTTTTGCTTGTGATTTGTTTAAGTTCTTTGTAGATTCTGG**

rs34071053

14101 ATATTAGACCTTTGTCTAGATGCAATAGTTTCGTGAATGTTTTCTCCTGTTCCGTGGGTTATC
-/C

14161 TGTTTACTCTGTTGATAATTCATTTGCTGTGCAGAAGTCCCACTTGTCAATTTTGTGTT

14221 TTGTTGCAATTGCTTATGGGGATTTAGCCATAAAATCTTTGCTGAAGCTGATGTTCAAAG

14281 GGTATTTCCCTAGGTTTTCTTCTAGGATTTCTATAATTTGAGGTCTTACATTTAAATTTTT

14341 AGTCTATCTTGGTTAATATTTGGGAGGTATATTGTGAGAGGTAGGGCTCCAGTTTCTTT

14401 TTTTTTTTTTTTTTGCATATGGATATCTAGTTTTCCCAACATAATTTATTGAAGAAACTG
LINE/L1# L1MA5 ->

14461 GAGCACATTATTCAGCAATCCCACTACTGGGTATATATGCAAAGGAAAGGAAATAAGTAT
rs1597877

14521 GTTGAAGAGATATCTGCACTATTATGTTTATTGCAGCATTATTCACAATAACCAAAGTAT
G

14581 GAAATTAACCTATGTCTATCAACTGATGAATGCATAAGAATTTGTGGTGTATTTACACAA

14641 TGAAATATGATTTAGCCATTACAGTGAATGAAATTCCTGTCATTTGTGACAACATGAATGT
rs11220489

14701 GCTTGGAGAATATTTTGCTAAGTAAAATAAGCCAGGCACAGAAAGACAAATACTGCATGT
T

14761 TCTCACTCATATGTGGAAGCTAAATGCATTGATTTTCATCGAAGTAGAGAGTAGAATTGTG

14821 GTAACACAGGTTAGGAAGGGTAGGGGGTAATGAGGATAGAGAGATGTTGGCTAATGGAT

14881 ACAAATACAGCTAGATAGGAGGAATAAGTTCTGGTGTTTATACCATGTAGCATGCCT

14941 ATAGTTACAATACTTTATATTTTCAAATAGCTAGAAAAGAGGATTTTGAATGTTTCTAA

15001 T

APPENDIX II: PCR PROFILES AND PRIMERS

Appendix II.I PCR Cycles

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
3.2.2, 5.2.1	4.3	DA1.6F + DA5.9R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 60°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 1 st Amplicon 1° PCR
3.2.2, 5.2.1	4.1	DA1.8F + DA5.9aR	1 x (96°C, 1.5'), 34 x (96°C, 20"; 58°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 1 st Amplicon 2° PCR
3.2.2, 5.2.1	5.3	DA5.1F + DA10.4R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 58°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 2 nd Amplicon 1° PCR
3.2.2, 5.2.1	5.1	DA5.2F + DA10.3R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 60°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 2 nd Amplicon 2° PCR
3.2.2, 5.2.1	4.7	DA9.9F + DA14.6R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 58°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 3 rd Amplicon 1° PCR
3.2.2, 5.2.1	4.6	DA9.9aF + da14.5R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 58°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA 3 rd Amplicon 2° PCR

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
3.2.2	3.5	DB2.0F + DB5.5R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 64°C, 30"; 65°C, 5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 1 st Amplicon 1° PCR
3.2.2	3.3	DB2.1F + DB5.4R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 58°C, 30"; 65°C, 4.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 1 st Amplicon 2° PCR
3.2.2	5.9	DB4.6F + DB10.5R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 64°C, 30"; 65°C, 7'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 2 nd Amplicon 1° PCR
3.2.2	5.0	DB5.1F + DB10.1R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 60°C, 30"; 65°C, 5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 2 nd Amplicon 2° PCR
3.2.2	4.6	DB9.9F + DB14.5R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 62°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 3 rd Amplicon 1° PCR
3.2.2	4.5	DB9.9aF + DB14.4R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 64°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DB 3 rd Amplicon 2° PCR

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
3.2.2	5.2	DC1.4F + DC6.6R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 62°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 1 st Amplicon 1° PCR
3.2.2	4.5	DC1.8F + DC6.3R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 62°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 1 st Amplicon 2° PCR
3.2.2	4.2	DC5.7F + DC9.9R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 62°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 2 nd Amplicon 1° PCR
3.2.2	3.5	DC6.1F + DC9.6F	1 x (96°C, 1.5'), 34 x (96°C, 20"; 62°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 2 nd Amplicon 2° PCR
3.2.2	5.4	DC9.2F + DC14.6R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 62°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 3 rd Amplicon 1° PCR
3.2.2	4.9	DC9.5F + DC14.4R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 62°C, 30"; 65°C, 5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DC 3 rd Amplicon 2° PCR

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
3.2.2	4.4	DD1.9F + DD6.3R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 63°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 1 st Amplicon 1° PCR
3.2.2	4.2	DD2.2 + DD6.0R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 58°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 1 st Amplicon 2° PCR
3.2.2	6.0	DD5.4F + DD11.4R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 61°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 2 nd Amplicon 1° PCR
3.2.2	5.6	DD5.5F + DD11.1F	1 x (96°C, 1.5'), 34 x (96°C, 20"; 63°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 2 nd Amplicon 2° PCR
3.2.2	4.5	DD10.3F + DD14.8R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 63°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 3 rd Amplicon 1° PCR
3.2.2	3.7	DD10.5F + DD14.2R	1 x (96°C, 1.5'), 34 x (96°C, 20"; 60°C, 30"; 65°C, 5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DD 3 rd Amplicon 2° PCR

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.4.1.1	3.3	DA2.6FG + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
4.4.1.1	3.3	DA2.6FC + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
4.4.1.1	2.2	DA3.7FT + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
4.4.1.1	2.2	DA3.7FG + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
4.4.1.1	1.9	DA4.0aFG + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
4.4.1.1	1.9	DA4.0aFA + DA5.9aR	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.4.1.2	0.6	DA9.9aF + DA10.6RG2	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	0.6	DA9.9aF + DA10.6RA2	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	0.7	DA9.9aF + DA10.6aRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	0.7	DA9.9aF + DA10.6aRC	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	0.7	DA9.9aF + DA10.6bRC	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	0.7	DA9.9aF + DA10.6bRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	2.1	DA9.9aF + DA12.0RC	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
4.4.1.2	2.1	DA9.9aF + DA12.0RT	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.4.1.3, 4.6.1	6.6	DA4.0aFG + DA10.6RG2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing
4.4.1.3, 4.6.1	6.6	DA4.0aFG + DA10.6RA2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing
4.4.1.3, 4.6.1	6.6	DA4.0aFA + DA10.6RG2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing
4.4.1.3, 4.6.1	6.6	DA4.0aFA + DA10.6RA2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.4.1.4	8	DA2.6FG + DA10.6bRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 64°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 63°C, 30"; 65°C, 10'), 16 x (96°C, 20"; 62°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 7 orientation A (1° PCR)
4.4.1.4	6.6	DA4.0aFG + DA10.6RA2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 59°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 7 orientation A (2° PCR)
4.4.1.4	8	DA2.6FC + DA10.6bRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 58°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 57°C, 30"; 65°C, 10'), 16 x (96°C, 20"; 56°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 7 orientation B (1° PCR)
4.4.1.4	6.6	DA4.0aFA + DA10.6RG2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 7 orientation B (2° PCR)
4.4.1.4, 4.4.1.5	6.4	DAXOF + DA10.4R	1 x (96°C, 1.5'), 30 x (96°C, 20"; 64°C, 30"; 65°C, 8'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor 7 orientations A and B

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.6.1	9.4	DA2.6FG + DA12.0RT	1 x (96°C, 1.5'), 5 x (96°C, 20"; 64°C, 30"; 65°C, 11.5'), 5 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 16 x (96°C, 20"; 62°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 6 orientation A (1° PCR)
4.6.1	6.9	DA3.7FT1 + DA10.6bRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 24 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 6 orientation A (2° PCR)
4.6.1	9.4	DA2.6FC + DA12.0RC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 6 orientation B (1° PCR)
4.6.1	6.9	DA3.7FG1 + 10.6bRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 57°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 10'), 24 x (96°C, 20"; 55°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 6 orientation B (2° PCR)
4.6.1	6.6	DA3.8XO + DA10.4R	1 x (96°C, 1.5'), 30 x (96°C, 20"; 64°C, 30"; 65°C, 9.5'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor 6 orientations A and B

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.6.2	8	DA2.6FG + DA10.6aRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 16 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 33 orientation A (1° PCR)
4.6.2	6.6	DA4.0aFG + DA10.6RG2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 63°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 62°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 33 orientation A (2° PCR)
4.6.2	8	DA2.6FC + DA10.6aRC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 33 orientation B (1° PCR)
4.6.2	6.6	DA4.0aFA + DA10.6RA2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 62°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 60°C, 5')	Hotspot DA, pilot and CO assay for donor 33 orientation B (2° PCR)
4.6.2	6.4	DAXO +DA10.4R	1 x (96°C, 1.5'), 30 x (96°C, 20"; 64°C, 30"; 65°C, 8'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor 33 orientations A and B

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.6.2	8	DA2.6FG + DA10.6bRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 64°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 63°C, 30"; 65°C, 10'), 16 x (96°C, 20"; 62°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 67 orientation A (1° PCR)
4.6.2	6.6	DA4.0aFG + DA10.6aRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 62°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 67 orientation A (2° PCR)
4.6.2	8	DA2.6FC+ DA10.6bRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 10'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 10'), 16 x (96°C, 20"; 59°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 67 orientation B (1° PCR)
4.6.2	6.6	DA4.0aDA + DA10.6aRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 59°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 67 orientation B (2° PCR)
4.6.2	6.4	DAXO +DA10.4R	1 x (96°C, 1.5'), 30 x (96°C, 20"; 64°C, 30"; 65°C, 8'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor 67 orientations A and B

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
4.6.2	9.4	DA2.6FG + DA12.0RC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 44 orientation A (1° PCR)
4.6.2	6.6	DA4.0aFG + DA10.6RA2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 62°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 44 orientation A (2° PCR)
4.6.2	9.4	DA2.6FC + DA10.20RT	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 44 orientation B (1° PCR)
4.6.2	6.6	DA4.0aFA + DA10.6RG2	1 x (96°C, 1.5'), 5 x (96°C, 20"; 62°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 61°C, 30"; 65°C, 8.5'), 24 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 44 orientation B (2° PCR)
4.6.2	6.4	DAXO +DA10.4R	1 x (96°C, 1.5'), 30 x (96°C, 20"; 64°C, 30"; 65°C, 8'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor 44 orientations A and B

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
5.2.3	5.5	DA4.8FA + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	5.5	DA4.8FC + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	5.3	DA5.0FT + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	5.3	DA5.0FC + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	5.0	DA5.3FA + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	5.0	DA5.3FT+ DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	4.3	DA6.0FA + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 5.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	4.3	DA6.0FG + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 5.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	4.2	DA6.1FC + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 5.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	4.2	DA6.1FT + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 5.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	3.3	DA7.0FA + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	3.3	DA7.0FG+ DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	3.3	DA7.0bFT+ DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	3.3	DA7.0bFG + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	2.9	DA7.4FA + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation
5.2.3	2.9	DA7.4FC + DA10.3R	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 5' ASP optimisation

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
5.2.3	4.8	DA5.2F + DA10.0RG	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 50°, 53°, 56°, 59°)	Hotspot DA, 3' ASP optimisation
5.2.3	4.8	DA5.2F + DA10.0RA	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 50°, 53°, 56°, 59°)	Hotspot DA, 3' ASP optimisation
5.2.3	5.0	DA5.2F + DA10.2RC	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 50°, 53°, 56°, 59°)	Hotspot DA, 3' ASP optimisation
5.2.3	5.0	DA5.2F + DA10.2RT	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 50°, 53°, 56°, 59°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.5	DA9.9aF + DA13.4R1-	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.5	DA9.9aF + DA13.4R1+	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, 3' ASP optimisation
5.2.3	3.5	DA9.9aF + DA13.4RA	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.5	DA9.9aF + DA13.4RG	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 4.5'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.6	DA9.9aF + DA13.5RT1	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, 3' ASP optimisation
5.2.3	3.6	DA9.9aF + DA13.5R1C	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.9	DA9.9aF + DA13.8aFG	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation
5.2.3	3.9	DA9.9aF + DA13.8aFA	1 x (96°C, 1.5'), 33 x (96°C, 20"; A°C, 30"; 65°C, 6'), 1 X (60°C, 30"; 65°C, 3') (A: 56°, 59°, 62°, 65°)	Hotspot DA, 3' ASP optimisation

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
5.2.4	6.5	DA3.7FG + DA10.2C	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.5	DA3.7FG + DA10.2T	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.5	DA3.7FT + DA10.2C	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.5	DA3.7FT + DA10.2T	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.6	DA4.0aFG + DA10.6bRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23

5.2.4	6.6	DA4.0aFG + DA10.6bRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.6	DA4.0aFT + DA10.6bRC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.6	DA4.0aFT + DA10.6bRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 60°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 58°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.2	DA4.0aFG + DA10.2RC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.2	DA4.0aFG + DA10.2RT	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.2	DA4.0aFT + DA10.2RC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23
5.2.4	6.2	DA4.0aFT + DA10.2RT	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	solving linkage phasing for d23

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
5.2.5	8	DA2.6FG + DA10.6bRC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 8 orientation B and for donor 12 and for donors 73, 211, 247 orientation A (1° PCR)
5.2.5	6.9	DA3.7FG1 + DA10.6RG2	1 x (96°C, 1.5'), 33 x (96°C, 20"; 59°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 8 orientation B (2° PCR)
5.2.5	6.9	DA3.7FG1 + DA10.6RA2	1 x (96°C, 1.5'), 33 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 12 orientation A (2° PCR)
5.2.5	9.4	DA2.6FG + DA12.0RC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 17, 256 orientation A (1° PCR)
5.2.5	6.9	DA3.7FT1 + DA10.6bRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 17 orientation A (2° PCR)
5.2.5	8.0	DA2.6FC + DA10.6bRC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 26 orientation B (1° PCR)
5.2.5	6.9	DA3.7FG1 + DA10.6aRA	1 x (96°C, 1.5'), 5 x (96°C, 20"; 59°C, 30"; 65°C, 8.5'), 5 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 23 x (96°C, 20"; 57°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 26 orientation B (2° PCR)
5.2.5	9.4	DA2.6FG + DA12.0RT	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 31, 185 orientation A (1° PCR)
5.2.5	6.9	DA3.7FT + DA10.6bRC	1 x (96°C, 1.5'), 33 x (96°C, 20"; 63°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 31 orientation A (2° PCR)
5.2.5	6.9	DA3.7FT1 + DA10.6aRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 73, 180, 269 orientation A (2° PCR)
5.2.5	8.7	DA4.8FC + DA13.5RC1	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 10.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 178 orientation A and for donor 261 orientation B (1° PCR)
5.2.5	8.1	DA5.3FT + DA13.4aR1-	1 x (96°C, 1.5'), 33 x (96°C, 20"; 56°C, 30"; 65°C, 10'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 178 orientation A and for donor 186 orientation B (2° PCR)
5.2.5	9.4	DA2.6FG + DA12.0RT	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 180, 253, 269, 280 orientation A (1° PCR)
5.2.5	7.7	DA6.1FT + DA13.8aRA	1 x (96°C, 1.5'), 26 x (96°C, 20"; 62°C, 30"; 65°C, 9.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 181, 184 orientation B (1° PCR)
5.2.5	6.5	DA7.0FG + DA13.5RC1	1 x (96°C, 1.5'), 33 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 181, 184 orientation B (2° PCR)

5.2.5	6.5	DA3.7FT1 + DA10.2C	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 185, 253, 256, 280 orientation A (2° PCR)
5.2.5	8.7	DA4.8FC + DA13.8aRG	1 x (96°C, 1.5'), 26 x (96°C, 20"; 59°C, 30"; 65°C, 11'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 186 orientation A (1° PCR)
5.2.5	6.2	DA4.0aFG + DA10.2RC	1 x (96°C, 1.5'), 33 x (96°C, 20"; 57°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 211, 236, 251 orientation A (2° PCR)
5.2.5	9.4	DA2.6FC + DA12.0RC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 11.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 232 orientation B (1° PCR)
5.2.5	6.9	DA3.7FG1 + DA10.6bRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 232 orientation B (2° PCR)
5.2.5	6.9	DA3.7FT + DA10.6bRC	1 x (96°C, 1.5'), 26 x (96°C, 20"; 63°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 236, 238, 251 orientation A (1° PCR)
5.2.5	6.2	DA4.0aFG + DA10.2RC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 8'), 5 x (96°C, 20"; 55°C, 30"; 65°C, 8'), 23 x (96°C, 20"; 54°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 238 orientation A (2° PCR)
5.2.5	7.7	DA6.1FC + DA13.8aRA	1 x (96°C, 1.5'), 26 x (96°C, 20"; 60°C, 30"; 65°C, 9.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 243, 272 orientation B (1° PCR)
5.2.5	6.9	DA7.4FA + DA13.4aR1+	1 x (96°C, 1.5'), 33 x (96°C, 20"; 60°C, 30"; 65°C, 7.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 243 orientation A (2° PCR)
5.2.5	6.4	DA7.0FG + DA13.4R1-	1 x (96°C, 1.5'), 26 x (96°C, 20"; 59°C, 30"; 65°C, 8'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 244, 259 orientation B (1° PCR)
5.2.5	3.2	DA7.0bFT + DA10.2RC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 57°C, 30"; 65°C, 4'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 4'), 23 x (96°C, 20"; 56°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 244 orientation B (2° PCR)
5.2.5	6.9	DA3.7FG1 + DA10.6aRA	1 x (96°C, 1.5'), 26 x (96°C, 20"; 58°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 247 orientation A (2° PCR)
5.2.5	2.8	DA7.4FC + DA10.2RC	1 x (96°C, 1.5'), 5 x (96°C, 20"; 57°C, 30"; 65°C, 4'), 5 x (96°C, 20"; 56°C, 30"; 65°C, 4'), 23 x (96°C, 20"; 56°C, 30"; 65°C, 4'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donors 259 orientation B (2° PCR)
5.2.5	5.3	DA5.3FT + DA10.6bRA	1 x (96°C, 1.5'), 33 x (96°C, 20"; 59°C, 30"; 65°C, 7'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 261 orientation B (2° PCR)
5.2.5	6.4	DA13.4aR+ + DA7.0bFG	1 x (96°C, 1.5'), 33 x (96°C, 20"; 60°C, 30"; 65°C, 7.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 272 orientation A (2° PCR)
5.2.5	6.8	DA7.0bRT + DA13.8aRA	1 x (96°C, 1.5'), 26 x (96°C, 20"; 60°C, 30"; 65°C, 8.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 279 orientation A (1° PCR)
5.2.5	6.0	DA7.4FA + DA13.4aR+	1 x (96°C, 1.5'), 33 x (96°C, 20"; 60°C, 30"; 65°C, 7.5'), 1 X (60°C, 30"; 65°C, 5')	Hotspot DA, pilot and CO assay for donor 279 orientation A (2° PCR)

Section	Target Molecule Size (kb)	Primers used	Cycling conditions	Remarks
5.2.7	2.6	DA7.4F + DA10.0R	1 x (96°C, 1.5'), 15 x (96°C, 20"; 58°C, 30"; 65°C, 3.5'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor homozygous for suppressing SNP DA7.5
5.2.7	2.6	DA7.4F + DA10.0R	1 x (96°C, 1.5'), 25 x (96°C, 20"; 58°C, 30"; 65°C, 3.5'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for donor homozygous for suppressing SNP DA7.5
5.2.9	3.3	DA5.2F + DA8.6R	1 x (96°C, 1.5'), 33 x (96°C, 20"; 62°C, 30"; 65°C, 4.5'), 1 X (65°C, 7')	Hotspot DA, tertiary PCR for sequencing
5.2.9		DA7.3F	1 x (96°C, 1.5'), 15 x (96°C, 10"; 50°C, 5"; 60°C, 4'), 1 X (65°C, 7')	Hotspot DA, sequencing using forward primer
5.2.9		DA7.6R	1 x (96°C, 1.5'), 15 x (96°C, 10"; 50°C, 5"; 60°C, 4'), 1 X (65°C, 7')	Hotspot DA, sequencing using reverse primer
5.2.9			98°C, 5'; 25°C, 10'	Hotspot DA, Big Dye V3.1 clean up after sequencing cycling

Appendix II.II Primers

II.II.I Universal Primers

Section	Universal Primer	Sequence (5' -> 3')
3.2.2, 5.2.1	DA1.6F	AGAATGTTCTGAGCTTGCCC
3.2.2, 5.2.1	DA1.8F	CATGTGTTGAGCCTGAACCC
3.2.2, 5.2.1	DA5.9R	GAACTGGTAAGCTTCCTGCC
3.2.2, 5.2.1	DA5.9aR	GGTGGATATCACATTGGACC
3.2.2, 5.2.1	DA5.1F	GGACTTTTGGTCTCTATCTGCC
3.2.2, 5.2.1, 5.2.3	DA5.2F	AGGACCCTAGAGCAGAGTCC
3.2.2, 5.2.1, 5.2.3	DA10.3R	TAGGCTAGCGTTCAGATCCC
3.2.2, 4.4.1.4, 4.4.1.5, 4.6.1, 4.6.2, 5.2.1	DA10.4R	ACATGTTTCCTTCCAAGTCCC
3.2.2, 5.2.1	DA9.9F	GACAAGGCACGACTGACTCC
3.2.2, 5.2.1, 5.2.3	DA9.9aF	CAGAAATGAGGCTAGATGCC
3.2.2, 5.2.1	DA14.5R	CTGAAACACAGTAAGAATGCC
3.2.2, 5.2.1	DA14.6R	AGGCCATATACAACAGGCCC

Section	Universal Primer	Sequence (5' -> 3')
3.2.2	DC1.4F	CGAGGAATCTGCGTTTTAGC
3.2.2	DC1.8F	GAATGTTTTAGTGGGAGAGCC
3.2.2	DC6.6R	GAACAGAGGTGGGATAGCAG
3.2.2	DC6.3R	GATGGTCAACAGAAAAGGATC
3.2.2	DC5.7F	GGCTTCTGGAATACTGCTGC
3.2.2	DC6.1F	CCCTTAATGTATCTGGCAGGTA
3.2.2	DC9.6R	GGTTGGTGTGTAAACGGC
3.2.2	DC9.9R	TAGAGTTTGCTGTCTGCACCC
3.2.2	DC9.2F	GGCTACAAGTCCCAAATTGC
3.2.2	DC9.5F	GGGTAATATCCAGTCCCAAGT
3.2.2	DC14.4R	ATGTTGTGTGTTGAAGCGGG
3.2.2	DC14.6R	GCTTTCTCACCTGTAAGATGGC

Section	Universal Primer	Sequence (5' -> 3')
3.2.2	DB2.5FT	ccccccAATATCTCATTTTTGAAAT
3.2.2	DB2.5FC	ccccccAATATCTCATTTTTGAAAC
3.2.2	DB4.3FC	GTTCTACCCCGACTCTGCTC
3.2.2	DB4.3FG	GTTCTACCCCGACTCTGCTG
3.2.2	DB10.5RA	ACCACTTGATGACTACAT
3.2.2	DB10.5RG	CCACTTGATGACTACAC
3.2.2	DB12.3RT	ccccGCTTTATTCATTATAGTCCA
3.2.2	DB12.3RA	ccccGCTTTATTCATTATAGTCTT
3.2.2	DB13.5RG	ccccGTCTCTAGACATTAGCAC
3.2.2	DB13.5RA	ccccGTCTCTAGACATTAGCAT
3.2.2	DB14.3RG	CAACCAGAAGGAAGAGCC
3.2.2	DB14.3RC	CAACCAGAAGGAAGAGCG

Section	Universal Primer	Sequence (5' -> 3')
3.2.2	DD 1.9F	GCCTGTAGGACTGTAGCCA
3.2.2	DD 2.2F	CCCTAAGATTATGGGTGC
3.2.2	DD 6.0R	GAGAGGAGACCAAAATGGG
3.2.2	DD 6.3R	CACTTCTCAGACTTTGTAAGGG
3.2.2	DD 5.4F	GGTCCCAAGTTACTCTGG
3.2.2	DD 5.5F	CAGGAACCCAACCTTTTCAGTC
3.2.2	DD 11.1R	CCTTGGCACAAATGGAGCC
3.2.2	DD 11.4R	CTTGCCAAAGCCCACTGC
3.2.2	DD 10.3F	GTGACTAATAGCAAGGTTTGAG
3.2.2	DD 10.5F	CTATCACTGAAGAGGAAAAAGC
3.2.2	DD 14.2R	GCTTCAGCAAAGATTTTATGGC
3.2.2	DD 14.8R	CATCTCTCTATCCTCATTACCC

Section	Universal Primer	Sequence (5' -> 3')
4.4.1.4, 4.4.1.5, 4.6.2	DA4.0X0F	CTGCAGTGGGAGCTCAGTCTCC
4.6.1	DA3.8XO	CCTGCTGTGTCTGATTTGTCATc
5.2.7	DA7.4F	GCTCCACAGGGCTAGGGAG
5.2.7	DA10.0R	CAGCATCCTCTAAATTGCAGG
5.2.9	DA7.3F	GGCAGTTAGTAGGTGTATTAG
5.2.9	DA7.6R	CATCCTGAGTTTTAGCTCCC

II.II.II Allele-Specific Primers (ASPs)

Section	Allele Specific Primer (ASP)	Sequence (5' -> 3')
4.4.1.1, 4.4.1.4, 4.6.1, 4.6.2, 5.2.5	DA2.6FG	cccccGATACTTCCCAACATTGAG
4.4.1.1, 4.4.1.4, 4.6.1, 4.6.2, 5.2.5	DA2.6FC	cccccGATACTTCCCAACATTGAC
4.4.1.1, 5.2.4, 5.2.5	DA3.7FT	cccccAAACCTCTTTTAGTGACAT
4.4.1.1, 5.2.4, 5.2.5	DA3.7FG	cccccAAACCTCTTTTAGTGACAG
4.4.1.1, 4.4.1.3, 4.6.1, 4.4.1.4, 4.6.2, 5.2.4, 5.2.5	DA4.0aFG	cccCTGTACGGGGAAAATACTG
4.4.1.1, 4.4.1.3, 4.6.1, 4.4.1.4, 4.6.2, 5.2.4	DA4.0aFA	ccccCTGTACGGGGAAAATACTA
4.4.1.2, 4.4.1.3, 4.6.1, 4.4.1.4, 4.6.2, 5.2.5	DA10.6G2	CAGGTTGTTAGCAAGC
4.4.1.2, 4.4.1.3, 4.6.1, 4.4.1.4, 4.6.2, 5.2.5	DA10.6A2	GCAGGTTGTTAGCAAGT
4.4.1.2, 4.6.2, 5.2.5	DA10.6aRA	CCCCATTCTCAGGAGAGT
4.4.1.2, 4.6.2	DA10.6aRC	CCCCATTCTCAGGAGAGG
4.4.1.2, 4.4.1.4, 4.6.1, 4.6.2, 5.2.4, 5.2.5	DA10.6bRC	TAACAGGAACTCCCCATTG
4.4.1.2, 4.4.1.4, 4.6.1, 4.6.2, 5.2.4, 5.2.5	DA10.6bRA	TAACAGGAACTCCCCATT
4.4.1.2, 4.6.1, 4.6.2, 5.2.5	DA12.0RC	TAGGTTAGGTACTGGGCG
4.4.1.2, 4.6.1, 4.6.2, 5.2.5	DA12.0RT	TAGGTTAGGTACTGGGCA
4.6.1, 5.2.5	DA3.7FT1	ccAAACCTCTTTTAGTGACAT
4.6.1, 5.2.5	DA3.7FG1	ccAAACCTCTTTTAGTGACAG
5.2.3	DA4.8FA	GGAGAGAGGCCTGGGGA
5.2.3, 5.2.5	DA4.8FC	GGAGAGAGGCCTGGGGC
5.2.3	DA5.0FT	CTTATGCAGGAGTCTGT
5.2.3	DA5.0FC	CTTATGCAGGAGTCTGC
5.2.3	DA5.3FA	CCCCATTATCTCACTGGATTTTCA
5.2.3, 5.2.5	DA5.3FT	CCCCATTATCTCACTGGATTTTCT

Section	Universal Primer	Sequence (5' - 3')
5.2.3	DA6.0FA	GCTCTCAGTCTCCTATTTCTTA
5.2.3	DA6.0FG	GCTCTCAGTCTCCTATTTCTTG
5.2.3, 5.2.5	DA6.1FC	CCAAGCTGTGAGAGAGTCC
5.2.3, 5.2.5	DA6.1FT	CCAAGCTGTGAGAGAGTCT
5.2.3	DA7.0FA	cGGATTTAAACCTGTCTGA
5.2.3, 5.2.5	DA7.0FG	cGGATTTAAACCTGTCTGG
5.2.3, 5.2.5	DA7.0bFT	ccGCAAAAAAAGTCTAAAGGCAT
5.2.3, 5.2.5	DA7.0bFG	ccGCAAAAAAAGTCTAAAGGCAG
5.2.3, 5.2.5	DA7.4FA	ccGAAGTTTAATGGACTCACAA
5.2.3	DA7.4FC	ccGAAGTTTAATGGACTCACCC
5.2.3	DA10.0RG	GTCAACTACTACTACCCCCC
5.2.3	DA10.0RA	GTCAACTACTACTACCCCCT
5.2.3, 5.2.4, 5.2.5	DA10.2RC	cccccccCTAAAAGAATGAAATAATG
5.2.3, 5.2.4	DA10.2RT	cccccccCTAAAAGAATGAAATAATA
5.2.3, 5.2.5	DA13.4aR1-	CAAACCTACCCATCTGATA
5.2.3, 5.2.5	DA13.4aR1+	CAAACCTACCCATCTGATAA
5.2.3	DA13.4RA	CGGGGATTCATAACTAGAATAT
5.2.3	DA13.4RG	CGGGGATTCATAACTAGAATAC
5.2.3	DA13.5RT1	GAAACTCTCCAAGACAAYA
5.2.3, 5.2.5	DA13.5RC1	GAAACTCTCCAAGACAAYG
5.2.3, 5.2.5	DA13.8aRG	ccccGAAAATCCATAAACAAAC
5.2.3, 5.2.5	DA13.8aRA	ccccGAAAATCCATAAACAAAA

APPENDIX III: ALLELE-SPECIFIC OLIGOS (ASOs)

ASO	Sequence (5' - 3')	ASO	Sequence (5' - 3')
DA1.9-	TCCAGTGGGAAGTACTAAA	DA7.6A	CTGTCATAAGAACAGCAT
DA1.9+	TCCAGTGGGAAGTACTAA	DA7.6C	CTGTCATCAGAACAGCAT
DA2.4-	AATCTCCCTGCAACATAG	DA8.2G	GAAGCCAGTAATGAATGT
DA2.4+	AATCTCCCCTGCAACATA	DA8.2A	GAAGCCAATAATGAATGT
DA2.6G	ACATTGAGTAAGATAGAC	DA8.4G	ACACTACGCTCCTGCATG
DA2.6C	ACATTGACTAAGATAGAC	DA8.4A	ACACTACACTCCTGCATG
DA3.5T	ACAAAATTGAGRACAGGG	DA8.5C	GGAAATACGAATGTCTCA
DA3.5G	ACAAAATGGAGRACAGGG	DA8.5G	GGAAATAGGAATGTCTCA
DA3.7T	AGTGACATCTGGTGCATG	DA9.2+	AGATTATTTTTTGAATGT
DA3.7G	AGTGACAGCTGGTGCATG	DA9.2-	TAGATTATTTTTGAATGT
DA4.0C	GACAGCCCCTCCTSTGGA	DA9.5C	GCAATTTCTGAAGAACTC
DA4.0T	GACAGCCTCTCCTSTGGA	DA9.5T	GCAATTTTTGAAGAACTC
DA4.0aG	AAATACTGTAATAAGCAC	DA10.0G	TGCTGGAGGGGGTAGTAG
DA4.0aA	AAATACTATAATAAGCAC	DA10.0A	TGCTGGAAGGGGGTAGTAG
DA4.8A	CCTGGGGACATTTAGGCT	DA10.2C	AGATGGGCATTATTTTCAT
DA4.8C	CCTGGGGCCATTTAGGCT	DA10.2T	AGATGGGTATTATTTTCAT
DA5.0T	GAGTCTGTACCCTGGCCC	DA10.6G	GCCCTGTGCTTGCTAACA
DA5.0C	GAGTCTGCACCCTGGCCC	DA10.6A	GCCCTGTACTTGCTAACA
DA5.3A	GATTTTCATAGTATATTT	DA10.6aA	ATCTCCATACTCTCCTGA
DA5.3T	GATTTTCTTAGTATATTT	DA10.6aC	ATCTCCATCCTCTCCTGA
DA6.0A	ATTTCTTAGATAACTCCA	DA10.6bC	CTCCTGACAATGGGGAGT
DA6.0G	ATTTCTTGATAACTCCA	DA10.6bA	CTCCTGAAAATGGGGAGT
DA6.1C	GAGAGTCCGAGTTTCCCA	DA10.8-	TGGAGTCTACTGGGTTGG
DA6.1T	GAGAGTCTGAGTTTCCCA	DA10.8+	TGGAGTCTTACTGGGTTG
DA6.1aA	AATTACCACAACTTAAT	DA11.5C	TATATAACATGGCCTGGC
DA6.1aG	AATTACCGCAAACTTAAT	DA11.5T	TATATAATATGGCCTGGC
DA6.3T	CATTCCTTGGCTTGTAGC	DA12.0C	ATTCACGCGCCCAGTACC
DA6.3C	CATTCCTCGGCTTGTAGC	DA12.0T	ATTCACGTGCCAGTACC
DA6.3aA	CCCTCTCACTCCAATCTC	DA13.4A	TSTTTGTATATTCTAGTT
DA6.3aT	CCCTCTCTCTCCAATCTC	DA13.4G	TSTTTGTGTATTCTAGTT
DA7.0A	CTGTCTGAGCATGTCCAG	DA13.4a-	GAATCCCCTATYAGATGG
DA7.0G	CTGTCTGGGCATGTCCAG	DA13.4a+	GAATCCCCTTATYAGATG
DA7.0a-	CAGCAAAGCCCTCTTTGC	DA13.4bC	CCCYTATCAGATGGGTAG
DA7.0a+	CAGCAAAGGACCCTCTTT	DA13.4bT	CCCYTATTAGATGGGTAG
DA7.0bT	AAAGGCATTGGAGAACAA	DA13.5T	CCCAGATTRTTGTCTTGG
DA7.0bG	AAAGGCAGTGGAGAACAA	DA13.5C	CCCAGATCRTTGTCTTGG
DA7.4A	GACTCACAGCTCCACAGG	DA13.8-	TTTTCCCCAGTGTGTGTT

DA7.4C	GACTCACCGCTCCACAGG	DA13.8+	TTTTCCCCCAGTGTGTGT
DA7.5T	TAGGGAGTCCTCACTATC	DA13.8aG	TGTTTGGGTTTGTATTATG
DA7.5G	TAGGGAGGCCTCACTATC	DA13.8aA	TGTTTGGATTGTGTATTATG
DA7.5aT	TAAGGCATGTGTTACACG	DA13.8bC	GCCACTACCATTCTGTTT
DA7.5aC	TAAGGCACGTGTTACACG	DA13.8bT	GCCACTATCATTCTGTTT
		DA14.4T	TCTCTTGTCTGATTGCTC
		DA14.4C	TCTCTTGCCTGATTGCTC

ASO	Sequence (5' - 3')	ASO	Sequence (5' - 3')
DB 2.2T	TGAGATATGTTACTACTA	DB 5.9A	GAGAAAGAAAGGAAGGAA
DB 2.2C	TGAGATACGTTACTACTA	DB 5.9-	GAGAAAGAAGGAAGGAAG
DB 2.3G	AAGGGAGGTGCCTAGACT	DB 5.9aGA	AGGAAGGAAGGAAGGAAG
DB 2.3C	AAGGGAGCTGCCTAGACT	DB 5.9a-	AGGAAGGAAGGAAGGAAG
DB 2.4G	AGCTTCCGGAGACCCAGA	DB 6.0T	AGGAAGGTAGGAAGGAAG
DB 2.4A	AGCTTCCAGAGACCCAGA	DB 6.0A	AGGAAGGAAGGAAGGAAG
DB 2.5T	TTTGAAATTGGTTACATA	DB 6.6A	ACCACACATGGTTGCTGA
DB 2.5C	TTTGAAACTGGTTACATA	DB 6.6G	ACCACACGTGGTTGCTGA
DB 2.7T	TCTTACTTTTTAATCTGG	DB 7.0T	ATTCTATTGGGCAATGCA
DB 2.7C	TCTTACTCTTTAATCTGG	DB 7.0C	ATTCTATCGGGCAATGCA
DB 2.7aC	TGTGAGTCGCATTATATT	DB 7.0aC	GTCATGCCGTGAAACCCC
DB 2.7aG	TGTGAGTGGCATTATATT	DB 7.0aA	GTCATGCAGTGAAACCCC
DB 3.2T	TGGATCATGAGGTCAGGA	DB 7.1G	AAAGGGTGTGGATAAATA
DB 3.2C	TGGATCACGAGGTCAGGA	DB 7.1T	AAAGGGTTTGGATAAATA
DB 3.2aC	TGAAACCCCGTCTTTACT	DB 7.2T	CACCTTATTGATCTGCAG
DB 3.2aT	TGAAACCTCGTCTTTACT	DB 7.2C	CACCTTACTGATCTGCAG
DB 3.3C	CTAAAAACACACAAAAAA	DB 7.5T	TGAGGCCTCCCTTTCCAC
DB 3.3A	CTAAAAAAACACAAAAAA	DB 7.5A	TGAGGCCACCCTTTCCAC
DB 3.3aG	GCTGGGCGTGGTGGTGTG	DB 7.6C	CCACAGTCACCTAGTCAC
DB 3.3aA	GCTGGGCATGGTGGTGTG	DB 7.6T	CCACAGTTACCTAGTCAC
DB 3.3bA	TAATCCCAGCTACTTGGG	DB 7.8T	ATACATGTGCCATGTTGG
DB 3.3bC	TAATCCCCGCTACTTGGG	DB 7.8C	ATACATGCGCCATGTTGG
DB 3.4A	TTGAACCAGGGAGTCGGA	DB 7.9T	GTATATCTCCTAATGCTA
DB 3.4G	TTGAACCGGGAGTCGGA	DB 7.9A	GTATATCACCTAATGCTA
DB 3.4aC	CTGAGATCACACCACAGC	DB 8.1C	AGTTCTTCGTAGATTCTG
DB 3.4aA	CTGAGATAACACCACAGC	DB 8.1T	AGTTCTTTGTAGATTCTG
DB 3.7A	ATATACTATAATAGACAC	DB 9.0C	CCCAGCACCATTATTAAT
DB 3.7G	ATATACTGTAATAGACAC	DB 9.0T	CCCAGCATCATTTATTAAT
DB 3.9G	TCCTCAGGTCTCTGTACA	DB 9.2G	TCTTTTGGCTTAGGATTG
DB 3.9C	TCCTCAGCTCTCTGTACA	DB 9.2A	TCTTTTGACTTAGGATTG
DB 4.1C	GAATATGCAGGTTTTACT	DB 9.6C	TTTTGGGCTGAGACGATG
DB 4.1A	GAATATGAAGGTTTTACT	DB 9.6T	TTTTGGGTTGAGACGATG
DB 4.1a-	TTTGCCATCTGAATATAG	DB 9.8C	CAGTTTTCAAAGGGAATG
DB 4.1aG	TTTGCCATGCTGAATATA	DB 9.8-	CAGTTTTAAAGGGAATGC
DB 4.1bA	CAGACAGAAAAGTATGAC	DB 10.5A	TCTGACCATGTAGTCATC
DB 4.1bG	CAGACAGGAAAAGTATGAC	DB 10.5G	TCTGACCGTGTAGTCATC
DB 4.2A	CCTCGATACTGACCAACT	DB 10.8T	ACAAAAATTAGCAGGGTA
DB 4.2G	CCTCGATGCTGACCAACT	DB 10.8C	ACAAAAACTAGCAGGGTA

DB 4.3C	CTCTGCTCCTGCTCRGCA	DB 11.0A	CCTGTATATGAAAGAAGT
DB 4.3G	CTCTGCTGCTGCTCRGCA	DB 11.0G	CCTGTATGTGAAAGAAGT
DB 4.3aA	SCTGCTCAGCAGCAAAGT	DB 11.2G	AAATTCAGCCTGGTCAAC
DB 4.3aG	SCTGCTCGGCAGCAAAGT	DB 11.2A	AAATTC AACCTGGTCAAC
DB 4.5A	AAGCCACATTTGAGGCAT	DB 12.3T	TCTAGTCTGGACTATAAT
DB 4.5G	AAGCCACGTTTGAGGCAT	DB 12.3A	TCTAGTCAGGACTATAAT
DB 5.2G	GCTGTTGTTTTCCCTGAC	DB 13.0C	TTACAACCCCTGTTTCTT
DB 5.2A	GCTGTTATTTTCCCTGAC	DB 13.0A	TTACAACACCTGTTTCTT
DB 5.3G	TCAGTGTGGACTCTGGCT	DB 13.4C	CACAGCCCTGATCTATTG
DB 5.3A	TCAGTGTAGACTCTGGCT	DB 13.4-	CACAGCCTGATCTATTGC
DB 5.4G	AGTCACTGCAATARGTTG	DB 13.4aA	ATGAAAAAGTTAATGAAG
DB 5.4A	AGTCACTACAATARGTTG	DB 13.4a-	ATGAAAAAGTTAATGAAGT
DB 5.4aG	TRCAATAGGTTGGGCCAG	DB 13.5G	GGACATCGTGCTAATGTC
DB 5.4aA	TRCAATAAGTTGGGCCAG	DB 13.5A	GGACATCATGCTAATGTC
		DB 14.3G	TTTCTTTGGCTCTTCCTT
		DB 14.3C	TTTCTTTCGCTCTTCCTT

ASO	Sequence (5' - 3')	Allele Specific Oligo	Sequence (5' - 3')
DC2.2G	CGAGCTTTGCAGCCTGAG	DC7.5bC1	CCCTGACCCCCTCACTCC
DC2.2T	CGAGCTTTTCAGCCTGAG	DC7.5bT2	CCCTGACCTCCTCACTCC
DC3.0G	GTTACGCAGAAGTATTAT	DC7.5cC	AGTAGCCCCCGTGTCTGT
DC3.0A	GTTACGCAAAAGTATTAT	DC7.5cT	AGTAGCCTCCGTGTCTGT
DC3.7TA	CTGTTTTTAAATGCGTCA T	DC7.6C	GCATCCACGTTGCTGCA
DC3.7-	CTGTTTTAATGCGTCAT	DC7.6T	GCATCCATGTTGCTGCA
DC4.5A	TCTAATCACTCCTTTGCT	DC7.7C	TTC ACTACTGATGGCCAC
DC4.5G	TCTAATCGCTCCTTTGCT	DC7.7T	TTC ACTATTGATGGCCAC
DC5.4C	ATGACAACGTCTCTCTAG	DC8.2C	TCATACTCGATATATTTG
DC5.4T	ATGACAATGTCTCTCTAG	DC8.2T	TCATACTTGATATATTTG
DC5.6T	AAATCTCTGGCTTAAATT	DC8.7G	TTTAAGCGTCATTTAAC
DC5.6C	AAATCTCCGGCTTAAATT	DC8.7A	TTTAAGCATCATTTAAC
DC5.8T	TTCTAAGTCAAGATTCTC	DC9.1A	CATAATTCAAGGCCTGATT
DC5.8-	TTCTAAGCAAGATTCTCA	DC9.1G	CATAATTCGAGGCCTGATT
DC6.1C	ATCTCATCTCTGAGTTTT	DC9.6G	TTGGGAAGAAGAAGTCAG
DC6.1T	ATCTCATTTCTGAGTTTT	DC9.6A	TTGGGAAAAAGAAGTCAG
DC6.3T	TCGCTGCTTATGTTTTAC	DC9.9C	GACTGAGCTGCGTCCCCC
DC6.3A	TCGCTGCATATGTTTCA C	DC9.9G	GACTGAGGTGCGTCCCCC
DC6.7G	CTGAGCTGCCCAATGAGT	DC11.1C	AGGAAAGCGCTTACCATC
DC6.7A	CTGAGCTACCCAATGAGT	DC11.1T	AGGAAAGTGCTTACCATC
DC6.7aG	GTGTTTCCGGCTTCCTCTT G	DC11.2G	AGAAGTCGCCATACAAT
DC6.7aA	GTGTTTCCAGCTTCCTCTT G	DC11.2A	AGAAGTCACCATACAAT

DC6.8A	GTTTGTCCACATCTACTT	DC12.1G	GACTTTGGTGCCTTTTTG
DC6.8G	GTTTGTCCGCATCTACTT	DC12.1C	GACTTTGCTGCCTTTTTG
DC6.8aT	CTACTTATATTTTGGGGT C	DC13.0A	TGGAATCAGTCTAGAAKC
DC6.8aC	CTACTTACATTTTGGGGT C	DC13.0G	TGGAATCGGTCTAGAAKC
DC7.1T	CTTTCTGATGTTTCATT	DC13.3C	CAGAACACGAGGACAAAC
DC7.1C	CTTTCTGACGTTTCATT	DC13.3T	CAGAACATGAGGACAAAC
DC7.2C	GAAAAGTCACAAGAAAT G	DC13.4T	GCGTTTATGTCTCCATGT
DC7.2T	GAAAAGTTACAAGAAAT G	DC13.4C	GCGTTTACGTCTCCATGT
DC7.4G	GCGTGCTGCCCAACAAC G	DC13.9A	TCAGATGATTTYGAGAAG
DC7.4A	GCGTGCTACCCAACAAC G	DC13.9G	TCAGATGGTTTYGAGAAG
DC7.5C	GTTTTTCCCTCCCTGAC	DC13.9aC	ATGRTTTTGAGAAGCTGTG
DC7.5A	GTTTTTCCCTCCCTGAC	DC13.9aT	ATGRTTTTGAGAAGCTGTG
DC7.5a-	TCCCTGACYCCTCACTCC	DC14.4A	ACAAAACACTGGTCGCTT
DC7.5aC	TCCCTGACCYCCTCACTC	DC14.4G	ACAAAACGCTGGTCGCTT
DC7.5bC	CCCTGACCCCTCACTCCC		
DC7.5bT	CCCTGACTCCTCACTCCC		

ASO	Sequence (5' - 3')	ASO	Sequence (5' - 3')
DD 2.2T	GTGCCATTTTTTCAGGATG	DD 8.5aG	CCACTGGGCTCTTTCTGC
DD 2.2C	GTGCCATCTTTTCAGGATG	DD 8.5aA	CCACTGGACTCTTTCTGC
DD 2.3G	CAAAGGGGTACATAAAAT	DD 8.5bA	CAGGCAGACTGCACTTAG
DD 2.3A	CAAAGGGGATACATAAAAT	DD 8.5bG	CAGGCAGGCTGCACTTAG
DD 2.7G	TGTTTTGGTTCACCGGCC	DD 8.6C	CATGGGGTCTGGCCACTG
DD 2.7A	TGTTTTGATTCACCGGCC	DD 8.6G	CATGGGGTGTGGCCACTG
DD 4.0T	GCAGCTATATTGGAGTCG	DD 8.9C	GTCATCCGCAACATGGTG
DD 4.0C	GCAGCTACATTGGAGTCG	DD 8.9T	GTCATCTGCAACATGGTG
DD 5.7T	TGTTTAATTAAAGGCACA	DD 9.2C	CAGCTCTCAGCAGAGGG
DD 5.7A	TGTTTAATAAAGGCACA	DD 9.2G	CAGCTCTGAGCAGAGGG
DD 5.7aG	CAATAATGGTGCCTTTAA	DD 10.9G	CCTTTATAGATAGATGCC
DD 5.7aA	CAATAATAGTGCCTTTAA	DD 10.9C	CCTTTATACATAGATGCC
DD 6.6A	ACTTGTAATCATTTATTTG	DD 11.0G	GAAACTGCCTGGATTTTC
DD 6.6G	ACTTGTAGTCATTTATTTG	DD 11.0A	GAAACTACCTGGATTTTC
DD 7.2-	CACACTGCTATATACTTT	DD 11.5G	GTAAAGCGCTTCTCCACTG
DD 7.2G	CACACTGGCTATATACTT	DD 11.5A	GTAAAGCACTTCTCCACTG
DD 7.3C	CTTTTTATTTCGCTCKGA	DD 11.9A	GAATAAAAATCTCCTGTCAC

DD 7.3A	CTTTTATTAGCTCKGA	DD 11.9G	GAATAAAAGTCTCCTGTCAC
DD 7.5G	AAGGGAGGTGCAGAAAGG	DD 12.0C	CATGTATTCTCTGACTTC
DD 7.5A	AAGGGAGATGCAGAAAGG	DD 12.0T	CATGTATTTTCTGACTTC
DD 7.5aC	CAAGTCTCCGCATGACCCA	DD 12.1G	GAATGAGGTTTTCTTAAATC
DD 7.5aT	CAAGTCTCTGCATGACCCA	DD 12.1A	GAATGAAGTTTTCTTAAATC
DD 7.6C	GCTGGTCGTATCTTTATTG	DD 12.4A	GGTATGCATGTCATCTTAC
DD 7.6T	GCTGGTTGTATCTTTATTG	DD 12.4G	GGTATGCGTGTCATCTTAC
DD 7.8A	AACACCAATGCCTTTTGTG	DD 12.6A	CTTTTAAGAACATTACACAG
DD 7.8G	AACACCAGTGCCTTTTGTG	DD 12.6G	CTTTTAAGAGCATTACACAG
DD 8.4G	GGGTGTTGGTTTCTGGCC	DD 13.6G	CTGGGTTGATTCCATGTA
DD 8.4T	GGGTGTTTGTTCCTGGCC	DD 13.6A	CTGGGTTAATTCCATGTA
DD 8.5A	GCTGGGACCCACTGGRC	DD 13.6aG	CATATGTGTGCATGTGTC
DD 8.5G	GCTGGGGCCCACTGGRC	DD 13.6aA	CATATGTATGCATGTGTC

APPENDIX IV RE-SEQUENCING RESULTS

The reference sequence of Hotspot DA is represented as a “Refseq”.

Donor 6

5' → 3' sequence for 1st haplotype

DONOR 6	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq 7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 6	CTAGGGAGGCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCATGTGTTACACG	120
Refseq 7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 6	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq 7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 6	AGACTTATTCCTGTGTCATAAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq 7613	AGACTTATTCCTGTGTCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR 6	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq 7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 6	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGACAATAGTAAGAACACAT	360
Refseq 7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGACAATAGTAAGAACACAT	7792
DONOR 6	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq 7793	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 6	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq 7853	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 6	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq 7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 6	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq 7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 6	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq 8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 6	TAAACAGTAGATTTCATTAAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq 8093	TAAACAGTAGATTTCATTAAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 6	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGGGA	780
Refseq 8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGG-A	8210
DONOR 6	GGAATAAAGGGGAAGCCAATAATGAATGTATGTAGTGGATTGGGGGAAGAGGATATGGGA	840
Refseq 8211	GGAATAAAGGGGAAGCCARTAATGAATGTATGWRGTGGATTGGGGGAAGAGGATATGGGA	8270
DONOR 6	GTTTATTCCATTCTATTCTATCTGNTACNNNNCTGGNNGGTGNAAGCACCTCCA-TTCGA	899
Refseq 8271	GTTTATTCCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATTTCGA	8330
DONOR 6	TTAGGGATATCTGANAACAANN-TCCCTTGANCCTCCCTGTCCTAAGTAACTCC-TAGGA	957
Refseq 8331	TTAGGGATATCTGAGAACAAAGATCCCTTGAGCCTCCCTGTCCTAAGTAGCTCCCTAGGA	8390

DONOR 6 958 AAGAGANTAC 967
 ||||| |||
 Refseq 8391 AAGAGACTAC 8400

5' → 3' sequence for 2nd haplotype

DONOR 6	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq 7433			7492
DONOR 6	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq 7493			7552
DONOR 6	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq 7553			7612
DONOR 6	181	AGACTTATTCACGTGTATCAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq 7613			7672
DONOR 6	241	TCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq 7673			7732
DONOR 6	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGTAGGAGACAATAGTAAGAACACAT	360
Refseq 7733			7792
DONOR 6	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq 7793			7852
DONOR 6	421	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq 7853			7912
DONOR 6	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq 7913			7972
DONOR 6	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq 7973			8032
DONOR 6	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq 8033			8092
DONOR 6	661	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq 8093			8152
DONOR 6	721	AGAAAAAGATTCCCTGAATCtggggagaggggatggtggtggtggtganggnnggggna	780
Refseq 8153			8210
DONOR 6	781	ggaataaagggaagCCAGTAATGAATGTATGAGGTGGATTTGGGGAAGAGGATATGGGA	840
Refseq 8211			8270
DONOR 6	841	GTTTATTCNNTTCTNTTCTATCTGTACTAACCTGGGANGNGAAAGNACCTCCNATTCGA	900
Refseq 8271			8330
DONOR 6	901	TTAGGGNATATCTGANAACNA-GANCCCTTGNGNCTNCCTGTCCTA	945
Refseq 8331			8375

3' → 5' sequence for 1st haplotype

DONOR 6	1	CTGTGGGAGGT-NNTGAATCATGGGGGCAGGTTTTTACATGCTGTTCTTATGACAGTGA	59
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTACATGCTGTTCTKATGACAGTGA	7621
DONOR 6	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCGCCGTCACACACCCCTCTTG	119
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCGCCGTCACACACCCCTCTTG	7561
DONOR 6	120	CCTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 6	180	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAACCTCTTTTTCTTTATAAATTACCCAG	239
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAACCTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 6	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAATGCCTTCT	299
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAATGCCTTCT	7381
DONOR 6	300	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCCTGTTGCTGC	359
Refseq	7380	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCCTGTTGCTGC	7321
DONOR 6	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 6	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAATCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAATCATTGTTTAACTTTGTTGGCTA	7201
DONOR 6	480	TGAGCCTATAGAGCTGGAGCAAGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	539
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR 6	540	ATGCCTTTAGACTtttttttGCTCCAAGCAGCAGCTCCGTGCTCTTTTGTCTCATCTT	599
Refseq	7140	MTGCCTTTAGACTTTTTTTTGCTCCAAGCAGCAGCTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR 6	600	GCAGGCTCCTGGGTCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGA	659
Refseq	7080	GCAGGCTCCTGGGTCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR 6	660	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	719
Refseq	7020	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR 6	720	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	779
Refseq	6960	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR 6	780	ACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTATTC	839
Refseq	6900	ACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR 6	840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANANACTNANNAGGGTACA	899
Refseq	6840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR 6	900	TGGGANGACAGTCCATGCCCTANAGAAATTGANGAANATAGCTTCTTCCTCATTTGGG	959
Refseq	6780	TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTTGGG	6721
DONOR 6	960	AGTACAGTNN-TTTTATACCATAATCNTCCNNTNNCTTCTCA 1001	
Refseq	6720	AGTACAGTGGCTTTTATACCATAATCTTCCATTCTCTTCTCA 6678	

3' → 5' sequence for 2nd haplotype

DONOR	6	1	CTGTGGGANGNAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGA	60
Sbjct	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	6	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAAGTGCAGTTCGCCGTCACACACCCCTCTTG	120
Sbjct	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAAGTGCAGTTCGCCGTCACACACCCCTCTTG	7561
DONOR	6	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	180
Sbjct	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	6	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	240
Sbjct	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR	6	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Sbjct	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	6	301	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCCTGTTGCTGC	360
Sbjct	7380		AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCCTGTTGCTGC	7321
DONOR	6	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Sbjct	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	6	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAAGTCTTAACTTTGTTGGCTA	480
Sbjct	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAAGTCTTAACTTTGTTGGCTA	7201
DONOR	6	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Sbjct	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	6	541	ATGCCCTTAGACTtttttttGCTCCAAGCAGCAGCTCCGTGCTCTTTTGTCTCATCTT	600
Sbjct	7140		MTGCCCTTAGACTTTTTTTTGCTCCAAGCAGCAGCTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	6	601	GCAGGCTCCTGGGTCCACAGGCAAGAGGGTCCTTTGCTGGGCCCTCTGGACATGCCCA	660
Sbjct	7080		GCAGGCTCCTGGGTCCACAGGCAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR	6	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	720
Sbjct	7022		GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR	6	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	780
Sbjct	6962		ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	6903
DONOR	6	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Sbjct	6902		GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR	6	841	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTNNN-AGGGTA	899
Sbjct	6842		TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR	6	900	CATGGGAGGANAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTG	959
Sbjct	6782		CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTG	6723
DONOR	6	960	GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCT	999
Sbjct	6722		GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCT	6683

Donor 7

5' → 3' sequence for 1st haplotype

DONOR 7	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Sbjct	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 7	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Sbjct	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 7	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATG	180
Sbjct	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 7	181	AGACTTATTCCTGTCATAAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Sbjct	7613	AGACTTATTCCTGTCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR 7	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Sbjct	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 7	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGACAATAGTAAGAACACAT	360
Sbjct	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGACAATAGTAAGAACACAT	7792
DONOR 7	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Sbjct	7793	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 7	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Sbjct	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 7	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Sbjct	7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 7	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Sbjct	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 7	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Sbjct	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 7	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Sbjct	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 7	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGGAG	780
Sbjct	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGG-AG	8211
DONOR 7	781	GAATAAAGGGGAAGCCAGTAATGAATGTATGANGTGGATTTGGGGAAGANGATATGGGAG	840
Sbjct	8212	GAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTTGGGGAAGAGGATATGGGAG	8271
DONOR 7	841	TTTATTCATTCTATTCTATCTGTTnnnnnnnnCTGGGAGGTGAAANCACCTCCNATTTTCG	900
Sbjct	8272	TTTATTCATTCTATTCTATCTGTTACTAAC-CTGGGAGGTGAAAGCACCTCCAATT-CG	8329
DONOR 7	901	ATTANGGANNCTGAGANCAAAGATCCCTTGAGCCTCCCTGTCC	944
Sbjct	8330	ATTAGGATATCTGAGAACAAAGATCCCTTGAGCCTCCCTGTCC	8373

5' → 3' sequence for 2nd haplotype

DONOR 7	1	ACCTGAGANTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 7	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 7	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACTTTATAAAACCATCAGATCTCATG	7612
DONOR 7	181	AGACTTATTCCTGTGTCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCCTGTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCAATTACC	7672
DONOR 7	241	TCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAACTCAGGATGAGAT	300
Refseq	7673	TCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAACTCAGGATGAGAT	7732
DONOR 7	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGACAATAGTAAGAACACAT	7792
DONOR 7	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 7	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 7	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 7	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 7	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 7	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 7	721	AGAAAAAGATTCCCTGAATCtgggggagaaggggatgggtgggtgggtgatgggtggggga	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGG-TGGGG-A	8210
DONOR 7	781	ngaataaaggggaagCCAGTAATGAATGTATGAGGTGNATTTGGGGAAGAGGATATGGGA	840
Refseq	8211	GGAATAAAGGGGAAGCCARTAATGAATGTATGWRGTGGATTGGGGAAGAGGATATGGGA	8270
DONOR 7	841	GTTTATTCNNTTCTATTCTATCTGTTACTAACCTGGGGANGTGAAAGCACCTCCAATTCGA	900
Refseq	8271	GTTTATTCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATTCGA	8330
DONOR 7	901	TNANGGATNTCTGANAAACANANATCCCNTGANCCCTCCCTGTNCTA	945
Refseq	8331	TTAGGGATATCTGAGAACAAAGATCCCTTGAGCCTCCCTGTCCTA	8375

3' → 5' sequence for 1st haplotype

DONOR 7	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTACATGCTGTTCTTATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTACATGCTGTTCTKATGACAGTGA	7621
DONOR 7	6	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTCCGCGCCACACCCCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTCCGCGCCACACCCCTCTTG	7561
DONOR 7	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGC	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 7	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 7	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 7	301	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAAGCTGCCTATTACATTTCCTGTTGCTGC	360
Refseq	7380	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAAGCTGCCTATTACATTTCCTGTTGCTGC	7321
DONOR 7	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 7	421	CCAGGGATTTTAGAGAAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 7	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR 7	541	CTGCCCTTAGACtttttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	600
Refseq	7140	MTGCCCTTAGAC-TTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	7082
DONOR 7	601	TGCAGGCTCCTGGGTCCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAG	660
Refseq	7081	TGCAGGCTCCTGGGTCCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAG	7022
DONOR 7	661	ACAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCA	720
Refseq	7021	ACAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCA	6962
DONOR 7	721	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	780
Refseq	6961	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6902
DONOR 7	781	CACTCATACCTATAGGTAGTAGAGGCTCAAAAAGCCAAGACTGAAAAAATTTTCTCTATT	840
Refseq	6901	CACTCATACCTATAGGTAGTAGAGGCTCAAAAAGCCAAGACTGAAAAAATTTTCTCTATT	6842
DONOR 7	841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTNNN-AGGGTAC	899
Refseq	6841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTAC	6782
DONOR 7	900	ATGGNANGACAGTCCATGCCCTANAGAAATTGANGAAGANAGCTTCTTCCTCATTGTTGG	959
Refseq	6781	ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGG	6722
DONOR 7	960	GANTACAGTGNNTTT-ATACCATAN-CTTCC-ATTCT	993
Refseq	6721	GAGTACAGTGGCTTTTATACCATAATCTTCCATTCT	6685

3' → 5' sequence for 2nd haplotype

DONOR 7	1	CTGTGGGAGGTAATTGAATCATGGGGGAGGTTTTTCACATGCTGTTCTTATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 7	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTG	7561
DONOR 7	121	CCTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 7	181	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 7	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 7	301	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAAGCTGCCTATTACATTTCTGTGTGC	360
Refseq	7380	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAAGCTGCCTATTACATTTCTGTGTGC	7321
DONOR 7	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 7	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTTGTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTTGTTAACTTTGTTGGCTA	7201
DONOR 7	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR 7	541	CTGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140	MTGCCTTTAGACTTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR 7	601	GCAGGCTCCTGGGTCCCACAGGCAAAGAGGGTCCTTTGCTGGGCCCTCTGGACATGTCA	660
Refseq	7080	GCAGGCTCCTGGGTCCCACAGGCAAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR 7	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTC	720
Refseq	7022	GACAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR 7	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	780
Refseq	6962	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	6903
DONOR 7	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR 7	841	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAANGAGGGTA	900
Refseq	6842	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR 7	901	CATGGGAGNACAGTCCATGCCCTANAGAAATTGAGGAANANAGCTTCTTCCTCATTGTTG	960
Refseq	6782	CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTG	6723
DONOR 7	961	GGAGTACAGNNGNTTTTATACCATNATCTTCCCATTCTCTTC	1002
Refseq	6722	GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTC	6681

Donor 12

5' → 3' sequence for 1st haplotype

DONOR 12	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACAGCTCCACAGGG	7492
DONOR 12	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACG	7552
DONOR 12	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAC TGCAC TTTATAAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAC TGCAC TTTATAAAAACCATCAGATCTCATG	7612
DONOR 12	181	AGACTTATTCACTGTGCATAAGAACAGCATGTGAAAAACCTGCCCCCATCATTC AATTACC	240
Refseq	7613	AGACTTATTCACTGTGCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	7672
DONOR 12	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAAC T CAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAAC T CAGGATGAGAT	7732
DONOR 12	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAAACAATAGTAAGAACACAT	7792
DONOR 12	361	TTTAGAATTCCTCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCTCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 12	421	TTGAAATTGCTAGTTGCAACAAAAC CAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAAC CAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 12	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	7972
DONOR 12	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 12	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 12	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 12	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGANNNGGGGGA	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGGT-GGGG-A	8210
DONOR 12	781	GGAATAAAGGGGAAGCCAATAATGAATGTATGTAG-TGGANTTGGGGAAGAGGATATGGG	839
Refseq	8211	GGAATAAAGGGGAAGCCAGTAATGAATGTATG-AGGTGGATTGGGGAAGAGGATATGGG	8269
DONOR 12	840	AGTTTATNCCATTCTATTCTATCTGTT	866
Refseq	8270	AGTTTATTCATTCTATTCTATCTGTT	8296

5' → 3' sequence for 2nd haplotype

DONOR 12	1	CCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACAGCTCCACAGGGC	60
Refseq	7434	CCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACMGCTCCACAGGGC	7493
DONOR 12	61	TAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACGG	120
Refseq	7494	TAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACGG	7553
DONOR 12	121	TGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACTTTATAAAACCATCAGATCTCATGA	180
Refseq	7554	TGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACTTTATAAAACCATCAGATCTCATGA	7613
DONOR 12	181	GACTTATTCACCTGTCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCT	240
Refseq	7614	GACTTATTCACCTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCT	7673
DONOR 12	241	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATT	300
Refseq	7674	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATT	7733
DONOR 12	301	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACATT	360
Refseq	7734	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACATT	7793
DONOR 12	361	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	420
Refseq	7794	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	7853
DONOR 12	421	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	480
Refseq	7854	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	7913
DONOR 12	481	TTAACAGGAATCATAATTTTCCTATTATTTCTATTACCCTGTAATCCCATGACCCATTT	540
Refseq	7914	TTAACAGGAATCATAATTTTCCTATTATTTCTATTACCCTGTAATCCCATGACCCATTT	7973
DONOR 12	541	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	600
Refseq	7974	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	8033
DONOR 12	601	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	660
Refseq	8034	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	8093
DONOR 12	661	AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	720
Refseq	8094	AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	8153
DONOR 12	721	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGANNNGNNGGGGAG	780
Refseq	8154	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGGT-GGGG-AG	8211
DONOR 12	781	GAATAAAGGGGAANGCCAGTAATGAATGTATGANGTGGATTGGGGGAAGAGGATATGGGA	840
Refseq	8212	GAATAAAGGGGAA-GCCARTAATGAATGTATGWRGTGGATTGGGGGAAGAGGATATGGGA	8270
DONOR 12	841	GTTTATTCCATTCCNATTCTATCNGNTACTAACCNGGGAGG	881
Refseq	8271	GTTTATTCCATTCT-ATTCTATCTGTACTAACCTGGGAGG	8310

3' → 5' sequence for 1st haplotype

DONOR 12	1	TGTGGGAGGTAATTGAATGATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGAA	60
Refseq	7679	TGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGAA	7620
DONOR 12	61	TAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTGC	120
Refseq	7619	TAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTGC	7560
DONOR 12	121	CTGCCACCGTGTAACACGTGCCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGCC	180
Refseq	7559	CTGCCACCGTGTAACACATGCCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGAC	7500
DONOR 12	181	TCCCTAGCCCTGTGGAGCTGTGAGTCCATTAACCTCTTTTTCTTTTATAAATTACCCAGT	240
Refseq	7499	TCCCTAGCCCTGTGGAGCTGTGAGTCCATTAACCTCTTTTTCTTTTATAAATTACCCAGT	7440
DONOR 12	241	CTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAAGTGCCTTCTA	300
Refseq	7439	CTCAGGTATTTCTTCATAGCAGTATGAAAAATGGACTAATACACCTACTAAGTGCCTTCTA	7380
DONOR 12	301	AACCCATAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCTGTTGCTGCT	360
Refseq	7379	AACCCATAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCCTGTTGCTGCT	7320
DONOR 12	361	CAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCC	420
Refseq	7319	CAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCC	7260
DONOR 12	421	CAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTAT	480
Refseq	7259	CAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTAT	7200
DONOR 12	481	GAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCAC	540
Refseq	7199	GAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCAA	7140
DONOR 12	541	TGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTG	600
Refseq	7139	TGCCTTTAGACTTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTG	7080
DONOR 12	601	CAGGCTCCTGGGTCCACAGGCAAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGAC	660
Refseq	7079	CAGGCTCCTGGGTCCACAGGCAAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGAC	7020
DONOR 12	661	AGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCACA	720
Refseq	7019	AGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCACA	6960
DONOR 12	721	CTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGCGCA	780
Refseq	6959	CTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGCGCA	6900
DONOR 12	781	CTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTCA	840
Refseq	6899	CTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTCA	6840
DONOR 12	841	TAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAAGTCTGAGAGTANN-AGGGTACAT	899
Refseq	6839	TAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAAGTCTGAGAGTAAAGGAGGTACAT	6780
DONOR 12	900	GGGAGGACAGTCCATGCCCTANAGAAATTGANGAANATAGCTTCTTCTCATTGTTGGGA	959
Refseq	6779	GGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTGTTGGGA	6720
DONOR 12	960	GTACAGTGGNTTTTATACCATAATCTTCCATTCTCTTCTCnnanaanCC-TTNGCAAG	1018
Refseq	6719	GTACAGTGGCTTTTATACCATAATCTTCCATTCTCTTCTCAGATAAACCTTTGGCAAG	6660
DONOR 12	1019	TATNANTTTTAANTANTTCNTTGAAAN-TGCTGA	1051
Refseq	6659	TATAATTTTAAATATTTCTTTGAAAAGTCTGA	6626

3' → 5' sequence for 2nd haplotype

DONOR 12	1	CTGTGGGAGGT-NNTGAATCATGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	59
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 12	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	119
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	7561
DONOR 12	120	CCTGCCACCCTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560	CCTGCCACCCTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 12	180	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	239
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 12	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 12	300	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	359
Refseq	7380	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 12	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 12	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 12	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	539
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 12	540	CTGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	599
Refseq	7140	MTGCCTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	7081
DONOR 12	600	GCAGGCTCCTGGGTCCCACAGGCAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCTCA	659
Refseq	7080	GCAGGCTCCTGGGTCCCACAGGCAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR 12	660	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	719
Refseq	7022	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR 12	720	ACACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTG	779
Refseq	6962	ACACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTG	6903
DONOR 12	780	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	839
Refseq	6902	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR 12	840	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTNANNAGGGTA	899
Refseq	6842	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR 12	900	CATGGGAGGACAGTCCATGCCCTANAGAAATTGAGGnaanaanaGCTTCTTCTCATTTGNTG	959
Refseq	6782	CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTTGTTG	6723
DONOR 12	960	GGAGTACAGTNNNTT-ATACCATAATCTTCCCATTTCTTCTC 1002	
Refseq	6722	GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTTCTTCTC 6679	

Donor 44

5' → 3' sequence for 1st haplotype

DONOR 44	1	ACCTGAGACTGGGTAATTTATAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 44	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 44	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 44	181	AGACTTATTCACTGTCATCAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACC	7672
DONOR 44	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	7732
DONOR 44	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAAATAGTAAGAACACAT	7792
DONOR 44	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 44	421	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 44	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 44	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 44	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 44	661	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 44	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGTGGGGA	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGTGGGGA	8210
DONOR 44	781	GGAAT	785
Refseq	8211	GGAAT	8215

5' → 3' sequence for 2nd haplotype

DONOR 44	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 44	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 44	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 44	181	AGACTTATTCACTGTGCTATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTGCTATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACC	7672
DONOR 44	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAGTCAAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAGTCAAGGATGAGAT	7732
DONOR 44	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 44	361	TTTAGAATTTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 44	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 44	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	7972
DONOR 44	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 44	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 44	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 44	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGAG	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGAG	8211
DONOR 44	781	GAATAAAGGGGAAGCCA	797
Refseq	8212	GAATAAAGGGGAAGCCA	8228

3' → 5' sequence for 1st haplotype

DONOR 44	1	CTGTGGGAGGNAATTGAATCATGGGGGAGGTTTTTCACATGCTGTTCTGATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 44	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	7561
DONOR 44	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 44	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 44	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 44	301	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTGCTGC	360
Refseq	7380	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTGCTGC	7321
DONOR 44	361	TCAAACCCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 44	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 44	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 44	541	ATGCCTTTAGACTtttttttGCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140	MTGCCTTTAGACTTTTTTTGCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR 44	601	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGTCTTTGCTGGTCCCCTCTGGACATGCTCA	660
Refseq	7080	GCAGGCTCCTGGGTCCACAGGCAAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR 44	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	720
Refseq	7022	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR 44	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	780
Refseq	6962	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTG	6903
DONOR 44	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR 44	841	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANANACTNANNAGGGTA	900
Refseq	6842	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR 44	901	CATGGGAGNACAGTCCATGCCCTANAGAAATTGAGGAAGANAGCTTCTTCTCCTATTGTTG	960
Refseq	6782	CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCCTATTGTTG	6723
DONOR 44	961	GGAGTACAGTGN-TTTTATACCATAATCTTCCCATTCNNCTNNTCNNANAA-CCCTTGG	1018
Refseq	6722	GGAGTACAGTGGCTTTTATACCATAATCTTCCCATCTCT-CTTCTCAGATAAACCCCTTGG	6664
DONOR 44	1019	CAAGNATANTTTT-AANNATTTCTTTGAAAAC TG	1051
Refseq	6663	CAAGTATAATTTTAAATATTTCTTTGAAAAC TG	6630

3' → 5' sequence for 2nd haplotype

DONOR 44	1	CTGTGGGANGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 44	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	7561
DONOR 44	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 44	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 44	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 44	301	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	360
Refseq	7380	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 44	361	TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 44	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATGTGTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATGTGTTAACTTTGTTGGCTA	7201
DONOR 44	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 44	541	CTGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140	MTGCCTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR 44	601	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCTCA	660
Refseq	7080	GCAGGCTCCTGGGTCCACAGGCAAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR 44	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	720
Refseq	7022	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR 44	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	780
Refseq	6962	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6903
DONOR 44	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR 44	841	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGANACTAANNAGGGTA	900
Refseq	6842	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR 44	901	CATGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAANATAGCTTCTTCCTCATGNGG	960
Refseq	6782	CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATGTTG	6723
DONOR 44	961	GGAGTACAGNGGNTTTTATACCATAN-CTTCCCATCTCTTCT	1002
Refseq	6722	GGAGTACAGTGGCTTTTATACCATAACTTCCCATCTCTTCT	6680

Donor 67

5' → 3' sequence for 1st haplotype

DONOR 67	1	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGGC	60
Refseq	7434	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGGC	7493
DONOR 67	61	TAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACGG	120
Refseq	7494	TAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACGG	7553
DONOR 67	121	TGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATGA	180
Refseq	7554	TGGCAGGCAAGAGGGTGTGGGCAGGGGAACGCACCTTTATAAAACCATCAGATCTCATGA	7613
DONOR 67	181	GACTTATTCCTGTCATCAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCT	240
Refseq	7614	GACTTATTCCTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCT	7673
DONOR 67	241	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAACTCAGGATGAGATT	300
Refseq	7674	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAACTCAGGATGAGATT	7733
DONOR 67	301	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGACAATAGTAAGAACACATT	360
Refseq	7734	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGACAATAGTAAGAACACATT	7793
DONOR 67	361	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	420
Refseq	7794	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	7853
DONOR 67	421	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	480
Refseq	7854	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	7913
DONOR 67	481	TTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7914	TTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7973
DONOR 67	541	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	600
Refseq	7974	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	8033
DONOR 67	601	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	660
Refseq	8034	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	8093
DONOR 67	661	AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	720
Refseq	8094	AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	8153
DONOR 67	721	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGNNGGGGAG	780
Refseq	8154	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGG--GGGGAG	8211
DONOR 67	781	GAATAAAGGGGAAGCCAATAATGAATGNNNGTAGTGGATTGGGGGAAGAGGATATGGGA	840
Refseq	8212	GAATAAAGGGGAAGCCARTAATGAATGTATGWRGTGGATTGGGG--AAGAGGATATGGGA	8270
DONOR 67	841	GTTTATTCCATTNCNATTCNATCTGTTACTNACCTGGGAGGTGA	884
Refseq	8271	GTTTATTCCATT-CTATTCTATCTGTTACTAACCTGGGAGGTGA	8313

5' → 3' sequence for 2nd haplotype

DONOR 67	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 67	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACATG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 67	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 67	181	AGACTTATTCACTGTCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCAATTACC	7672
DONOR 67	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	7732
DONOR 67	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAAATAGTAAGAACACAT	7792
DONOR 67	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 67	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 67	481	ATTAACAGGAATCATAATTTTCCTATTATTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 67	541	TTTGTTCAGCCAGCCAGCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTCAGCCAGCCAGCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 67	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 67	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 67	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGAG	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGGAG	8211
DONOR 67	781	GAATAAAGGGGAAGCCAGTAATGAATGTATGAGGTGGATTGGGGAGAGGATATGGGAG	840
Refseq	8212	GAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAGAGGATATGGGAG	8271
DONOR 67	841	TTTATTCATTTCNATTCNATCNGNTACTAACNNGGAGGTGAAAGCACTTCAAATT	896
Refseq	8272	TTTATTCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATT	8327

3' → 5' sequence for 1st haplotype

DONOR 67	1	CTGTGGGAGGNAATTGAATCATGGGGGAGGTTTTTCACATGCTGTTCTGATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 67	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTG	7561
DONOR 67	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 67	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 67	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 67	301	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	360
Refseq	7380	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 67	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 67	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 67	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 67	541	ATGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140	MTGCCTTTAGACTTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR 67	601	GCAGGCTCCTGGGTCCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGA	660
Refseq	7080	GCAGGCTCCTGGGTCCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR 67	661	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	720
Refseq	7020	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR 67	721	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	780
Refseq	6960	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR 67	781	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	840
Refseq	6900	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR 67	841	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCANAGACTAANNAGGGTACA	900
Refseq	6840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTACA	6781
DONOR 67	901	TGGGANGACAGTCCATGCCCTANAGAAATTGAGGAANANAGCTTCTCCTCATTGTTGGG	960
Refseq	6780	TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTCCTCATTGTTGGG	6721
DONOR 67	961	AGTACAGNGGNTTTTATACATAATCNTCCCATTTCTTCTCANNATAANCCCTTTGGNA	1020
Refseq	6720	AGTACAGTGGCTTTT-ATACATAATCTTCCCATTTCTTCTCAGATAAACCCCTTTGGCA	6662
DONOR 67	1021	AGTA 1024	
Refseq	6661	AGTA 6658	

3' → 5' sequence for 2nd haplotype

DONOR 67	1	CTGTGGGAGG-NNNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	59
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 67	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	119
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	7561
DONOR 67	120	CCTGCCACCATGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560	CCTGCCACCATGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 67	180	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	239
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 67	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 67	300	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTGCTGC	359
Refseq	7380	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTGCTGC	7321
DONOR 67	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 67	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 67	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	539
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 67	540	CTGCCTTTAGACttttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	599
Refseq	7140	MTGCCTTTAGAC-TTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	7082
DONOR 67	600	TGCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAG	659
Refseq	7081	TGCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAG	7022
DONOR 67	660	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	719
Refseq	7021	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	6962
DONOR 67	720	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGG	779
Refseq	6961	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGG	6902
DONOR 67	780	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	839
Refseq	6901	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	6842
DONOR 67	840	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTNNGGAGGGTAC	899
Refseq	6841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTAC	6782
DONOR 67	900	ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGANAGCTTCTTCTCATTGTTGG	959
Refseq	6781	ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTGTTGG	6722
DONOR 67	960	GNAGTACANNNN-TTTTATACCATNATCTTCCCATTCNCTTCTCAGANAAACCCCTTTGGN	1018
Refseq	6721	G-AGTACAGTGGCTTTTATACCATAATCTTCCCATCTCTTCTCAGATAAACCCCTTTGGC	6663
DONOR 67	1019	AAGTATANTTT--AANTATTTTNTTGAAG-CTGCTGAACCTGAC	1059
Refseq	6662	AAGTATAATTTTAAATATTTCTTTTGAAGACTGCTGAACCTGAC	6619

Donor 73

5' → 3' sequence for 1st haplotype

DONOR 73	1	ACCTGAGANTGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 73	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTACACG	7552
DONOR 73	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 73	181	AGACTTATTCACTGTTCATCAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTTCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR 73	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 73	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 73	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 73	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 73	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 73	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 73	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 73	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 73	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGANGNNNNGGGA	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGGTG-G-GGA	8210
DONOR 73	781	GGAATAAAGGGGAAGCCAGTAATGAATGTATGAGGTGGATTGGGGGAAGAGGATATGGG	840
Refseq	8211	GGAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGG-AAGAGGATATGGG	8269
DONOR 73	841	AGTTTATTCCATTCTATTCTATCTGTTACNAACNTGGGAGGTGA	885
Refseq	8270	AGTTTATTCCATTCTATTCTATCTGTTACTAACC-TGGGAGGTGA	8313

5' → 3' sequence for 2nd haplotype

DONOR	73	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433		ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR	73	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493		CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR	73	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553		GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR	73	181	AGACTTATTCACTGTCTATAAGAACAGCATGTGAAAAACCTGCCCCATCATTCAATTACC	240
Refseq	7613		AGACTTATTCACTGTCTATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR	73	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	300
Refseq	7673		TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	7732
DONOR	73	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733		TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR	73	361	TTTAGAATTTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793		TTTAGAATTTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR	73	421	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853		TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR	73	481	AATAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913		ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR	73	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973		TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR	73	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033		TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR	73	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093		TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR	73	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGANNNNNGGGGA	780
Refseq	8153		AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGGT-GGGG-A	8210
DONOR	73	781	GGAATAAAGGGGAAGCCAGTAATGAATGTATGAGGTGGATTGGGGGAAGAGGATATGGGA	840
Refseq	8211		GGAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGGAAGAGGATATGGGA	8270
DONOR	73	841	GTTTATTCCATTCTATTCTATCTGTACTAACCTGGGNGGTGAAAGCACCTCCAATTCNA	900
Refseq	8271		GTTTATTCCATTCTATTCTATCTGTACTAACCTGGGAGGTGAAAGCACCTCCAATTCGA	8330
DONOR	73	901	TTANGGATATCTGANAACAAAGATCCCTTGANCCNTCCNTGTCCTANGTAGCTCCCTA	958
Refseq	8331		TTAGGGATATCTGAGAACAAAGATCCCTTGAGCC-TCCCTGTCCTAAGTAGCTCCCTA	8387

3' → 5' sequence for 1st haplotype

DONOR 73	1	CTGTGGGAGG-NNNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGA	59
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 73	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	119
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	7561
DONOR 73	120	CCTGCCACCCTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGA	179
Refseq	7560	CCTGCCACCCTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 73	180	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	239
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAG	7441
DONOR 73	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 73	300	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	359
Refseq	7380	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 73	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 73	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 73	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	539
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 73	540	ATGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	599
Refseq	7140	MTGCCTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	7081
DONOR 73	600	GCAGGCTCCTGGGTCCCACAGGCAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCCCA	659
Refseq	7080	GCAGGCTCCTGGGTCCCACAGGCAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR 73	660	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	719
Refseq	7022	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR 73	720	ACACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTG	779
Refseq	6962	ACACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTG	6903
DONOR 73	780	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	839
Refseq	6902	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR 73	840	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTNANNAGGGTA	899
Refseq	6842	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTA	6783
DONOR 73	900	CATGGGAGGACAGTCCATGCCCTANAGAAATTGAGNAANATAGCTTCTTCTCATTTGTTG	959
Refseq	6782	CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTTGTTG	6723
DONOR 73	960	GGAGTACAGTGGNTTTTATACCATAATCTTCCCATTTCTTCTC 1003	
Refseq	6722	GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTTCTTCTC 6679	

3' → 5' sequence for 2nd haplotype

DONOR 73	1	CTGTGGGAGGT-NNTGAATGATGGGGGAGGTTTTTCACATGCTGTTCTTATGACAGTGA	59
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 73	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTG	119
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCTCTTG	7561
DONOR 73	120	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 73	180	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	239
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 73	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 73	300	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	359
Refseq	7380	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 73	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 73	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 73	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	539
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 73	540	CTGCCTTTAGACtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	599
Refseq	7140	MTGCCTTTAGAC-TTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCT	7082
DONOR 73	600	TGCAGGCTCCTGGGTCCACAGGCCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAG	659
Refseq	7081	TGCAGGCTCCTGGGTCCACAGGCCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAG	7022
DONOR 73	660	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	719
Refseq	7021	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	6962
DONOR 73	720	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGG	779
Refseq	6961	CACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGG	6902
DONOR 73	780	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	839
Refseq	6901	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	6842
DONOR 73	840	CATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCANAGACTNNN-AGGGTAC	898
Refseq	6841	CATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTAC	6782
DONOR 73	899	ATGGGAGGACAGTCCATGCCCTANAGAAATTGAGNAANATAGCTTCTTCCTCATTGNTGG	958
Refseq	6781	ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGG	6722
DONOR 73	959	GAGTACAGTGN-TTTTATACCANNANCTTCCCATTNCNCTTCTCNGANAA-CCCTTTNGCA	1016
Refseq	6721	GAGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCTCAGATAAACCTTTGGCA	6662
DONOR 73	1017	AGTA 1020	
Refseq	6661	AGTA 6658	

5' → 3' sequence for 1st haplotype

223

5' → 3' sequence for 2nd haplotype

DONOR	180	1	CCTGAGANTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGGC	60
Refseq	7434			
			CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGGC	7493
DONOR	180	61	TAGGGAGTCCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACGG	120
Refseq	7494			
			TAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACGG	7553
DONOR	180	121	TGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	180
Refseq	7554			
			TGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	7613
DONOR	180	181	GACTTATTCACGTGTCTATAAGAACAGCATGTGAAAACCTGCCCCATGATTC AATTACCT	240
Refseq	7614			
			GACTTATTCACGTGTCTATMAGAACAGCATGTGAAAACCTGCCCCATGATTC AATTACCT	7673
DONOR	180	241	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGATT	300
Refseq	7674			
			CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGATT	7733
DONOR	180	301	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAAACAATAGTAAGAACACATT	360
Refseq	7734			
			TGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAAACAATAGTAAGAACACATT	7793
DONOR	180	361	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	420
Refseq	7794			
			TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	7853
DONOR	180	421	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	480
Refseq	7854			
			TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	7913
DONOR	180	481	TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7914			
			TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	7973
DONOR	180	541	TTGTTTCAAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	600
Refseq	7974			
			TTGTTTCAAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	8033
DONOR	180	601	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	660
Refseq	8034			
			ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	8093
DONOR	180	661	AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	720
Refseq	8094			
			AAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	8153
DONOR	180	721	GAAAAAGATTCCCTGAATCtggggagagaaggggatggtggtggtggtgatgggtgggggag	780
Refseq	8154			
			GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGG-TGGGG-AG	8211
DONOR	180	781	gaataaagggggaAGCCAGTAATGAATGTATGAGGTGGATTGGGGGAAGAGGATATGGGAG	840
Refseq	8212			
			GAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGGAAGAGGATATGGGAG	8271
DONOR	180	841	TTTATTTCCCATTTCTATTCTATCTGTNNNNANCTGGGAGGTGAAANCACCTCCAATTC	898
Refseq	8272			
			TTTATTTCC-ATPCTATPCTATCTGTTACTAAGCTGGGAGGTGAAAGCACCTCCAATTC	8328

3' → 5' sequence for 1st haplotype

DONOR	180	3	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	62
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	180	63	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	122
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTG	7561
DONOR	180	123	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	182
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	180	183	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	242
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	180	243	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	302
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	180	303	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	362
Refseq	7380		AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	180	363	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	422
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	180	423	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTTGTTTAACTTTGTTGGCTA	482
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTTGTTTAACTTTGTTGGCTA	7201
DONOR	180	483	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	542
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	180	543	ATGCCTTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	602
Refseq	7140		MTGCCTTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	180	603	GCAGGCTCCTGGGTCCCANNGGCAAAGAGGGCTTTGCTGGGCCCCCTCTGGACATGCCCAG	662
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCC-TCTGGACATGCYCAG	7022
DONOR	180	663	ACAGGTTTAAATCC	676
Refseq	7021		ACAGGTTTAAATCC	7008

3' → 5' sequence for 2nd haplotype

DONOR	180	1	TGTGGGGANGTAATTGAATCATGGGGGAGGTTTTTCACATGCTGTTCTTATGACAGTGAA	60
Refseq		7679	TGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTCACATGCTGTTCTKATGACAGTGAA	7620
DONOR	180	61	TAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTGC	120
Refseq		7619	TAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCCACACCCTCTTGC	7560
DONOR	180	121	CTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGAC	180
Refseq		7559	CTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGMC	7500
DONOR	180	181	TCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAGT	240
Refseq		7499	TCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAGT	7440
DONOR	180	241	CTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTA	300
Refseq		7439	CTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTA	7380
DONOR	180	301	AACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCT	360
Refseq		7379	AACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCT	7320
DONOR	180	361	CAAACCCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCC	420
Refseq		7319	CAAACCCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCC	7260
DONOR	180	421	CAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTAT	480
Refseq		7259	CAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTAT	7200
DONOR	180	481	GAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAC	540
Refseq		7199	GAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAM	7140
DONOR	180	541	TGCCTTTAGACttttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq		7139	TGCCTTTAGAC-ttttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	180	601	GCAGGCTCCTGGGTCCACAGGCCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGA	660
Refseq		7080	GCAGGCTCCTGGGTCCACAGGCCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR	180	661	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	720
Refseq		7020	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR	180	721	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	780
Refseq		6960	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR	180	781	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	840
Refseq		6900	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR	180	841	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANANACTNNNGAGGGTACA	900
Refseq		6840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR	180	901	TGGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAANANAGCTTCTTCCTCATTGTTGN	960
Refseq		6780	TGGG-AGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGG	6722
DONOR	180	961	-AGTACAGTNNNTTT-ATACCATAATCTTCCCATTCT	994
Refseq		6721	GAGTACAGTGGCTTTTATACCATAATCTTCCCATTCT	6686

5' → 3' sequence for 1st haplotype

227

5' → 3' sequence for 2nd haplotype

DONOR	185	1	ACCTGAGANTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433		ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR	185	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493		CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR	185	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553		GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR	185	181	AGACTTATTCAGTGTGCATAGAAGCAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq	7613		AGACTTATTCAGTGTGCATMAGAAGCAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR	185	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAGTCTCAGGATGAGAT	300
Refseq	7673		TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAGTCTCAGGATGAGAT	7732
DONOR	185	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733		TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR	185	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793		TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR	185	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853		TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR	185	481	ATTAACAGGAATCATAATTTTCTATTATTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7913		ATTAACAGGAATCATAATTTTCTATTATTTCTATTACCTGTAATCCCATGACCCATT	7972
DONOR	185	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973		TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR	185	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033		TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR	185	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093		TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR	185	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGT	773
Refseq	8153		AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGGT	8205

3' → 5' sequence for 1st haplotype

DONOR	185	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGA	60
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	185	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	120
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	7561
DONOR	185	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	185	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAAATTACCCAG	240
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAAATTACCCAG	7441
DONOR	185	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	185	301	AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	360
Refseq	7380		AAACCCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	185	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	185	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	185	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCCTCA	540
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCCTCA	7141
DONOR	185	541	ATGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140		MTGCCTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	185	601	GCAGGCTCCTGGGTCCACAGGCAAGAGGGTCCTTTGCTGGGCCCTCTGGACATGCCCA	660
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR	185	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCANGCTGAGACCCACAACCTC	720
Refseq	7022		GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR	185	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	780
Refseq	6962		ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6903
DONOR	185	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902		GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR	185	841	TCATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCNNAGACTAANGAGGGTA	900
Refseq	6842		TCATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTA	6783
DONOR	185	901	CATGGGAGGACAGTCCATGCCCTananaaaTTGAGGAAGANAGCTTCTTCCTCATGTGTG	960
Refseq	6782		CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATGTGTG	6723
DONOR	185	961	GGNGTACAGTNN-TTT-ATACCATAAT	985
Refseq	6722		GGAGTACAGTGGCTTTTATACCATAAT	6696

3' → 5' sequence for 2nd haplotype

DONOR	185	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	60
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	185	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCCCTCTTG	120
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCCCTCTTG	7561
DONOR	185	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	185	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	185	241	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	185	301	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	360
Refseq	7380		AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	185	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	185	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	185	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	185	541	ATGCCTTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140		MTGCCTTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	185	601	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCCCAGA	660
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR	185	661	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	720
Refseq	7020		CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR	185	721	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	780
Refseq	6960		ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR	185	781	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	840
Refseq	6900		ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR	185	841	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTNANNAGGGTACA	900
Refseq	6840		ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR	185	901	TGGGANGACAGTCCATGCCCTANAGAAATTGAGNAANATAGCTTCTTCCTCATTGNTGGG	960
Refseq	6780		TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGGG	6721
DONOR	185	961	AGTACAGTGN-TTTTATACCATAN-CTTCCCATTNCNCTTCTC	1000
Refseq	6720		AGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCTC	6679

5' → 3' sequence for 1st haplotype

231

5' → 3' sequence for 2nd haplotype

DONOR 211	1	TGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGGCTAGGGAGG	60
Refseq	7442	TGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGGCTAGGGAGK	7501
DONOR 211	61	CCTCACTATCACGGCAGAAGGCAAGGAGGAGCTAAGGCACGTGTTACACGGTGGCAGGC	120
Refseq	7502	CCTCACTATCACGGCAGAAGGCAAGGAGGAGCTAAGGCAYGTGTTACACGGTGGCAGGC	7561
DONOR 211	121	AAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGAGACTTATT	180
Refseq	7562	AAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGAGACTTATT	7621
DONOR 211	181	CACTGTCATAAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACCTCCCACAGA	240
Refseq	7622	CACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACCTCCCACAGA	7681
DONOR 211	241	GTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATTTGGGTGGG	300
Refseq	7682	GTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATTTGGGTGGG	7741
DONOR 211	301	GACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACATTTTAGAATT	360
Refseq	7742	GACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACATTTTAGAATT	7801
DONOR 211	361	CCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCTTGAAATTG	420
Refseq	7802	CCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCTTGAAATTG	7861
DONOR 211	421	CTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATATTAACAGG	480
Refseq	7862	CTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATATTAACAGG	7921
DONOR 211	481	AATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATTTTGTTC	540
Refseq	7922	AATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATTTTGTTC	7981
DONOR 211	541	AGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATTACACAGC	600
Refseq	7982	AGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATTACACAGC	8041
DONOR 211	601	AGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCATAAACAGTA	660
Refseq	8042	AGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCATAAACAGTA	8101
DONOR 211	661	GATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACTAGAAAAAGA	720
Refseq	8102	GATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACTAGAAAAAGA	8161
DONOR 211	721	TTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTNNNGGGAGGAATAAA	780
Refseq	8162	TTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGTGG-T--GGGGAGGAATAAA	8218
DONOR 211	781	GGGGAANCCNNTAATGAATGTATGAGGTGGATTTGGGGAAGAGGATATGGGAGTTNNTTC	840
Refseq	8219	GGGGAAGCCARTAAATGAATGTATGWRGTGGATTTGGGGAAGAGGATATGGGAGTTTATTC	8278
DONOR 211	841	CATTCTATTCNATCTGNTACTAACNNGGGANGTGAAA	877
Refseq	8279	CATTCTATTCATCTGTTACTAACCTGGGAGGTGAAA	8315

3' → 5' sequence for 1st haplotype

DONOR	211	16	TGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGAATAAGTCTCATGAG	75
Refseq		7666	TGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGAATAAGTCTCATGAG	7607
DONOR	211	76	ATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTGCCCTGCCACCGTGTA	135
Refseq		7606	ATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTGCCCTGCCACCGTGTA	7547
DONOR	211	136	ACACGTGCCTTAGCTCCTCCTTTGCGCTTCTGCCGTGATAGTGAGGACTCCCTAGCCCTGT	195
Refseq		7546	ACACRTGCCTTAGCTCCTCCTTTGCGCTTCTGCCGTGATAGTGAGGMCTCCCTAGCCCTGT	7487
DONOR	211	196	GGAGCTGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	255
Refseq		7486	GGAGCKGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	7427
DONOR	211	256	TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCTAAAAAGC	315
Refseq		7426	TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCTAAAAAGC	7367
DONOR	211	316	ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	375
Refseq		7366	ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	7307
DONOR	211	376	TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCCAGGGATTTTGA	435
Refseq		7306	TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCCAGGGATTTTGA	7247
DONOR	211	436	GAAACAGACCTTTTAGCTTGTACTCATTGTTAACTTTGTTGGCTATGAGCCTATAGAGC	495
Refseq		7246	GAAACAGACCTTTTAGCTTGTACTCATTGTTAACTTTGTTGGCTATGAGCCYATAGAGC	7187
DONOR	211	496	TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAATGCCTTTAGACTt	555
Refseq		7186	TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAMTGCCTTTAGACTT	7127
DONOR	211	556	tttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTGCAGGCTCCTGGGT	615
Refseq		7126	TTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTGCAGGCTCCTGGGT	7067
DONOR	211	616	CCCACAGGCAAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCCGACAGGTTTAAATC	675
Refseq		7066	CCCACAGGCAAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCAGACAGGTTTAAATC	7009
DONOR	211	676	CTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACAC	735
Refseq		7008	CTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACAC	6949
DONOR	211	736	ATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGCACTCATACCTAT	795
Refseq		6948	ATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGCACTCATACCTAT	6889
DONOR	211	796	AGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGT	855
Refseq		6888	AGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGT	6829
DONOR	211	856	CTGGCTACCTCCATCTCTACTCTGAACTCANANACTNNN-AGGGTACATGGGANGANAGT	914
Refseq		6828	CTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTACATGGGAGGACAGT	6769
DONOR	211	915	CCATGCCCTANAGAAATTGAGNAAGATAGCTTCTTCCTCATTTGTTGGGAGTACAGTGGNT	974
Refseq		6768	CCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTTGTTGGGAGTACAGTGGCT	6709
DONOR	211	975	TTTATACCATAN-CTTCCCATTTCTTCTCA	1004
Refseq		6708	TTTATACCATAATCTTCCCATTTCTTCTCA	6678

3' → 5' sequence for 2nd haplotype

DONOR 211	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 211	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	7561
DONOR 211	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	180
Refseq	7560	CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 211	181	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 211	241	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 211	301	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	360
Refseq	7380	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR 211	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 211	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 211	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR 211	541	CTGCCTTTTAGACtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCT	600
Refseq	7140	MTGCCTTTTAGAC-TTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCT	7082
DONOR 211	601	TGCAGGCTCCTGGGTCCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAG	660
Refseq	7081	TGCAGGCTCCTGGGTCCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAG	7022
DONOR 211	661	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	720
Refseq	7021	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	6962
DONOR 211	721	CACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTGG	780
Refseq	6961	CACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTGG	6902
DONOR 211	781	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	840
Refseq	6901	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	6842
DONOR 211	841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTANAGACTNANNAGGGTAC	900
Refseq	6841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTAC	6782
DONOR 211	901	ATGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAAGANAGCTTCNTCCTCATTGTTGG	960
Refseq	6781	ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGG	6722
DONOR 211	961	GAGTACAGTNNNTTT-ATACCANAN-CTTCCCATTCT	995
Refseq	6721	GAGTACAGTGGCTTTTATACCATAATCTTCCCATTCT	6685

Donor 232

5' → 3' sequence for 1st haplotype

DONOR 232	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 232	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 232	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 232	181	AGACTTATTCACTGTCATCAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACC	7672
DONOR 232	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 232	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 232	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 232	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 232	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 232	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 232	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 232	661	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 232	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGNNGGGGGA	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGT-GGGG-A	8210
DONOR 232	781	GGAATAAAGGGGAAGCCAATAATGAATGTATGTAGTGGATTGGGGAAGAGGATATGGGA	840
Refseq	8211	GGAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAAGAGGATATGGGA	8270
DONOR 232	841	GTTTATTCCATTCTAATTCTATCTGTTACNNNCNTGGGAGGTGAAAGCNCNNCNTTCG	900
Refseq	8271	GTTTATTCCATTCTA-TTCTATCTGTACTAACCTGGGAGGTGAAAGCACCTCCAATTTCG	8329
DONOR 232	901	ATTAGGGATATCTGANANCAA-GNATCCCTTGAGCNTCCCTGTCC	944
Refseq	8330	ATTAGGGATATCTGAGAACAAAG-ATCCCTTGAGCCTCCCTGTCC	8373

5' → 3' sequence for 2nd haplotype

DONOR 232	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 232	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 232	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 232	181	AGACTTATTCAGTGTGCATAGAAGCAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCAGTGTGCATMAGAAGCAGCATGTGAAAAACCTGCCCCCATSATTCAATTACC	7672
DONOR 232	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 232	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 232	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 232	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 232	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	7972
DONOR 232	541	TTTGTTTCAAGCCCAGACCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 232	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 232	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 232	721	AGAAAAAGATTCCCTGAATCTGGGAGAAAGGGGATGGTGGTGGTGGTGANNNGNNGGGN	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGAGAAAGGGGATGGTGGTGGTGGTGAT-GGT-GGGG-	8209
DONOR 232	781	AGGAANTAAAGGGGAAGCCAGTAATGAATGTATGAGGTGGATTGGGGAAGAGGATATGG	840
Refseq	8210	AGGAA-TAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAAGAGGATATGG	8268
DONOR 232	841	GGAGTTTATTCN-TTCTATTCTATCTGTTACTAACCTGGNANGTGAA	886
Refseq	8269	G-AGTTTATTCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAA	8314

3' → 5' sequence for 1st haplotype

DONOR 232	1	TGTGGGAGGTANTTTGAATCATGGGGGAGGTTTTTTCACATGCTGTTCTGATGACAGTGA	60
Refseq	7680	CTGTGGGAGGTAATTGAATSATGGGGGAGGTTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR 232	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCACACCCTCTTG	120
Refseq	7620	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCACACCCTCTTG	7561
DONOR 232	121	CCTGCCACCCTGTAACACGTGCCTTAGCTCCTCCTTTCCTTCTGCCGTGATAGTGAGGC	180
Refseq	7560	CCTGCCACCCTGTAACACRTGCCTTAGCTCCTCCTTTCCTTCTGCCGTGATAGTGAGGM	7501
DONOR 232	181	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500	CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR 232	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR 232	301	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	360
Refseq	7380	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR 232	361	TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320	TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR 232	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR 232	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	540
Refseq	7200	TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR 232	541	ATGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	600
Refseq	7140	MTGCCTTTAGACTTTTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCTT	7081
DONOR 232	601	GCAGGCTCCTGGGTCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGA	660
Refseq	7080	GCAGGCTCCTGGGTCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR 232	661	CAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	720
Refseq	7020	CAGGTTTAAATCCTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR 232	721	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTGCC	780
Refseq	6960	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTGCC	6901
DONOR 232	781	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	840
Refseq	6900	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR 232	841	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCANAGACTNANNAGGGTACA	900
Refseq	6840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTACA	6781
DONOR 232	901	TGGGAGGACAGTCCATGCCCTANAGAAATTGAGNAAGANAGCTTCTTCCTCATTGTTGGG	960
Refseq	6780	TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGGG	6721
DONOR 232	961	AGTACAGTGGNTTTTATACCATAATCTTCCATTCTCTTCT	1001
Refseq	6720	AGTACAGTGGCTTTTATACCATAATCTTCCATTCTCTTCT	6680

3' → 5' sequence for 2nd haplotype

DONOR	232	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	60
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	232	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	120
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCACACCCCTCTTG	7561
DONOR	232	121	CCTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	232	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	232	241	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	232	301	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	360
Refseq	7380		AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	232	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	232	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTIONTGTGTTAACTTTGTTGGCTA	480
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTIONTGTGTTAACTTTGTTGGCTA	7201
DONOR	232	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	232	541	CTGCCTTTTAGACttttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCT	600
Refseq	7140		MTGCCTTTTAGAC-TTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTTGTCTCATCT	7082
DONOR	232	601	TGCAGGCTCCTGGGTCCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAG	660
Refseq	7081		TGCAGGCTCCTGGGTCCCACAGGCAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAG	7022
DONOR	232	661	ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	720
Refseq	7021		ACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCA	6962
DONOR	232	721	CACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTGG	780
Refseq	6961		CACTGAAAAACACATTGATACCAAGACTGATTAATATGCATGTAAATACTGGCATTTGG	6902
DONOR	232	781	CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	840
Refseq	6901		CACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATT	6842
DONOR	232	841	CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTANNAGGGGTAC	900
Refseq	6841		CATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTAC	6782
DONOR	232	901	ATGGGANGACAGTCCATGCCCTAGAGAAATTGAGGnaananagCTTCTTCTCATTTGTTGG	960
Refseq	6781		ATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTTGTTGG	6722
DONOR	232	961	GAGTACAGTG-CTTTTATAACCANNANCTTCCCATTCNCTTCT	1001
Refseq	6721		GAGTACAGTGGCTTTTATAACCATAATCTTCCCATTCCTTCT	6680

Donor 238

5' → 3' sequence for 1st haplotype

DONOR 238	1	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTAATGGACTCACCGCTCCACAGGGC	60
Refseq	7434	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTAATGGACTCACMGCTCCACAGGGC	7493
DONOR 238	61	TAGGAGAGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACGG	120
Refseq	7494	TAGGAGAGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACGG	7553
DONOR 238	121	TGGCAGGCAAGAGGGTGTGTGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	180
Refseq	7554	TGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	7613
DONOR 238	181	GACTTATTCACCTGTCATCAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACCT	240
Refseq	7614	GACTTATTCACCTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACCT	7673
DONOR 238	241	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATT	300
Refseq	7674	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGATT	7733
DONOR 238	301	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAAACAATAGTAAGAACACATT	360
Refseq	7734	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAAACAATAGTAAGAACACATT	7793
DONOR 238	361	TTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	420
Refseq	7794	TTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	7853
DONOR 238	421	TGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAATA	480
Refseq	7854	TGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAATA	7913
DONOR 238	481	TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATTT	540
Refseq	7914	TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATTT	7973
DONOR 238	541	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	600
Refseq	7974	TTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	8033
DONOR 238	601	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	660
Refseq	8034	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	8093
DONOR 238	661	AAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACTA	720
Refseq	8094	AAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACTA	8153
DONOR 238	721	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGnnnnnnnG-GGGGAGG	779
Refseq	8154	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATG-GTGGGGAGG	8212
DONOR 238	780	AATAAAGGGGAAGCCAGTAATGAATGTATGANGTGGATTGGGGAGAGGATATGGGAGT	839
Refseq	8213	AATAAAGGGGAAGCCARTAATGAATGTATGWRGTGGATTGGGGAGAGGATATGGGAGT	8272
DONOR 238	840	TTATTCCATTCTNATTCTNTCTGTACTAACCNNGGGAGGTGAAAGCNCNTCCAATTCTN	899
Refseq	8273	TTATTCCATTCT-ATTCTATCTGTACTAACCT-GGGAGGTGAAAGCACC-TCCAATTCTG	8329
DONOR 238	900	NNTNNGGATATCTGAGAACAA-GNTCCCTTGAGCCTTCCCTGTCTTA-GTAGCTCCCTAG	957
Refseq	8330	ATTAGGGATATCTGAGAACAAAGATCCCTTGAGCCT-CCCTGTCTTAAGTAGCTCCCTAG	8388
DONOR 238	958	GAAN-AGACTACACCCC	973
Refseq	8389	GAAAGAGACTACACCCC	8405

5' → 3' sequence for 2nd haplotype

DONOR	238	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433		ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR	238	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACG	120
Refseq	7493		CTAGGGAGKCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR	238	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553		GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR	238	181	AGACTTATTCACTGTCTATAAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq	7613		AGACTTATTCACTGTCTATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCATTACC	7672
DONOR	238	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673		TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR	238	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733		TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR	238	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793		TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR	238	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853		TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR	238	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	540
Refseq	7913		ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCTGTAATCCCATGACCCATT	7972
DONOR	238	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973		TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR	238	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033		TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR	238	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093		TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR	238	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGT	764
Refseq	8153		AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGT	8196

3' → 5' sequence for 1st haplotype

DONOR	238	1	CTGTGGGAGGTAATTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACNGTGA	60
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	238	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCCTGCACACACCCTCTTG	120
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCCTGCCACACACCCTCTTG	7561
DONOR	238	121	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	180
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	238	181	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	238	241	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	238	301	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	360
Refseq	7380		AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	238	361	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	238	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	238	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	540
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	238	541	CTGCCTTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140		MTGCCTTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	238	601	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCCCAGA	660
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR	238	661	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	720
Refseq	7020		CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR	238	721	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	780
Refseq	6960		ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR	238	781	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	840
Refseq	6900		ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR	238	841	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANAGACTANN-AGGGTACA	899
Refseq	6840		ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR	238	900	TGGGAGGANAGTCCATGCCCTANAGAANT-Gnnnan-anaGCTTCTTCTCATTGNTGGG	957
Refseq	6780		TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCTCATTGTTGGG	6721
DONOR	238	958	ANTACAGTGN-TTTTATACCATNATCTTCCNTTNNCTTCTCAGA	1001
Refseq	6720		AGTACAGTGGCTTTTATACCATAATCTTCCCATCTCTTCTCAGA	6676

3' → 5' sequence for 2nd haplotype

DONOR	238	14	TGAATCNTGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGAATAAGTCTCATGAG	73
Refseq		7666	TGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGAATAAGTCTCATGAG	7607
DONOR	238	74	ATCTGATGGTTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTGCCCTGCCACCGTGTA	133
Refseq		7606	ATCTGATGGTTTTTATAAAGTGCAGTTCCTGCCCCACACCTCTTGCCCTGCCACCGTGTA	7547
DONOR	238	134	ACACATGCCTTAGCTCCTCCTTTGCGCTTCTGCCGTGATAGTGAGGACTCCCTAGCCCTGT	193
Refseq		7546	ACACRTGCCTTAGCTCCTCCTTTGCGCTTCTGCCGTGATAGTGAGGMCTCCCTAGCCCTGT	7487
DONOR	238	194	GGAGCGGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	253
Refseq		7486	GGAGCKGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	7427
DONOR	238	254	TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCTAAAAAGC	313
Refseq		7426	TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCTAAAAAGC	7367
DONOR	238	314	ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	373
Refseq		7366	ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	7307
DONOR	238	374	TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCAGGGATTTTAGA	433
Refseq		7306	TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCAGGGATTTTAGA	7247
DONOR	238	434	GAAACAGACCTTTTAGCTTGTACTCATTGTTAACTTTGTTGGCTATGAGCCTATAGAGC	493
Refseq		7246	GAAACAGACCTTTTAGCTTGTACTCATTGTTAACTTTGTTGGCTATGAGCCYATAGAGC	7187
DONOR	238	494	TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCACTGCCTTTAGACTt	553
Refseq		7186	TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAMTGCCTTTAGACTT	7127
DONOR	238	554	tttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTGCAGGCTCCTGGGT	613
Refseq		7126	TTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTTGCAGGCTCCTGGGT	7067
DONOR	238	614	CCCACAGGCAAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCCGACAGAGTTTAAATC	673
Refseq		7066	CCCACAGGCAAAGAGGG--CTTTGCTGGGCCCTCTGGACATGCYCAGACAGGTTTAAATC	7009
DONOR	238	674	CTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACAC	733
Refseq		7008	CTAGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACAC	6949
DONOR	238	734	ATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGCACTCATACCTAT	793
Refseq		6948	ATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGCACTCATACCTAT	6889
DONOR	238	794	AGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGT	853
Refseq		6888	AGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGT	6829
DONOR	238	854	CTGGCTACCTCCATCTCTACTCTGAACTCANAGACTAAGNAGGGTACATGGGAGGACAGT	913
Refseq		6828	CTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTACATGGGAGGACAGT	6769
DONOR	238	914	CCATGCCCTANAGAAATTGAGGAAGATAGCTTCTTCCTCATTTGTTGGGAGTACAGTGGNT	973
Refseq		6768	CCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTTGTTGGGAGTACAGTGGCT	6709
DONOR	238	974	TTTATACCATNATCTTCCCATTTCTTCTC	1003
Refseq		6708	TTTATACCATAATCTTCCCATTTCTTCTC	6679

Donor 251

5' → 3' sequence for 1st haplotype

DONOR 251	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 251	61	CTAGGGAGTCTCTACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCATGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 251	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 251	181	AGACTTATTCACTGTCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACC	7672
DONOR 251	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 251	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 251	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 251	421	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACCAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 251	481	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 251	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 251	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 251	661	TAAACAGTAGATTTCATTAAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	720
Refseq	8093	TAAACAGTAGATTTCATTAAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACT	8152
DONOR 251	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGANGNNGGGGGA	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGATGGT-GGGG-A	8210
DONOR 251	781	GGAATAAAGGGGACGCCAATAATGAATGTATGTAGTGGATTTTGGGGAAGAGGATATGGG	840
Refseq	8211	GGAATAAAGGGGAAGCCARTAATGAATGTATGWRGTGGATTT-GGGGAAGAGGATATGGG	8269
DONOR 251	841	AGTTTATTCCATTCTATTCTATCTGTTACTAACCTGGGANGTGAAAGCACCTCCAATTCTG	900
Refseq	8270	AGTTTATTCCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATTCTG	8329
DONOR 251	901	ATTANGGATATCTGANAACAAAGATCCCTTGAGCCTCCCTGTCCTAAGTAGCTCCCTAGG	960
Refseq	8330	ATTAGGGATATCTGAGAACAAAGATCCCTTGAGCCTCCCTGTCCTAAGTAGCTCCCTAGG	8389
DONOR 251	961	AAAGAGACTACNCCCNCCANNACGCTCCTGCATGTTGTTT	1000
Refseq	8390	AAAGAGACTACACCCACACTACRCTCCTGCATGTTGTTT	8429

5' → 3' sequence for 2nd haplotype

DONOR	251	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAAATGGACTCACCGCTCCACAGGG	60
Refseq	7433			
			ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAAATGGACTCACMGCTCCACAGGG	7492
DONOR	251	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493			
			CTAGGGAGKCCCTCACTATCACGGCAGAAGGCCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR	251	121	GTGGCAGGCAAGAGGGTGTGTGCAGGGGAACCTGCACTTTATAAAAACCATCAGATCTCATG	180
Refseq	7553			
			GTGGCAGGCAAGAGGGTGTGGGCAGGGGAACCTGCACTTTATAAAAACCATCAGATCTCATG	7612
DONOR	251	181	AGACTTATTCACTGTCATCAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613			
			AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCAATTACC	7672
DONOR	251	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	300
Refseq	7673			
			TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGAT	7732
DONOR	251	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAAACAATAGTAAGAACACAT	360
Refseq	7733			
			TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAAACAATAGTAAGAACACAT	7792
DONOR	251	361	TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793			
			TTTAGAATTCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR	251	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853			
			TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR	251	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913			
			ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR	251	541	TTTGTTC AAGCCAGACCCAGACTTGAGG GTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973			
			TTTGTTC AAGCCAGACCCAGACTTGAGG GTTGATTACCACGGACAATTGATGTTAT	8032
DONOR	251	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033			
			TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR	251	661	TAAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093			
			TAAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR	251	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGNNGNNGG	780
Refseq	8153			
			AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTATGGT---GGGG	8209
DONOR	251	781	NNAGGAATTAAANGGGGAAGCCAGTAATGAATGTATGAGGTGGATTGGGGAAGAGGATA	840
Refseq	8210			
			--AGGAAT-AAA-GGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAAGAGGATA	8265
DONOR	251	841	TGGGAGTTTATTCCATTCTATTCTATCTGTTACTAACCCTGGGANGTGAAAGCACCTCCNA	900
Refseq	8266			
			TGGGAGTTTATTCCATTCTATTCTATCTGTTACTAACCCTGGGAGGTGAAAGCACCTCCAA	8325
DONOR	251	901	TTCNATTAGGGNTATCTGANAACAAAGATCCCTTGAGCCTCCCTGT	946
Refseq	8326			
			TTCGATTAGGGATATCTGAGAACAAGATCCCTTGAGCCTCCCTGT	8371

3' → 5' sequence for 1st haplotype

DONOR	251	1	CTGTGGGAGGTNNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGA	59
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	251	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCACACCCCTCTTG	119
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCCCTGCCACACCCCTCTTG	7561
DONOR	251	120	CCTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	179
Refseq	7560		CCTGCCACCGTGTAACACATGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	251	180	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	239
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	251	240	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	251	300	AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	359
Refseq	7380		AAACCCATAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR	251	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	251	420	CCAGGGATTTTAGAGAAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260		CCAGGGATTTTAGAGAAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	251	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	539
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	251	540	CTGCCTTTTAGACTtttttttGCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	599
Refseq	7140		MTGCCTTTTAGACTTTTTTGTCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	251	600	GCAGGCTCCTGGGTCCACAGGCAAGAGGGTCTTTGTGGGCCCTCTGGACATGCCCA	659
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAGAGGG--CTTTGTGGGCCCTCTGGACATGCYCA	7023
DONOR	251	660	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTCTCAAGCTGAGACCCACAACCTC	719
Refseq	7022		GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTCTCAAGCTGAGACCCACAACCTC	6963
DONOR	251	720	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	779
Refseq	6962		ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6903
DONOR	251	780	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	839
Refseq	6902		GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR	251	840	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCANAGACTNNN-AGGGTA	898
Refseq	6842		TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTA	6783
DONOR	251	899	CATGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAANATAGCTTCTTCCTCATTGTTG	958
Refseq	6782		CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTG	6723
DONOR	251	959	GGAGTACAGTGGCTTTTATACCANNATCTTCCCATTCTCTTCTC	1002
Refseq	6722		GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCTC	6781

3' → 5' sequence for 2nd haplotype

DONOR	251	1	CTGTGGGAGGT-NNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGA	59
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	251	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCACACACCCTCTTG	119
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTCCCCTGCCCACACCCTCTTG	7561
DONOR	251	120	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	251	180	CTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	239
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	251	240	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	251	300	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	359
Refseq	7380		AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	251	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	251	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	251	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	539
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	251	540	CTGCCTTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	599
Refseq	7140		MTGCCTTTTAGACTTTTTTTGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	251	600	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCCCAGA	659
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR	251	660	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	719
Refseq	7020		CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR	251	720	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	779
Refseq	6960		ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR	251	780	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	839
Refseq	6900		ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR	251	840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCANANACTNANNAGGGTACA	899
Refseq	6840		ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR	251	900	TGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAANATAGCTTCTTCCTCATTGTTGG-	958
Refseq	6780		TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGGG	6721
DONOR	251	959	AGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCTCAGA	1003
Refseq	6720		AGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCTCAGA	6676

Donor 253

5' → 3' sequence for 1st haplotype

DONOR 253	1	ACCTGAGANTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR 253	61	CTAGGGAGTCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493	CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR 253	121	GTGGCAGGCAAGAGGGTGTGTGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR 253	181	AGACTTATTCACTGTCATAAGAACAGCATGTGAAAAACCTGCCCCCATGATTCAATTACC	240
Refseq	7613	AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCCATSATTCATTACC	7672
DONOR 253	241	TCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673	TCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR 253	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR 253	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR 253	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR 253	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR 253	541	TTTGTTC AAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973	TTTGTTC AAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR 253	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR 253	661	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093	TAAACAGTAGATTTCGATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR 253	721	AGAAAAAGATTCCCTGAATCtgggggagaaggggatgggtgggtgggtgatgggtggggga	780
Refseq	8153	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTGGTGGG-TGGGG-A	8210
DONOR 253	781	ggaataaaggggaAGCCNGTNATGAATGTATGANGTGGATTGGGGAAGAGGATATGGGA	840
Refseq	8211	GGAATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAAGAGGATATGGGA	8270
DONOR 253	841	GTTTNTTCCATTCTATTCTATCTGTTACTAACCTGGGANGTGAAANCACCTCCNATTCGA	900
Refseq	8271	GTTTATTCCATTCTATTCTATCTGTTACTAACCTGGGAGGTGAAAGCACCTCCAATTCGA	8330
DONOR 253	901	TTAGGGNNATCTGAGAACNAAGATCCCTTGAG	932
Refseq	8331	TTAGGGATATCTGAGAACAAAGATCCCTTGAG	8362

5' → 3' sequence for 2nd haplotype

DONOR	253	1	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACAGCTCCACAGGGC	60
Refseq	7434			
		7434	CCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGGC	7493
DONOR	253	61	TAGGGAGTCCTCACTATCACGGCAGAAGGCAAGGAGGAGCTAAGGCACGTGTTACACGG	120
Refseq	7494			
		7494	TAGGGAGKCCTCACTATCACGGCAGAAGGCAAGGAGGAGCTAAGGCAYGTGTTACACGG	7553
DONOR	253	121	TGGCAGGCAAGAGGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	180
Refseq	7554			
		7554	TGGCAGGCAAGAGGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATGA	7613
DONOR	253	181	GACTTATTCACTGTGCATCAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACCT	240
Refseq	7614			
		7614	GACTTATTCACTGTGCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACCT	7673
DONOR	253	241	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGATT	300
Refseq	7674			
		7674	CCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACCTCAGGATGAGATT	7733
DONOR	253	301	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACATT	360
Refseq	7734			
		7734	TGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACATT	7793
DONOR	253	361	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	420
Refseq	7794			
		7794	TTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTCT	7853
DONOR	253	421	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	480
Refseq	7854			
		7854	TGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAATA	7913
DONOR	253	481	TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7914			
		7914	TTAACAGGAATCATAATTTTCCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7973
DONOR	253	541	TTGTTTCAAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	600
Refseq	7974			
		7974	TTGTTTCAAGCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTATT	8033
DONOR	253	601	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	660
Refseq	8034			
		8034	ACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCAT	8093
DONOR	253	661	AAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	720
Refseq	8094			
		8094	AAACAGTAGATTTCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAACTA	8153
DONOR	253	721	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGNNGGGAGG	780
Refseq	8154			
		8154	GAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGT-GGGGAGG	8212
DONOR	253	781	AATAAAGGGGAAGCCAGTAATGAATGTATGANGTGGATTGGGGAAGANGATATGGGAGT	840
Refseq	8213			
		8213	AATAAAGGGGAAGCCARTAAATGAATGTATGWRGTGGATTGGGGAAGAGGATATGGGAGT	8272
DONOR	253	841	TTATTCCNTTCTATTCTATCTGTTACTAACCTGGGANGGNGAAANNCCCTCCNATTCNAN	900
Refseq	8273			
		8273	TTATTCCATTCTATTCTATCTGTTACTAACCTGGGA-GGTGAAAGCACCTCCAATTCGAT	8331
DONOR	253	901	TAGGGANANCCTGANAACNAAGAANCCCTTGANCCTCCCTGTC-TAN-TANCTCCCTNNG	958
Refseq	8332			
		8332	TAGGGATATC-TGAGAACAAAGAT-CCCTTGAGCCTCCCTGTCTAAGTAGCTCCCTAGG	8389
DONOR	253	959	AAAGANACTA	968
Refseq	8390			
		8390	AAAGAGACTA	8399

3' → 5' sequence for 1st haplotype

DONOR	253	2	TCTGTGGGAGG-NNNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTG	60
Refseq	7681		TCTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTG	7622
DONOR	253	61	AATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGAGTCCCCCTGCACACACCTCTT	120
Refseq	7621		AATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGAGTCCCCCTGCCACACACCTCTT	7562
DONOR	253	121	GCCTGCCACCGTGTAAACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGG	180
Refseq	7561		GCCTGCCACCGTGTAAACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGG	7502
DONOR	253	181	ACTCCCTAGCCCTGTGGAGCGGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCA	240
Refseq	7501		MCTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAACTTCTTTTTCTTTATAAATTACCCA	7442
DONOR	253	241	GTCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTC	300
Refseq	441		GTCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTC	7382
DONOR	253	301	TAAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTCTG	360
Refseq	7381		TAAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGTCTG	7322
DONOR	253	361	CTCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCC	420
Refseq	7321		CTCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCC	7262
DONOR	253	421	CCCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAATGTTTAACTTTGTGTGGCT	480
Refseq	7261		CCCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTAATGTTTAACTTTGTGTGGCT	7202
DONOR	253	481	ATGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCC	540
Refseq	7201		ATGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCC	7142
DONOR	253	541	ACTGCCTTTAGACtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATC	600
Refseq	7141		AMTGCCTTTAGAC-TTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATC	7083
DONOR	253	601	TTGCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCA	660
Refseq	7082		TTGCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR	253	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTCTCAAGCTGAGACCCACAACCTC	720
Refseq	7022		GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTCTCAAGCTGAGACCCACAACCTC	6963
DONOR	253	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	780
Refseq	6962		ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6903
DONOR	253	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902		GCACTCATACCTATAGGTAGTAGAGGCTCAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR	253	841	TCATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCAGANACTNNN-AGGGTA	899
Refseq	6842		TCATAGATACCACTCTGGCTACCTCCATCTCTACTCTGAACTCAGAGACTAAGGAGGGTA	6783
DONOR	253	900	CATGGGANGACAGTCCATGCCCTANAGAAATTGAGGAANANNGCTTCTTCCTCATGTG	959
Refseq	6782		CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATGTG	6723
DONOR	253	960	GGANTACNGTNNNTT-ATACCATAN-CNTCCCNNTNCNTTCTCA	1002
Refseq	6722		GGAGTACAGTGGCTTTTATACCATAATCTCCCATCTCTCTCTCA	6678

3' → 5' sequence for 2nd haplotype

DONOR	253	1	CTGTGGGGANGTAATTGAATCATGGGGGCAGGTTTTTTCACATGCTGTTCTGATGACAGTGA	60
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	253	61	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	120
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCACACCCTCTTG	7561
DONOR	253	121	CCTGCCACCCTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGA	180
Refseq	7560		CCTGCCACCCTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	253	181	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	240
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	253	241	TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	300
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	253	301	AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	360
Refseq	7380		AAACCTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGC	7321
DONOR	253	361	TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	420
Refseq	7320		TCAAACCAGCAGCATCATGTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	253	421	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	480
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	253	481	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	540
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCA	7141
DONOR	253	541	ATGCCTTTAGACTtttttttGCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	600
Refseq	7140		MTGCCTTTAGACTTTTTTGTCTCCAAGCACGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	253	601	GCAGGCTCCTGGGTCCCACAGGCAAGAGGGTCTTTGCTGGGCCCTCTGGACATGCCCA	660
Refseq	7080		GCAGGCTCCTGGGTCCCACAGGCAAGAGGG--CTTGCTGGGCCCTCTGGACATGCYCA	7023
DONOR	253	661	GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	720
Refseq	7022		GACAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTC	6963
DONOR	253	721	ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	780
Refseq	6962		ACACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTG	6903
DONOR	253	781	GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	840
Refseq	6902		GCACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTAT	6843
DONOR	253	841	TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAAGTCTGAGACTNANNAGGGTA	900
Refseq	6842		TCATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAAGTCTGAGACTAAGGAGGGTA	6783
DONOR	253	901	CATGGGAGGACAGTCCATGCCCTANAGAAATTGAGGAANATAGCTTCTTCCTCATTGTTG	960
Refseq	6782		CATGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTG	6723
DONOR	253	961	GGAGTACAGNGGNTTTTATACCATAATCTTCCCATTTCTCTTC	1002
Refseq	6722		GGAGTACAGTGGCTTTTATACCATAATCTTCCCATTTCTCTTC	6681

5' → 3' sequence for 1st haplotype

251

5' → 3' sequence for 2nd haplotype

DONOR	280	1	ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACCGCTCCACAGGG	60
Refseq	7433		ACCTGAGACTGGGTAATTTATAAAGAAAAAGAAGTTTAATGGACTCACMGCTCCACAGGG	7492
DONOR	280	61	CTAGGGAGGCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCACGTGTTACACG	120
Refseq	7493		CTAGGGAGKCCTCACTATCACGGCAGAAGGCAAAGGAGGAGCTAAGGCAYGTGTTACACG	7552
DONOR	280	121	GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	180
Refseq	7553		GTGGCAGGCAAGAGGGTGTGGGCAGGGGAAGTGCACCTTTATAAAACCATCAGATCTCATG	7612
DONOR	280	181	AGACTTATTCACTGTCATAAGAACAGCATGTGAAAAACCTGCCCCATGATTCAATTACC	240
Refseq	7613		AGACTTATTCACTGTCATMAGAACAGCATGTGAAAAACCTGCCCCATSATTCAATTACC	7672
DONOR	280	241	TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	300
Refseq	7673		TCCCACAGAGTCCCTCCCATGACACATGCGGATTATGGGAGCTAAAACTCAGGATGAGAT	7732
DONOR	280	301	TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGGAGGAGAACAATAGTAAGAACACAT	360
Refseq	7733		TTGGGTGGGGACACAGCCAAACCATATCAGTAGGGKAGGAGAACAATAGTAAGAACACAT	7792
DONOR	280	361	TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	420
Refseq	7793		TTTAGAATTCCCCAAGGATGAGTTGAAGGGCTGAAGAGCTTTGAAGATGAGCTGAAGCTC	7852
DONOR	280	421	TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	480
Refseq	7853		TTGAAATTGCTAGTTGCAACAAAACAGAGAATATTTGTGGCAGAATAATATTTTAAAT	7912
DONOR	280	481	ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	540
Refseq	7913		ATTAACAGGAATCATAATTTTCTATTATTTTCTATTACCCTGTAATCCCATGACCCATT	7972
DONOR	280	541	TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	600
Refseq	7973		TTTGTTTCAAGCCCAGACCCAGACTTGGAGGTGTTGATTACCACGGACAATTGATGTTAT	8032
DONOR	280	601	TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	660
Refseq	8033		TACAACAGCAGAATAAAGGCTTTGAGTTTCATAAGCCTAGCCTTGAGGGCACTTAAGGCA	8092
DONOR	280	661	TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	720
Refseq	8093		TAAACAGTAGATTTGCATTAATATCTGATGAGTTAGAAAAAGGTGGTTTACTTCCAAACT	8152
DONOR	280	721	AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGNNGGGGGA	780
Refseq	8153		AGAAAAAGATTCCCTGAATCTGGGGAGAAGGGGATGGTGGTGGTGGTATGGT-GGGG-A	8210
DONOR	280	781	GGAATAAAGGGGAAGCCAGTAATGNANTGTATGAGGTGGATTTGGGGAAGAGGATATGGG	840
Refseq	8211		GGAATAAAGGGGAAGCCARTAAATGAA-TGTATGWRGTGGATTTGGGGAAGAGGATATGGG	8269

3' → 5' sequence for 1st haplotype

DONOR	280	1	CTGTGGGAGG-NNNTGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTGATGACAGTGA	59
Refseq	7680		CTGTGGGAGGTAATTGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGA	7621
DONOR	280	60	ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCCTCTTG	119
Refseq	7620		ATAAGTCTCATGAGATCTGATGGTTTTATAAAGTGCAGTTCCTGCCCCACACCCTCTTG	7561
DONOR	280	120	CCTGCCACCGTGTAACACGTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGC	179
Refseq	7560		CCTGCCACCGTGTAACACRTGCCTTAGCTCCTCCTTGCCTTCTGCCGTGATAGTGAGGM	7501
DONOR	280	180	CTCCCTAGCCCTGTGGAGCTGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	239
Refseq	7500		CTCCCTAGCCCTGTGGAGCKGTGAGTCCATTAAACTTCTTTTCTTTATAAATTACCCAG	7441
DONOR	280	240	TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	299
Refseq	7440		TCTCAGGTATTTCTTCATAGCAGTATGAAATGGACTAATACACCTACTAACTGCCTTCT	7381
DONOR	280	300	AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	359
Refseq	7380		AAACCTTAAAAAGCATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTGCTGC	7321
DONOR	280	360	TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	419
Refseq	7320		TCAAACCAGCAGCATCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCC	7261
DONOR	280	420	CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	479
Refseq	7260		CCAGGGATTTTAGAGAAACAGACCTTTTAGCTTGTACTCATTGTTTAACTTTGTTGGCTA	7201
DONOR	280	480	TGAGCCTATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	539
Refseq	7200		TGAGCCYATAGAGCTGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTCTCCA	7141
DONOR	280	540	CTGCCTTTTAGACTtttttttGCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	599
Refseq	7140		MTGCCTTTTAGACTTTTTTTGCTCCAAGCAGCAGCTTCCGTGCTCTTTTGTCTCATCTT	7081
DONOR	280	600	GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCCCAGA	659
Refseq	7080		GCAGGCTCCTGGGTCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGA	7021
DONOR	280	660	CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	719
Refseq	7020		CAGGTTTAAATCCTAGGATAGAGACAGCCAGGTTCTCAAGCTGAGACCCACAACCTCAC	6961
DONOR	280	720	ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	779
Refseq	6960		ACTGAAAAACACATTGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTGGC	6901
DONOR	280	780	ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	839
Refseq	6900		ACTCATACCTATAGGTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTC	6841
DONOR	280	840	ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTNANNAGGGTACA	899
Refseq	6840		ATAGATACCAGTCTGGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACA	6781
DONOR	280	900	TGGGAGGACAGTCCATGCCCTananaaaTTGAGGAANATAGCTTCTTCCTCATTGTTGGG	959
Refseq	6780		TGGGAGGACAGTCCATGCCCTAGAGAAATTGAGGAAGATAGCTTCTTCCTCATTGTTGGG	6721
DONOR	280	960	AGTACAGTNNNTTT-ATACCATAATCTTCCCATTCTCTTCT	999
Refseq	6720		AGTACAGTGGCTTTTATACCATAATCTTCCCATTCTCTTCT	6680

3' → 5' sequence for 2nd haplotype

DONOR	280	14	TGAATCATGGGGGCAGGTTTTTCACATGCTGTTCTTATGACAGTGAATAAGTCTCATGAG	73
Refseq	7666		TGAATSATGGGGGCAGGTTTTTCACATGCTGTTCTKATGACAGTGAATAAGTCTCATGAG	7607
DONOR	280	74	ATCTGATGGTTTTTATAAAGTGCAGTTC CCTGCCACACCTCTTG CCTGCCACCGTGTA	133
Refseq	7606		ATCTGATGGTTTTTATAAAGTGCAGTTC CCTGCCACACCTCTTG CCTGCCACCGTGTA	7547
DONOR	280	134	ACACGTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGCCTCCCTAGCCCTGT	193
Refseq	7546		ACACRTGCCTTAGCTCCTCCTTTGCCTTCTGCCGTGATAGTGAGGMCTCCCTAGCCCTGT	7487
DONOR	280	194	GGAGCGGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	253
Refseq	7486		GGAGCKGTGAGTCCATTAAACTTCTTTTTCTTTATAAATTACCCAGTCTCAGGTATTTCT	7427
DONOR	280	254	TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCCTAAAAAGC	313
Refseq	7426		TCATAGCAGTATGAAAATGGACTAATACACCTACTAACTGCCTTCTAAACCCTAAAAAGC	7367
DONOR	280	314	ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	373
Refseq	7366		ATGAGGTGCCACTATAAAAGCTGCCTATTACATTTCTGTTGCTGCTCAAACCAGCAGCA	7307
DONOR	280	374	TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCCAGGGATTTTAGA	433
Refseq	7306		TCATGCTGCCAAGTCAGTGAAGGCTTTTCTGCATTCTCAATGTCCCCCAGGGATTTTAGA	7247
DONOR	280	434	GAAACAGACCTTTTAGCTTG TACTCATTGTTTAACTTTGTTGGCTATGAGCCTATAGAGC	493
Refseq	7246		GAAACAGACCTTTTAGCTTG TACTCATTGTTTAACTTTGTTGGCTATGAGCCYATAGAGC	7187
DONOR	280	494	TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCACTGCCTTTAGACTt	553
Refseq	7186		TGGAGCAAGGGGTACTCTTAGTGAGAGACATGGCCCTTGTTCTCCAMTGCCTTTAGACTT	7127
DONOR	280	554	ttttttGCTCCAAGCAGCAGCTTCCGTGCTCTTTTTGTCTCATCTTG CAGGCTCCTGGGT	613
Refseq	7126		TTTTTGCTCCAAGCAGCAGCTTCCGTGCTCTTTTTGTCTCATCTTG CAGGCTCCTGGGT	7067
DONOR	280	614	CCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCTCAGACAGGTTTAAATCCT	673
Refseq	7066		CCCACAGGCAAAGAGGGCTTTGCTGGGCCCTCTGGACATGCYCAGACAGGTTTAAATCCT	7007
DONOR	280	674	AGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACACAT	733
Refseq	7006		AGGATAGAGACAGCCCAGGTTCTCAAGCTGAGACCCACAACCTCACACTGAAAAACACAT	6947
DONOR	280	734	TGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTGGCACTCATACCTATAG	793
Refseq	6946		TGATACCAAAGACTGATTAATATGCATGTAAATACTGGCATTTGGCACTCATACCTATAG	6887
DONOR	280	794	GTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGTCT	853
Refseq	6886		GTAGTAGAGGCTCAAAAGCCAAGACTGAAAAAATTTTCTCTATTTCATAGATACCAGTCT	6827
DONOR	280	854	GGCTACCTCCATCTCTACTCTGAACCTCANAGACTAANGAGGGTACATGGGAGGACAGTCC	913
Refseq	6826		GGCTACCTCCATCTCTACTCTGAACCTCAGAGACTAAGGAGGGTACATGGGAGGACAGTCC	6767
DONOR	280	914	ATGCCCTANAGAAATTGANGAANANAGCTTCTTCCTCATTGTTGGGAGTACAGTGGCTTT	973
Refseq	6766		ATGCCCTAGAGAAATTGAGGAAGTAGCTTCTTCCTCATTGTTGGGAGTACAGTGGCTTT	6707
DONOR	280	974	TATACCATAATCTTCCATTCTCTTCT	1000
Refseq	6706		TATACCATAATCTTCCATTCTCTTCT	6680

REFERENCES

- Alani E, Padmore R, Kleckner N (1990) Analysis of wild-type and rad50 mutants of yeast suggests an intimate relationship between meiotic chromosome synapsis and recombination. *Cell* 61:419-36
- Allers T, Lichten M (2001) Differential timing and control of noncrossover and crossover recombination during meiosis. *Cell* 106:47-57
- Anderson LK, Offenberg HH, Verkuijlen WM, Heyting C (1997) RecA-like proteins are components of early meiotic nodules in lily. *Proc Natl Sci Acad USA* 94:6868-73
- Antonarakis SE, Boehm CD, Giardina PJ, Kazazian HH, Jr. (1982) Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. *Proc Natl Acad Sci USA* 79:137-41
- Ardlie KG, Kruglyak L, Seielstad M (2002) patterns of linkage disequilibrium in the human genome. *Nat Rev Genet* 3:299-309
- Baird DM, Jeffreys AJ, Royle NJ (1995) Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. *EMBO J* 14:5433-43
- Baker SM, Plug AW, Prolla TA, Bronner CE, Harris AC, Yao X, Christie DM, Monell C, Arnheim N, Bradley A, Ashley T, Liskay RM (1996) Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. *Nat Genet* 13:336-42
- Bass HW (2003) Telomere dynamics unique to meiotic prophase: formation and significance of the bouquet. *Cell Mol Life Sci* 60:2319-24
- Baudat F, Buard J, Grey C, Fledel-Alon A, Ober C, Przeworski M, Coop G, de Massy B (2010) PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. *Science* 327:836-40
- Baudat F, de Massy B (2007) Cis- and trans-acting elements regulate the mouse Psmb9 meiotic recombination hotspot. *PLoS Genet* 3:e100
- Baudat F, Nicolas A (1997) Clustering of meiotic double-strand breaks on yeast chromosome III. *Proc Natl Acad Sci USA* 94:5213-8
- Berg IL, Neumann R, Lam KW, Sarbajna S, Odenthal-Hesse L, May CA, Jeffreys AJ (2010) PRDM9 variation strongly influences recombination hot-spot activity and meiotic instability in humans. *Nat Genet* 42:859-63
- Berg IL, Neumann R, Sarbajna S, Odenthal-Hesse L, Butler NJ, Jeffreys AJ (2011) Variants of the protein PRDM9 differentially regulate a set human

meiotic recombination hotspots highly active in African populations. *Proc Natl Acad Sci USA* 108:12378-83

Blat Y, Protacio RU, Hunter N, Kleckner N (2002) Physical and functional interactions among basic chromosome organizational features govern early steps of meiotic chiasma formation. *Cell* 111:791-802

Borde V, Robine N, Lin W, Bonfils S, Geli V, Nicolas A (2009) Histone H3 lysine 4 trimethylation marks meiotic recombination initiation sites. *EMBO J* 28:99-111

Boulton A, Myers RS, Redfield RJ (1997) The hotspot conversion paradox and the evolution of meiotic recombination. *Proc Natl Acad Sci USA* 94:8058-63

Börner GV, Kleckner N, Hunter N (2004) Crossover/ noncrossover differentiation, synaptonemal complex formation, and regulatory surveillance at the leptotene/zygotene transition of meiosis. *Cell* 117:29-45

Brown TC, Jiricny J (1988) Different base/base mispairs are corrected with different efficiencies and specificities in monkey kidney cells. *Cell* 54:705-11

Brunschwig H, Levi L, Ben-David E, Williams RW (2012) Fine-scale map of recombination rates and hotspots in the mouse genome. *Genetics* 10.1534

Buard J, Barthes P, Grey C, de Massy B (2009) Distinct histone modifications define initiation and repair of meiotic recombination in the mouse. *EMBO J* 28:2616-24

Bullard SA, Kim S, Galbraith AM, Malone RE (1996) Double strand breaks at the HIS2 recombination hot spot in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA* 93:13054-9

Cao L, Alani E, Kleckner N (1990) A pathway for generation and processing of double-strand breaks during meiotic recombination in *S. cerevisiae*. *Cell* 61:1089-101

Cervantes MD, Farah JA, Smith GR (2000) Meiotic DNA breaks associated with recombination in *S.pombe*. *Mol Cell* 5:883-3

Chakravarti A, Buetow KH, Antonarakis SE, Waber PG, Boehm CD, Kazazian HH (1984) Nonuniform recombination within the human beta-globin gene cluster. *Am J Hum Genet* 36:1239-58.

Cromie GA, Hyppa RW, Taylor AF, Zakharyevich K, Hunter N, Smith GR (2006) Single Holliday junctions are intermediates of meiotic recombination. *Cell* 127:1167-78

Collins A, Morton NE (1998) Mapping a disease locus by allelic association. *Proc Natl Acad Sci USA* 95:1741-1745

Copenhaver GP, Housworth EA, Stahl FW (2002) Crossover interference in Arabidopsis. Genetics 160:1631-9

Coop G, Wen X, Ober C, Pritchard JK, Przeworski M (2008) High-resolution mapping of crossovers reveals extensive variation in fine-scale recombination patterns among humans Science 319:1395-8

Cullen M, Erlich H, Klitz W, Carrington M (1995) Molecular Mapping of a Recombination Hotspot Located in the Second Intron of the Human TAP2 locus. Am J Hum Genet 56:1350-1358

Cullen M, Noble J, Erlich H, Thorpe K, Beck S, Klitz W, Trowsdale J, Carrington M (1997) Characterization of Recombination in the HLA Class II Region. Am J Hum Genet 60:397-407

Cullen M, Perfectto SP, Klitz W, Nelson G, Carrington M (2002) High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet 71:759-76

Dalganov GM, Maser RS, Novikov A, Tosto L, Chong S, Bressan DA, Petrini JH (1996) Human Rad50 is physically associated with human Mre11: identification of a conserved multiprotein complex implicated in recombination DNA repair. Mol Cell Biol 16:4832-41

de los Santos T, Hunter N, Lee C, Larkin B, Loidi J, Hollingsworth NM (2003) The Mus81/Mms4 endonuclease acts independently of double-Holliday junction resolution to promote a distinct subset of crossovers during meiosis in budding yeast. Genetics 164:81-94

Dean FB, Hosono S, Fang L, Wu X, Faruqi AF, Bray-Ward P, Sun Z, Zong Q, Du Y, Du J, Driscoll M, Song W, Kingsmore SF, Egholm M, Lasken RS (2002) Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci USA. 99:5261-6

Dobson MJ, Pearlman RE, Karaiskakis A, Spyropoulos B, Moens PB (1994) Synaptonemal complex proteins: occurrence, epitope mapping and chromosome disjunction. J Cell Sci 107:2749-60

Dooner HK (1986) Genetic Fine Structure of the BRONZE Locus in Maize. Genetics 113:1021-1036.

Dooner HK, Martínez-Férez IM (1997) Germinal excisions of the maize transposon activator do not stimulate meiotic recombination or homology-dependent repair at the bz locus. Genetics 147:1923-32.

Egel-Mitani M, Olson LW, Egel R (1982) Meiosis in *Aspergillus nidulans*: another example for lacking synaptonemal complexes in the absence of crossover interference. Hereditas 97:179-87

Fan Q, Xu F, Petes TD (1995) Meiosis-specific double-strand DNA breaks at the HIS4 recombination hot spot in the yeast *Saccharomyces cerevisiae*: control in cis and trans. *Mol Cell Biol* 15:1679-88

Fan QQ, Petes TD (1996) Relationship between nuclease-hypersensitive sites and meiotic recombination hot spot activity at the HIS4 locus of *Saccharomyces cerevisiae*. *Mol Cell Biol* 16:2037-43.

Ferguson DO, Holloman WK (1996) Recombinational repair of gaps in DNA is asymmetric in *Ustilago maydis* and can be explained by a migrating D-loop model. *Proc Natl Acad Sci USA* 93:5419-24

Fearnhead P, Harding RM, Schneider JA, Myers S, Donnelly P (2004) Application of coalescent methods to reveal fine-scale rate variation and recombination hotspots. *Genetics* 167:2067-81

Fox ME, Yamada T, Ohta K, Smith GR (2000) A family of cAMP-response-element-related DNA sequences with meiotic recombination hotspot activity in *Schizosaccharomyces pombe*. *Genetics* 156:59-68

Freije D, Helms C, Watson MS, Donis-Keller H (1992) Identification of a second pseudoautosomal region near the Xq and Yq telomeres. *Science* 258:1784-7

Gerton JL, DeRisi J, Shroff R, Lichten M, Brown PO, Petes TD (2000) Inaugural article: global mapping of meiotic recombination hotspots and coldspots in the yeast *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA* 97:11383-90

Grey C, Barthes P, Chauveau-Le Fric G, Baudat F, de Massy B (2011) Mouse PRDM9 DNA-binding specificity determines sites of histone H3 lysine 4 trimethylation for initiation of meiotic recombination. *PLoS Biol* 9:e1001176

Grey C, Baudat F, de Massy B (2009) Genome-wide control of the distribution of meiotic recombination. *PLoS Biol* 7:e35

Guillon H, de Massy B (2002) An initiation site for meiotic crossing-over and gene conversion in the mouse. *Nat Genet* 32:296-9

Hartung F, Puchta H (2000) Molecular characterisation of two paralogous SPO11 homologues in *Arabidopsis thaliana*. *Nucleic Acids Res* 28:1548-54

Hayashi K, Yoshida K, Matsul Y (2005) A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. *Nature* 438:374-8

Henderson KA, Keeney S (2005) Synaptonemal complex formation: where does it start? *Bioessays* 27:995-8

Henke A, Fisher C, Rappoid GA (1993) Genetics map of the human pseudoautosomal region reveals a high rate of recombination in female meiosis at the Xp telomere. *Genomics* 18:478-85

Holliday R (1964) The Induction of Mitotic Recombination by Mitomycin C in Ustilago and Saccharomyces. Genetics 50:323-35

Holloway K, Lawson VE, Jeffreys AJ (2006) Allelic recombination and de novo deletions in sperm in the human beta-globin gene region. Hum Mol Genet 15:1099-111

Housworth EA, Stahl FW (2003) Crossover interference in humans. Am J Hum Genet 73:188-97

Hubert R, MacDonald M, Gusella J, Arnheim N (1994) High resolution localization of recombination hot spots using sperm typing. Nat Genet 7:420-424

Hunter N, Borts RH (1997) Mlh1 is unique among mismatch repair proteins in its ability to promote crossing-over during meiosis. Genes Dev 11:1573-82

International HapMap Consortium (2005) A haplotype map of human genome. Nature 437:299-320

The International HapMap Consortium (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-61

International HapMap 3 Consortium (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467:52-8

International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921

International SNP Map Working Group (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-33

Jeffreys AJ, Kauppi L, Neumann R (2001) Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet 29:217-22

Jeffreys AJ, May CA (2004) Intense and highly localized gene conversion activity in human meiotic crossover hot spots. Nat Genet 36:151-6

Jeffreys AJ, Murray J, Neumann R (1998a) High-resolution mapping of crossovers in human sperm defines a minisatellite-associated recombination hotspot. Mol Cell 2:267-73

Jeffreys AJ, Neil DL, Neumann R (1998b) Repeat instability at human minisatellites arising from meiotic recombination. EMBO J 17:4147-57

Jeffreys AJ, Neumann R (2002) Reciprocal crossover asymmetry and meiotic drive in a human recombination hot spot. Nat Genet 31:267-71

Jeffreys AJ, Neumann R (2005) Factors influencing recombination frequency and distribution in a human meiotic crossover hotspot. *Hum Mol Genet* 14:2277-87

Jeffreys AJ, Neumann R (2009) The rise and fall of a human recombination hot spot. *Nat Genet* 41:625-9

Jeffreys AJ, Neumann R, Panayi M, Myers S, Donnelly P (2005) Human recombination hot spots hidden in regions of strong marker association. *Nat Genet* 37:601-606

Jeffreys AJ, Neumann R, Wilson V (1990) Repeat unit sequence variation in minisatellites: a novel source of DNA polymorphism for studying variation and mutation by single molecule analysis. *Cell* 60:473-85

Jeffreys AJ, Ritchie A, Neumann R (2000) High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. *Hum Mol Genet* 9:725-33

Johzuka K, Ogawa H (1995) Interaction of Mre11 and Rad50: two proteins required for DNA repair and meiosis-specific double-strand break formation in *Saccharomyces cerevisiae*. *Genetics* 139:1521-32

Kaback DB, Guacci V, Barber D, Mahon JW (1992) Chromosome size-dependent control of meiotic recombination. *Science* 256:228-32

Kauppi L, Jeffreys AJ, Keeney S (2004) Where the crossovers are: recombination distributions in mammals. *Nat Rev Genet* 5:413-24

Kauppi L, May CA, Jeffreys AJ (2009) Analysis of meiotic recombination products from human sperm. *Methods Mol Biol* 557:323-55

Kauppi L, Stumpf MP, Jeffreys AJ (2005) Localized breakdown in linkage disequilibrium does not always predict sperm crossover hot spots in the human MHC class II region. *Genomics* 86:13-24

Keeney S (2008) Spo11 and the formation of DNA double-strand breaks in meiosis. *Genome Dyn Stab* 2:81-123

Keeney S, Baudat F, Angeles M, Zhou ZH, Copeland NG, Jenkins NA, Manova K, Jasin M (1999) A mouse homolog of the *Saccharomyces cerevisiae* meiotic recombination DNA transesterase Spo11p. *Genomics* 61:170-82

Keeney S, Giroux CN, Kleckner N (1997) Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. *Cell* 88:375-84

Keeney S, Kleckner N (1995) Covalent protein-DNA complexes at the 5' strand termini of meiosis-specific double-strand breaks in yeast. *Proc Natl Acad Sci USA* 92:11274-8

Kirkpatrick DT, Fan Q, Petes TD (1999) Maximal stimulation of meiotic recombination by a yeast transcription factor requires the transcription activation domain and a DNA-binding domain. *Genetics* 152:101-15

Kohli J, Bahler J (1994) Homologous recombination in fission yeast: absence of crossover interference and synaptonemal complex. *Experientia* 50:295-306

Kon N, Krawchuk MD, Warren BG, Wahls WP (1997) Transcription factor Mts1/Mts2 (Atf1/Pcr1) activates the M26 meiotic recombination hotspot in *Schizosaccharomyces pombe*. *Proc Natl Acad Sci USA* 94:13765-70

Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson TE, Gulcher JR, Stefansson K (2002) A high-resolution recombination map of the human genome. *Nat Genet* 31:241-7.

Kong A, Barnard J, Gudbjartsson DF, Thorleifsson G, Jonsdottir G, Sigurdardottir S, Richardsson B, Jonsdottir J, Thorgeirsson T, Frigge ML, Lamb NE, Sherman S, Gulcher JR, Stefansson K (2004) Recombination rate and reproductive success in humans. *Nat Genet* 36:1203-6

Lee JY, Orr-Weaver TL (2001) The molecular basis of sister-chromatid cohesion. *Annu Rev Cell Dev Biol* 17:753-77

Lewontin RC (1964) The Interaction of Selection and Linkage. II. Optimum Models. *Genetics* 50:757-782.

Li HH, Gyllenstein UB, Cui XF, Saiki RK, Erlich HA, Arnheim N (1988) Amplification and analysis of DNA sequences in single human sperm and diploid cells. *Nature* 335:414-7

Li L, Hamer DH (1995) Recombination and allelic association in the Xq/Yq homology region. *Hum Mol Genet* 4:2013-6

Lichten M, Goldman AS (1995) Meiotic recombination hotspots. *Annu Rev Genet* 29:423-44

Lien S, Szyda J, Schechinger B, Rappold G, Arnheim N (2000) Evidence for heterogeneity in recombination in the human pseudoautosomal region: high resolution analysis by sperm typing and radiation-hybrid mapping. *Am J Hum Genet.* 66(2):557-66

Lin Y, Smith GR (1994) Transient, meiosis-induced expression of the *rec6* and *rec12* genes of *Schizosaccharomyces pombe*. *Genetics* 136:769-79

Liu Y, Masson JY, Shah R, O'Regan P, West SC (2004) RAD51C is required for Holliday junction processing in mammalian cells. *Science* 303:243-6

Liu J, Wu TC, Linchten M (1995) The location and structure of double-strand DNA breaks induced during yeast meiosis: evidence for a covalently linked DNA-protein intermediate. EMBO J 14:4599-608

Malécot G (1948) Les mathématiques de l'hérédité. Masson et Cie, Paris. [The mathematics of heredity (1968 English translation by D.M. Yermanos). W.H. Freeman and Co., San Francisco.]

Mani P, Yadav VK, Das SK, Chowdhury S (2009) Genome-wide analyses of recombination prone regions predict role of DNA structural motif in recombination. PLoS One 4:e4399

Maniatis N, Collins A, Xu CF, McCarthy LC, Hewett DR, Tapper W, Ennis S, Ke X, Morton NE (2002) The first linkage disequilibrium (LD) maps: delineation of hot and cold blocks by diplotype analysis. Proc Natl Acad Sci USA 99:228-33

Martini E, Diaz RL, Hunter N, Keeney S (2006) Crossover homeostasis in yeast meiosis. Cell 126:285-95

Marsischky GT, Filosi N, Kane MF, Kolodner R (1996) Redundancy of *Saccharomyces cerevisiae* MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10:407-20

May CA, Shone AC, Kalaydjieva L, Sajantila A, Jeffreys AJ (2002) Crossover clustering and rapid decay of linkage disequilibrium in the Xp/Yp pseudoautosomal gene SHOX. Nat Genet 31:272-5.

McVean GA, Myers SR, Hunt S, Deloukas P, Bentley DR, Donnelly P (2004) The fine-scale structure of recombination rate variation in the human genome. Science 304:581-4

McKee AH, Kleckner N (1997) Mutations in *Saccharomyces cerevisiae* that block meiotic prophase chromosome metabolism and confer cell cycle arrest at pachytene identify two meiosis-specific genes SAE1 and SAE3. Genetics 146:817-34

McKim KS, Green-Marroquin BL, Sekelsky JJ, Chin G, Steinberg C, Khodosh R, Hawley RS (1998) Meiotic synapsis in the absence of recombination. Science 279:876-8

Meuwissen RL, Meerts I, Hoovers JM, Leschot NJ, Heyting C (1997) Human synaptonemal complex protein 1 (SCP1): isolation and characterization of the cDNA and chromosomal localization of the gene. Genomics 39:377-84

Morton NE, Zhang W, Taillon-Miller W, Ennis S, Kwok -Y, Collins A (2001) The optimal measure of allelic association. Proc Natl Acad Sci USA 98:5217-5221

Moses MJ, Counce SJ, Paulson DF (1975) Synaptonemal complex complement of man in spreads of spermatocytes, with details of the sex chromosome pair. Science 187:363-5

Myers S, Bottolo Leonardo, Freeman C, McVean G, Donnelly P (2005) A fine-scale map of recombination rates and hotspots across the human genome Science 310: 321-324

Myers S, Bowden R, Tumian A, Bontrop RE, Freeman C, MacFie TS, McVean G, Donnelly P (2010) Drive against hotspot motifs in primates implicates the PRDM9 gene in meiotic recombination. Science 327:876

Myers S, Freeman C, Auton A, Donnelly P, McVean G (2008) A common sequence motif associated with recombination hot spots and genome instability in humans. Nat Genet 40:1124-9

Myers S, Spencer CC, Auton A, Bottolo L, Freeman C, Donnelly P, McVean G (2006) The distribution and causes of meiotic recombination in the human genome. Biochem Soc Trans 34:526-30

Nairz K, Klein F (1997) mre11S—a yeast mutation that blocks double-strand-break processing and permits nonhomologous synapsis in meiosis. Genes Dev 11: 2272-90

Nassif N, Penney J, Pal S, Engels WR, Gloor GB (1994) Efficient copying of nonhomologous sequences from ectopic sites via P-element-induced gap repair. Mol Cell Biol 14:1613-25

Nag DK, Scherthan H, Rockmill B, Bhargava J, Roeder GS (1995) Heterodublex DNA formation and homolog pairing in yeast meiotic mutants. Genetics 141:75-86

Neumann R, Jeffreys AJ (2006) Polymorphism in the activity of human crossover hotspots independent of local DNA sequence variation. Hum Mol Genet. 15:1401-11.

Novak JE, Ross-Macdonald PB, Roeder GS (2001) The budding yeast Msh4 protein functions in chromosome synapsis and the regulation of crossover distribution. Genetics 158:1013-25

Page SL, Hawley RS (2003) Chromosome choreography: the meiotic ballet. Science 301:785-9

Oudet C, Hanauer A, Clemens P, Caskey T, Mandel JL (1992) Two hot spots of recombination in the DMD gene correlate with the deletion prone regions. Hum Mol Genet 1:599-603

Page SL, Hawley RS (2003) Chromosome choreography: the meiotic ballet. Science 301:785-9

Paques F, Haber JE (1999) Multiple pathways of recombination induced by double-strand breaks in *Saccharomyces cerevisiae*. Microbiol Mol Biol Rev 63:349-404

Paques F, Leung WY, Haber JE (1998) Expansions and contractions in a tandem repeat induced by double-strand break repair. *Mol Cell Biol* 18:2045-54

Parvanov ED, Ng SH, Petkov PM, Paigen K (2009) Trans-regulation of mouse meiotic recombination hotspots by Rcr1. *PLoS Biol* 7:e36

Parvanov ED, Petkov PM, Paigen Kenneth (2010) Prdm9 controls activation of mammalian recombination hotspots. *Science* 327:835

Petes TD (2001) Meiotic recombination hot spots and cold spots. *Nat Rev Genet* 2:360-9

Petit C, Levilliers J, Weissenbach J (1988) Physical mapping of the human pseudo-autosomal region; comparison with genetics linkage map. *EMBO J* 7:2369-76

Pineda-Krch M, Redfield RJ (2005) Persistence and loss of meiotic recombination hotspots. *Genetics* 169:2319-33

Ponting CP (2011) What are the genomic drivers of the rapid evolution of PRDM9? *Trends Genet* 27:165-71

Prolla TA, Pang Q, Alani E, Kolodner RD, Liskay RM (1994) MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. *Science* 265:1091-3

Ptak SE, Hinds DA, Koehler K, Nickel B, Patil, Ballinger DG, Przeworski M, Frazer KA, Paabo S (2005) Fine-scale recombination pattern differ between chimpanzees and humans. *Nat Genet* 37:429-434

Ptak SE, Voelpel K, Przeworski M (2004) insights into recombination from patterns of linkage disequilibrium in humans. *Genetics* 167:387-97

Rao E, Weiss B, Fukami M, Mertz A, Meder J, Ogata T, Heinrich U, Garcia-Heras J, Schiebel K, Rappoid GA (1997) *Hum Genet* 100:236-9

Rattray AJ, McGill CB, Shafer BK, Strahern JN (2001) Fidelity of meiotic double-strand-breaks repair in *Saccharomyces cerevisiae*: a role for SAE/COM1. *Genetics* 158:109-22

Rocco V, Nicolas A (1996) Sensing of DNA non-homology lowers the initiation of meiotic recombination in yeast. *Genes Cells* 1:645-61

Roeder GS (1995) Sex and the single cell: meiosis in yeast. *Proc Natl Acad Sci USA* 92:10450-6

Roeder GS (1997) Meiotic chromosomes: it takes two to tango. *Genes Dev* 11:2600-21

Ross-Macdonald P, Roeder GS (1994) Mutation of a meiosis-specific MutS homolog decreases crossing over but not mismatch correction. *Cell* 79:1069-80

Sarbajna S, Denniff M, Jeffreys AJ, Neumann R, Soler Artigas M, Veselis A, May CA (2012) A major recombination hotspot in the XqYq pseudoautosomal region gives new sights into processing of human gene conversion events. *Hum Mol Genet* 21:2029-38

Schneider JA, Peto TE, Boone RA, Boyce AJ, Clegg JB (2002) Direct measurement of the male recombination fraction in the human beta- globin hot spot. *Hum Mol Genet* 11:207-15.

Schwacha A, Kleckner N (1995) Identification of double Holliday junctions as intermediates in meiotic recombination. *Cell* 83:783-91

Schwacha A, Kleckner N (1997) Interhomolog bias during meiotic recombination: meiotic functions promote a highly differentiated interhomolog-only pathway. *Cell* 90:1123-35

Shannon M, Richardson L, Christian A, Handel MA, Thelen MP (1999) Differential gene expression of mammalian SPO11/TOP6A homologs during meiosis. *FEBS Lett* 462:329-34

Shinohara A, Ogawa H, Ogawa T (1992) Rad51 protein involved in repair and recombination in *S. cerevisiae* is a RecA-like protein. *Cell* 69:457-70

Shiroishi T, Koide T, Yoshino M, Sagai T, Moriwaki K (1995) Hotspots of homologous recombination in mouse meiosis. *Adv Biophys* 31:119-32

Shiroishi T, Sagai T, Hanzawa N, Gotoh H, Moriwaki K (1991) Genetic control of sex-dependent meiotic recombination in the major histocompatibility complex of the mouse. *EMBO J* 10:68106

Sipiczki M (2000) Where does fission yeast sit on the ree of life? *Genome Biol* 10:1186

Smith RA, Ho PJ, Clegg JB, Kidd JR, Thein SL (1998) Recombination breakpoints in the human beta-globin gene cluster. *Blood* 92:4415-21.

Steiner WW, Schreckhise RW, Smith GR (2002) Meiotic DNA breaks at the *S. pombe* recombination hot spot M26. *Mol Cell* 9:847-55

Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. *Am J Hum Genet* 73:1162-9

Storiazzi A, Xu L, Cao L, Kleckner N (1995) Crossover and noncrossover recombination during meiosis: timing and pathway relationships. *Proc Natl Acad Sci USA* 92:8512-6

Sun H, Treco D, Schultes NP, Szostak JW (1989) Double-strand breaks at an initiation site for meiotic gene conversion. *Nature* 338:87-90

Sun H, Treco D, Szostak JW (1991) Extensive 3'-overhanging, single-stranded DNA associated with the meiosis-specific double-strand breaks at the ARG4 recombination initiation site. *Cell* 64:1155-61

Sung P (1994) Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. *Science* 265:1241-3

Svetlanov A, Cohen PE (2004) Mismatch repair proteins, meiosis, and mice: understanding the complexities of mammalian meiosis. *Exp Cell Res* 296:71-9

Sym M, Engebrecht JA, Roeder GS (1993) ZIP1 is a synaptonemal complex protein required for meiotic chromosome synapsis. *Cell* 72:365-78

Sym M, Roeder GS (1994) Crossover interference is abolished in the absence of a synaptonemal complex protein. *Cell* 79:283-92

Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW (1983) The double-strand-break repair model for recombination. *Cell* 33:25-35

Tapper W, Collins A, Gibson J, Maniatis N, Ennis S, Morton NE (2005) A map of the human genome in linkage disequilibrium units. *Proc Natl Acad Sci USA* 102:11835-9

Tapper W, Maniatis N, Morton NE, Collins A (2003) A metric linkage disequilibrium map of human chromosome. *Ann Hum Genet* 67:487-94

Tease C, Hartshorne GM, Hulten MA (2002) Patterns of meiotic recombination in human fetal oocytes. *Am J Hum Genet* 70:1469-79

Tiemann-Boege I, Calabrese P, Cochran DM, Sokol R, Arnheim N (2006) High-resolution recombination patterns in a region of human chromosome 21 measured by sperm typing. *PLoS Genet* 2:e70

Trujillo KM, Sung P (2001) DNA structure-specific nuclease activities in the *Saccharomyces cerevisiae* Rad50-Mre11 complex. *J Biol Chem* 276:35458-64

Tsubouchi H, Roeder GC (2003) The importance of genetics recombination for fidelity of chromosome pairing in meiosis. *Dev Cell* 5:915-25

Tung KS, Roeder GS (1998) Meiotic chromosome morphology and behavior in zip1 mutants of *Saccharomyces cerevisiae*. *Genetics* 149:817-32

Wahls WP (1998) Meiotic recombination hotspots: shaping the genome and insights into hypervariable minisatellite DNA change. *Curr Top Dev Biol* 37:37-75

Wall JD, Frisse LA, Hudson RR, Di Rienzo A (2003) Comparative linkage-disequilibrium analysis of the beta-globin hotspot in primates. *Am J Hum Genet* 73:1330-40

Wang TF, Kleckner N, Hunter N (1999) Functional specificity of MutL homologs in yeast: evidence for three Mlh1-based heterocomplexes with distinct roles during meiosis in recombination and mismatch correction. *Proc Natl Acad Sci USA* 96:13914-9

Webb AJ, Berg IL, Jeffreys A (2008) Sperm cross-over activity in regions of the human genome showing extreme breakdowns of marker association. *Proc Natl Acad Sci USA* 105:10471-6

Weiner BM, Kleckner N (1994) Chromosome pairing via multiple interstitial interactions before and during meiosis in yeast. *Cell* 77:977-91

Winckler W, Myers SR, Richter DJ, Onofrio RC, McDonald GJ, Bontrop RE, McVean GA, Gabriel SB, Reich D, Donnelly P, Altshuler D (2005) Comparison of fine-scale recombination rates in humans and chimpanzees. *Science* 308:107-11

White MA, Dominska M, Petes TD (1993) Transcription factors are required for the meiotic recombination hotspot at the HIS4 locus in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA* 90:6621-5

Wu TC, Lichten M (1994) Meiosis-induced double-strand-break sites determined by yeast chromatin structure. *Science* 263:515-8

Wu TC, Lichten M (1995) Factors that affect the location and frequency of meiosis-induced double-strand breaks in *Saccharomyces cerevisiae*. *Genetics* 140:55-66

Xu L, Kleckner N (1995) Sequence non-specific double-strand breaks and interhomolog interactions prior to double-strand break formation at a meiotic recombination hot spot in yeast. *EMBO J* 14:5115-28

Yauk CL, Bois PR, Jeffreys AJ (2003) High-resolution sperm typing of meiotic recombination in the mouse MHC Ebeta gene. *EMBO J* 22:1389-97

Yip SP, Lovegrove JU, Rana NA, Hopkinson DA, Whitehouse DB (1999) Mapping recombination hotspots in human phosphoglucomutase (PGM1). *Hum Mol Genet* 8:1699-706.

Zhang W, Collins A, Maniatis N, Tapper W, Morton NE (2002) Properties of linkage disequilibrium (LD) maps. *Proc Natl Acad Sci USA* 99:17004-7

Zickler D, Kleckner N (1999) Meiotic chromosomes: integrating structure and function. *Annu Rev Genet* 33:603-754

Zickler D, Olson LW (1975) The synaptonemal complex and the spindle plaque during meiosis in yeast. Chromosoma 50:1-23